{"PMC7356800": [], "PMC7121724": [["\u201cWhy Mass Shootings May Be Contagious, New Study Examines\u201d; \u201cIs there an Antidote to Emotional Contagion\u201d; \u201cGaining Weight Is Socially Contagious\u2014So Is Losing It.\u201d", [["Mass", "OBSERVATION", 5, 9], ["May Be", "UNCERTAINTY", 20, 26], ["Contagious", "OBSERVATION_MODIFIER", 27, 37]]], ["In 2015, these headlines appeared alongside those pertaining to Ebola virus disease (EVD), West Nile virus, and the recently infamous \u201cGiant Frozen Virus Still Infectious After 3000 Years.\u201d1", [["Ebola virus disease", "DISEASE", 64, 83], ["EVD", "DISEASE", 85, 88], ["Ebola virus", "ORGANISM", 64, 75], ["West Nile virus", "ORGANISM", 91, 106], ["Ebola virus", "SPECIES", 64, 75], ["Nile virus", "SPECIES", 96, 106], ["Ebola virus", "SPECIES", 64, 75], ["West Nile virus", "SPECIES", 91, 106], ["Ebola virus disease", "PROBLEM", 64, 83], ["EVD", "PROBLEM", 85, 88], ["West Nile virus", "PROBLEM", 91, 106], ["Giant", "OBSERVATION_MODIFIER", 135, 140], ["Frozen Virus", "OBSERVATION", 141, 153]]]], "3b5977fde4a4e177c16edcdf7d70407a8ff8f074": [["The novel severe acute respiratory syndrome-coronavirus-2 pandemic has spread to Africa, where nearly all countries have reported laboratory-confirmed cases of novel coronavirus disease .", [["acute respiratory syndrome-coronavirus-2 pandemic", "DISEASE", 17, 66], ["coronavirus disease", "DISEASE", 166, 185], ["severe acute respiratory syndrome-coronavirus-2", "ORGANISM", 10, 57], ["coronavirus", "ORGANISM", 166, 177], ["-coronavirus-2 pandemic", "SPECIES", 43, 66], ["The novel severe acute respiratory syndrome", "PROBLEM", 0, 43], ["coronavirus", "PROBLEM", 44, 55], ["pandemic", "PROBLEM", 58, 66], ["novel coronavirus disease", "PROBLEM", 160, 185], ["severe", "OBSERVATION_MODIFIER", 10, 16], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["respiratory syndrome", "OBSERVATION", 23, 43], ["coronavirus disease", "OBSERVATION", 166, 185]]], ["Although there are ongoing clinical trials of repurposed and investigational antiviral and immune-based therapies, there are as yet no scientifically proven, clinically effective pharmacological treatments for COVID-19.", [["COVID-19", "CHEMICAL", 210, 218], ["investigational antiviral", "TREATMENT", 61, 86], ["immune-based therapies", "TREATMENT", 91, 113], ["pharmacological treatments", "TREATMENT", 179, 205], ["COVID", "TEST", 210, 215]]], ["Among the repurposed drugs, the commonly used antimalarials chloroquine (CQ) and hydroxychloroquine (HCQ) have become the focus of global scientific, media, and political attention despite a lack of randomized clinical trials supporting their efficacy.", [["chloroquine", "CHEMICAL", 60, 71], ["CQ", "CHEMICAL", 73, 75], ["hydroxychloroquine", "CHEMICAL", 81, 99], ["HCQ", "CHEMICAL", 101, 104], ["chloroquine", "CHEMICAL", 60, 71], ["CQ", "CHEMICAL", 73, 75], ["hydroxychloroquine", "CHEMICAL", 81, 99], ["HCQ", "CHEMICAL", 101, 104], ["chloroquine", "SIMPLE_CHEMICAL", 60, 71], ["CQ", "SIMPLE_CHEMICAL", 73, 75], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 81, 99], ["HCQ", "SIMPLE_CHEMICAL", 101, 104], ["the repurposed drugs", "TREATMENT", 6, 26], ["antimalarials chloroquine (CQ)", "TREATMENT", 46, 76], ["hydroxychloroquine (HCQ", "TREATMENT", 81, 104], ["randomized clinical trials", "TREATMENT", 199, 225]]], ["Chloroquine has been used worldwide for about 75 years and is listed by the WHO as an essential medicine to treat malaria.", [["Chloroquine", "CHEMICAL", 0, 11], ["malaria", "DISEASE", 114, 121], ["Chloroquine", "CHEMICAL", 0, 11], ["Chloroquine", "SIMPLE_CHEMICAL", 0, 11], ["Chloroquine", "TREATMENT", 0, 11], ["an essential medicine", "TREATMENT", 83, 104], ["malaria", "PROBLEM", 114, 121], ["malaria", "OBSERVATION", 114, 121]]], ["Hydroxychloroquine is mainly used as a therapy for autoimmune diseases.", [["Hydroxychloroquine", "CHEMICAL", 0, 18], ["autoimmune diseases", "DISEASE", 51, 70], ["Hydroxychloroquine", "CHEMICAL", 0, 18], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 0, 18], ["Hydroxychloroquine", "TREATMENT", 0, 18], ["a therapy", "TREATMENT", 37, 46], ["autoimmune diseases", "PROBLEM", 51, 70]]], ["However, the efficacy and safety of CQ/HCQ for the treatment of COVID-19 remains to be defined.", [["CQ", "CHEMICAL", 36, 38], ["HCQ", "CHEMICAL", 39, 42], ["COVID-19", "CHEMICAL", 64, 72], ["CQ", "CHEMICAL", 36, 38], ["HCQ", "CHEMICAL", 39, 42], ["COVID-19", "CHEMICAL", 64, 72], ["CQ", "SIMPLE_CHEMICAL", 36, 38], ["HCQ", "SIMPLE_CHEMICAL", 39, 42], ["CQ/HCQ", "TREATMENT", 36, 42], ["the treatment", "TREATMENT", 47, 60], ["COVID", "TEST", 64, 69]]], ["Indiscriminate promotion and widespread use of CQ/HCQ have led to extensive shortages, self-treatment, and fatal overdoses.", [["CQ", "CHEMICAL", 47, 49], ["HCQ", "CHEMICAL", 50, 53], ["overdoses", "DISEASE", 113, 122], ["CQ", "CHEMICAL", 47, 49], ["HCQ", "CHEMICAL", 50, 53], ["CQ", "SIMPLE_CHEMICAL", 47, 49], ["HCQ", "SIMPLE_CHEMICAL", 50, 53], ["CQ/HCQ", "TREATMENT", 47, 53], ["self-treatment", "TREATMENT", 87, 101], ["fatal overdoses", "PROBLEM", 107, 122], ["widespread", "OBSERVATION_MODIFIER", 29, 39], ["extensive", "OBSERVATION_MODIFIER", 66, 75]]], ["Shortages and increased market prices leave all countries vulnerable to substandard and falsified medical products, and safety issues are especially concerning for Africa because of its healthcare system limitations.", [["increased market prices", "TREATMENT", 14, 37], ["Africa", "PROBLEM", 164, 170], ["increased", "OBSERVATION_MODIFIER", 14, 23]]], ["Much needed in Africa is a cross-continental collaborative network for coordinated production, distribution, and post-marketing surveillance aligned to low-cost distribution of any approved COVID-19 drug; this would ideally be piggybacked on existing global aid efforts.", [["COVID-19", "CHEMICAL", 190, 198], ["COVID-19", "CHEMICAL", 190, 198], ["post-marketing surveillance", "TEST", 113, 140]]], ["Meanwhile, African countries should strongly consider implementing prescription monitoring schemes to ensure that any off-label CQ/HCQ use is appropriate and beneficial during this pandemic.PERSPECTIVENovel coronavirus disease , caused by the novel severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), has rapidly spread into a global pandemic.", [["CQ", "CHEMICAL", 128, 130], ["HCQ", "CHEMICAL", 131, 134], ["coronavirus disease", "DISEASE", 207, 226], ["acute respiratory syndrome-coronavirus", "DISEASE", 256, 294], ["HCQ", "CHEMICAL", 131, 134], ["CQ", "SIMPLE_CHEMICAL", 128, 130], ["HCQ", "SIMPLE_CHEMICAL", 131, 134], ["severe acute respiratory syndrome-coronavirus-2", "ORGANISM", 249, 296], ["SARS-CoV-2", "ORGANISM", 298, 308], ["-coronavirus", "SPECIES", 282, 294], ["severe acute respiratory syndrome-coronavirus", "SPECIES", 249, 294], ["SARS-CoV-2", "SPECIES", 298, 308], ["prescription monitoring schemes", "TREATMENT", 67, 98], ["coronavirus disease", "PROBLEM", 207, 226], ["the novel severe acute respiratory syndrome", "PROBLEM", 239, 282], ["coronavirus", "PROBLEM", 283, 294], ["SARS", "PROBLEM", 298, 302], ["CoV", "TEST", 303, 306], ["a global pandemic", "PROBLEM", 335, 352], ["coronavirus disease", "OBSERVATION", 207, 226], ["severe", "OBSERVATION_MODIFIER", 249, 255], ["acute", "OBSERVATION_MODIFIER", 256, 261], ["respiratory syndrome", "OBSERVATION", 262, 282], ["global", "OBSERVATION_MODIFIER", 337, 343], ["pandemic", "OBSERVATION", 344, 352]]], ["Africa initially appeared spared, but as of this writing, all countries except Lesotho have confirmed cases.", [["spared", "OBSERVATION_MODIFIER", 26, 32]]], ["As of April 15, 2020, there were 11,367 confirmed COVID-19 cases, with 523 deaths (4.6% case fatality) reported across the WHO African region.", [["deaths", "DISEASE", 75, 81], ["COVID", "TEST", 50, 55]]], ["1 In other settings such as the United States, Europe, and China, morbidity and mortality have been highest in those older than 60 years and with underlying comorbidities such as arterial hypertension, heart disease, diabetes, and chronic lung disease; young adults and children seem to have relatively mild disease and low mortality.", [["arterial", "ANATOMY", 179, 187], ["heart", "ANATOMY", 202, 207], ["lung", "ANATOMY", 239, 243], ["arterial hypertension", "DISEASE", 179, 200], ["heart disease", "DISEASE", 202, 215], ["diabetes", "DISEASE", 217, 225], ["chronic lung disease", "DISEASE", 231, 251], ["arterial", "MULTI-TISSUE_STRUCTURE", 179, 187], ["heart", "ORGAN", 202, 207], ["lung", "ORGAN", 239, 243], ["adults", "ORGANISM", 259, 265], ["children", "ORGANISM", 270, 278], ["children", "SPECIES", 270, 278], ["underlying comorbidities", "PROBLEM", 146, 170], ["arterial hypertension", "PROBLEM", 179, 200], ["heart disease", "PROBLEM", 202, 215], ["diabetes", "PROBLEM", 217, 225], ["chronic lung disease", "PROBLEM", 231, 251], ["relatively mild disease", "PROBLEM", 292, 315], ["low mortality", "PROBLEM", 320, 333], ["arterial", "ANATOMY", 179, 187], ["hypertension", "OBSERVATION", 188, 200], ["heart", "ANATOMY", 202, 207], ["disease", "OBSERVATION", 208, 215], ["diabetes", "OBSERVATION", 217, 225], ["chronic", "OBSERVATION_MODIFIER", 231, 238], ["lung", "ANATOMY", 239, 243], ["disease", "OBSERVATION", 244, 251], ["mild", "OBSERVATION_MODIFIER", 303, 307], ["disease", "OBSERVATION", 308, 315], ["low mortality", "OBSERVATION", 320, 333]]], ["2, 3 To date, there are no proven, clinically effective pharmacological treatments against COVID-19, but multiple ongoing trials are evaluating novel and repurposed drugs.", [["COVID-19", "CHEMICAL", 91, 99], ["COVID-19", "CHEMICAL", 91, 99], ["COVID", "TEST", 91, 96], ["repurposed drugs", "TREATMENT", 154, 170], ["no proven", "UNCERTAINTY", 24, 33]]], ["4 Among the repurposed drugs being rapidly investigated are the commonly used antimalarial and anti-inflammatory drugs chloroquine (CQ) and hydroxychloroquine (HCQ).", [["chloroquine", "CHEMICAL", 119, 130], ["CQ", "CHEMICAL", 132, 134], ["hydroxychloroquine", "CHEMICAL", 140, 158], ["HCQ", "CHEMICAL", 160, 163], ["chloroquine", "CHEMICAL", 119, 130], ["CQ", "CHEMICAL", 132, 134], ["hydroxychloroquine", "CHEMICAL", 140, 158], ["HCQ", "CHEMICAL", 160, 163], ["chloroquine", "SIMPLE_CHEMICAL", 119, 130], ["CQ", "SIMPLE_CHEMICAL", 132, 134], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 140, 158], ["HCQ", "SIMPLE_CHEMICAL", 160, 163], ["the repurposed drugs", "TREATMENT", 8, 28], ["antimalarial", "TREATMENT", 78, 90], ["anti-inflammatory drugs chloroquine", "TREATMENT", 95, 130], ["hydroxychloroquine (HCQ)", "TREATMENT", 140, 164]]], ["5 These drugs have become the focus of global scientific, media, and political attention despite the lack of randomized controlled trials supporting their efficacy against COVID-19.", [["These drugs", "TREATMENT", 2, 13], ["randomized controlled trials", "TREATMENT", 109, 137], ["COVID", "TEST", 172, 177]]], ["6 Chloroquine has been used worldwide for about 75 years, and it is listed by the WHO as an essential medicine for malaria, whereas HCQ is widely used to treat autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).", [["Chloroquine", "CHEMICAL", 2, 13], ["malaria", "DISEASE", 115, 122], ["HCQ", "CHEMICAL", 132, 135], ["autoimmune diseases", "DISEASE", 160, 179], ["systemic lupus erythematosus", "DISEASE", 188, 216], ["SLE", "DISEASE", 218, 221], ["rheumatoid arthritis", "DISEASE", 227, 247], ["RA", "DISEASE", 249, 251], ["Chloroquine", "CHEMICAL", 2, 13], ["HCQ", "CHEMICAL", 132, 135], ["Chloroquine", "SIMPLE_CHEMICAL", 2, 13], ["HCQ", "SIMPLE_CHEMICAL", 132, 135], ["Chloroquine", "TREATMENT", 2, 13], ["malaria", "PROBLEM", 115, 122], ["HCQ", "TREATMENT", 132, 135], ["autoimmune diseases", "PROBLEM", 160, 179], ["systemic lupus erythematosus", "PROBLEM", 188, 216], ["SLE)", "PROBLEM", 218, 222], ["rheumatoid arthritis", "PROBLEM", 227, 247], ["systemic", "OBSERVATION_MODIFIER", 188, 196], ["lupus erythematosus", "OBSERVATION", 197, 216], ["rheumatoid", "OBSERVATION_MODIFIER", 227, 237], ["arthritis", "OBSERVATION", 238, 247], ["RA", "ANATOMY", 249, 251]]], ["7 Both drugs have an established clinical safety profile, 8 but their efficacy and safety for COVID-19 treatment or prevention remain to be defined.", [["COVID-19", "CHEMICAL", 94, 102], ["COVID-19", "CHEMICAL", 94, 102], ["COVID-19 treatment", "TREATMENT", 94, 112], ["prevention", "TREATMENT", 116, 126]]], ["9, 10 Chloroquine is a 4-aminoquinoline that was synthesized in Germany by Bayer in 1934 and emerged in the 1940s as an effective substitute for quinine, an antimalarial therapy used for centuries.", [["Chloroquine", "CHEMICAL", 6, 17], ["4-aminoquinoline", "CHEMICAL", 23, 39], ["quinine", "CHEMICAL", 145, 152], ["Chloroquine", "CHEMICAL", 6, 17], ["4-aminoquinoline", "CHEMICAL", 23, 39], ["quinine", "CHEMICAL", 145, 152], ["Chloroquine", "SIMPLE_CHEMICAL", 6, 17], ["4-aminoquinoline", "SIMPLE_CHEMICAL", 23, 39], ["quinine", "SIMPLE_CHEMICAL", 145, 152], ["Chloroquine", "TREATMENT", 6, 17], ["quinine", "TREATMENT", 145, 152], ["an antimalarial therapy", "TREATMENT", 154, 177]]], ["11 Once a frontline drug for the treatment and prophylaxis of malaria, the efficacy of CQ was mostly lost because of the emergence of CQ-resistant Plasmodium falciparum strains in all endemic regions, including sub-Saharan Africa.", [["malaria", "DISEASE", 62, 69], ["CQ", "CHEMICAL", 87, 89], ["CQ", "CHEMICAL", 134, 136], ["Plasmodium falciparum", "DISEASE", 147, 168], ["CQ", "SIMPLE_CHEMICAL", 87, 89], ["CQ", "SIMPLE_CHEMICAL", 134, 136], ["Plasmodium falciparum", "ORGANISM", 147, 168], ["Plasmodium falciparum", "SPECIES", 147, 168], ["Plasmodium falciparum", "SPECIES", 147, 168], ["a frontline drug", "TREATMENT", 8, 24], ["the treatment", "TREATMENT", 29, 42], ["prophylaxis", "TREATMENT", 47, 58], ["malaria", "PROBLEM", 62, 69], ["CQ", "PROBLEM", 87, 89], ["CQ", "PROBLEM", 134, 136], ["resistant Plasmodium falciparum strains", "PROBLEM", 137, 176], ["malaria", "OBSERVATION", 62, 69], ["Plasmodium falciparum strains", "OBSERVATION", 147, 176], ["endemic", "OBSERVATION_MODIFIER", 184, 191], ["Saharan Africa", "OBSERVATION", 215, 229]]], ["Since about 2005, CQ has been replaced by artemisininbased combination therapy to treat uncomplicated P. falciparum malaria across Africa, but it is still widely used to treat nonfalciparum malaria, primarily outside of Africa.", [["CQ", "CHEMICAL", 18, 20], ["P. falciparum malaria", "DISEASE", 102, 123], ["nonfalciparum malaria", "DISEASE", 176, 197], ["CQ", "SIMPLE_CHEMICAL", 18, 20], ["artemisininbased", "SIMPLE_CHEMICAL", 42, 58], ["P. falciparum", "ORGANISM", 102, 115], ["P. falciparum", "SPECIES", 102, 115], ["P. falciparum", "SPECIES", 102, 115], ["artemisininbased combination therapy", "TREATMENT", 42, 78], ["uncomplicated P. falciparum malaria across Africa", "PROBLEM", 88, 137], ["nonfalciparum malaria", "PROBLEM", 176, 197], ["malaria", "OBSERVATION", 190, 197]]], ["12 After CQ was found to have persistent immunomodulatory effects after cessation of short-term treatment, Winthrop developed and patented HCQ, which has an N-hydroxyl-ethyl side chain in place of the N-diethyl group, and therefore less tissue accumulation and a more favorable safety profile than CQ.", [["tissue", "ANATOMY", 237, 243], ["CQ", "CHEMICAL", 9, 11], ["HCQ", "CHEMICAL", 139, 142], ["N-hydroxyl-ethyl", "CHEMICAL", 157, 173], ["N-diethyl", "CHEMICAL", 201, 210], ["CQ", "CHEMICAL", 298, 300], ["HCQ", "CHEMICAL", 139, 142], ["N-hydroxyl-ethyl", "CHEMICAL", 157, 173], ["N-diethyl", "CHEMICAL", 201, 210], ["CQ", "SIMPLE_CHEMICAL", 9, 11], ["HCQ", "SIMPLE_CHEMICAL", 139, 142], ["N-diethyl", "SIMPLE_CHEMICAL", 201, 210], ["tissue", "TISSUE", 237, 243], ["CQ", "SIMPLE_CHEMICAL", 298, 300], ["persistent immunomodulatory effects", "PROBLEM", 30, 65], ["short-term treatment", "TREATMENT", 85, 105], ["Winthrop", "TREATMENT", 107, 115], ["an N-hydroxyl-ethyl side chain", "TREATMENT", 154, 184], ["the N-diethyl group", "TREATMENT", 197, 216], ["less tissue accumulation", "PROBLEM", 232, 256], ["persistent", "OBSERVATION_MODIFIER", 30, 40], ["immunomodulatory effects", "OBSERVATION", 41, 65], ["short-term treatment", "OBSERVATION_MODIFIER", 85, 105], ["less tissue", "OBSERVATION_MODIFIER", 232, 243], ["accumulation", "OBSERVATION", 244, 256]]], ["13, 14 There are rational arguments, preclinical evidence of activity, and long-term evidence of safety for other indications to justify CQ/HCQ trials for the treatment and prevention of COVID-19.", [["CQ", "CHEMICAL", 137, 139], ["HCQ", "CHEMICAL", 140, 143], ["HCQ", "CHEMICAL", 140, 143], ["COVID-19", "CHEMICAL", 187, 195], ["CQ", "SIMPLE_CHEMICAL", 137, 139], ["HCQ", "SIMPLE_CHEMICAL", 140, 143], ["CQ/HCQ trials", "TREATMENT", 137, 150], ["the treatment", "TREATMENT", 155, 168], ["COVID", "TEST", 187, 192], ["activity", "OBSERVATION_MODIFIER", 61, 69]]], ["15 Their mechanisms of action are incompletely understood but may include fusion and uncoating blockade, 17 lysosomal alkalinization, 18 interaction with the angiotensin-2 converting enzyme receptor, 19 and immune modulation.", [["lysosomal", "ANATOMY", 108, 117], ["angiotensin", "CHEMICAL", 158, 169], ["angiotensin-2 converting enzyme receptor", "GENE_OR_GENE_PRODUCT", 158, 198], ["angiotensin-2 converting enzyme receptor", "PROTEIN", 158, 198], ["fusion", "TREATMENT", 74, 80], ["uncoating blockade", "TREATMENT", 85, 103], ["lysosomal alkalinization", "TREATMENT", 108, 132], ["the angiotensin", "TREATMENT", 154, 169], ["enzyme receptor", "TEST", 183, 198], ["immune modulation", "TREATMENT", 207, 224], ["immune modulation", "OBSERVATION", 207, 224]]], ["20 However, in vitro antiviral activity of CQ/HCQ has not yet been translated into efficacy for any viral infection, and these drugs have been detrimental in some studies (e.g., for the treatment of chikungunya).", [["CQ", "CHEMICAL", 43, 45], ["HCQ", "CHEMICAL", 46, 49], ["viral infection", "DISEASE", 100, 115], ["chikungunya", "DISEASE", 199, 210], ["CQ", "CHEMICAL", 43, 45], ["HCQ", "CHEMICAL", 46, 49], ["CQ", "SIMPLE_CHEMICAL", 43, 45], ["HCQ", "SIMPLE_CHEMICAL", 46, 49], ["CQ/HCQ", "TREATMENT", 43, 49], ["any viral infection", "PROBLEM", 96, 115], ["these drugs", "TREATMENT", 121, 132], ["chikungunya", "PROBLEM", 199, 210], ["viral", "OBSERVATION_MODIFIER", 100, 105], ["infection", "OBSERVATION", 106, 115]]], ["16 Of note, for SARS-CoV-2, the in vitro activity of HCQ appears to be greater than that of CQ, which might allow for a lower dosage for HCQ.", [["SARS", "DISEASE", 16, 20], ["HCQ", "CHEMICAL", 53, 56], ["CQ", "CHEMICAL", 92, 94], ["HCQ", "CHEMICAL", 137, 140], ["HCQ", "CHEMICAL", 53, 56], ["HCQ", "CHEMICAL", 137, 140], ["HCQ", "SIMPLE_CHEMICAL", 53, 56], ["CQ", "SIMPLE_CHEMICAL", 92, 94], ["HCQ", "SIMPLE_CHEMICAL", 137, 140], ["SARS-CoV", "SPECIES", 16, 24], ["SARS", "PROBLEM", 16, 20], ["CoV", "TEST", 21, 24], ["HCQ", "TREATMENT", 53, 56], ["HCQ", "TREATMENT", 137, 140]]], ["21, 22 To date, the quality of available evidence for the clinical effectiveness of CQ/HCQ alone or in combination with other drugs (e.g., azithromycin) is low, because of small sample size, poorly defined clinical outcomes, and lack of randomization in published studies.", [["CQ", "CHEMICAL", 84, 86], ["HCQ", "CHEMICAL", 87, 90], ["azithromycin", "CHEMICAL", 139, 151], ["CQ", "CHEMICAL", 84, 86], ["HCQ", "CHEMICAL", 87, 90], ["azithromycin", "CHEMICAL", 139, 151], ["CQ", "SIMPLE_CHEMICAL", 84, 86], ["HCQ", "SIMPLE_CHEMICAL", 87, 90], ["azithromycin", "SIMPLE_CHEMICAL", 139, 151], ["CQ/HCQ", "TREATMENT", 84, 90], ["other drugs", "TREATMENT", 120, 131], ["azithromycin", "TREATMENT", 139, 151], ["small sample size", "PROBLEM", 172, 189], ["published studies", "TEST", 254, 271], ["small", "OBSERVATION_MODIFIER", 172, 177], ["size", "OBSERVATION_MODIFIER", 185, 189], ["poorly defined", "OBSERVATION_MODIFIER", 191, 205]]], ["[23] [24] [25] [26] Thus, the results of early clinical studies cannot yet be considered conclusive.PERSPECTIVEThere remains an urgent need for high-quality evidence on the clinical value of CQ/HCQ alone or in combination with other drugs for the treatment of COVID-19.", [["CQ", "CHEMICAL", 191, 193], ["HCQ", "CHEMICAL", 194, 197], ["CQ", "CHEMICAL", 191, 193], ["HCQ", "CHEMICAL", 194, 197], ["COVID-19", "CHEMICAL", 260, 268], ["[23] [24] [25] [26]", "SIMPLE_CHEMICAL", 0, 19], ["CQ", "SIMPLE_CHEMICAL", 191, 193], ["HCQ", "SIMPLE_CHEMICAL", 194, 197], ["early clinical studies", "TEST", 41, 63], ["CQ/HCQ", "TREATMENT", 191, 197], ["other drugs", "TREATMENT", 227, 238], ["COVID", "TEST", 260, 265]]], ["One global-scale effort is the ongoing WHO Solidarity trial, a large, adaptive, five-arm multinational (including South Africa) trial comparing four potential COVID-19 regimens: remdesivir, HCQ, lopinavir-ritonavir, and lopinavir-ritonavir plus interferon beta, all of which are compared with optimal supportive care, with in-hospital mortality as the primary end point.", [["remdesivir", "CHEMICAL", 178, 188], ["HCQ", "CHEMICAL", 190, 193], ["lopinavir-ritonavir", "CHEMICAL", 195, 214], ["lopinavir-ritonavir", "CHEMICAL", 220, 239], ["remdesivir", "CHEMICAL", 178, 188], ["HCQ", "CHEMICAL", 190, 193], ["lopinavir", "CHEMICAL", 195, 204], ["ritonavir", "CHEMICAL", 205, 214], ["lopinavir", "CHEMICAL", 220, 229], ["ritonavir", "CHEMICAL", 230, 239], ["remdesivir", "SIMPLE_CHEMICAL", 178, 188], ["HCQ", "SIMPLE_CHEMICAL", 190, 193], ["lopinavir-ritonavir", "SIMPLE_CHEMICAL", 195, 214], ["lopinavir-ritonavir", "SIMPLE_CHEMICAL", 220, 239], ["interferon beta", "GENE_OR_GENE_PRODUCT", 245, 260], ["interferon beta", "PROTEIN", 245, 260], ["potential COVID", "TREATMENT", 149, 164], ["remdesivir", "TREATMENT", 178, 188], ["HCQ", "TREATMENT", 190, 193], ["lopinavir", "TREATMENT", 195, 204], ["ritonavir", "TREATMENT", 205, 214], ["lopinavir", "TREATMENT", 220, 229], ["ritonavir", "TREATMENT", 230, 239], ["interferon beta", "TREATMENT", 245, 260], ["large", "OBSERVATION_MODIFIER", 63, 68]]], ["Secondary end points will be the duration of hospital stay and proportion of patients requiring intensive care unit admission or mechanical ventilation.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["mechanical ventilation", "TREATMENT", 129, 151], ["mechanical ventilation", "OBSERVATION", 129, 151]]], ["The adaptive study design allows for dropping poorly performing arms and including additional promising therapeutics.", [["The adaptive study", "TEST", 0, 18], ["dropping poorly performing arms", "PROBLEM", 37, 68]]], ["27 Discovery is a component of the Solidarity trial, with identical arms and more complex end points, and is funded by the \"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale,\" France's national health and medical research agency.", [["Solidarity", "OBSERVATION", 35, 45]]], ["More than 500 patients have already been enrolled in the Discovery trial, and preliminary analysis is ongoing.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["preliminary analysis", "TEST", 78, 98]]], ["Also, the Recovery trial (for randomized evaluation) is a UK component of Solidarity, with more than 1,500 participants already enrolled.", [["participants", "SPECIES", 107, 119], ["randomized evaluation", "TEST", 30, 51], ["Solidarity", "OBSERVATION", 74, 84]]], ["27 Also, CQ/HCQ Prevention of COVID-19 in the Healthcare Setting (COPCOV), a large (n = 40,000) multicentric trial in which participants will be randomized to receive either CQ or HCQ versus placebo, is being launched in Europe and Asia, and participation of African sites is being considered.", [["CQ", "CHEMICAL", 9, 11], ["HCQ", "CHEMICAL", 12, 15], ["CQ", "CHEMICAL", 174, 176], ["HCQ", "CHEMICAL", 180, 183], ["HCQ", "CHEMICAL", 12, 15], ["HCQ", "CHEMICAL", 180, 183], ["participants", "ORGANISM", 124, 136], ["CQ", "SIMPLE_CHEMICAL", 174, 176], ["HCQ", "SIMPLE_CHEMICAL", 180, 183], ["participants", "SPECIES", 124, 136], ["COVID", "TEST", 30, 35], ["multicentric trial", "TREATMENT", 96, 114], ["CQ", "TREATMENT", 174, 176], ["HCQ", "TREATMENT", 180, 183], ["placebo", "TREATMENT", 191, 198], ["African sites", "TREATMENT", 259, 272], ["large", "OBSERVATION_MODIFIER", 77, 82]]], ["28 Unfortunately, indiscriminate promotion of CQ/HCQ (with or without azithromycin) based on the aforementioned low-quality data for COVID-19 treatment has led to widespread shortages, self-use, and fatal overdoses.", [["CQ", "CHEMICAL", 46, 48], ["HCQ", "CHEMICAL", 49, 52], ["azithromycin", "CHEMICAL", 70, 82], ["COVID-19", "CHEMICAL", 133, 141], ["overdoses", "DISEASE", 205, 214], ["CQ", "CHEMICAL", 46, 48], ["HCQ", "CHEMICAL", 49, 52], ["azithromycin", "CHEMICAL", 70, 82], ["COVID-19", "CHEMICAL", 133, 141], ["CQ", "SIMPLE_CHEMICAL", 46, 48], ["HCQ", "SIMPLE_CHEMICAL", 49, 52], ["azithromycin", "SIMPLE_CHEMICAL", 70, 82], ["CQ/HCQ", "TREATMENT", 46, 52], ["azithromycin", "TREATMENT", 70, 82], ["COVID", "TEST", 133, 138], ["treatment", "TREATMENT", 142, 151], ["fatal overdoses", "PROBLEM", 199, 214], ["widespread", "OBSERVATION_MODIFIER", 163, 173], ["shortages", "OBSERVATION_MODIFIER", 174, 183]]], ["29 Chloroquine (and to a lesser extent HCQ) has been used for decades with few major safety issues at the usual antimalarial dosages in short-course regimens (2.5 g in 3 days for \u00b3 60 kg adults).", [["Chloroquine", "CHEMICAL", 3, 14], ["HCQ", "CHEMICAL", 39, 42], ["Chloroquine", "CHEMICAL", 3, 14], ["HCQ", "CHEMICAL", 39, 42], ["Chloroquine", "SIMPLE_CHEMICAL", 3, 14], ["HCQ", "SIMPLE_CHEMICAL", 39, 42], ["Chloroquine", "TREATMENT", 3, 14], ["a lesser extent HCQ)", "TREATMENT", 23, 43], ["the usual antimalarial dosages", "TREATMENT", 102, 132], ["short-course regimens", "TREATMENT", 136, 157]]], ["30 Although rare, cardiac toxicity (corrected QT interval [QTc] prolongation leading to torsades de pointes and ventricular fibrillation) is a serious, lifethreatening complication, especially in patients with underlying cardiac disease, concurrent use of other drugs with QTc effect, or with supratherapeutic dosing.", [["cardiac", "ANATOMY", 18, 25], ["ventricular", "ANATOMY", 112, 123], ["cardiac", "ANATOMY", 221, 228], ["cardiac toxicity", "DISEASE", 18, 34], ["torsades de pointes", "DISEASE", 88, 107], ["ventricular fibrillation", "DISEASE", 112, 136], ["cardiac disease", "DISEASE", 221, 236], ["cardiac", "ORGAN", 18, 25], ["ventricular", "MULTI-TISSUE_STRUCTURE", 112, 123], ["patients", "ORGANISM", 196, 204], ["cardiac", "ORGAN", 221, 228], ["patients", "SPECIES", 196, 204], ["cardiac toxicity", "PROBLEM", 18, 34], ["corrected QT interval", "PROBLEM", 36, 57], ["QTc", "TEST", 59, 62], ["prolongation", "PROBLEM", 64, 76], ["torsades de pointes", "PROBLEM", 88, 107], ["ventricular fibrillation", "PROBLEM", 112, 136], ["a serious, lifethreatening complication", "PROBLEM", 141, 180], ["underlying cardiac disease", "PROBLEM", 210, 236], ["other drugs", "TREATMENT", 256, 267], ["QTc effect", "PROBLEM", 273, 283], ["supratherapeutic dosing", "TREATMENT", 293, 316], ["cardiac", "ANATOMY", 18, 25], ["toxicity", "OBSERVATION", 26, 34], ["ventricular", "ANATOMY", 112, 123], ["fibrillation", "OBSERVATION", 124, 136], ["serious", "OBSERVATION_MODIFIER", 143, 150], ["cardiac", "ANATOMY", 221, 228], ["disease", "OBSERVATION", 229, 236]]], ["26 The therapeutic window is however larger with HCQ, which is mainly used in chronic administration for rheumatic disorders, usually at dosages of 200 to 400 mg/day in adults.", [["HCQ", "CHEMICAL", 49, 52], ["rheumatic disorders", "DISEASE", 105, 124], ["HCQ", "CHEMICAL", 49, 52], ["HCQ", "SIMPLE_CHEMICAL", 49, 52], ["The therapeutic window", "TREATMENT", 3, 25], ["HCQ", "TREATMENT", 49, 52], ["chronic administration", "TREATMENT", 78, 100], ["rheumatic disorders", "PROBLEM", 105, 124], ["therapeutic", "OBSERVATION_MODIFIER", 7, 18], ["window", "OBSERVATION", 19, 25], ["larger", "OBSERVATION_MODIFIER", 37, 43], ["chronic", "OBSERVATION_MODIFIER", 78, 85]]], ["The major toxicity of chronic CQ/HCQ use is retinopathy.", [["toxicity", "DISEASE", 10, 18], ["CQ", "CHEMICAL", 30, 32], ["HCQ", "CHEMICAL", 33, 36], ["retinopathy", "DISEASE", 44, 55], ["CQ", "CHEMICAL", 30, 32], ["HCQ", "CHEMICAL", 33, 36], ["CQ", "SIMPLE_CHEMICAL", 30, 32], ["HCQ", "SIMPLE_CHEMICAL", 33, 36], ["chronic CQ/HCQ", "TREATMENT", 22, 36], ["retinopathy", "PROBLEM", 44, 55], ["major", "OBSERVATION_MODIFIER", 4, 9], ["toxicity", "OBSERVATION_MODIFIER", 10, 18], ["chronic", "OBSERVATION_MODIFIER", 22, 29], ["retinopathy", "OBSERVATION", 44, 55]]], ["31 Other important adverse effects associated with CQ/HCQ are listed in Table 1 .", [["CQ", "CHEMICAL", 51, 53], ["HCQ", "CHEMICAL", 54, 57], ["HCQ", "CHEMICAL", 54, 57], ["CQ", "SIMPLE_CHEMICAL", 51, 53], ["HCQ", "SIMPLE_CHEMICAL", 54, 57], ["CQ/HCQ", "TREATMENT", 51, 57]]], ["[31] [32] [33] [34] [35] [36] Of great concern are frequent drug-drug interactions between CQ/HCQ and other medications used for prevalent chronic diseases in Africa, such as HIV infection and tuberculosis, and the concurrent use of antibiotics such as fluoroquinolones (Table 2) .", [["CQ", "CHEMICAL", 91, 93], ["HCQ", "CHEMICAL", 94, 97], ["chronic diseases", "DISEASE", 139, 155], ["HIV infection", "DISEASE", 175, 188], ["tuberculosis", "DISEASE", 193, 205], ["fluoroquinolones", "CHEMICAL", 253, 269], ["[31] [32] [33] [34] [35]", "CHEMICAL", 0, 24], ["CQ", "CHEMICAL", 91, 93], ["HCQ", "CHEMICAL", 94, 97], ["fluoroquinolones", "CHEMICAL", 253, 269], ["[31] [32] [33] [34] [35] [36]", "SIMPLE_CHEMICAL", 0, 29], ["CQ", "SIMPLE_CHEMICAL", 91, 93], ["HCQ", "SIMPLE_CHEMICAL", 94, 97], ["HIV", "ORGANISM", 175, 178], ["fluoroquinolones", "SIMPLE_CHEMICAL", 253, 269], ["HIV", "SPECIES", 175, 178], ["HIV", "SPECIES", 175, 178], ["HCQ", "TREATMENT", 94, 97], ["other medications", "TREATMENT", 102, 119], ["prevalent chronic diseases", "PROBLEM", 129, 155], ["Africa", "PROBLEM", 159, 165], ["HIV infection", "PROBLEM", 175, 188], ["tuberculosis", "PROBLEM", 193, 205], ["antibiotics", "TREATMENT", 233, 244], ["fluoroquinolones", "TREATMENT", 253, 269], ["chronic", "OBSERVATION_MODIFIER", 139, 146], ["diseases", "OBSERVATION", 147, 155], ["infection", "OBSERVATION", 179, 188], ["tuberculosis", "OBSERVATION", 193, 205]]], ["[37] [38] [39] [40] [41] [42] [43] [44] As an example, coadministration of azithromycin with CQ/HCQ should be cautiously approached and closely monitored because of additive risk for QTc prolongation and subsequent cardiac complications.", [["cardiac", "ANATOMY", 215, 222], ["[37] [38] [39] [40] [41] [42]", "CHEMICAL", 0, 29], ["azithromycin", "CHEMICAL", 75, 87], ["CQ", "CHEMICAL", 93, 95], ["HCQ", "CHEMICAL", 96, 99], ["QTc prolongation", "DISEASE", 183, 199], ["cardiac complications", "DISEASE", 215, 236], ["[37] [38] [39] [40] [41] [42] [43] [44] As", "CHEMICAL", 0, 42], ["azithromycin", "CHEMICAL", 75, 87], ["CQ", "CHEMICAL", 93, 95], ["HCQ", "CHEMICAL", 96, 99], ["[37] [38] [39] [40] [41] [42] [43] [44]", "SIMPLE_CHEMICAL", 0, 39], ["azithromycin", "SIMPLE_CHEMICAL", 75, 87], ["CQ", "SIMPLE_CHEMICAL", 93, 95], ["HCQ", "SIMPLE_CHEMICAL", 96, 99], ["cardiac", "ORGAN", 215, 222], ["azithromycin", "TREATMENT", 75, 87], ["CQ", "TREATMENT", 93, 95], ["HCQ", "TREATMENT", 96, 99], ["QTc prolongation", "PROBLEM", 183, 199], ["subsequent cardiac complications", "PROBLEM", 204, 236], ["cardiac", "ANATOMY", 215, 222], ["complications", "OBSERVATION", 223, 236]]], ["32 Of note, P. falciparum resistance to CQ is widespread in sub-Saharan Africa, and artemisinin-based combination therapy has been the first-line treatment for uncomplicated malaria in all African countries for more than 10 years.", [["P. falciparum", "DISEASE", 12, 25], ["CQ", "CHEMICAL", 40, 42], ["artemisinin", "CHEMICAL", 84, 95], ["malaria", "DISEASE", 174, 181], ["artemisinin", "CHEMICAL", 84, 95], ["P. falciparum", "ORGANISM", 12, 25], ["CQ", "SIMPLE_CHEMICAL", 40, 42], ["artemisinin", "SIMPLE_CHEMICAL", 84, 95], ["P. falciparum", "SPECIES", 12, 25], ["P. falciparum", "SPECIES", 12, 25], ["P. falciparum resistance", "PROBLEM", 12, 36], ["CQ", "PROBLEM", 40, 42], ["artemisinin", "TREATMENT", 84, 95], ["therapy", "TREATMENT", 114, 121], ["the first-line treatment", "TREATMENT", 131, 155], ["uncomplicated malaria", "PROBLEM", 160, 181], ["falciparum resistance", "OBSERVATION", 15, 36], ["widespread", "OBSERVATION_MODIFIER", 46, 56], ["uncomplicated", "OBSERVATION_MODIFIER", 160, 173], ["malaria", "OBSERVATION", 174, 181]]], ["11 Although currently inappropriate, widespread CQ/HCQ use for COVID-19 treatment or prevention should therefore have little impact on P. falciparum treatment outcomes.", [["CQ", "CHEMICAL", 48, 50], ["HCQ", "CHEMICAL", 51, 54], ["COVID-19", "CHEMICAL", 63, 71], ["P. falciparum", "DISEASE", 135, 148], ["HCQ", "CHEMICAL", 51, 54], ["COVID-19", "CHEMICAL", 63, 71], ["CQ", "SIMPLE_CHEMICAL", 48, 50], ["HCQ", "SIMPLE_CHEMICAL", 51, 54], ["P. falciparum", "ORGANISM", 135, 148], ["P. falciparum", "SPECIES", 135, 148], ["COVID-19 treatment", "TREATMENT", 63, 81], ["prevention", "TREATMENT", 85, 95], ["P. falciparum treatment outcomes", "TREATMENT", 135, 167]]], ["However, this may increase selection of resistance to CQ in P. falciparum, which has decreased in recent years, or in other Plasmodium species, for which CQ remains the treatment of choice.", [["CQ", "CHEMICAL", 54, 56], ["P. falciparum", "DISEASE", 60, 73], ["CQ", "CHEMICAL", 154, 156], ["CQ", "SIMPLE_CHEMICAL", 54, 56], ["P. falciparum", "ORGANISM", 60, 73], ["Plasmodium species", "ORGANISM", 124, 142], ["CQ", "SIMPLE_CHEMICAL", 154, 156], ["P. falciparum", "SPECIES", 60, 73], ["P. falciparum", "SPECIES", 60, 73], ["CQ", "PROBLEM", 54, 56], ["P. falciparum", "PROBLEM", 60, 73], ["other Plasmodium species", "PROBLEM", 118, 142], ["decreased", "OBSERVATION_MODIFIER", 85, 94], ["Plasmodium species", "OBSERVATION", 124, 142]]], ["45 Furthermore, we call for caution regarding the widespread use of azithromycin (coadministered with CQ/HCQ) for treatment of COVID-19, as it may increase selection of bacterial resistance to this macrolide.", [["azithromycin", "CHEMICAL", 68, 80], ["CQ", "CHEMICAL", 102, 104], ["HCQ", "CHEMICAL", 105, 108], ["COVID-19", "CHEMICAL", 127, 135], ["macrolide", "CHEMICAL", 198, 207], ["azithromycin", "CHEMICAL", 68, 80], ["CQ", "CHEMICAL", 102, 104], ["HCQ", "CHEMICAL", 105, 108], ["COVID-19", "CHEMICAL", 127, 135], ["macrolide", "CHEMICAL", 198, 207], ["azithromycin", "SIMPLE_CHEMICAL", 68, 80], ["CQ", "SIMPLE_CHEMICAL", 102, 104], ["HCQ", "SIMPLE_CHEMICAL", 105, 108], ["macrolide", "SIMPLE_CHEMICAL", 198, 207], ["azithromycin", "TREATMENT", 68, 80], ["CQ/HCQ", "TREATMENT", 102, 108], ["COVID", "TEST", 127, 132], ["bacterial resistance", "PROBLEM", 169, 189], ["this macrolide", "TREATMENT", 193, 207], ["bacterial resistance", "OBSERVATION", 169, 189]]], ["In sub-Saharan Africa, azithromycin is an important treatment for bacterial infections including typhoid fever, especially where multidrug resistance (ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole, and fluorquinolones) in Salmonella typhi is on the rise.", [["azithromycin", "CHEMICAL", 23, 35], ["bacterial infections", "DISEASE", 66, 86], ["typhoid fever", "DISEASE", 97, 110], ["ampicillin", "CHEMICAL", 151, 161], ["chloramphenicol", "CHEMICAL", 163, 178], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 180, 209], ["fluorquinolones", "CHEMICAL", 215, 230], ["Salmonella typhi", "DISEASE", 235, 251], ["azithromycin", "CHEMICAL", 23, 35], ["ampicillin", "CHEMICAL", 151, 161], ["chloramphenicol", "CHEMICAL", 163, 178], ["trimethoprim-sulfamethoxazole", "CHEMICAL", 180, 209], ["fluorquinolones", "CHEMICAL", 215, 230], ["azithromycin", "SIMPLE_CHEMICAL", 23, 35], ["ampicillin", "SIMPLE_CHEMICAL", 151, 161], ["chloramphenicol", "SIMPLE_CHEMICAL", 163, 178], ["trimethoprim-sulfamethoxazole", "SIMPLE_CHEMICAL", 180, 209], ["fluorquinolones", "SIMPLE_CHEMICAL", 215, 230], ["Salmonella typhi", "ORGANISM", 235, 251], ["Salmonella typhi", "SPECIES", 235, 251], ["Salmonella typhi", "SPECIES", 235, 251], ["azithromycin", "TREATMENT", 23, 35], ["an important treatment", "TREATMENT", 39, 61], ["bacterial infections", "PROBLEM", 66, 86], ["typhoid fever", "PROBLEM", 97, 110], ["multidrug resistance", "TREATMENT", 129, 149], ["ampicillin", "TREATMENT", 151, 161], ["chloramphenicol", "TREATMENT", 163, 178], ["trimethoprim", "TREATMENT", 180, 192], ["sulfamethoxazole", "TREATMENT", 193, 209], ["fluorquinolones", "TREATMENT", 215, 230], ["Salmonella typhi", "PROBLEM", 235, 251], ["sub", "OBSERVATION_MODIFIER", 3, 6], ["bacterial", "OBSERVATION_MODIFIER", 66, 75], ["infections", "OBSERVATION", 76, 86]]], ["46, 47 Other concerns regarding the promotion of untested therapies for COVID-19 include fraud related to the growing 49 Safety issues are especially concerning for Africa because of relatively weak monitoring systems for off-label drug use and adverse events; these systems are robust in countries with strong national insurance schemes or with adequate private sector medical insurance.", [["untested therapies", "TREATMENT", 49, 67], ["COVID", "TEST", 72, 77], ["relatively weak monitoring systems", "PROBLEM", 183, 217], ["adverse events", "PROBLEM", 245, 259]]], ["In addition, the promotion of CQ/HCQ for COVID-19 may lead to shortages and/or increased market prices of these medicines for malaria, SLE, and RA.", [["CQ", "CHEMICAL", 30, 32], ["HCQ", "CHEMICAL", 33, 36], ["COVID-19", "CHEMICAL", 41, 49], ["malaria", "DISEASE", 126, 133], ["SLE", "DISEASE", 135, 138], ["RA", "DISEASE", 144, 146], ["HCQ", "CHEMICAL", 33, 36], ["COVID-19", "CHEMICAL", 41, 49], ["CQ", "SIMPLE_CHEMICAL", 30, 32], ["HCQ", "SIMPLE_CHEMICAL", 33, 36], ["CQ/HCQ", "TREATMENT", 30, 36], ["COVID", "TEST", 41, 46], ["these medicines", "TREATMENT", 106, 121], ["malaria", "PROBLEM", 126, 133], ["SLE", "PROBLEM", 135, 138], ["RA", "ANATOMY", 144, 146]]], ["One strategy to protect African countries from these threats is to leverage a collaborative network like the African Vaccine Regulatory Forum to coordinate cross-continental production, distribution chains, and post-marketing surveillance.", [["the African Vaccine", "TREATMENT", 105, 124], ["post-marketing surveillance", "TEST", 211, 238]]], ["Another model for quick, low-cost distribution of a COVID-19 drug or vaccine (once proven efficacious) would be to piggyback on platforms currently supported by the Global Fund, the U.S. President's Emergency Plan for AIDS Relief, and other organizations.", [["AIDS", "DISEASE", 218, 222], ["a COVID-19 drug", "TREATMENT", 50, 65], ["vaccine", "TREATMENT", 69, 76], ["AIDS Relief", "TREATMENT", 218, 229]]], ["For example, in South Africa, prescribers are required to inform the regulatory agency about off-label use of existing drugs in COVID-19 treatment.", [["COVID-19", "CHEMICAL", 128, 136], ["COVID-19", "CHEMICAL", 128, 136], ["existing drugs", "TREATMENT", 110, 124], ["COVID-19 treatment", "TREATMENT", 128, 146]]], ["This process will help gather information on treatment outcomes pending results from clinical trials.", [["treatment outcomes", "TREATMENT", 45, 63]]], ["Importantly, patients at risk of COVID-19 complications are also those most at risk of drug-drug interactions and drugassociated toxicity.", [["COVID", "DISEASE", 33, 38], ["toxicity", "DISEASE", 129, 137], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["COVID-19 complications", "PROBLEM", 33, 55], ["drugassociated toxicity", "PROBLEM", 114, 137]]], ["These include the following patients: 1) older than 60 years (estimated at 10-20% of the African population) 50 ; 2) with comorbidities, such as arterial hypertension (30% of African adults), 51 diabetes (4% of African adults), 52 chronic lung disease, malignancies, and immunosuppressive conditions; and 3) concurrently receiving medications with potential for drug interactions or additive toxicity.", [["arterial", "ANATOMY", 145, 153], ["lung", "ANATOMY", 239, 243], ["malignancies", "ANATOMY", 253, 265], ["arterial hypertension", "DISEASE", 145, 166], ["diabetes", "DISEASE", 195, 203], ["chronic lung disease", "DISEASE", 231, 251], ["malignancies", "DISEASE", 253, 265], ["toxicity", "DISEASE", 392, 400], ["patients", "ORGANISM", 28, 36], ["arterial", "MULTI-TISSUE_STRUCTURE", 145, 153], ["lung", "ORGAN", 239, 243], ["malignancies", "CANCER", 253, 265], ["patients", "SPECIES", 28, 36], ["comorbidities", "PROBLEM", 122, 135], ["arterial hypertension", "PROBLEM", 145, 166], ["diabetes", "PROBLEM", 195, 203], ["52 chronic lung disease", "PROBLEM", 228, 251], ["malignancies", "PROBLEM", 253, 265], ["immunosuppressive conditions", "TREATMENT", 271, 299], ["medications", "TREATMENT", 331, 342], ["drug interactions", "PROBLEM", 362, 379], ["additive toxicity", "PROBLEM", 383, 400], ["arterial", "ANATOMY", 145, 153], ["hypertension", "OBSERVATION", 154, 166], ["chronic", "OBSERVATION_MODIFIER", 231, 238], ["lung", "ANATOMY", 239, 243], ["disease", "OBSERVATION", 244, 251], ["malignancies", "OBSERVATION", 253, 265]]], ["For these vulnerable populations, off-label CQ/HCQ use should be considered with the utmost care, ideally following monitored research protocols in hospital and outpatient settings.PERSPECTIVEIn conclusion, there is currently no evidence that CQ or HCQ, two low-cost drugs for which we have extensive experience for treatment of malaria and rheumatic disorders, has beneficial effects on the clinical course of COVID-19 patients.", [["CQ", "CHEMICAL", 44, 46], ["HCQ", "CHEMICAL", 47, 50], ["CQ", "CHEMICAL", 243, 245], ["HCQ", "CHEMICAL", 249, 252], ["malaria", "DISEASE", 329, 336], ["rheumatic disorders", "DISEASE", 341, 360], ["COVID", "DISEASE", 411, 416], ["HCQ", "CHEMICAL", 47, 50], ["CQ", "CHEMICAL", 243, 245], ["HCQ", "CHEMICAL", 249, 252], ["CQ", "SIMPLE_CHEMICAL", 44, 46], ["HCQ", "SIMPLE_CHEMICAL", 47, 50], ["CQ", "SIMPLE_CHEMICAL", 243, 245], ["HCQ", "SIMPLE_CHEMICAL", 249, 252], ["patients", "ORGANISM", 420, 428], ["patients", "SPECIES", 420, 428], ["these vulnerable populations", "PROBLEM", 4, 32], ["HCQ", "TREATMENT", 47, 50], ["CQ", "PROBLEM", 243, 245], ["HCQ", "TEST", 249, 252], ["two low-cost drugs", "TREATMENT", 254, 272], ["treatment", "TREATMENT", 316, 325], ["malaria", "PROBLEM", 329, 336], ["rheumatic disorders", "PROBLEM", 341, 360], ["vulnerable", "OBSERVATION_MODIFIER", 10, 20], ["populations", "OBSERVATION", 21, 32], ["no evidence", "UNCERTAINTY", 226, 237], ["malaria", "OBSERVATION", 329, 336], ["rheumatic", "OBSERVATION", 341, 350]]], ["There are more than 80 ongoing trials of CQ or HCQ, used alone or in combination with a variety of other drugs registered on ClinicalTrials.gov.", [["CQ", "CHEMICAL", 41, 43], ["HCQ", "CHEMICAL", 47, 50], ["CQ", "CHEMICAL", 41, 43], ["HCQ", "CHEMICAL", 47, 50], ["CQ", "SIMPLE_CHEMICAL", 41, 43], ["HCQ", "SIMPLE_CHEMICAL", 47, 50], ["CQ", "TREATMENT", 41, 43], ["HCQ", "TREATMENT", 47, 50], ["other drugs", "TREATMENT", 99, 110]]], ["The results of these studies, including Solidarity and its companion trials (Discovery and Recovery) as well as COPCOV are eagerly awaited.", [["these studies", "TEST", 15, 28], ["COPCOV", "TREATMENT", 112, 118]]], ["Meanwhile, the offlabel use of CQ and HCQ to prevent or treat COVID-19 in Africa and elsewhere must be viewed with greatest caution, considering potential serious toxicities and benefit versus risk.", [["CQ", "CHEMICAL", 31, 33], ["HCQ", "CHEMICAL", 38, 41], ["COVID-19", "CHEMICAL", 62, 70], ["toxicities", "DISEASE", 163, 173], ["CQ", "CHEMICAL", 31, 33], ["HCQ", "CHEMICAL", 38, 41], ["COVID-19", "CHEMICAL", 62, 70], ["CQ", "SIMPLE_CHEMICAL", 31, 33], ["HCQ", "SIMPLE_CHEMICAL", 38, 41], ["CQ", "TREATMENT", 31, 33], ["HCQ", "TREATMENT", 38, 41], ["COVID", "TEST", 62, 67], ["potential serious toxicities", "PROBLEM", 145, 173]]], ["If the effectiveness of these and other drugs is established in global trials, therapeutics for COVID-19 will require further operational evaluation in Africa.", [["COVID-19", "CHEMICAL", 96, 104], ["other drugs", "TREATMENT", 34, 45], ["COVID", "TEST", 96, 101], ["further operational evaluation", "TEST", 118, 148]]], ["Concurrent use may increase the risk of QTc interval prolongation.", [["QTc interval prolongation", "PROBLEM", 40, 65], ["prolongation", "OBSERVATION_MODIFIER", 53, 65]]], ["CQ = chloroquine; HCQ = hydroxychloroquine.", [["CQ", "CHEMICAL", 0, 2], ["chloroquine", "CHEMICAL", 5, 16], ["HCQ", "CHEMICAL", 18, 21], ["hydroxychloroquine", "CHEMICAL", 24, 42], ["chloroquine", "CHEMICAL", 5, 16], ["HCQ", "CHEMICAL", 18, 21], ["hydroxychloroquine", "CHEMICAL", 24, 42], ["CQ", "SIMPLE_CHEMICAL", 0, 2], ["chloroquine", "SIMPLE_CHEMICAL", 5, 16], ["HCQ", "SIMPLE_CHEMICAL", 18, 21], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 24, 42], ["chloroquine", "TREATMENT", 5, 16], ["HCQ", "TREATMENT", 18, 21], ["hydroxychloroquine", "TREATMENT", 24, 42]]], ["The metabolism of HCQ and CQ is predominantly mediated by the hepatic cytochrome P450 (CYP) enzymes 3A4 and 2D6, but 2C8 and 3A5 are also important.", [["HCQ", "CHEMICAL", 18, 21], ["CQ", "CHEMICAL", 26, 28], ["HCQ", "CHEMICAL", 18, 21], ["CQ", "CHEMICAL", 26, 28], ["HCQ", "SIMPLE_CHEMICAL", 18, 21], ["CQ", "SIMPLE_CHEMICAL", 26, 28], ["cytochrome P450", "GENE_OR_GENE_PRODUCT", 70, 85], ["CYP) enzymes 3A4", "GENE_OR_GENE_PRODUCT", 87, 103], ["2D6", "GENE_OR_GENE_PRODUCT", 108, 111], ["2C8", "GENE_OR_GENE_PRODUCT", 117, 120], ["3A5", "GENE_OR_GENE_PRODUCT", 125, 128], ["hepatic cytochrome P450 (CYP) enzymes", "PROTEIN", 62, 99], ["3A4", "PROTEIN", 100, 103], ["2D6", "PROTEIN", 108, 111], ["2C8", "PROTEIN", 117, 120], ["3A5", "PROTEIN", 125, 128], ["The metabolism of HCQ and CQ", "PROBLEM", 0, 28], ["the hepatic cytochrome P450", "TEST", 58, 85], ["enzymes 3A4", "TEST", 92, 103], ["2D6", "TEST", 108, 111], ["2C8", "TEST", 117, 120], ["metabolism", "OBSERVATION_MODIFIER", 4, 14], ["HCQ", "OBSERVATION", 18, 21], ["hepatic", "ANATOMY", 62, 69]]], ["Any drug that induces or inhibits these CYP enzymes may potentially alter CQ/HCQ concentrations.", [["CQ", "CHEMICAL", 74, 76], ["HCQ", "CHEMICAL", 77, 80], ["CQ", "CHEMICAL", 74, 76], ["HCQ", "CHEMICAL", 77, 80], ["CYP enzymes", "GENE_OR_GENE_PRODUCT", 40, 51], ["CQ", "SIMPLE_CHEMICAL", 74, 76], ["HCQ", "SIMPLE_CHEMICAL", 77, 80], ["CYP enzymes", "PROTEIN", 40, 51], ["these CYP enzymes", "TEST", 34, 51], ["HCQ concentrations", "PROBLEM", 77, 95]]], ["[37] [38] [39] [40] [41] [42] [43] [44] Eric H. Decloedt, Division of Clinical Pharmacology, Department of", [["[37] [38] [39] [40] [41] [42] [43", "CHEMICAL", 0, 33], ["[37] [38] [39] [40] [41] [42] [43]", "CHEMICAL", 0, 34], ["[37] [38] [39] [40] [41] [42] [43] [44", "SIMPLE_CHEMICAL", 0, 38]]]], "e0f75415777f21a9155772f75c4fbe5a0314ac6f": [["A great shortage of healthcare capacity is looming over us as the COVID-19 (SARS-CoV-2) crisis advances.", [["the COVID", "TEST", 62, 71], ["crisis", "PROBLEM", 88, 94], ["great", "OBSERVATION_MODIFIER", 2, 7], ["shortage", "OBSERVATION_MODIFIER", 8, 16]]], ["In the future, economic and/or political pressure to alleviate lockdown measures, combined with a risk of faltering public compliance with long-term social distancing requirements, could cause new outbreaks.", [["political pressure", "TREATMENT", 31, 49], ["alleviate lockdown measures", "TREATMENT", 53, 80], ["long-term social distancing requirements", "TREATMENT", 139, 179], ["new", "OBSERVATION_MODIFIER", 193, 196], ["outbreaks", "OBSERVATION", 197, 206]]], ["This creates a realistic possibility of future waves in Europe or elsewhere, which could put healthcare capacity under higher pressure still, either in general or locally.", [["higher pressure", "OBSERVATION", 119, 134]]]], "PMC7304707": [["IntroductionUncertainty quantification (UQ) in physical models governed by systems of partial differential equations is important to build confidence in the resulting predictions.", [["partial differential equations", "PROBLEM", 86, 116]]], ["A common approach is to represent the sources of uncertainty as stochastic variables; in this context the solution to the original differential equations becomes random.", [["A common approach", "TREATMENT", 0, 17], ["stochastic variables", "PROBLEM", 64, 84], ["is to represent", "UNCERTAINTY", 18, 33]]], ["Stochastic Galerkin schemes (SGS) are used to approximate the solution to parametrized differential equations.", [["Stochastic Galerkin schemes", "PROBLEM", 0, 27]]], ["A Galerkin method projects the randomness in a solution onto a finite-dimensional basis, making deterministic computations possible.", [["A Galerkin method", "TREATMENT", 0, 17]]], ["SGS are part of a broader class known as spectral methods.IntroductionThe most common UQ strategies involve Monte Carlo (MC) algorithms, which suffer from a slow convergence rate proportional to the inverse square root of the number of samples [5].", [["Monte Carlo", "CHEMICAL", 108, 119], ["The most common UQ strategies", "TREATMENT", 70, 99], ["a slow convergence rate", "PROBLEM", 155, 178]]], ["If each sample evaluation is expensive \u2014 as is often the case for the solution of a PDE\u2014this slow convergence can make obtaining tens of thousands of samples computationally infeasible.", [["each sample evaluation", "TEST", 3, 25], ["a PDE\u2014this slow convergence", "TREATMENT", 82, 109]]], ["Initial spectral method applications to UQ problems showed orders-of-magnitude reductions in the cost needed to estimate statistics with comparable accuracy [3].IntroductionIn the present approach for SGS, the unknown quantities are expressed as an infinite series of orthogonal polynomials in the space of the random input variable.", [["Initial spectral method applications", "TREATMENT", 0, 36], ["UQ problems", "PROBLEM", 40, 51], ["magnitude reductions", "PROBLEM", 69, 89], ["SGS", "PROBLEM", 201, 204]]], ["This representation has its roots in the work of Wiener [7], who expressed a Gaussian process as an infinite series of Hermite polynomials.", [["roots", "ANATOMY", 28, 33], ["roots", "ORGAN", 28, 33], ["Hermite polynomials", "PROBLEM", 119, 138], ["roots", "OBSERVATION_MODIFIER", 28, 33]]], ["Ghanem and Spanos [4] truncated Wiener\u2019s representation and used the resulting finite series as a key ingredient in a stochastic finite element method.", [["Ghanem", "CHEMICAL", 0, 6], ["Ghanem", "SIMPLE_CHEMICAL", 0, 6]]], ["SGS based on polynomial expansions are often referred to as polynomial chaos approaches.IntroductionLet", [["SGS", "PROBLEM", 0, 3], ["polynomial expansions", "PROBLEM", 13, 34], ["polynomial expansions", "OBSERVATION", 13, 34]]]], "40470023462dcfcc8ed653d73a5dd255699abcad": [["Many attribute the popularization of the term to Nobel laureate Joshua Lederberg, where he (anthropocentrically) defined the microbiome as \"the ecological community of commensal, symbiotic, and pathogenic microorganisms that literally share our body space and have been all but ignored as determinants of health and disease\" [2] .", [["body", "ANATOMY", 245, 249], ["body", "ORGANISM_SUBDIVISION", 245, 249], ["pathogenic microorganisms", "PROBLEM", 194, 219]]], ["The community of microorganisms referenced in these definitions includes viruses, bacteria, fungi, protozoa, and archaea.", [["microorganisms", "PROBLEM", 17, 31], ["viruses", "PROBLEM", 73, 80], ["bacteria", "PROBLEM", 82, 90], ["fungi", "PROBLEM", 92, 97], ["protozoa", "PROBLEM", 99, 107], ["archaea", "PROBLEM", 113, 120], ["microorganisms", "OBSERVATION", 17, 31], ["viruses", "OBSERVATION", 73, 80]]], ["Within this community there is an inherent plasticity arising from the interaction of organisms with one another and with their environment.", [["an inherent plasticity", "PROBLEM", 31, 53], ["inherent", "OBSERVATION_MODIFIER", 34, 42], ["plasticity", "OBSERVATION", 43, 53]]], ["Such meta-interactions lead to complex repercussions for each level of life, and this review will focus on the consequences that have implications for human health.INTRODUCTIONThe viral component of the microbiome, termed the \"virome\" [3] is a poorly understood facet of the microbiome, despite having the potential to significantly impact human health.", [["human", "ORGANISM", 151, 156], ["human", "ORGANISM", 340, 345], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 340, 345], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 340, 345], ["viral", "OBSERVATION_MODIFIER", 180, 185], ["component", "OBSERVATION_MODIFIER", 186, 195]]], ["From a philosophical perspective, viruses were likely integral to the very existence of man as the primordial precursor to all current life on earth [4] .", [["man", "ORGANISM", 88, 91], ["man", "SPECIES", 88, 91], ["viruses", "PROBLEM", 34, 41]]], ["More tangibly, during the course of human evolution, the viruses in and around humans not only drove evolution via selective pressure, but also contributed novel genetic material.", [["human", "ORGANISM", 36, 41], ["humans", "ORGANISM", 79, 85], ["human", "SPECIES", 36, 41], ["humans", "SPECIES", 79, 85], ["human", "SPECIES", 36, 41], ["humans", "SPECIES", 79, 85], ["the viruses", "PROBLEM", 53, 64], ["viruses", "OBSERVATION", 57, 64]]], ["In fact, approximately 42 percent of the human genome is composed of viral sequence [5] .", [["human", "ORGANISM", 41, 46], ["human genome", "DNA", 41, 53], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["viral sequence", "PROBLEM", 69, 83], ["approximately", "OBSERVATION_MODIFIER", 9, 22], ["42 percent", "OBSERVATION_MODIFIER", 23, 33]]], ["This role as a major agent driving horizontal (i.e., non-reproductive) gene transfer between biomes [6] [7] [8] [9] and the fact that the diversity, complexity, and abundance of viruses surpasses any other biological entity make it apparent that understanding viromes will impart unparalleled understanding of the organisms they inhabit [10] .INTRODUCTIONHowever, the obvious importance of viruses in the composition of all biomes has not (yet) been met with an appropriate fervor for the characterization of the viral REVIEW Recent advances in sequencing technologies have opened the door for the classification of the human virome.", [["[6] [7] [8] [9", "CHEMICAL", 100, 114], ["human", "ORGANISM", 620, 625], ["virome", "CANCER", 626, 632], ["human", "SPECIES", 620, 625], ["human", "SPECIES", 620, 625], ["viruses", "PROBLEM", 178, 185], ["viruses", "PROBLEM", 390, 397], ["viruses", "OBSERVATION", 178, 185], ["viruses", "OBSERVATION", 390, 397], ["human virome", "OBSERVATION", 620, 632]]], ["While taxonomic classification can be applied to the viruses identified in such studies, this gives no information as to the type of interaction the virus has with the host.", [["the viruses", "PROBLEM", 49, 60], ["such studies", "TEST", 75, 87], ["the virus", "PROBLEM", 145, 154], ["viruses", "OBSERVATION", 53, 60]]], ["As follow-up studies are performed to address these questions, the description of these virus-host interactions would be greatly enriched by applying a standard set of definitions that typify them.", [["follow-up studies", "TEST", 3, 20], ["these virus", "PROBLEM", 82, 93], ["a standard set of definitions", "TREATMENT", 150, 179]]], ["This paper describes a framework with which all members of the human virome can be classified based on principles of ecology.", [["human", "ORGANISM", 63, 68], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68]]], ["The scaffold not only enables categorization of the human virome, but can also inform research aimed at identifying novel virus-host interactions. component of microbiomes.", [["human", "ORGANISM", 52, 57], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["human virome", "OBSERVATION", 52, 64], ["microbiomes", "OBSERVATION", 160, 171]]], ["The original explosion of microbiome information was spurred by the utilization of 16S sequencing technology, which can give vast information about microbial communities using universal primers [11] .", [["communities", "ANATOMY", 158, 169], ["universal primers", "TREATMENT", 176, 193]]], ["However, this technique is specific to organisms with ribosomes, so early research focused on analysis of bacterial sequences rather than much more technically challenging viral sequences [12] .", [["ribosomes", "ANATOMY", 54, 63], ["ribosomes", "CELLULAR_COMPONENT", 54, 63], ["bacterial sequences", "TEST", 106, 125]]], ["Thankfully, recent advances in next generation sequencing technologies are making virome characterization more technologically and financially possible and will ensure an explosion of virome description in the near future [13, 14] .INTRODUCTIONIn an effort to facilitate such classification of the human virome, it is prudent to use basic ecological interactions both to organize current knowledge as well as identify areas where new information may be found.", [["human", "ORGANISM", 298, 303], ["human", "SPECIES", 298, 303], ["human", "SPECIES", 298, 303], ["next generation sequencing technologies", "TREATMENT", 31, 70], ["virome characterization", "TEST", 82, 105], ["the human virome", "PROBLEM", 294, 310]]], ["This review will build a framework of the human virome from an ecological perspective, identify currently underappreciated and possibly undiscovered roles of the virome, and apply these principles to analysis of the role of the virome in human health.", [["human", "ORGANISM", 42, 47], ["human", "ORGANISM", 238, 243], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 238, 243], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 238, 243]]], ["Such a systematic conception of the structure of these ecological interactions can also facilitate the application of similar conventions to the other components of the microbiome.AN ECOLOGICAL FRAMEWORK OF THE HUMAN VIROMEWhile appreciation of the possible benefits of the human microbiome accumulated in the latter half of the 20th century, a concordant acknowledgement for the human virome was not so quickly realized [15] .", [["human", "ORGANISM", 274, 279], ["human", "ORGANISM", 380, 385], ["human", "SPECIES", 274, 279], ["human", "SPECIES", 380, 385], ["human", "SPECIES", 274, 279], ["human", "SPECIES", 380, 385], ["the human microbiome", "PROBLEM", 270, 290], ["the human virome", "PROBLEM", 376, 392]]], ["It is likely this was because human viruses rely on invasion of host cells to replicate and this provokes an overwhelmingly negative impression.", [["cells", "ANATOMY", 69, 74], ["human", "ORGANISM", 30, 35], ["host cells", "CELL", 64, 74], ["host cells", "CELL_TYPE", 64, 74], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["human viruses", "PROBLEM", 30, 43], ["invasion of host cells", "TREATMENT", 52, 74], ["negative", "OBSERVATION", 124, 132]]], ["However, all interactions of viruses with their hosts are symbioses in the classical sense [16] and fall along a spectrum from exclusively antagonistic to exclusively mutualistic [17] .", [["fall", "PROBLEM", 100, 104]]], ["In general, these interactions are facultative for the human and obligate for the virus, but cases like the presence of viral sequences in human genomes exemplify where this simplistic view breaks down [5] .", [["human", "ORGANISM", 55, 60], ["human", "ORGANISM", 139, 144], ["viral sequences", "DNA", 120, 135], ["human genomes", "DNA", 139, 152], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 139, 144], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 139, 144], ["the virus", "PROBLEM", 78, 87], ["viral sequences in human genomes", "PROBLEM", 120, 152]]], ["While the position of a particular virus along this spectrum is not fixed, it is obvious that many viruses have varied, intimate relationships with their hosts.AN ECOLOGICAL FRAMEWORK OF THE HUMAN VIROMEBotanists and entomologists were among the first to notice the intricacy of virus-host interactions, which challenged the purely parasitic dogma of virus-host interaction (reviewed in [17] [18] [19] [20] ).", [["[17] [18] [19] [20]", "SIMPLE_CHEMICAL", 387, 406], ["a particular virus", "PROBLEM", 22, 40], ["virus", "PROBLEM", 279, 284], ["many", "OBSERVATION_MODIFIER", 94, 98], ["viruses", "OBSERVATION", 99, 106]]], ["For example, parasitoid wasps harboring polydnavirus genomes utilize virally packaged host genes to prevent rejection of wasp eggs introduced into the parasitized caterpillar [21] .", [["eggs", "ANATOMY", 126, 130], ["polydnavirus genomes", "ORGANISM", 40, 60], ["polydnavirus genomes", "DNA", 40, 60], ["virally packaged host genes", "DNA", 69, 96], ["parasitoid wasps harboring polydnavirus genomes", "TREATMENT", 13, 60], ["virally packaged host genes", "TREATMENT", 69, 96], ["rejection of wasp eggs", "TREATMENT", 108, 130], ["host genes", "OBSERVATION", 86, 96], ["rejection", "OBSERVATION", 108, 117], ["wasp eggs", "OBSERVATION", 121, 130]]], ["In a more benign example, the white clover suppresses nodulation in conditions of sufficient nitrogen in a manner dependent on viral coat proteins of a persistently infecting cryptic virus [22] .", [["nitrogen", "CHEMICAL", 93, 101], ["nitrogen", "CHEMICAL", 93, 101], ["clover", "ORGANISM_SUBDIVISION", 36, 42], ["nitrogen", "SIMPLE_CHEMICAL", 93, 101], ["viral coat proteins", "PROTEIN", 127, 146], ["white clover", "SPECIES", 30, 42], ["the white clover suppresses nodulation", "PROBLEM", 26, 64], ["sufficient nitrogen", "TREATMENT", 82, 101], ["viral coat proteins", "TEST", 127, 146], ["a persistently infecting cryptic virus", "PROBLEM", 150, 188], ["benign", "OBSERVATION_MODIFIER", 10, 16], ["viral coat", "OBSERVATION_MODIFIER", 127, 137], ["persistently", "OBSERVATION_MODIFIER", 152, 164], ["infecting", "OBSERVATION_MODIFIER", 165, 174], ["cryptic virus", "OBSERVATION", 175, 188]]], ["While the breadth of knowledge of interactions types is surely incomplete, their presence in other organisms al-ludes to the possibility of the existence of similar interactions between humans and viruses.AN ECOLOGICAL FRAMEWORK OF THE HUMAN VIROMERecent reviews have addressed the issue of the current, primarily negative, view of the human virome [18, [23] [24] [25] [26] .", [["humans", "ORGANISM", 186, 192], ["human", "ORGANISM", 336, 341], ["[23] [24] [25] [26]", "SIMPLE_CHEMICAL", 354, 373], ["humans", "SPECIES", 186, 192], ["human", "SPECIES", 336, 341], ["humans", "SPECIES", 186, 192], ["human", "SPECIES", 336, 341], ["the human virome", "TEST", 332, 348]]], ["Virologists are beginning to realize that the viruses within us may be more important than previously appreciated.", [["the viruses", "PROBLEM", 42, 53], ["viruses", "OBSERVATION", 46, 53]]], ["The discovery of intimate interactions of viruses with humans, like the role of endogenous retrovirus (ERV \u2020) syncytins in placentation [27] , are categorically dissimilar to the classical view of viruses only as parasites and brings to issue how scientists are approaching the study of the virome.", [["humans", "ORGANISM", 55, 61], ["endogenous retrovirus", "ORGANISM", 80, 101], ["ERV \u2020) syncytins", "GENE_OR_GENE_PRODUCT", 103, 119], ["endogenous retrovirus (ERV \u2020) syncytins", "PROTEIN", 80, 119], ["humans", "SPECIES", 55, 61], ["humans", "SPECIES", 55, 61], ["endogenous retrovirus", "PROBLEM", 80, 101], ["the study", "TEST", 274, 283], ["viruses", "OBSERVATION", 42, 49], ["viruses", "OBSERVATION", 197, 204]]], ["A lack of structure in this endeavor has arguably hindered the true understanding of non-pathogenic consequences of human-virome interactions.AN ECOLOGICAL FRAMEWORK OF THE HUMAN VIROMETo address this issue, an ecological framework can be constructed for more informative classification of the virome based on how viruses fill niches in humans.", [["human", "ORGANISM", 116, 121], ["virome", "GENE_OR_GENE_PRODUCT", 122, 128], ["humans", "ORGANISM", 337, 343], ["human", "SPECIES", 116, 121], ["humans", "SPECIES", 337, 343], ["human", "SPECIES", 116, 121], ["humans", "SPECIES", 337, 343], ["the virome", "PROBLEM", 290, 300]]], ["Here, I describe a conception of the human virome with three general classifications of virus types: Parasitic, Commensal, and Mutualistic ( Figure 1 ).", [["human", "ORGANISM", 37, 42], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["the human virome", "PROBLEM", 33, 49], ["Parasitic", "OBSERVATION_MODIFIER", 101, 110]]], ["Within these groupings are subcategories containing more specific characteristics germane to different viral groups.", [["viral groups", "OBSERVATION", 103, 115]]], ["Table 1 illustrates how representative members of the human virome spanning a vast array of families, replication schemes, genome architectures, and tropisms can be succinctly classified with this scheme.", [["human", "ORGANISM", 54, 59], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59]]], ["This arrangement provides functional information about the nature and plasticity of virus-host interaction, the most critical defining characteristic of a virus in the context of human health, in a way absent in the more classical types of organization mentioned above.", [["human", "ORGANISM", 179, 184], ["human", "SPECIES", 179, 184], ["human", "SPECIES", 179, 184], ["a virus", "PROBLEM", 153, 160], ["virus", "OBSERVATION", 155, 160]]], ["The application of this scaffold will not only deepen the understanding of known virus-host interactions in the ecological context of the virome, but will also identify logical next steps and gaps in current knowledge that are tantalizing areas for future exploration.THE PARASITIC VIROMEThe canonical classification of viruses is as parasites.", [["this scaffold", "TREATMENT", 19, 32], ["known virus", "PROBLEM", 75, 86], ["future exploration", "TEST", 249, 267], ["THE PARASITIC VIROME", "PROBLEM", 268, 288], ["viruses", "PROBLEM", 320, 327], ["parasites", "PROBLEM", 334, 343], ["virus", "OBSERVATION", 81, 86], ["PARASITIC VIROME", "OBSERVATION", 272, 288], ["viruses", "OBSERVATION", 320, 327]]], ["In general, parasitic viruses are transmitted horizontally from host to host, and this process is necessary for the virus' survival.", [["parasitic viruses", "PROBLEM", 12, 29], ["the virus' survival", "TREATMENT", 112, 131], ["parasitic viruses", "OBSERVATION", 12, 29]]], ["Their obligate life cycles necessitate manipulation of cellular processes and have been classically linked to disease manifestation.", [["cellular", "ANATOMY", 55, 63], ["cellular", "CELL", 55, 63], ["Their obligate life cycles", "TREATMENT", 0, 26], ["manipulation of cellular processes", "TREATMENT", 39, 73], ["disease manifestation", "PROBLEM", 110, 131], ["cellular processes", "OBSERVATION", 55, 73]]], ["While the role of viruses in human disease was not appreciated until the 19th century [28] , throughout human history, the diseases caused by particularly pathogenic viruses have been some of the most feared and deadly.", [["human disease", "DISEASE", 29, 42], ["human", "ORGANISM", 29, 34], ["human", "ORGANISM", 104, 109], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 104, 109], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 104, 109], ["viruses in human disease", "PROBLEM", 18, 42], ["the diseases", "PROBLEM", 119, 131], ["pathogenic viruses", "PROBLEM", 155, 173], ["viruses", "OBSERVATION", 18, 25], ["diseases", "OBSERVATION", 123, 131], ["viruses", "OBSERVATION", 166, 173]]], ["Currently, there are 129 known human viral pathogens [29] and at least 219 viruses that can infect humans [30] , with more being discovered every year [31, 32] .", [["human", "ORGANISM", 31, 36], ["humans", "ORGANISM", 99, 105], ["human", "SPECIES", 31, 36], ["humans", "SPECIES", 99, 105], ["human", "SPECIES", 31, 36], ["humans", "SPECIES", 99, 105], ["known human viral pathogens", "PROBLEM", 25, 52]]], ["The apparent bias toward pathogenic species is undeniably because phenotype (read: pathogenesis) has traditionally been a major factor in the discovery of new viruses.THE PARASITIC VIROMEWhile parasitic viruses are a morose facet of human history, they have contributed to man's evolution as a species.", [["parasitic viruses", "DISEASE", 193, 210], ["human", "ORGANISM", 233, 238], ["human", "SPECIES", 233, 238], ["man", "SPECIES", 273, 276], ["human", "SPECIES", 233, 238], ["pathogenic species", "PROBLEM", 25, 43], ["pathogenesis", "PROBLEM", 83, 95], ["new viruses", "PROBLEM", 155, 166], ["THE PARASITIC VIROMEWhile parasitic viruses", "PROBLEM", 167, 210], ["bias", "OBSERVATION", 13, 17], ["pathogenic species", "OBSERVATION", 25, 43], ["new", "OBSERVATION_MODIFIER", 155, 158], ["viruses", "OBSERVATION", 159, 166], ["PARASITIC", "OBSERVATION_MODIFIER", 171, 180], ["VIROMEWhile", "OBSERVATION_MODIFIER", 181, 192], ["parasitic viruses", "OBSERVATION", 193, 210]]], ["The biologist's viewpoint includes the selective pressure on man in which viruses kill susceptible hosts, leading to the emergence of fitter genotypes.", [["man", "ORGANISM", 61, 64], ["man", "SPECIES", 61, 64]]], ["Some viruses play a similar role by limiting an infected host's reproductive fitness [33] .", [["Some viruses", "PROBLEM", 0, 12], ["viruses", "OBSERVATION", 5, 12]]], ["The presence of deadly viruses has also supplied pressure for behavioral and psychological adaptation via influence on practices in mate selection, food preparation, and sanitation [34] .", [["deadly viruses", "PROBLEM", 16, 30], ["deadly", "OBSERVATION_MODIFIER", 16, 22], ["viruses", "OBSERVATION", 23, 30], ["pressure", "OBSERVATION_MODIFIER", 49, 57]]], ["A modern example of such behavioral adaptation is the development of vaccination, kick-started by Edward Jenner's famous work with cowpox [35] .THE PARASITIC VIROMEHowever, not all parasitic viruses are deadly.", [["parasitic viruses", "DISEASE", 181, 198], ["cowpox", "ORGANISM", 131, 137], ["such behavioral adaptation", "PROBLEM", 20, 46], ["all parasitic viruses", "PROBLEM", 177, 198], ["PARASITIC VIROMEHowever", "OBSERVATION", 148, 171], ["not", "UNCERTAINTY", 173, 176], ["all", "OBSERVATION_MODIFIER", 177, 180], ["parasitic", "OBSERVATION_MODIFIER", 181, 190], ["viruses", "OBSERVATION", 191, 198]]], ["In fact, excessive pathogenicity is an evolutionarily poor strategy for a virus' survival unless balanced with a number of other trade-offs such as transmission rate and recovery rate [36] .", [["excessive pathogenicity", "PROBLEM", 9, 32], ["a virus' survival", "TREATMENT", 72, 89], ["transmission rate", "TEST", 148, 165], ["recovery rate", "TEST", 170, 183], ["excessive", "OBSERVATION_MODIFIER", 9, 18], ["pathogenicity", "OBSERVATION", 19, 32]]], ["Most parasitic infections occur horizontally (though there are rare exceptions [37] ) and the equilibrium between pathogenicity and other trade-offs is crucial to ensuring continuation of the viral lineage.", [["parasitic infections", "DISEASE", 5, 25], ["Most parasitic infections", "PROBLEM", 0, 25], ["the equilibrium between pathogenicity", "PROBLEM", 90, 127], ["parasitic", "OBSERVATION_MODIFIER", 5, 14], ["infections", "OBSERVATION", 15, 25], ["viral lineage", "OBSERVATION", 192, 205]]], ["While parasitic viruses by definition have some level of pathogenic effect on their host, it is not the intent of the virus to do so, because viruses don't have intentions.", [["parasitic viruses", "DISEASE", 6, 23], ["parasitic viruses", "PROBLEM", 6, 23], ["the virus", "PROBLEM", 114, 123], ["viruses", "PROBLEM", 142, 149], ["parasitic", "OBSERVATION_MODIFIER", 6, 15], ["viruses", "OBSERVATION", 16, 23], ["pathogenic", "OBSERVATION_MODIFIER", 57, 67], ["effect", "OBSERVATION_MODIFIER", 68, 74]]], ["Viral genomes (particularly those of RNA viruses) exist as a pool of non-identical, related sequences, termed quasispecies, and are constantly adapting in response to selective pressures [38] .", [["Viral genomes", "DNA", 0, 13], ["Viral genomes", "PROBLEM", 0, 13], ["RNA viruses", "PROBLEM", 37, 48], ["termed quasispecies", "PROBLEM", 103, 122], ["selective pressures", "TEST", 167, 186], ["genomes", "OBSERVATION", 6, 13], ["quasispecies", "OBSERVATION", 110, 122]]], ["In some cases, the virus' environment can select for changes that create a balance of the above-mentioned trade-offs where pathogenicity may be a successful, or at least not detrimental, strategy [39] .", [["pathogenicity", "PROBLEM", 123, 136]]], ["In this light, I will define types of parasitic viruses according to both their degree of pathogenesis and the way in which they interact with their host.Pathogenic VirusesThe key characteristic of pathogenic viruses is that they cause an acute disease in which the host either lives or dies, with the virus simply using it as a vessel to move to the next host.", [["vessel", "ANATOMY", 329, 335], ["vessel", "MULTI-TISSUE_STRUCTURE", 329, 335], ["parasitic viruses", "PROBLEM", 38, 55], ["Pathogenic Viruses", "PROBLEM", 154, 172], ["pathogenic viruses", "PROBLEM", 198, 216], ["an acute disease", "PROBLEM", 236, 252], ["the virus", "PROBLEM", 298, 307], ["parasitic viruses", "OBSERVATION", 38, 55], ["pathogenic", "OBSERVATION_MODIFIER", 198, 208], ["viruses", "OBSERVATION", 209, 216], ["acute", "OBSERVATION_MODIFIER", 239, 244], ["disease", "OBSERVATION", 245, 252], ["vessel", "ANATOMY", 329, 335]]], ["This is not to say that all pathogenic infections are deadly or resolved immediately, since the degree of pathogenicity and time to resolution vary widely, as will be discussed in following sections.", [["sections", "ANATOMY", 190, 198], ["infections", "DISEASE", 39, 49], ["all pathogenic infections", "PROBLEM", 24, 49], ["pathogenicity", "PROBLEM", 106, 119], ["pathogenic", "OBSERVATION_MODIFIER", 28, 38], ["infections", "OBSERVATION", 39, 49], ["pathogenicity", "OBSERVATION", 106, 119]]], ["Rather, the virus-host interactions classified here as \"pathogenic\" represent perturbations of homeostasis for which the only resolution is that one side must prevail.", [["perturbations of homeostasis", "PROBLEM", 78, 106]]], ["Either the host completely clears its body of the virus, or it succumbs to infection.", [["body", "ANATOMY", 38, 42], ["infection", "DISEASE", 75, 84], ["body", "ORGANISM_SUBDIVISION", 38, 42], ["the virus", "PROBLEM", 46, 55], ["infection", "PROBLEM", 75, 84], ["virus", "OBSERVATION", 50, 55], ["infection", "OBSERVATION", 75, 84]]], ["While this sounds like a poor transmission strategy, history has shown it can be quite effective, as long as the proper trade-offs are satisfied (see The Parasitic Virome, above).", [["a poor transmission strategy", "PROBLEM", 23, 51]]], ["Influenza virus is a prime example of the success of a pathogenic strategy.", [["Influenza virus", "DISEASE", 0, 15], ["Influenza virus", "ORGANISM", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "SPECIES", 0, 15], ["Influenza virus", "PROBLEM", 0, 15], ["a pathogenic strategy", "TREATMENT", 53, 74]]], ["Most humans can expect to be infected with at least one influenza virus per year, and in general they will observe a fairly robust set of symptoms including, but not limited to, fever, chills, headache, nasal congestion, and coughing [40] .", [["nasal", "ANATOMY", 203, 208], ["fever", "DISEASE", 178, 183], ["chills", "DISEASE", 185, 191], ["headache", "DISEASE", 193, 201], ["nasal congestion", "DISEASE", 203, 219], ["coughing", "DISEASE", 225, 233], ["humans", "ORGANISM", 5, 11], ["nasal", "ORGANISM_SUBDIVISION", 203, 208], ["humans", "SPECIES", 5, 11], ["humans", "SPECIES", 5, 11], ["symptoms", "PROBLEM", 138, 146], ["fever", "PROBLEM", 178, 183], ["chills", "PROBLEM", 185, 191], ["headache", "PROBLEM", 193, 201], ["nasal congestion", "PROBLEM", 203, 219], ["coughing", "PROBLEM", 225, 233], ["infected", "OBSERVATION", 29, 37], ["nasal", "ANATOMY", 203, 208], ["congestion", "OBSERVATION", 209, 219]]], ["While infection can be severe and even cause death, this is typically limited to hosts in an immunocompromised state, as selective pressure typically drives virus evolution to less virulence [41] .", [["infection", "DISEASE", 6, 15], ["death", "DISEASE", 45, 50], ["infection", "PROBLEM", 6, 15], ["death", "PROBLEM", 45, 50], ["an immunocompromised state", "PROBLEM", 90, 116], ["selective pressure", "TREATMENT", 121, 139], ["infection", "OBSERVATION", 6, 15], ["immunocompromised", "OBSERVATION", 93, 110]]], ["In general, virus is shed one to two days after infection, with symptoms usually presenting one day later, ensuring that a person shedding virus will be out and about among currently uninfected individuals [42] .", [["infection", "DISEASE", 48, 57], ["person", "SPECIES", 123, 129], ["infection", "PROBLEM", 48, 57], ["symptoms", "PROBLEM", 64, 72], ["virus", "OBSERVATION", 12, 17], ["infection", "OBSERVATION", 48, 57]]], ["Severe symptoms may be due to viral replication and destruction of tissue; however, over-reaction of the immune system is often the cause [41] .", [["tissue", "ANATOMY", 67, 73], ["immune system", "ANATOMY", 105, 118], ["tissue", "TISSUE", 67, 73], ["Severe symptoms", "PROBLEM", 0, 15], ["viral replication", "PROBLEM", 30, 47], ["destruction of tissue", "PROBLEM", 52, 73], ["may be due to", "UNCERTAINTY", 16, 29], ["viral replication", "OBSERVATION", 30, 47], ["tissue", "OBSERVATION_MODIFIER", 67, 73]]], ["This is exemplified by secondary bacterial pneumonia where blooms of pathogenic and/or commensal bacteria can result in severe disease or death [38] [39] [40] [41] .", [["pneumonia", "DISEASE", 43, 52], ["death", "DISEASE", 138, 143], ["secondary bacterial pneumonia", "PROBLEM", 23, 52], ["pathogenic", "PROBLEM", 69, 79], ["commensal bacteria", "PROBLEM", 87, 105], ["severe disease or death", "PROBLEM", 120, 143], ["secondary", "OBSERVATION_MODIFIER", 23, 32], ["bacterial", "OBSERVATION_MODIFIER", 33, 42], ["pneumonia", "OBSERVATION", 43, 52], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["disease", "OBSERVATION", 127, 134]]], ["However, by the time a person has become ill, they have likely spread the virus by direct contact with an uninfected individual, contaminated fomites, or aerosolized respiratory droplets [46] .Pathogenic VirusesThe fact that many pathogenic viruses have circulated in humans for hundreds to thousands of years, despite our best efforts to eliminate them, speaks to their success.", [["fomites", "ANATOMY", 142, 149], ["humans", "ORGANISM", 268, 274], ["person", "SPECIES", 23, 29], ["humans", "SPECIES", 268, 274], ["humans", "SPECIES", 268, 274], ["the virus", "PROBLEM", 70, 79], ["aerosolized respiratory droplets", "PROBLEM", 154, 186], ["Pathogenic Viruses", "PROBLEM", 193, 211], ["many pathogenic viruses", "PROBLEM", 225, 248], ["many", "OBSERVATION_MODIFIER", 225, 229], ["pathogenic", "OBSERVATION_MODIFIER", 230, 240], ["viruses", "OBSERVATION", 241, 248]]], ["As far back as the 16th-11th centuries B.C., there is evidence of poliomyelitis caused by poliovirus in Egypt [47] .", [["poliomyelitis", "DISEASE", 66, 79], ["poliomyelitis", "PROBLEM", 66, 79], ["poliovirus", "PROBLEM", 90, 100], ["evidence of", "UNCERTAINTY", 54, 65], ["poliomyelitis", "OBSERVATION", 66, 79], ["poliovirus", "OBSERVATION", 90, 100]]], ["A more recent example is measles virus, which appears to have diverged from rinderpest sometime in the 11th or 12th century B.C. [48] .", [["measles virus", "ORGANISM", 25, 38], ["measles virus", "SPECIES", 25, 38], ["measles virus", "PROBLEM", 25, 38]]], ["The long histories of human disease caused by these and other pathogenic viruses made them low hanging fruits for study in the new field of microbiology in the early 19th century [47] .", [["fruits", "ANATOMY", 103, 109], ["human disease", "DISEASE", 22, 35], ["human", "ORGANISM", 22, 27], ["fruits", "ORGANISM_SUBDIVISION", 103, 109], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["human disease", "PROBLEM", 22, 35], ["other pathogenic viruses", "PROBLEM", 56, 80]]], ["This can explain much of the bias of current knowledge toward pathogenic viruses.", [["pathogenic viruses", "PROBLEM", 62, 80]]], ["While it can be argued that in the majority of human history these viruses were the most formative in terms of social, cultural, and behavioral characteristics of humans, it cannot be overlooked that this point may also be similarly biased.", [["human", "ORGANISM", 47, 52], ["humans", "ORGANISM", 163, 169], ["human", "SPECIES", 47, 52], ["humans", "SPECIES", 163, 169], ["human", "SPECIES", 47, 52], ["humans", "SPECIES", 163, 169], ["these viruses", "PROBLEM", 61, 74], ["viruses", "OBSERVATION", 67, 74]]], ["The notion that some viruses could live in relative homeostasis with the organisms they infect is very recent, and such interactions may prove to be a renaissance in the thinking of the importance of different portions of the virome.", [["some viruses", "PROBLEM", 16, 28], ["the organisms", "PROBLEM", 69, 82], ["some", "OBSERVATION_MODIFIER", 16, 20], ["viruses", "OBSERVATION", 21, 28], ["virome", "OBSERVATION", 226, 232]]], ["In fact, some of the most clinically important viruses of the last century were not classically pathogenic, but rather, persist within the host in relative silence for long periods of time.Persistent VirusesThe characteristic strategy of persistent viruses is one of immune evasion and long term interaction with the host.", [["Persistent Viruses", "PROBLEM", 189, 207], ["persistent viruses", "PROBLEM", 238, 256], ["immune evasion", "PROBLEM", 267, 281], ["viruses", "OBSERVATION", 47, 54], ["not classically", "UNCERTAINTY", 80, 95], ["pathogenic", "OBSERVATION", 96, 106], ["Viruses", "OBSERVATION", 200, 207], ["persistent", "OBSERVATION_MODIFIER", 238, 248], ["viruses", "OBSERVATION", 249, 256], ["long term", "OBSERVATION_MODIFIER", 286, 295]]], ["Typically, these viruses exhibit mild and short-lived acute phase infections followed by establishment of a long term niche within a host.", [["infections", "DISEASE", 66, 76], ["these viruses", "PROBLEM", 11, 24], ["mild and short-lived acute phase infections", "PROBLEM", 33, 76], ["a long term niche", "TREATMENT", 106, 123], ["viruses", "OBSERVATION", 17, 24], ["mild", "OBSERVATION_MODIFIER", 33, 37], ["short-lived", "OBSERVATION_MODIFIER", 42, 53], ["acute", "OBSERVATION_MODIFIER", 54, 59], ["phase", "OBSERVATION_MODIFIER", 60, 65], ["infections", "OBSERVATION", 66, 76]]], ["In this niche, the virus may go through stages of dormancy and reactivation, or slow replication for a long period of time [50] .", [["the virus", "PROBLEM", 15, 24], ["dormancy", "PROBLEM", 50, 58], ["reactivation", "PROBLEM", 63, 75], ["virus", "OBSERVATION", 19, 24]]], ["This ability to progress to persistence for months, years, or the entire life of the host clearly delineates these viruses from the pathogenic viruses [51] .", [["these viruses", "PROBLEM", 109, 122], ["the pathogenic viruses", "PROBLEM", 128, 150]]], ["These relationships straddle the border somewhere between symbiosis and pathogenesis, traditionally making it difficult to classify them.", [["pathogenesis", "PROBLEM", 72, 84], ["symbiosis", "OBSERVATION", 58, 67]]], ["In this context, I will typify long-term infections with well-described detriment to the host as persistent, and other longterm interactions as either commensal or mutualistic (see respective sections, below).Persistent VirusesWhile the virus has a safe home during persistence, the question arises that if a virus is not replicating, or is present at very low levels, how is it transmitted to the next host?", [["sections", "ANATOMY", 192, 200], ["infections", "DISEASE", 41, 51], ["long-term infections", "PROBLEM", 31, 51], ["Persistent Viruses", "PROBLEM", 209, 227], ["the virus", "PROBLEM", 233, 242], ["a virus", "PROBLEM", 307, 314], ["Viruses", "OBSERVATION", 220, 227]]], ["The most conventional method by which persistent viruses are transmitted is contact between mucous membranes.", [["mucous membranes", "ANATOMY", 92, 108], ["mucous membranes", "MULTI-TISSUE_STRUCTURE", 92, 108], ["persistent viruses", "PROBLEM", 38, 56], ["persistent", "OBSERVATION_MODIFIER", 38, 48], ["viruses", "OBSERVATION", 49, 56], ["mucous membranes", "OBSERVATION", 92, 108]]], ["The prototypical example is herpes simplex virus 1 (HSV-1) which, after an initial acute or subclinical infection, moves into a sensory neuron and enters a period of latency [52] .", [["sensory neuron", "ANATOMY", 128, 142], ["herpes simplex virus", "DISEASE", 28, 48], ["infection", "DISEASE", 104, 113], ["herpes simplex virus 1", "ORGANISM", 28, 50], ["HSV-1", "ORGANISM", 52, 57], ["herpes simplex virus 1", "SPECIES", 28, 50], ["HSV-1", "SPECIES", 52, 57], ["herpes simplex virus 1", "SPECIES", 28, 50], ["HSV-1", "SPECIES", 52, 57], ["herpes simplex virus", "PROBLEM", 28, 48], ["HSV", "TEST", 52, 55], ["an initial acute or subclinical infection", "PROBLEM", 72, 113], ["acute", "OBSERVATION_MODIFIER", 83, 88], ["subclinical", "OBSERVATION_MODIFIER", 92, 103], ["infection", "OBSERVATION", 104, 113]]], ["Later in life the virus can break latency, move down the neuron to the skin, and begin to replicate, the prototypical presentation of which is a cold sore.", [["neuron", "ANATOMY", 57, 63], ["skin", "ANATOMY", 71, 75], ["sore", "DISEASE", 150, 154], ["skin", "ORGAN", 71, 75], ["the virus", "PROBLEM", 14, 23], ["break latency", "PROBLEM", 28, 41], ["a cold sore", "PROBLEM", 143, 154], ["skin", "ANATOMY", 71, 75]]], ["These lesions release infectious virus that can be transmitted to a new host.", [["lesions", "ANATOMY", 6, 13], ["lesions", "PATHOLOGICAL_FORMATION", 6, 13], ["These lesions release infectious virus", "PROBLEM", 0, 38], ["lesions", "OBSERVATION", 6, 13], ["infectious", "OBSERVATION", 22, 32]]], ["After a short time, the virus returns to latency and the lesion will heal [52] .", [["lesion", "ANATOMY", 57, 63], ["the virus", "PROBLEM", 20, 29], ["latency", "PROBLEM", 41, 48], ["the lesion", "PROBLEM", 53, 63], ["latency", "OBSERVATION_MODIFIER", 41, 48], ["lesion", "OBSERVATION", 57, 63]]], ["The success of this strategy of latency and mild pathogenic effect is made obvious by the fact that approximately two-thirds of the world's population is infected with HSV-1 [53] .Persistent VirusesNon-conventional methods of inoculation have arisen concomitant with certain human tendencies and interactions.", [["HSV-1", "ORGANISM", 168, 173], ["human", "ORGANISM", 275, 280], ["human", "SPECIES", 275, 280], ["HSV-1", "SPECIES", 168, 173], ["human", "SPECIES", 275, 280], ["latency", "PROBLEM", 32, 39], ["mild pathogenic effect", "PROBLEM", 44, 66], ["HSV", "TEST", 168, 171], ["Persistent Viruses", "PROBLEM", 180, 198], ["inoculation", "PROBLEM", 226, 237], ["latency", "OBSERVATION", 32, 39], ["mild", "OBSERVATION_MODIFIER", 44, 48], ["pathogenic", "OBSERVATION", 49, 59], ["infected", "OBSERVATION", 154, 162], ["Viruses", "OBSERVATION", 191, 198]]], ["The most common examples include intravenous drug use, blood transfusion, and organ transplantation, all of which break typically impassable barriers [54] .", [["intravenous", "ANATOMY", 33, 44], ["blood", "ANATOMY", 55, 60], ["organ", "ANATOMY", 78, 83], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 33, 44], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["organ", "ORGAN", 78, 83], ["blood transfusion", "TREATMENT", 55, 72], ["organ transplantation", "TREATMENT", 78, 99], ["organ", "ANATOMY", 78, 83], ["transplantation", "OBSERVATION", 84, 99]]], ["For viruses like hepatitis C virus (HCV) and human immunodeficiency virus (HIV) that circulate in the blood of their host, these disruptions of natural barriers created a heyday for transmission.", [["blood", "ANATOMY", 102, 107], ["hepatitis C virus (HCV) and human immunodeficiency virus (HIV)", "DISEASE", 17, 79], ["viruses like", "ORGANISM", 4, 16], ["hepatitis C virus", "ORGANISM", 17, 34], ["HCV", "ORGANISM", 36, 39], ["human immunodeficiency virus", "ORGANISM", 45, 73], ["HIV", "ORGANISM", 75, 78], ["blood", "ORGANISM_SUBSTANCE", 102, 107], ["hepatitis C virus", "SPECIES", 17, 34], ["human", "SPECIES", 45, 50], ["immunodeficiency virus (HIV", "SPECIES", 51, 78], ["hepatitis C virus", "SPECIES", 17, 34], ["HCV", "SPECIES", 36, 39], ["human immunodeficiency virus", "SPECIES", 45, 73], ["HIV", "SPECIES", 75, 78], ["viruses", "PROBLEM", 4, 11], ["hepatitis C virus", "PROBLEM", 17, 34], ["HCV", "PROBLEM", 36, 39], ["human immunodeficiency virus", "PROBLEM", 45, 73], ["HIV", "PROBLEM", 75, 78], ["hepatitis", "OBSERVATION", 17, 26]]], ["An important development of modern medicine was the implementation of standard blood screening for these and other persistent viruses and has led to a decrease in medically acquired disease [55, 56] .Persistent VirusesBecause of the longevity of asymptomatic interaction, those who are infected with persistent viruses may not know for years.", [["blood", "ANATOMY", 79, 84], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["standard blood screening", "TEST", 70, 94], ["other persistent viruses", "PROBLEM", 109, 133], ["a decrease in medically acquired disease", "PROBLEM", 149, 189], ["asymptomatic interaction", "PROBLEM", 246, 270], ["persistent viruses", "PROBLEM", 300, 318], ["persistent", "OBSERVATION_MODIFIER", 115, 125], ["viruses", "OBSERVATION", 126, 133], ["decrease", "OBSERVATION_MODIFIER", 151, 159], ["longevity", "OBSERVATION_MODIFIER", 233, 242], ["persistent", "OBSERVATION_MODIFIER", 300, 310], ["viruses", "OBSERVATION", 311, 318]]], ["This has consequences not only for transmission to others, but also for eventual progression to disease, as treatment is delayed until symptoms emerge when the damage is often irreparable.", [["disease", "PROBLEM", 96, 103], ["treatment", "TREATMENT", 108, 117], ["symptoms", "PROBLEM", 135, 143], ["the damage", "PROBLEM", 156, 166]]], ["For HIV, the condition of Acquired Immune Deficiency Syndrome (AIDS) weakens the immune system drastically, allowing opportunistic microbes to cause fatal disease [57] .", [["immune system", "ANATOMY", 81, 94], ["Acquired Immune Deficiency Syndrome", "DISEASE", 26, 61], ["AIDS", "DISEASE", 63, 67], ["HIV", "SPECIES", 4, 7], ["HIV", "SPECIES", 4, 7], ["HIV", "PROBLEM", 4, 7], ["Acquired Immune Deficiency Syndrome", "PROBLEM", 26, 61], ["AIDS)", "PROBLEM", 63, 68], ["the immune system", "PROBLEM", 77, 94], ["fatal disease", "PROBLEM", 149, 162], ["Immune Deficiency", "OBSERVATION", 35, 52]]], ["HCV is the most common cause of chronic liver disease, cirrhosis, and liver cancer in the form of Hepatocellular Carcinoma, all caused by years of persistent viral presence [58, 59] .Persistent VirusesThe delayed onset and long-term homeostasis of persistent viruses within their hosts makes them a unique class within the human virome.", [["liver", "ANATOMY", 40, 45], ["liver cancer", "ANATOMY", 70, 82], ["Hepatocellular Carcinoma", "ANATOMY", 98, 122], ["HCV", "DISEASE", 0, 3], ["chronic liver disease", "DISEASE", 32, 53], ["cirrhosis", "DISEASE", 55, 64], ["liver cancer", "DISEASE", 70, 82], ["Hepatocellular Carcinoma", "DISEASE", 98, 122], ["HCV", "ORGANISM", 0, 3], ["liver", "ORGAN", 40, 45], ["liver cancer", "CANCER", 70, 82], ["Hepatocellular Carcinoma", "CANCER", 98, 122], ["human", "ORGANISM", 323, 328], ["virome", "CANCER", 329, 335], ["human", "SPECIES", 323, 328], ["HCV", "SPECIES", 0, 3], ["human", "SPECIES", 323, 328], ["HCV", "PROBLEM", 0, 3], ["chronic liver disease", "PROBLEM", 32, 53], ["cirrhosis", "PROBLEM", 55, 64], ["liver cancer", "PROBLEM", 70, 82], ["Hepatocellular Carcinoma", "PROBLEM", 98, 122], ["persistent viral presence", "PROBLEM", 147, 172], ["Persistent Viruses", "PROBLEM", 183, 201], ["The delayed onset", "PROBLEM", 201, 218], ["long-term homeostasis", "PROBLEM", 223, 244], ["persistent viruses", "PROBLEM", 248, 266], ["most common", "OBSERVATION_MODIFIER", 11, 22], ["chronic", "OBSERVATION_MODIFIER", 32, 39], ["liver", "ANATOMY", 40, 45], ["disease", "OBSERVATION", 46, 53], ["cirrhosis", "OBSERVATION", 55, 64], ["liver", "ANATOMY", 70, 75], ["cancer", "OBSERVATION", 76, 82], ["Hepatocellular", "ANATOMY", 98, 112], ["Carcinoma", "OBSERVATION", 113, 122], ["persistent", "OBSERVATION_MODIFIER", 147, 157], ["viral", "OBSERVATION", 158, 163], ["Viruses", "OBSERVATION", 194, 201], ["delayed", "OBSERVATION_MODIFIER", 205, 212], ["onset", "OBSERVATION_MODIFIER", 213, 218], ["long-term homeostasis", "OBSERVATION_MODIFIER", 223, 244], ["persistent", "OBSERVATION_MODIFIER", 248, 258], ["viruses", "OBSERVATION", 259, 266], ["human virome", "OBSERVATION", 323, 335]]], ["Understanding the biology of these viruses and the development of methods to control and eliminate them is an area of much importance in future medical science.", [["these viruses", "PROBLEM", 29, 42], ["viruses", "OBSERVATION", 35, 42]]], ["Additionally, further characterization of the human virome is likely to uncover more viruses that persistently infect humans [31] , and such discoveries could pave the way for the treatment of diseases of currently unknown etiology.Atypically Pathogenic VirusesAs will be discussed in later sections, not all viruses are pathogenic.", [["sections", "ANATOMY", 291, 299], ["human", "ORGANISM", 46, 51], ["humans", "ORGANISM", 118, 124], ["human", "SPECIES", 46, 51], ["humans", "SPECIES", 118, 124], ["human", "SPECIES", 46, 51], ["humans", "SPECIES", 118, 124], ["further characterization", "TEST", 14, 38], ["the human virome", "PROBLEM", 42, 58], ["diseases", "PROBLEM", 193, 201], ["Atypically Pathogenic VirusesAs", "PROBLEM", 232, 263], ["pathogenic", "PROBLEM", 321, 331], ["diseases", "OBSERVATION", 193, 201]]], ["Herein, I classify viruses that impact host physiology without directly eliciting a disease state as atypically pathogenic viruses.", [["a disease state", "PROBLEM", 82, 97], ["atypically pathogenic viruses", "PROBLEM", 101, 130], ["disease", "OBSERVATION", 84, 91]]], ["For example, some viruses infect humans without ever causing disease while others inhabit and change the composition of the human microbiome without ever infecting human cells.", [["cells", "ANATOMY", 170, 175], ["humans", "ORGANISM", 33, 39], ["human", "ORGANISM", 124, 129], ["human", "ORGANISM", 164, 169], ["cells", "CELL", 170, 175], ["human cells", "CELL_TYPE", 164, 175], ["humans", "SPECIES", 33, 39], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 164, 169], ["humans", "SPECIES", 33, 39], ["human", "SPECIES", 124, 129], ["human", "SPECIES", 164, 169], ["some viruses infect humans", "PROBLEM", 13, 39], ["disease", "PROBLEM", 61, 68], ["infecting human cells", "PROBLEM", 154, 175], ["some", "OBSERVATION_MODIFIER", 13, 17], ["viruses", "OBSERVATION", 18, 25], ["human cells", "OBSERVATION", 164, 175]]], ["Since our immune system can't tell the difference between harmful or benign viral signatures, the mere presence of these viruses harbors potential to cause disease.", [["benign viral signatures", "PROBLEM", 69, 92], ["disease", "PROBLEM", 156, 163], ["benign", "OBSERVATION_MODIFIER", 69, 75], ["viral", "OBSERVATION", 76, 81], ["viruses", "OBSERVATION", 121, 128]]], ["So far, this type of interaction has not been defined as a facet of the virome, but in this section I will review examples from the scientific literature that hint at such scenarios.Atypically Pathogenic VirusesEndogenous retroelements (EREs) represent a unique class of human-colonizing viral material that is resident in the germ line and include endogenous retroviruses (ERVs), retrotransposons, and retrotranscripts [60] .", [["germ line", "ANATOMY", 327, 336], ["human", "ORGANISM", 271, 276], ["germ line", "CELL", 327, 336], ["retroviruses", "GENE_OR_GENE_PRODUCT", 360, 372], ["ERVs", "GENE_OR_GENE_PRODUCT", 374, 378], ["Endogenous retroelements", "DNA", 211, 235], ["EREs", "DNA", 237, 241], ["endogenous retroviruses", "DNA", 349, 372], ["ERVs", "DNA", 374, 378], ["retrotransposons", "DNA", 381, 397], ["human", "SPECIES", 271, 276], ["human", "SPECIES", 271, 276], ["colonizing viral material", "PROBLEM", 277, 302], ["endogenous retroviruses", "PROBLEM", 349, 372], ["virome", "OBSERVATION", 72, 78], ["Pathogenic", "OBSERVATION_MODIFIER", 193, 203], ["Viruses", "OBSERVATION", 204, 211], ["Endogenous retroelements", "OBSERVATION", 211, 235], ["colonizing viral material", "OBSERVATION", 277, 302], ["germ line", "OBSERVATION", 327, 336], ["endogenous retroviruses", "OBSERVATION", 349, 372]]], ["While the general classification of these genetic elements will be defined in this work as mutualistic (see The Mutualistic Virome, below), it is evident from a number of studies that they can sometimes contribute to pathogenesis.", [["pathogenesis", "PROBLEM", 217, 229]]], ["In the autoimmune disease Multiple Sclerosis (MS), human endogenous retrovirus (HERV) syncytin expression is upregulated in lesions and leads to an increase of cellular protein oxidation and destruction of oligodendrocytes [61] .", [["lesions", "ANATOMY", 124, 131], ["cellular", "ANATOMY", 160, 168], ["oligodendrocytes", "ANATOMY", 206, 222], ["autoimmune disease", "DISEASE", 7, 25], ["Multiple Sclerosis", "DISEASE", 26, 44], ["MS", "DISEASE", 46, 48], ["human", "ORGANISM", 51, 56], ["endogenous retrovirus", "ORGANISM", 57, 78], ["HERV", "ORGANISM", 80, 84], ["syncytin", "GENE_OR_GENE_PRODUCT", 86, 94], ["lesions", "PATHOLOGICAL_FORMATION", 124, 131], ["cellular", "CELL", 160, 168], ["syncytin", "PROTEIN", 86, 94], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["the autoimmune disease", "PROBLEM", 3, 25], ["Multiple Sclerosis (MS)", "PROBLEM", 26, 49], ["human endogenous retrovirus (HERV) syncytin expression", "PROBLEM", 51, 105], ["lesions", "PROBLEM", 124, 131], ["an increase of cellular protein oxidation", "PROBLEM", 145, 186], ["destruction of oligodendrocytes", "PROBLEM", 191, 222], ["autoimmune", "OBSERVATION_MODIFIER", 7, 17], ["Multiple", "OBSERVATION_MODIFIER", 26, 34], ["Sclerosis", "OBSERVATION", 35, 44], ["endogenous retrovirus", "OBSERVATION", 57, 78], ["upregulated", "OBSERVATION_MODIFIER", 109, 120], ["lesions", "OBSERVATION", 124, 131], ["increase", "OBSERVATION_MODIFIER", 148, 156], ["cellular protein oxidation", "OBSERVATION", 160, 186]]], ["Another possible autoimmune contribution of EREs is by their engagement of nucleic acid pattern recognition and downstream immune activation during both their RNA and cDNA synthesis [62, 63] .", [["nucleic acid", "CHEMICAL", 75, 87], ["EREs", "DNA", 44, 48], ["autoimmune contribution of EREs", "PROBLEM", 17, 48], ["nucleic acid pattern recognition", "PROBLEM", 75, 107], ["downstream immune activation", "PROBLEM", 112, 140], ["cDNA synthesis", "TEST", 167, 181], ["possible", "UNCERTAINTY", 8, 16], ["autoimmune", "OBSERVATION", 17, 27]]], ["Carcinogenesis may also occur, as exemplified by the Rec protein of HERV-K(HML2), which can facilitate tumorigenesis when expressed in mice [64] .", [["Carcinogenesis", "DISEASE", 0, 14], ["HERV-K", "GENE_OR_GENE_PRODUCT", 68, 74], ["HML2", "GENE_OR_GENE_PRODUCT", 75, 79], ["mice", "ORGANISM", 135, 139], ["Rec protein", "PROTEIN", 53, 64], ["HERV", "DNA", 68, 72], ["HML2", "PROTEIN", 75, 79], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 135, 139]]], ["A final example of deleterious consequences conferred by EREs is their ability to destabilize the genome via insertion, rearrangement, and deletion [65] .", [["genome", "CELLULAR_COMPONENT", 98, 104], ["EREs", "DNA", 57, 61]]], ["Continued exploration is necessary to expand upon these data to elucidate the mechanisms behind the negative impacts of EREs on human health.", [["human", "ORGANISM", 128, 133], ["EREs", "DNA", 120, 124], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133], ["Continued exploration", "TEST", 0, 21], ["these data", "TEST", 50, 60], ["negative", "OBSERVATION", 100, 108]]], ["Bacteriophages (from here, referred to as phages), which are canonically classified as commensals (see The Commensal Virome, below), may also play an atypically negative role.", [["Bacteriophages", "PROBLEM", 0, 14]]], ["While these viruses do not infect human cells, the estimated 10 15 phages present in the human gut [66] and those elsewhere on the body are not likely to be completely benign.", [["cells", "ANATOMY", 40, 45], ["gut", "ANATOMY", 95, 98], ["body", "ANATOMY", 131, 135], ["human", "ORGANISM", 34, 39], ["cells", "CELL", 40, 45], ["human", "ORGANISM", 89, 94], ["gut", "ORGANISM_SUBDIVISION", 95, 98], ["body", "ORGANISM_SUBDIVISION", 131, 135], ["human cells", "CELL_TYPE", 34, 45], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 89, 94], ["viruses", "OBSERVATION", 12, 19], ["body", "ANATOMY", 131, 135], ["not likely to be", "UNCERTAINTY", 140, 156], ["completely", "OBSERVATION_MODIFIER", 157, 167], ["benign", "OBSERVATION", 168, 174]]], ["While it is known that phages can be co-opted for benefit to the host [66] , I postulate that the presence of this amount of genomic and proteinaceous material is unlikely to be immunologically inert.Atypically Pathogenic VirusesAn example of how a phage could affect human health is as an endogenous ligand for immune activation.", [["human", "ORGANISM", 268, 273], ["human", "SPECIES", 268, 273], ["human", "SPECIES", 268, 273], ["genomic and proteinaceous material", "PROBLEM", 125, 159], ["immune activation", "PROBLEM", 312, 329], ["amount", "OBSERVATION_MODIFIER", 115, 121], ["genomic", "OBSERVATION", 125, 132], ["proteinaceous material", "OBSERVATION", 137, 159], ["unlikely to be", "UNCERTAINTY", 163, 177]]], ["It is known that humans harbor antibodies to phage proteins [67] [68] [69] [70] and that phagocytic cells of the immune system can ingest phages [71] , but whether this has any negative impact on health is unknown.", [["phagocytic cells", "ANATOMY", 89, 105], ["immune system", "ANATOMY", 113, 126], ["humans", "ORGANISM", 17, 23], ["phagocytic cells", "CELL", 89, 105], ["antibodies", "PROTEIN", 31, 41], ["phage proteins", "PROTEIN", 45, 59], ["phagocytic cells", "CELL_TYPE", 89, 105], ["humans", "SPECIES", 17, 23], ["humans", "SPECIES", 17, 23], ["phage proteins", "TEST", 45, 59], ["phagocytic cells", "TEST", 89, 105]]], ["Toll-like Receptors (TLRs) -7 and -9 play key roles in the production of autoantibodies, presumably via sensing of nucleic acid containing immune complexes (reviewed in [72] ).", [["nucleic acid", "CHEMICAL", 115, 127], ["Toll-like Receptors (TLRs) -7", "GENE_OR_GENE_PRODUCT", 0, 29], ["-9", "GENE_OR_GENE_PRODUCT", 34, 36], ["nucleic acid", "SIMPLE_CHEMICAL", 115, 127], ["Toll-like Receptors (TLRs) -7 and -9", "PROTEIN", 0, 36], ["autoantibodies", "PROTEIN", 73, 87], ["immune complexes", "PROTEIN", 139, 155], ["autoantibodies", "PROBLEM", 73, 87], ["nucleic acid", "TREATMENT", 115, 127]]], ["These autoantibodies could be derived from any number of endogenous sources, including those of phages.", [["autoantibodies", "PROTEIN", 6, 20], ["These autoantibodies", "PROBLEM", 0, 20], ["endogenous sources", "OBSERVATION", 57, 75]]], ["Interestingly, identifying the particular nucleic acids responsible for this activation in vivo has been challenging, though functional work has vetted this mechanism with immune complexes containing nucleic acids [73, 74] .", [["nucleic acids", "CHEMICAL", 42, 55], ["nucleic acids", "CHEMICAL", 200, 213], ["nucleic acids", "SIMPLE_CHEMICAL", 200, 213], ["immune complexes", "PROTEIN", 172, 188], ["the particular nucleic acids", "PROBLEM", 27, 55], ["nucleic acids", "TEST", 200, 213]]], ["It is possible that B-cell Receptor (BCR)-mediated endocytic or plasmacytoid dendritic cell (pDC) phagocytic internalization of phages could deliver ligands necessary for these responses.", [["B-cell", "ANATOMY", 20, 26], ["plasmacytoid dendritic cell", "ANATOMY", 64, 91], ["pDC", "ANATOMY", 93, 96], ["B-cell Receptor", "GENE_OR_GENE_PRODUCT", 20, 35], ["BCR", "GENE_OR_GENE_PRODUCT", 37, 40], ["plasmacytoid dendritic cell", "CELL", 64, 91], ["pDC", "CELL", 93, 96], ["BCR", "PROTEIN", 37, 40], ["plasmacytoid dendritic cell", "CELL_TYPE", 64, 91], ["pDC", "CELL_TYPE", 93, 96], ["B-cell Receptor (BCR)", "PROBLEM", 20, 41], ["plasmacytoid dendritic cell (pDC) phagocytic internalization of phages", "TREATMENT", 64, 134], ["possible", "UNCERTAINTY", 6, 14], ["plasmacytoid dendritic cell", "OBSERVATION", 64, 91]]], ["In this light, I would argue that correlating phage localization and expression with disease state is a particularly intriguing area of research moving forward.", [["disease state", "PROBLEM", 85, 98]]], ["Such research may also elucidate mechanisms by which specific bacteria (and their viral cargo) are linked to autoimmune, allergic, and pathogenic phenotypes.Atypically Pathogenic VirusesProtozoan parasite-associated viruses have emerged as another source of atypically pathogenic effects in humans [75] .", [["autoimmune, allergic, and pathogenic phenotypes", "DISEASE", 109, 156], ["humans", "ORGANISM", 291, 297], ["humans", "SPECIES", 291, 297], ["humans", "SPECIES", 291, 297], ["specific bacteria", "PROBLEM", 53, 70], ["autoimmune", "PROBLEM", 109, 119], ["allergic", "PROBLEM", 121, 129], ["pathogenic phenotypes", "PROBLEM", 135, 156], ["Pathogenic VirusesProtozoan parasite", "PROBLEM", 168, 204], ["associated viruses", "PROBLEM", 205, 223], ["pathogenic phenotypes", "OBSERVATION", 135, 156], ["Pathogenic", "OBSERVATION_MODIFIER", 168, 178], ["Viruses", "OBSERVATION", 179, 186], ["viruses", "OBSERVATION", 216, 223], ["atypically", "OBSERVATION_MODIFIER", 258, 268], ["pathogenic", "OBSERVATION", 269, 279]]], ["Such interactions are reminiscent of the uses of viruses as agents for forwarding their host's survival in parasitoid wasps and plants (see An Ecological Framework of the Human Virome, above).", [["Human", "ORGANISM", 171, 176], ["Human", "SPECIES", 171, 176], ["viruses", "TREATMENT", 49, 56]]], ["The recognition of the Leishmania-infecting LRV1 virus by human macrophages can promote inflammation, subvert the immune response, and ultimately promote persistence of the parasite [76] .", [["macrophages", "ANATOMY", 64, 75], ["inflammation", "DISEASE", 88, 100], ["Leishmania-infecting", "ORGANISM", 23, 43], ["LRV1 virus", "ORGANISM", 44, 54], ["human", "ORGANISM", 58, 63], ["macrophages", "CELL", 64, 75], ["human macrophages", "CELL_TYPE", 58, 75], ["human", "SPECIES", 58, 63], ["LRV1 virus", "SPECIES", 44, 54], ["human", "SPECIES", 58, 63], ["the Leishmania", "PROBLEM", 19, 33], ["infecting LRV1 virus", "PROBLEM", 34, 54], ["inflammation", "PROBLEM", 88, 100], ["Leishmania", "OBSERVATION", 23, 33], ["inflammation", "OBSERVATION", 88, 100]]], ["Trichomonas vaginalis harbors a Trichomonasvirus that triggers IFN responses via TLR-3, leading to inflammatory sequelae [77] .", [["Trichomonas vaginalis", "DISEASE", 0, 21], ["Trichomonas vaginalis", "ORGANISM", 0, 21], ["IFN", "GENE_OR_GENE_PRODUCT", 63, 66], ["TLR-3", "GENE_OR_GENE_PRODUCT", 81, 86], ["IFN", "PROTEIN", 63, 66], ["TLR-3", "PROTEIN", 81, 86], ["Trichomonas vaginalis", "SPECIES", 0, 21], ["Trichomonas vaginalis", "SPECIES", 0, 21], ["Trichomonas vaginalis", "PROBLEM", 0, 21], ["TLR", "TEST", 81, 84], ["inflammatory sequelae", "PROBLEM", 99, 120], ["inflammatory", "OBSERVATION_MODIFIER", 99, 111]]], ["At present, there is insufficient data as to whether these are evolutionarily adapted mechanisms meant to perturb host immunity to benefit the parasite, but the extensive literature of such interaction in insects and plants makes this a tantalizing conjecture.", [["the parasite", "PROBLEM", 139, 151]]], ["Additional characterization should explore the nature of the interactions of protozoan viruses with humans.Atypically Pathogenic VirusesWhile all the above postulates are conjecture on the limited knowledge base regarding atypically pathogenic virus-host interactions, it must be noted that these are certainly not overlying principles.", [["protozoan viruses", "DISEASE", 77, 94], ["humans", "ORGANISM", 100, 106], ["humans", "SPECIES", 100, 106], ["humans", "SPECIES", 100, 106], ["Additional characterization", "TEST", 0, 27], ["protozoan viruses", "PROBLEM", 77, 94], ["Atypically Pathogenic Viruses", "PROBLEM", 107, 136], ["atypically pathogenic virus", "PROBLEM", 222, 249], ["Pathogenic", "OBSERVATION_MODIFIER", 118, 128], ["Viruses", "OBSERVATION", 129, 136], ["atypically", "OBSERVATION_MODIFIER", 222, 232], ["pathogenic", "OBSERVATION_MODIFIER", 233, 243], ["virus", "OBSERVATION", 244, 249]]], ["Associated pathologies likely require particular genetic dispositions and/or external stressor states.", [["Associated pathologies", "PROBLEM", 0, 22], ["external stressor states", "PROBLEM", 77, 101], ["pathologies", "OBSERVATION", 11, 22]]], ["It cannot be understated, however, that a better understanding of the viruses that typically inhabit humans will likely lead to a concomitant rise in the cases of viruses identified as atypically pathogenic.THE COMMENSAL VIROMEThe term commensal was originally coined to describe an organism that benefitted from being on or in a host but did not have any direct detriment or benefit for the host [78] .", [["humans", "ORGANISM", 101, 107], ["humans", "SPECIES", 101, 107], ["humans", "SPECIES", 101, 107], ["the viruses", "PROBLEM", 66, 77], ["a concomitant rise", "PROBLEM", 128, 146], ["viruses", "PROBLEM", 163, 170], ["an organism", "PROBLEM", 280, 291], ["viruses", "OBSERVATION", 70, 77], ["viruses", "OBSERVATION", 163, 170], ["atypically", "OBSERVATION_MODIFIER", 185, 195], ["pathogenic", "OBSERVATION_MODIFIER", 196, 206], ["COMMENSAL VIROME", "OBSERVATION", 211, 227]]], ["These organisms may be more accurately defined as atypically pathogenic or mutualistic (see sections above and below, respectively) if these effects are common or stable, but in general, scientists have followed the practice of innocence until proven guilty.", [["sections", "ANATOMY", 92, 100], ["stable", "OBSERVATION_MODIFIER", 163, 169]]], ["However, it is likely that many commensals exist that either rarely or never have effects on the host.", [["is likely", "UNCERTAINTY", 12, 21]]], ["While at the local level some commensal viruses may have detrimental effects on individual cells, many eukaryotic and prokaryotic viruses are associated with healthy human tissues [80] [81] [82] [83] [84] [85] [86] [87] .THE COMMENSAL VIROMEThe prototypical examples of commensal viruses are phages that infect bacteria [88] .", [["cells", "ANATOMY", 91, 96], ["tissues", "ANATOMY", 172, 179], ["[80] [81] [82] [83] [84] [85] [86]", "CHEMICAL", 180, 214], ["cells", "CELL", 91, 96], ["prokaryotic viruses", "ORGANISM", 118, 137], ["human", "ORGANISM", 166, 171], ["tissues", "TISSUE", 172, 179], ["[82] [83] [84] [85] [86] [87]", "SIMPLE_CHEMICAL", 190, 219], ["commensal viruses", "ORGANISM", 270, 287], ["human", "SPECIES", 166, 171], ["human", "SPECIES", 166, 171], ["some commensal viruses", "PROBLEM", 25, 47], ["detrimental effects on individual cells", "PROBLEM", 57, 96], ["many eukaryotic and prokaryotic viruses", "PROBLEM", 98, 137], ["commensal viruses", "PROBLEM", 270, 287], ["infect bacteria", "PROBLEM", 304, 319], ["commensal", "OBSERVATION_MODIFIER", 30, 39], ["viruses", "OBSERVATION", 40, 47], ["prokaryotic viruses", "OBSERVATION", 118, 137], ["COMMENSAL VIROME", "OBSERVATION", 225, 241], ["commensal viruses", "OBSERVATION", 270, 287]]], ["No phages are known to infect human cells and therefore their presence may be primarily innocuous.", [["cells", "ANATOMY", 36, 41], ["human", "ORGANISM", 30, 35], ["cells", "CELL", 36, 41], ["human cells", "CELL_TYPE", 30, 41], ["human", "SPECIES", 30, 35], ["human", "SPECIES", 30, 35], ["phages", "PROBLEM", 3, 9], ["phages", "OBSERVATION", 3, 9]]], ["The effect of phages on the composition of the microbiome, in that they may kill or inhibit growth of some bacteria, could be considered a possible detriment or benefit depending on the situation, albeit indirect.", [["phages", "TREATMENT", 14, 20], ["some bacteria", "PROBLEM", 102, 115]]], ["In fact, the targeted utilization of phages to eliminate unwanted bacterial pathogens (phage therapy) was introduced in the early 1900s and has many potential benefits including, but not limited to, low toxicity, treatment of antibiotic resistant infections, and rapid discovery/generation [89] .", [["toxicity", "DISEASE", 203, 211], ["infections", "DISEASE", 247, 257], ["phages", "TREATMENT", 37, 43], ["unwanted bacterial pathogens", "PROBLEM", 57, 85], ["phage therapy", "TREATMENT", 87, 100], ["low toxicity", "PROBLEM", 199, 211], ["antibiotic resistant infections", "PROBLEM", 226, 257]]], ["However, concern over unknown health implications and the rise of antibiotics stalled the field, though a renaissance has been building since the 1990s [90] .", [["antibiotics", "TREATMENT", 66, 77]]], ["Many different levels of this application exist, such as treatment of animals and plants with phages to ensure better yield as well as to kill human pathogens that may grow on or in these food sources [91] .", [["human", "ORGANISM", 143, 148], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 143, 148], ["this application", "TREATMENT", 25, 41], ["treatment of animals and plants with phages", "TREATMENT", 57, 100], ["human pathogens", "PROBLEM", 143, 158]]], ["Phages are also known to be able to stimulate and/or modulate immune action in humans at multiple levels including antibody generation, development of adaptive immune cells, and innate pattern recognition (reviewed in [88] ), and the possible applications of phages in these contexts are intriguing.", [["immune cells", "ANATOMY", 160, 172], ["humans", "ORGANISM", 79, 85], ["immune cells", "CELL", 160, 172], ["adaptive immune cells", "CELL_TYPE", 151, 172], ["humans", "SPECIES", 79, 85], ["humans", "SPECIES", 79, 85], ["antibody generation", "TREATMENT", 115, 134], ["adaptive immune cells", "TREATMENT", 151, 172], ["phages", "TREATMENT", 259, 265], ["immune cells", "OBSERVATION", 160, 172]]], ["In the future, sections of this group may be able to re-classified as atypically pathogenic or mutualistic if their presence can be linked to roles in specific disease phenotypes, but for now they are most appropriately classified as commensal.THE COMMENSAL VIROMEViruses can also infect fungal members of the human microbiome (mycoviruses) and protozoa of the human macrobiome [77, [92] [93] [94] [95] [96] [97] [98] .", [["sections", "ANATOMY", 15, 23], ["mycoviruses", "ANATOMY", 328, 339], ["human", "ORGANISM", 310, 315], ["mycoviruses", "CANCER", 328, 339], ["human", "ORGANISM", 361, 366], ["[92] [93] [94] [95] [96] [97] [98]", "SIMPLE_CHEMICAL", 383, 417], ["human", "SPECIES", 310, 315], ["human", "SPECIES", 361, 366], ["human", "SPECIES", 310, 315], ["human", "SPECIES", 361, 366], ["specific disease phenotypes", "PROBLEM", 151, 178]]], ["While much less is known about these particular types of viruses, similar conjectures have been made as for phages in regard to their potential as both atypical pathogens and mutualists.", [["viruses", "PROBLEM", 57, 64], ["viruses", "OBSERVATION", 57, 64]]], ["Direct effects on human health are likely rare, though they have been observed for protozoan parasite viruses (see Atypically Pathogenic Viruses, above).", [["protozoan parasite viruses", "DISEASE", 83, 109], ["human", "ORGANISM", 18, 23], ["protozoan parasite viruses", "ORGANISM", 83, 109], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23], ["protozoan parasite viruses", "PROBLEM", 83, 109]]], ["The presence of these viruses may ultimately have an indirect effect on human health of unknown consequence.", [["human", "ORGANISM", 72, 77], ["human", "SPECIES", 72, 77], ["human", "SPECIES", 72, 77], ["these viruses", "PROBLEM", 16, 29], ["viruses", "OBSERVATION", 22, 29]]], ["Investigation of the breadth and impact of such viruses is an interesting and important area of future research, particularly for the benefit of the immunocompromised and those in developing countries who are most affected by diseases caused by fungi and protozoa.", [["diseases caused by fungi and protozoa", "DISEASE", 226, 263], ["such viruses", "PROBLEM", 43, 55], ["the immunocompromised", "PROBLEM", 145, 166], ["fungi", "PROBLEM", 245, 250], ["protozoa", "PROBLEM", 255, 263], ["breadth", "OBSERVATION_MODIFIER", 21, 28], ["viruses", "OBSERVATION", 48, 55], ["immunocompromised", "OBSERVATION", 149, 166]]], ["There is also an abundance of prototypically planttropic viruses found in the human gut [99] .", [["gut", "ANATOMY", 84, 87], ["human", "ORGANISM", 78, 83], ["gut", "ORGANISM_SUBDIVISION", 84, 87], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["prototypically planttropic viruses", "PROBLEM", 30, 64], ["abundance", "OBSERVATION_MODIFIER", 17, 26], ["prototypically planttropic viruses", "OBSERVATION", 30, 64], ["human gut", "ANATOMY", 78, 87]]], ["It is likely these viruses have been acquired via agricultural crops in the diet and the effect of their presence is unknown, but assembly of plant viral particles in Escherichia coli has been exhibited, so it is possible that these viruses may interact with gut bacteria [100] .THE COMMENSAL VIROMESome commensal viruses can infect human cells and use the human as a vessel for transmission.", [["cells", "ANATOMY", 339, 344], ["vessel", "ANATOMY", 368, 374], ["Escherichia coli", "ORGANISM", 167, 183], ["gut", "ORGANISM_SUBDIVISION", 259, 262], ["VIROMESome commensal viruses", "ORGANISM", 293, 321], ["human", "ORGANISM", 333, 338], ["cells", "CELL", 339, 344], ["human", "ORGANISM", 357, 362], ["vessel", "MULTI-TISSUE_STRUCTURE", 368, 374], ["human cells", "CELL_TYPE", 333, 344], ["Escherichia coli", "SPECIES", 167, 183], ["human", "SPECIES", 333, 338], ["human", "SPECIES", 357, 362], ["Escherichia coli", "SPECIES", 167, 183], ["human", "SPECIES", 333, 338], ["human", "SPECIES", 357, 362], ["these viruses", "PROBLEM", 13, 26], ["plant viral particles", "PROBLEM", 142, 163], ["Escherichia coli", "PROBLEM", 167, 183], ["these viruses", "PROBLEM", 227, 240], ["gut bacteria", "PROBLEM", 259, 271], ["COMMENSAL VIROMESome commensal viruses", "TREATMENT", 283, 321], ["viruses", "OBSERVATION", 19, 26], ["viral particles", "OBSERVATION", 148, 163], ["Escherichia coli", "OBSERVATION", 167, 183], ["viruses", "OBSERVATION", 233, 240], ["vessel", "ANATOMY", 368, 374]]], ["These viruses establish asymptomatic infections that do not result in a change in host health or behavior.", [["infections", "DISEASE", 37, 47], ["These viruses", "PROBLEM", 0, 13], ["asymptomatic infections", "PROBLEM", 24, 47], ["asymptomatic", "OBSERVATION_MODIFIER", 24, 36], ["infections", "OBSERVATION", 37, 47]]], ["This represents a veritable antithesis to the strategy of parasitic human viruses (see The Parasitic Virome, above), wherein viruses have prioritized trade-offs other than pathogenicity to ensure their transmission to a new host.", [["parasitic human viruses", "DISEASE", 58, 81], ["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human viruses", "SPECIES", 68, 81], ["a veritable antithesis", "PROBLEM", 16, 38], ["parasitic human viruses", "PROBLEM", 58, 81], ["wherein viruses", "PROBLEM", 117, 132], ["pathogenicity", "PROBLEM", 172, 185], ["parasitic human viruses", "OBSERVATION", 58, 81]]], ["The most well documented examples of asymptomatic infection of humans by commensal viruses are the rhinoviruses and other infections of the nasopharynx and upper respiratory tract [80, [101] [102] [103] [104] .", [["nasopharynx", "ANATOMY", 140, 151], ["upper respiratory tract", "ANATOMY", 156, 179], ["infection", "DISEASE", 50, 59], ["rhinoviruses", "DISEASE", 99, 111], ["infections of the nasopharynx", "DISEASE", 122, 151], ["humans", "ORGANISM", 63, 69], ["commensal viruses", "ORGANISM", 73, 90], ["rhinoviruses", "ORGANISM", 99, 111], ["nasopharynx", "ORGAN", 140, 151], ["upper respiratory", "ORGANISM_SUBDIVISION", 156, 173], ["tract", "ORGANISM_SUBDIVISION", 174, 179], ["humans", "SPECIES", 63, 69], ["humans", "SPECIES", 63, 69], ["asymptomatic infection of humans", "PROBLEM", 37, 69], ["commensal viruses", "PROBLEM", 73, 90], ["the rhinoviruses", "PROBLEM", 95, 111], ["other infections of the nasopharynx", "PROBLEM", 116, 151], ["upper respiratory tract", "TEST", 156, 179], ["asymptomatic", "OBSERVATION_MODIFIER", 37, 49], ["infection", "OBSERVATION", 50, 59], ["commensal viruses", "OBSERVATION", 73, 90], ["rhinoviruses", "OBSERVATION", 99, 111], ["nasopharynx", "ANATOMY", 140, 151], ["upper", "ANATOMY_MODIFIER", 156, 161], ["respiratory tract", "ANATOMY", 162, 179]]], ["Many of the Human Papilloma Viruses (HPVs) interact with human cells as an asymptomatic infection of mucous membranes or skin [105] .", [["cells", "ANATOMY", 63, 68], ["mucous membranes", "ANATOMY", 101, 117], ["skin", "ANATOMY", 121, 125], ["Human Papilloma Viruses", "DISEASE", 12, 35], ["infection", "DISEASE", 88, 97], ["Human Papilloma Viruses", "ORGANISM", 12, 35], ["HPVs", "ORGANISM", 37, 41], ["human", "ORGANISM", 57, 62], ["cells", "CELL", 63, 68], ["mucous membranes", "CELLULAR_COMPONENT", 101, 117], ["skin", "ORGAN", 121, 125], ["human cells", "CELL_TYPE", 57, 68], ["Human", "SPECIES", 12, 17], ["human", "SPECIES", 57, 62], ["Human Papilloma Viruses", "SPECIES", 12, 35], ["human", "SPECIES", 57, 62], ["the Human Papilloma Viruses", "PROBLEM", 8, 35], ["human cells", "TREATMENT", 57, 68], ["an asymptomatic infection of mucous membranes", "PROBLEM", 72, 117], ["Papilloma Viruses", "OBSERVATION", 18, 35], ["asymptomatic", "OBSERVATION_MODIFIER", 75, 87], ["infection", "OBSERVATION", 88, 97], ["mucous membranes", "ANATOMY", 101, 117], ["skin", "ANATOMY", 121, 125]]], ["Anelloviruses are also well described human commensals [106] [107] [108] [109] [110] .", [["Anelloviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["human", "ORGANISM", 38, 43], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43], ["Anelloviruses", "TREATMENT", 0, 13]]], ["While immune detection of non-human tropic commensal viruses is avoided by physical separation, the human-tropic commensal viruses assuredly engage with host innate and adaptive immune responses, and so must avoid or subvert these mechanisms to maintain their immunological silence.", [["non-human tropic commensal viruses", "ORGANISM", 26, 60], ["human", "ORGANISM", 100, 105], ["tropic commensal viruses", "ORGANISM", 106, 130], ["human", "SPECIES", 100, 105], ["human", "SPECIES", 100, 105], ["non-human tropic commensal viruses", "PROBLEM", 26, 60], ["the human-tropic commensal viruses", "TREATMENT", 96, 130]]], ["Description of the viral techniques enabling this evasion is an important direction for future research on these viruses, as this may point to novel avenues of therapeutic intervention for suppression or activation of immune responses.THE COMMENSAL VIROMEWhile commensal viruses do not have any direct effect on human health during homeostatic equilibrium, perturbation of homeostasis may cause them to contribute to pathogenesis (see Atypically Pathogenic Viruses, above).", [["human", "ORGANISM", 312, 317], ["human", "SPECIES", 312, 317], ["human", "SPECIES", 312, 317], ["the viral techniques", "TREATMENT", 15, 35], ["these viruses", "TREATMENT", 107, 120], ["therapeutic intervention", "TREATMENT", 160, 184], ["immune responses", "PROBLEM", 218, 234], ["pathogenesis", "PROBLEM", 417, 429], ["viruses", "OBSERVATION", 271, 278]]], ["Contrarily, the presence of viruses from the final major group of the human virome, mutualistic viruses, exhibit positive effects on host health via an assortment of mechanisms.THE MUTUALISTIC VIROMEPerhaps the most underappreciated portion of the virome are those viruses that have a positive health benefit for humans.", [["human", "ORGANISM", 70, 75], ["virome", "GENE_OR_GENE_PRODUCT", 248, 254], ["humans", "ORGANISM", 313, 319], ["human", "SPECIES", 70, 75], ["humans", "SPECIES", 313, 319], ["human", "SPECIES", 70, 75], ["humans", "SPECIES", 313, 319], ["viruses", "PROBLEM", 28, 35], ["the human virome", "PROBLEM", 66, 82], ["mutualistic viruses", "PROBLEM", 84, 103], ["viruses", "OBSERVATION", 28, 35], ["human virome", "OBSERVATION", 70, 82], ["positive", "OBSERVATION_MODIFIER", 113, 121]]], ["It is reasonable to assume that it may be beneficial for a virus to encourage and aid in its host's health to facilitate a longer lasting and amenable environment for survival.", [["a virus", "PROBLEM", 57, 64]]], ["But this is a bit counterintuitive considering that above I discussed that viruses are intrinsically parasitic.", [["a bit counterintuitive", "PROBLEM", 12, 34], ["viruses", "PROBLEM", 75, 82], ["viruses", "OBSERVATION", 75, 82], ["parasitic", "OBSERVATION", 101, 110]]], ["This can be rationalized with the assertion that nearly all mutualistic interactions were probably at some point a form of parasitism, then passed through a commensal stage, and finally adjusted to mutualistic harmony through co-evolution.", [["parasitism", "PROBLEM", 123, 133], ["parasitism", "OBSERVATION", 123, 133]]], ["This stipulation is based on the reasoning that the amount of evolutionary change necessitated in the virus and/or the host to switch interaction types requires significant adaptation and thus is more likely to proceed stepwise [112] .", [["evolutionary change", "PROBLEM", 62, 81], ["the virus", "PROBLEM", 98, 107], ["amount", "OBSERVATION_MODIFIER", 52, 58], ["evolutionary change", "OBSERVATION", 62, 81]]], ["A relationship must become sufficiently non-pathogenic to allow interaction without rejection as well as develop benefit for both sides, and an intermediate state seems a logical platform for this.", [["rejection", "PROBLEM", 84, 93]]], ["Indeed, this postulation seems bolstered by the spectrum of mutualistic relationships that exist, spanning obligate to conditional mutualistic benefits [18] .THE MUTUALISTIC VIROMEA classic non-viral example that illustrates this point is the integration of the mitochondrion into the cells of ancient prokaryotes or eukaryotes.", [["mitochondrion", "ANATOMY", 262, 275], ["cells", "ANATOMY", 285, 290], ["mitochondrion", "CELLULAR_COMPONENT", 262, 275], ["cells", "CELL", 285, 290]]], ["This kind of relationship is considered symbiogenic, meaning that once separate organisms have now fused into a distinct new species [18] .", [["symbiogenic", "PROBLEM", 40, 51], ["a distinct new species", "PROBLEM", 110, 132], ["distinct", "OBSERVATION_MODIFIER", 112, 120], ["new", "OBSERVATION_MODIFIER", 121, 124]]], ["Either by phagocytosis or infection, an endosymbiosis was established in which the mitochondrial bacterial progenitor supplied some benefit to its host.", [["mitochondrial", "ANATOMY", 83, 96], ["progenitor", "ANATOMY", 107, 117], ["infection", "DISEASE", 26, 35], ["mitochondrial", "CELLULAR_COMPONENT", 83, 96], ["mitochondrial bacterial progenitor", "CELL_TYPE", 83, 117], ["phagocytosis", "PROBLEM", 10, 22], ["infection", "PROBLEM", 26, 35], ["an endosymbiosis", "PROBLEM", 37, 53], ["the mitochondrial bacterial progenitor", "PROBLEM", 79, 117], ["phagocytosis", "OBSERVATION", 10, 22], ["infection", "OBSERVATION", 26, 35], ["endosymbiosis", "OBSERVATION", 40, 53], ["bacterial progenitor", "OBSERVATION", 97, 117]]], ["Millions of years later, mitochondria are part of all eukaryotic organisms with functions spanning energy production, innate immunity, and membrane potential, to name a few [113, 114] .THE MUTUALISTIC VIROMEIt is now appreciated from data on the microbiome that it would be to the host's benefit if the power of the genetic information in and around them could be harnessed as an evolutionary (and medical) tool for self-betterment [115] [116] [117] .", [["mitochondria", "ANATOMY", 25, 37], ["membrane", "ANATOMY", 139, 147], ["mitochondria", "CELLULAR_COMPONENT", 25, 37], ["membrane", "CELLULAR_COMPONENT", 139, 147], ["mitochondria", "PROBLEM", 25, 37]]], ["This could occur in a number of ways, either through encouraging colonization by beneficial microbes or even by integrating the genetic material of these microbes into the human genome.", [["human", "ORGANISM", 172, 177], ["human genome", "DNA", 172, 184], ["human", "SPECIES", 172, 177], ["human", "SPECIES", 172, 177], ["human genome", "OBSERVATION", 172, 184]]], ["A small body of literature characterizing virus-human mutualism has given a glimpse into this facet of the virome.", [["human", "ORGANISM", 48, 53], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53], ["A small body of literature characterizing virus-human mutualism", "PROBLEM", 0, 63], ["small body", "OBSERVATION_MODIFIER", 2, 12], ["virus", "OBSERVATION", 42, 47], ["human mutualism", "OBSERVATION", 48, 63], ["virome", "OBSERVATION", 107, 113]]], ["In the next sections, I will review two levels of symbiotic relationships and discuss important gaps in knowledge important for the understanding and possible utilization of these interactions for human health.Primary Symbiotic VirusesSymbiotic viruses that are transmitted vertically from parent to child in the germ line are considered primary symbionts [118] .", [["germ line", "ANATOMY", 313, 322], ["human", "ORGANISM", 197, 202], ["Symbiotic VirusesSymbiotic viruses", "ORGANISM", 218, 252], ["germ line", "CELL", 313, 322], ["human", "SPECIES", 197, 202], ["human", "SPECIES", 197, 202], ["Primary Symbiotic VirusesSymbiotic viruses", "PROBLEM", 210, 252], ["Symbiotic", "OBSERVATION_MODIFIER", 218, 227], ["VirusesSymbiotic viruses", "OBSERVATION", 228, 252], ["germ line", "OBSERVATION", 313, 322]]], ["The most obvious example is the EREs that have integrated themselves into human genomes at many points throughout millions of years of evolution.", [["human", "ORGANISM", 74, 79], ["EREs", "DNA", 32, 36], ["human genomes", "DNA", 74, 87], ["human", "SPECIES", 74, 79], ["human", "SPECIES", 74, 79], ["human genomes", "OBSERVATION", 74, 87]]], ["While some have been inactivated by recombination, deletions, and random mutations, many still appear to be expressed [65] .", [["random mutations", "PROBLEM", 66, 82]]], ["It is also obvious the control of these elements is an important challenge for the host, as many strategies have evolved to control replication and reinfection of inserted EREs [120, 121] .", [["EREs", "DNA", 172, 176]]], ["To date, the role of most EREs in the human genome is unknown, but a few human and mammalian examples indicate that their presence confers a number of benefits.Primary Symbiotic VirusesSome of the most important effects of ERE colonization come in the form of genomic diversity and plasticity.", [["human", "ORGANISM", 38, 43], ["human", "ORGANISM", 73, 78], ["ERE", "GENE_OR_GENE_PRODUCT", 223, 226], ["EREs", "DNA", 26, 30], ["human genome", "DNA", 38, 50], ["ERE", "DNA", 223, 226], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 73, 78], ["ERE colonization", "TREATMENT", 223, 239], ["Symbiotic VirusesSome", "OBSERVATION", 168, 189], ["most important", "OBSERVATION_MODIFIER", 197, 211], ["colonization", "OBSERVATION", 227, 239], ["genomic diversity", "OBSERVATION", 260, 277]]], ["EREs can not only insert new genetic material, including protein coding genes, but also play roles in genetic mobility and control.", [["EREs", "DNA", 0, 4], ["protein coding genes", "DNA", 57, 77]]], ["The recombinatorial ability of EREs is conferred upon insertion and has facilitated recombination and duplication of large swathes of genomic material [122, 123] .", [["EREs", "DNA", 31, 35], ["insertion", "TREATMENT", 54, 63], ["duplication of large swathes of genomic material", "PROBLEM", 102, 150], ["large", "OBSERVATION_MODIFIER", 117, 122]]], ["Where an ERE inserts itself can be an important factor in how it affects the genome, as insertion into a protein coding gene could be innocuous or catastrophic.", [["genome", "CELLULAR_COMPONENT", 77, 83], ["ERE inserts", "DNA", 9, 20], ["protein coding gene", "DNA", 105, 124], ["an ERE inserts", "TREATMENT", 6, 20], ["a protein coding gene", "TREATMENT", 103, 124], ["catastrophic", "PROBLEM", 147, 159], ["catastrophic", "OBSERVATION_MODIFIER", 147, 159]]], ["Alternatively, insertion in or near promotion and regulatory elements can result in changes in transcriptional control [124] , as can the native regulatory sequences in the EREs themselves [125, 126] .", [["regulatory elements", "DNA", 50, 69], ["native regulatory sequences", "DNA", 138, 165], ["EREs", "DNA", 173, 177]]], ["Of course, all of these benefits can have similarly damaging consequences, as destabilization of the genome or particular genes could have profound negative effects on the host (see Atypically Pathogenic Viruses, above).", [["genome", "CELLULAR_COMPONENT", 101, 107]]], ["However, natural selection dictates such effects will not successfully continue in the host lineage.Primary Symbiotic VirusesEREs also have important immunologic and developmental roles.", [["host lineage", "CELL", 87, 99], ["VirusesEREs", "GENE_OR_GENE_PRODUCT", 118, 129], ["host lineage", "CELL_TYPE", 87, 99], ["natural selection", "TREATMENT", 9, 26], ["host lineage", "OBSERVATION", 87, 99], ["Symbiotic VirusesEREs", "OBSERVATION", 108, 129]]], ["Building off of the transcriptional control effects mentioned in the last paragraph, EREs appear to have a role in gene upregulation via pattern recognition during the initiation of adaptive immune responses [127, 128] .", [["EREs", "DNA", 85, 89], ["the transcriptional control effects", "TREATMENT", 16, 51]]], ["Adaptive responses to EREs can also play a role in restricting viruses by neutralizing incoming exogenous virus via antibody development against ERE surface glycoprotein antigens [129] .", [["ERE surface glycoprotein antigens", "GENE_OR_GENE_PRODUCT", 145, 178], ["EREs", "DNA", 22, 26], ["ERE surface glycoprotein antigens", "PROTEIN", 145, 178], ["restricting viruses", "PROBLEM", 51, 70], ["neutralizing incoming exogenous virus", "TREATMENT", 74, 111], ["ERE surface glycoprotein antigens", "TEST", 145, 178]]], ["Examples from mice also indicate that the expression of the ERV glycoprotein env can competitively bind surface receptors important for exogenous virus entry and that a short product of an ERV gag gene can inhibit the nuclear translocation of incoming capsids.", [["surface", "ANATOMY", 104, 111], ["nuclear", "ANATOMY", 218, 225], ["mice", "ORGANISM", 14, 18], ["ERV", "GENE_OR_GENE_PRODUCT", 60, 63], ["env", "GENE_OR_GENE_PRODUCT", 77, 80], ["ERV", "GENE_OR_GENE_PRODUCT", 189, 192], ["gag", "GENE_OR_GENE_PRODUCT", 193, 196], ["nuclear", "CELLULAR_COMPONENT", 218, 225], ["capsids", "CELLULAR_COMPONENT", 252, 259], ["ERV glycoprotein env", "DNA", 60, 80], ["surface receptors", "PROTEIN", 104, 121], ["ERV gag gene", "DNA", 189, 201], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["the ERV glycoprotein env", "TREATMENT", 56, 80], ["exogenous virus entry", "PROBLEM", 136, 157], ["an ERV gag gene", "TREATMENT", 186, 201]]], ["Developmentally, the acquisition of ERV syncytins has been a critical step in the evolution of placentation in humans [27, 132, 133] .", [["ERV", "ORGANISM", 36, 39], ["syncytins", "GENE_OR_GENE_PRODUCT", 40, 49], ["humans", "ORGANISM", 111, 117], ["ERV syncytins", "DNA", 36, 49], ["humans", "SPECIES", 111, 117], ["humans", "SPECIES", 111, 117], ["ERV syncytins", "TREATMENT", 36, 49]]], ["The presence of retroviral nucleic acids in human cells also suggests that ERE reverse transcription may be able to activate host innate immunity [62] .Primary Symbiotic VirusesWhether humans can harness the beneficial properties of EREs is of much scientific import.", [["cells", "ANATOMY", 50, 55], ["nucleic acids", "CHEMICAL", 27, 40], ["retroviral", "ORGANISM", 16, 26], ["human", "ORGANISM", 44, 49], ["cells", "CELL", 50, 55], ["ERE", "GENE_OR_GENE_PRODUCT", 75, 78], ["humans", "ORGANISM", 185, 191], ["human cells", "CELL_TYPE", 44, 55], ["ERE", "DNA", 75, 78], ["EREs", "DNA", 233, 237], ["human", "SPECIES", 44, 49], ["humans", "SPECIES", 185, 191], ["human", "SPECIES", 44, 49], ["humans", "SPECIES", 185, 191], ["retroviral nucleic acids in human cells", "PROBLEM", 16, 55], ["ERE reverse transcription", "TREATMENT", 75, 100], ["retroviral nucleic acids", "OBSERVATION", 16, 40]]], ["For years it has been debated whether gene therapy using retroviral vectors for insertion of genes into an individual would be of more help than harm.", [["retroviral", "ORGANISM", 57, 67], ["gene therapy", "TREATMENT", 38, 50], ["retroviral vectors", "TREATMENT", 57, 75], ["insertion of genes", "TREATMENT", 80, 98]]], ["Overall the utility of such methods have been tempered by the observed oncogenic potential of such therapies [134] .", [["such therapies", "TREATMENT", 94, 108]]], ["Recently, studies with retroviral-modified Chimeric Antigen Receptor T-cells (CAR Tcells) have shown impressive application for the activation of adaptive immunity against cancers, though there have also been morbid failures in this field [135] .", [["T-cells", "ANATOMY", 69, 76], ["cancers", "ANATOMY", 172, 179], ["cancers", "DISEASE", 172, 179], ["retroviral", "ORGANISM", 23, 33], ["CAR Tcells", "CELL", 78, 88], ["cancers", "CANCER", 172, 179], ["Chimeric Antigen Receptor T-cells", "CELL_LINE", 43, 76], ["CAR Tcells", "CELL_LINE", 78, 88], ["studies", "TEST", 10, 17], ["retroviral-modified Chimeric Antigen Receptor T-cells", "TREATMENT", 23, 76], ["cancers", "PROBLEM", 172, 179], ["morbid failures", "PROBLEM", 209, 224], ["impressive", "OBSERVATION_MODIFIER", 101, 111], ["morbid", "OBSERVATION_MODIFIER", 209, 215], ["failures", "OBSERVATION", 216, 224]]], ["The application of retroviral-modified CAR T-cells could presumably be expanded to infectious disease as well.", [["CAR T-cells", "ANATOMY", 39, 50], ["infectious disease", "DISEASE", 83, 101], ["retroviral", "ORGANISM", 19, 29], ["CAR T-cells", "CELL", 39, 50], ["retroviral-modified CAR T-cells", "CELL_LINE", 19, 50], ["retroviral-modified CAR T-cells", "TREATMENT", 19, 50], ["infectious disease", "PROBLEM", 83, 101], ["retroviral", "ANATOMY", 19, 29], ["presumably be", "UNCERTAINTY", 57, 70], ["infectious", "OBSERVATION", 83, 93]]], ["These progressive areas of medical science will continue to be explored and debated well into the future, and better understanding the relationship of EREs with their human hosts will be indispensable for these studies.Secondary Symbiotic VirusesSimilar to the primary symbionts, secondary symbionts form mutualistic relationships with their host, but are instead acquired via non-germline vertical transmission or horizontally during the post-natal life of the host.", [["human", "ORGANISM", 167, 172], ["EREs", "DNA", 151, 155], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["these studies", "TEST", 205, 218], ["Secondary Symbiotic VirusesSimilar", "PROBLEM", 219, 253], ["progressive", "OBSERVATION_MODIFIER", 6, 17], ["areas", "OBSERVATION_MODIFIER", 18, 23], ["Symbiotic VirusesSimilar", "OBSERVATION", 229, 253]]], ["Beginning with the microbial colonization of a child during birth, phages hitch a ride with their host bacteria.", [["child", "SPECIES", 47, 52], ["their host bacteria", "PROBLEM", 92, 111], ["microbial", "OBSERVATION_MODIFIER", 19, 28], ["colonization", "OBSERVATION", 29, 41]]], ["Phages can regulate bacterial species in the gut, as it is known that phages can be coopted into mucosal surfaces for this purpose [136] .", [["gut", "ANATOMY", 45, 48], ["mucosal", "ANATOMY", 97, 104], ["gut", "ORGANISM_SUBDIVISION", 45, 48], ["mucosal surfaces", "TISSUE", 97, 113], ["Phages", "TREATMENT", 0, 6], ["bacterial species", "PROBLEM", 20, 37], ["phages", "PROBLEM", 70, 76], ["bacterial species", "OBSERVATION", 20, 37], ["gut", "ANATOMY", 45, 48]]], ["Free phages may also serve a similar role as sentinels maintaining a balanced microbiota.", [["Free phages", "TREATMENT", 0, 11]]], ["These benefits have been studied extensively as possible medical tools in phage therapy (reviewed in [137, 138] ) and there has recently been a resurgence of interest as the problem of antimicrobial resistance has become more dire [139] .", [["phage therapy", "TREATMENT", 74, 87], ["antimicrobial resistance", "PROBLEM", 185, 209], ["antimicrobial resistance", "OBSERVATION", 185, 209]]], ["These same principles can likely be extended to viruses that parasitize other microbes and macrobes as well.Secondary Symbiotic VirusesOther examples of secondary symbiotic viruses are isolated, but numerous.", [["macrobes", "CANCER", 91, 99], ["macrobes", "PROBLEM", 91, 99], ["secondary symbiotic viruses", "PROBLEM", 153, 180], ["can likely be", "UNCERTAINTY", 22, 35], ["viruses", "OBSERVATION", 48, 55], ["secondary", "OBSERVATION_MODIFIER", 153, 162], ["symbiotic viruses", "OBSERVATION", 163, 180], ["numerous", "OBSERVATION_MODIFIER", 199, 207]]], ["In general, these viruses likely compete for receptors, cellular resources, or niches within hosts to confer protection.", [["cellular", "ANATOMY", 56, 64], ["cellular", "CELL", 56, 64]]], ["Hepatitis G Virus (HGV) is known to slow development of HIV infection to AIDS pathogenesis [140, 141] and Human Cytomegalovirus (HCMV) infection can suppress HIV infection by limiting availability of the coreceptor CCR5 on macrophages [142] .", [["macrophages", "ANATOMY", 223, 234], ["Hepatitis G Virus", "DISEASE", 0, 17], ["HIV infection", "DISEASE", 56, 69], ["AIDS", "DISEASE", 73, 77], ["Human Cytomegalovirus (HCMV) infection", "DISEASE", 106, 144], ["HIV infection", "DISEASE", 158, 171], ["Hepatitis G Virus", "ORGANISM", 0, 17], ["HGV", "ORGANISM", 19, 22], ["HIV", "ORGANISM", 56, 59], ["Human Cytomegalovirus", "ORGANISM", 106, 127], ["HCMV", "ORGANISM", 129, 133], ["HIV", "ORGANISM", 158, 161], ["CCR5", "GENE_OR_GENE_PRODUCT", 215, 219], ["macrophages", "CELL", 223, 234], ["coreceptor CCR5", "PROTEIN", 204, 219], ["macrophages", "CELL_TYPE", 223, 234], ["Hepatitis G Virus", "SPECIES", 0, 17], ["HIV", "SPECIES", 56, 59], ["Human", "SPECIES", 106, 111], ["HIV", "SPECIES", 158, 161], ["Hepatitis G Virus", "SPECIES", 0, 17], ["HGV", "SPECIES", 19, 22], ["HIV", "SPECIES", 56, 59], ["Human Cytomegalovirus", "SPECIES", 106, 127], ["HCMV", "SPECIES", 129, 133], ["HIV", "SPECIES", 158, 161], ["Hepatitis G Virus (HGV", "PROBLEM", 0, 22], ["HIV infection", "PROBLEM", 56, 69], ["AIDS pathogenesis", "PROBLEM", 73, 90], ["Human Cytomegalovirus (HCMV) infection", "PROBLEM", 106, 144], ["HIV infection", "PROBLEM", 158, 171], ["HIV", "OBSERVATION_MODIFIER", 56, 59], ["infection", "OBSERVATION", 60, 69]]], ["Infection with Hepatitis A Virus (HAV) can suppress infection with HCV and may actually promote clearance [143] .", [["Hepatitis A Virus", "DISEASE", 15, 32], ["HAV", "DISEASE", 34, 37], ["infection", "DISEASE", 52, 61], ["HCV", "DISEASE", 67, 70], ["Hepatitis A Virus", "ORGANISM", 15, 32], ["HAV", "ORGANISM", 34, 37], ["HCV", "ORGANISM", 67, 70], ["Hepatitis A Virus", "SPECIES", 15, 32], ["Hepatitis A Virus", "SPECIES", 15, 32], ["HAV", "SPECIES", 34, 37], ["HCV", "SPECIES", 67, 70], ["Infection", "PROBLEM", 0, 9], ["Hepatitis A Virus (HAV)", "PROBLEM", 15, 38], ["infection", "PROBLEM", 52, 61], ["HCV", "PROBLEM", 67, 70], ["Hepatitis", "OBSERVATION", 15, 24]]], ["Evidence from mice supports the assertion that viruses can confer resistance to non-viral disease as well, as infection with murine gammaherpesvirus results in protection from challenge with Listeria [144] and Type 1 Diabetes can be prevented in mice infected with lymphotropic viruses [145] .", [["non-viral disease", "DISEASE", 80, 97], ["infection", "DISEASE", 110, 119], ["Diabetes", "DISEASE", 217, 225], ["lymphotropic viruses", "DISEASE", 265, 285], ["mice", "ORGANISM", 14, 18], ["murine", "ORGANISM", 125, 131], ["gammaherpesvirus", "ORGANISM", 132, 148], ["mice", "ORGANISM", 246, 250], ["lymphotropic viruses", "ORGANISM", 265, 285], ["mice", "SPECIES", 14, 18], ["murine", "SPECIES", 125, 131], ["mice", "SPECIES", 246, 250], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 246, 250], ["viruses", "PROBLEM", 47, 54], ["non-viral disease", "PROBLEM", 80, 97], ["infection", "PROBLEM", 110, 119], ["murine gammaherpesvirus", "TREATMENT", 125, 148], ["Listeria", "PROBLEM", 191, 199], ["Type 1 Diabetes", "PROBLEM", 210, 225], ["lymphotropic viruses", "PROBLEM", 265, 285]]], ["Oncolytic viruses, which specifically target, infect, and kill tumor cells are also notable in both their novelty and their clinical utility (reviewed in [146] [147] [148] ).", [["tumor cells", "ANATOMY", 63, 74], ["tumor", "DISEASE", 63, 68], ["tumor cells", "CELL", 63, 74], ["tumor cells", "CELL_TYPE", 63, 74], ["Oncolytic viruses", "PROBLEM", 0, 17], ["kill tumor cells", "PROBLEM", 58, 74], ["tumor cells", "OBSERVATION", 63, 74]]], ["Viruses may even be able to provide developmental and immunological benefits not unlike that of the bacterial microbiota, as evidenced by the establishment of gut homeostasis in mice colonized with norovirus [149] .", [["gut", "ANATOMY", 159, 162], ["gut", "ORGANISM_SUBDIVISION", 159, 162], ["mice", "ORGANISM", 178, 182], ["mice", "SPECIES", 178, 182], ["mice", "SPECIES", 178, 182], ["Viruses", "PROBLEM", 0, 7], ["the bacterial microbiota", "PROBLEM", 96, 120], ["gut homeostasis", "PROBLEM", 159, 174], ["norovirus", "PROBLEM", 198, 207], ["bacterial microbiota", "OBSERVATION", 100, 120]]], ["Endogenous retroelements could also presumably be included here in the case of their population of a nongermline subset of cells within an individual and conferral of benefit to the host.Secondary Symbiotic VirusesOne of the main functions of secondary symbionts may be to help maintain a baseline of immune activation in order to give the host a head start upon challenge with incoming pathogens.", [["cells", "ANATOMY", 123, 128], ["head", "ANATOMY", 347, 351], ["cells", "CELL", 123, 128], ["head", "ORGANISM_SUBDIVISION", 347, 351], ["nongermline subset of cells", "CELL_TYPE", 101, 128], ["Endogenous retroelements", "PROBLEM", 0, 24], ["a nongermline subset of cells", "PROBLEM", 99, 128], ["secondary symbionts", "PROBLEM", 243, 262], ["immune activation", "PROBLEM", 301, 318], ["incoming pathogens", "PROBLEM", 378, 396], ["retroelements", "OBSERVATION", 11, 24], ["could also presumably be", "UNCERTAINTY", 25, 49], ["Symbiotic VirusesOne", "OBSERVATION", 197, 217], ["main", "OBSERVATION_MODIFIER", 225, 229], ["secondary symbionts", "OBSERVATION", 243, 262]]], ["It has been estimated that healthy humans are infected with > 10 viral infections at any given time [51] .", [["infections", "DISEASE", 71, 81], ["humans", "ORGANISM", 35, 41], ["humans", "SPECIES", 35, 41], ["humans", "SPECIES", 35, 41], ["10 viral infections", "PROBLEM", 62, 81], ["infected", "OBSERVATION", 46, 54]]], ["This constant barrage of immunogenic material presumably drives a smoldering activation of both innate and adaptive immunity.", [["immunogenic material", "PROBLEM", 25, 45], ["barrage", "OBSERVATION_MODIFIER", 14, 21], ["immunogenic material", "OBSERVATION", 25, 45]]], ["From this, it may be concluded that a state of continual challenge may be integral for the immune system to be fortified against incoming pathogens.Secondary Symbiotic VirusesWhile there is a plethora of research about secondary symbiotic bacteria, similar attention must to be paid to the virome.", [["immune system", "ANATOMY", 91, 104], ["the immune system", "TREATMENT", 87, 104], ["incoming pathogens", "PROBLEM", 129, 147], ["Secondary Symbiotic Viruses", "PROBLEM", 148, 175], ["secondary symbiotic bacteria", "PROBLEM", 219, 247], ["Symbiotic Viruses", "OBSERVATION", 158, 175], ["symbiotic bacteria", "OBSERVATION", 229, 247]]], ["The examples outlined above point to incredible benefit derived from the interaction of humans with these mutualists, and significant effort must be made to discover and harness such potentially impactful relationships.CONCLUSIONS AND OUTLOOKMoving forward, consideration of the effects of the human virome will be crucial in disease treatment and discovery of disease etiologies.", [["humans", "ORGANISM", 88, 94], ["human", "ORGANISM", 294, 299], ["humans", "SPECIES", 88, 94], ["human", "SPECIES", 294, 299], ["humans", "SPECIES", 88, 94], ["human", "SPECIES", 294, 299], ["the human virome", "TREATMENT", 290, 306], ["disease treatment", "TREATMENT", 326, 343], ["disease etiologies", "PROBLEM", 361, 379]]], ["From purely pathogenic viruses to those mutualists helping humans adapt to their world, the human virome has the potential to lend insight into the basic and applied biology of human health.", [["humans", "ORGANISM", 59, 65], ["human", "ORGANISM", 92, 97], ["human", "ORGANISM", 177, 182], ["humans", "SPECIES", 59, 65], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 177, 182], ["humans", "SPECIES", 59, 65], ["human", "SPECIES", 92, 97], ["human", "SPECIES", 177, 182], ["pathogenic", "OBSERVATION_MODIFIER", 12, 22], ["viruses", "OBSERVATION", 23, 30]]], ["In light of this, further exploration into the composition, tropism, and evolution of the human virome will undoubtedly make way for innovations in the treatment of human disease.CONCLUSIONS AND OUTLOOKThroughout this manuscript, I have assembled the components of the human virome into broad classifications of Parasitic, Commensal, and Mutualistic.", [["human", "ORGANISM", 90, 95], ["human", "ORGANISM", 165, 170], ["human", "ORGANISM", 269, 274], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 269, 274], ["human", "SPECIES", 90, 95], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 269, 274], ["further exploration", "TEST", 18, 37], ["tropism", "PROBLEM", 60, 67], ["the human virome", "PROBLEM", 86, 102], ["human disease", "PROBLEM", 165, 178], ["Parasitic", "OBSERVATION_MODIFIER", 312, 321]]], ["Disruption of the yin and yang of virus-host interactions can contribute to this transitory nature and may blur the lines that delineate the three main groups.", [["yin", "GENE_OR_GENE_PRODUCT", 18, 21], ["yang", "GENE_OR_GENE_PRODUCT", 26, 30], ["Disruption of the yin", "PROBLEM", 0, 21], ["this transitory nature", "PROBLEM", 76, 98], ["blur the lines", "PROBLEM", 107, 121], ["yin", "ANATOMY", 18, 21]]], ["This acknowledgement of convention and the departures from it gives both structure and flexibility to this conception of the human virome.", [["human", "ORGANISM", 125, 130], ["virome", "CANCER", 131, 137], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130], ["human virome", "OBSERVATION", 125, 137]]], ["I look on with anticipation to the continuation of the scientific soul search that is the exploration of the virome, where as we learn more about viruses, we come to better know ourselves.CONCLUSIONS AND OUTLOOKAcknowledgments: I would like to thank William Ruff for thoughtful discussion, critical evaluation, and editorial comments that contributed to this manuscript.", [["critical evaluation", "TEST", 290, 309]]], ["DGE1122492.", [["DGE1122492", "CHEMICAL", 0, 10], ["DGE1122492", "CHEMICAL", 0, 10], ["DGE1122492", "SIMPLE_CHEMICAL", 0, 10]]]], "9b6060a910dd95d43bf90727afb705e70665e12a": [["IntroductionSouth-East Asia (SEA) is considered a hotspot for emerging infectious diseases (Jones et al., 2008) .", [["infectious diseases", "DISEASE", 71, 90], ["emerging infectious diseases", "PROBLEM", 62, 90]]], ["The region is undergoing major demographic and economic development with major impacts on environment and biodiversity (Sodhi et al., 2004) .", [["major", "OBSERVATION_MODIFIER", 73, 78], ["impacts", "OBSERVATION_MODIFIER", 79, 86]]], ["Outbreaks of Nipah virus infections and severe acute respiratory syndrome (SARS) pandemic in SEA both originated from bats (Chua et al., 2000; Wang et al., 2006; Field, 2009) .", [["Nipah virus infections", "DISEASE", 13, 35], ["acute respiratory syndrome", "DISEASE", 47, 73], ["SARS", "DISEASE", 75, 79], ["Nipah virus", "ORGANISM", 13, 24], ["Nipah virus", "SPECIES", 13, 24], ["Nipah virus", "SPECIES", 13, 24], ["Nipah virus infections", "PROBLEM", 13, 35], ["severe acute respiratory syndrome", "PROBLEM", 40, 73], ["SARS", "PROBLEM", 75, 79], ["pandemic", "PROBLEM", 81, 89], ["Nipah virus infections", "OBSERVATION", 13, 35], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["acute", "OBSERVATION_MODIFIER", 47, 52], ["respiratory syndrome", "OBSERVATION", 53, 73]]], ["SEA is hosting a high bat diversity and is habitat for 30% of the known global bat fauna (Kingston, 2010) .", [["SEA", "GENE_OR_GENE_PRODUCT", 0, 3], ["SEA", "PROTEIN", 0, 3]]], ["In SEA, bats are often hunted for food (Mildenstein et al., 2016) .", [["bats", "ORGANISM", 8, 12], ["SEA", "PROTEIN", 3, 6], ["SEA", "ANATOMY", 3, 6]]], ["In Cambodia, bat guano is collected on guano farms to be used as a plant fertilizer (Chhay, 2012) .IntroductionLogging and conversion of forests into agricultural lands, monoculture plantations and urban areas have impacted the land cover configuration (Flint, 1994; Sodhi et al., 2004; DeFries et al., 2010) .", [["a plant fertilizer", "TREATMENT", 65, 83], ["IntroductionLogging", "TREATMENT", 99, 118], ["agricultural lands", "TREATMENT", 150, 168], ["monoculture plantations", "TREATMENT", 170, 193], ["urban areas", "TREATMENT", 198, 209], ["impacted", "OBSERVATION_MODIFIER", 215, 223], ["land", "OBSERVATION_MODIFIER", 228, 232]]], ["The Greater Mekong Subregion has lost 30% of its forest since 1970 (Costenbader et al., 2015) .", [["Greater", "OBSERVATION_MODIFIER", 4, 11], ["Mekong", "OBSERVATION_MODIFIER", 12, 18], ["Subregion", "OBSERVATION_MODIFIER", 19, 28], ["lost", "OBSERVATION_MODIFIER", 33, 37], ["30%", "OBSERVATION_MODIFIER", 38, 41]]], ["SEA is predicted to lose 75% of its original forest and 42% of its mammal species by 2100 (Sodhi et al., 2004) .", [["SEA", "GENE_OR_GENE_PRODUCT", 0, 3], ["SEA", "PROTEIN", 0, 3]]], ["The deforestation rates in SEA are the highest in any tropical regions which could bring bats even closer to humans (Achard et al., 2002; Sodhi et al., 2004; Stibig et al., 2007) .IntroductionBats were discovered as a reservoir for the progenitor virus of the SARS-coronavirus (SARS-CoV) species, responsible for the SARS pandemic between 2002 and 2004 (Wang et al., 2006) .", [["SARS-coronavirus", "DISEASE", 260, 276], ["SARS", "DISEASE", 317, 321], ["humans", "ORGANISM", 109, 115], ["Bats", "CELL", 192, 196], ["SARS-coronavirus", "ORGANISM", 260, 276], ["SARS-CoV", "ORGANISM", 278, 286], ["SEA", "PROTEIN", 27, 30], ["humans", "SPECIES", 109, 115], ["SARS-coronavirus", "SPECIES", 260, 276], ["humans", "SPECIES", 109, 115], ["SARS-coronavirus", "SPECIES", 260, 276], ["SARS-CoV", "SPECIES", 278, 286], ["The deforestation rates", "TEST", 0, 23], ["a reservoir", "TREATMENT", 216, 227], ["the progenitor virus", "PROBLEM", 232, 252], ["the SARS", "PROBLEM", 256, 264], ["coronavirus (SARS-CoV) species", "PROBLEM", 265, 295], ["deforestation", "OBSERVATION", 4, 17], ["highest", "OBSERVATION_MODIFIER", 39, 46]]], ["Coronaviruses belonging to alpha-CoV and beta-CoV, including MERS-like viruses have been recently detected in Cambodia and Lao bat populations (Lacroix et al., 2017a) .", [["alpha-CoV", "GENE_OR_GENE_PRODUCT", 27, 36], ["beta-CoV", "GENE_OR_GENE_PRODUCT", 41, 49], ["MERS-like viruses", "ORGANISM", 61, 78], ["alpha-CoV and beta-CoV", "DNA", 27, 49], ["beta-CoV", "SPECIES", 41, 49], ["Lao bat", "SPECIES", 123, 130], ["Coronaviruses", "PROBLEM", 0, 13], ["alpha", "TEST", 27, 32], ["CoV", "TEST", 33, 36], ["beta-CoV", "PROBLEM", 41, 49], ["MERS-like viruses", "PROBLEM", 61, 78]]], ["Several other viral families have also been detected, including astroviruses, flaviviruses, lyssaviruses, bunyaviruses or henipaviruses (Sala\u00fcn et al., 1974; Olson et al., 2002; Osborne et al., 2003; Reynes et al., 2004 Reynes et al., , 2005 Lacroix et al., 2017b) .IntroductionOther works have shed light on how anthropogenic and environmental changes may impact the dynamic of virus transmission and public health (Calisher et al., 2006; Han et al., 2015) .", [["flaviviruses", "DISEASE", 78, 90], ["lyssaviruses", "DISEASE", 92, 104], ["henipaviruses", "DISEASE", 122, 135], ["astroviruses", "GENE_OR_GENE_PRODUCT", 64, 76], ["Several other viral families", "PROBLEM", 0, 28], ["astroviruses", "PROBLEM", 64, 76], ["flaviviruses", "PROBLEM", 78, 90], ["lyssaviruses", "PROBLEM", 92, 104], ["bunyaviruses", "PROBLEM", 106, 118], ["henipaviruses", "PROBLEM", 122, 135], ["viral", "OBSERVATION", 14, 19]]], ["Bats are usually sensitive to environmental changes which can modify the dynamic of populations with a consequent impact on the risk of virus transmission.", [["Bats", "CELL", 0, 4], ["virus transmission", "PROBLEM", 136, 154], ["virus", "OBSERVATION", 136, 141]]], ["In order to investigate if bat viruses can be found in any kind of environment or are associated with specific landscapes, we conducted a multivariate analysis of isolated bat viruses, bats and environments previously described (Lacroix et al., 2017a (Lacroix et al., , 2017b .Description of the study areaThe study was carried out in Cambodia and Lao PDR which experience a rainy season from May to October, and a dry season from November to April.", [["bat viruses", "ORGANISM", 27, 38], ["bat viruses", "PROBLEM", 27, 38], ["a multivariate analysis", "TEST", 136, 159], ["isolated bat viruses", "PROBLEM", 163, 183], ["the study area", "TEST", 292, 306], ["The study", "TEST", 306, 315]]], ["The thickly forested Lao PDR landscape consists of rugged mountains (up to 2800 m) surrounded by plains and plateaus.", [["rugged", "OBSERVATION_MODIFIER", 51, 57], ["plateaus", "ANATOMY", 108, 116]]], ["In Cambodia, the landscape is characterized by a low-lying central plain including the Tonle Sap Lake and the upper areas of the Mekong River delta dominated by irrigated cultures.", [["cultures", "ANATOMY", 171, 179], ["irrigated cultures", "CELL_LINE", 161, 179], ["a low-lying central plain", "TREATMENT", 47, 72], ["the Tonle Sap Lake", "TREATMENT", 83, 101], ["irrigated cultures", "TEST", 161, 179], ["Cambodia", "OBSERVATION", 3, 11], ["upper", "ANATOMY_MODIFIER", 110, 115]]], ["These areas are flooded during the rainy season (Wildlife, 2014) .", [["flooded", "OBSERVATION", 16, 23]]], ["They are surrounded by uplands and low mountains, and thinly forested and transitional plains at around 200 m above sea level (Wildlife, 2014) .", [["low mountains", "OBSERVATION_MODIFIER", 35, 48]]], ["Cambodia and Lao PDR experienced an important forest loss and fragmentation: 22% and 24% of their forest cover disappeared between 1973 and 2009 , respectively (WWF, 2013 .", [["PDR", "DISEASE", 17, 20], ["Lao PDR", "PROBLEM", 13, 20], ["an important forest loss and fragmentation", "PROBLEM", 33, 75], ["forest loss", "OBSERVATION", 46, 57], ["fragmentation", "OBSERVATION_MODIFIER", 62, 75]]], ["In 2010, the forest covered 57.2% and 77.2% of Cambodia and Lao PDR respectively (FAO and World Bank, 2016; World Development Indicators, 2016) .Bats collectionBats were collected from 43 sites in Cambodia and Lao PDR between 2010 and 2013 as previously described (Lacroix et al., 2017a (Lacroix et al., , 2017b (Supplementary Table 1 ; Fig. 1 ).", [["Bats", "CELL", 145, 149], ["Bats", "CELL", 160, 164], ["Bats collectionBats", "PROBLEM", 145, 164]]], ["Sampling was conducted in two phases (Lacroix et al., 2017a (Lacroix et al., , 2017b .", [["Sampling", "TEST", 0, 8]]], ["Bats were captured using harp traps, stored in Mist Net bags and humanely euthanized under supervision of the National Veterinary Research Institute in full compliance with local ethical and legal guidelines at the sampling sites in the Cambodian provinces of Ratanakiri, Stung Treng and Preah Vihear.", [["Bats", "CELL", 0, 4], ["harp traps", "TREATMENT", 25, 35], ["Mist Net bags", "TREATMENT", 47, 60], ["local ethical", "TREATMENT", 173, 186], ["legal guidelines", "TREATMENT", 191, 207]]], ["Phase 2 of sampling was performed by the Wildlife Conservation Society (WCS), as part of USAID PREDICT project, from 2011 to 2013.", [["sampling", "TEST", 11, 19]]], ["Samples were taken at the human-bat interface and thus mostly from bats dedicated to human consumption, in markets, restaurants or directly from hunters.", [["Samples", "ANATOMY", 0, 7], ["human", "ORGANISM", 26, 31], ["human", "ORGANISM", 85, 90], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 85, 90], ["human", "SPECIES", 26, 31], ["human", "SPECIES", 85, 90], ["Samples", "TEST", 0, 7]]], ["Fresh guano samples were also taken from guano farms in Cambodia.", [["samples", "ANATOMY", 12, 19], ["Fresh guano samples", "ORGANISM_SUBSTANCE", 0, 19], ["Fresh guano samples", "TEST", 0, 19]]], ["Geographical coordinates of each collection site were recorded using a Global Positioning System (GPS).Detection of coronavirus and astrovirusViral RNA was extracted from rectal swabs, oral swabs and lung samples as previously described (Lacroix et al., 2017a (Lacroix et al., , 2017b ( Table 1) .", [["rectal swabs", "ANATOMY", 171, 183], ["oral swabs", "ANATOMY", 185, 195], ["lung samples", "ANATOMY", 200, 212], ["coronavirus", "ORGANISM", 116, 127], ["astrovirus", "ORGANISM", 132, 142], ["rectal swabs", "MULTI-TISSUE_STRUCTURE", 171, 183], ["oral swabs", "ORGANISM_SUBSTANCE", 185, 195], ["lung samples", "CANCER", 200, 212], ["coronavirus", "SPECIES", 116, 127], ["coronavirus", "PROBLEM", 116, 127], ["astrovirusViral RNA", "PROBLEM", 132, 151], ["rectal swabs", "TEST", 171, 183], ["oral swabs and lung samples", "TEST", 185, 212], ["coronavirus", "OBSERVATION", 116, 127], ["rectal", "ANATOMY", 171, 177], ["lung", "ANATOMY", 200, 204]]], ["The detection was based on broadly reactive reverse transcription-polymerase chain reaction (RT-PCR) assays, following previously described procedures (Chu et al., 2008; Watanabe et al., 2010) .Environmental indicesLand cover data were obtained from GlobeLand30 (GLC30) service operated by the National Geomatics Center of China (NGCC, 2014) .", [["The detection", "TEST", 0, 13], ["broadly reactive reverse transcription", "PROBLEM", 27, 65], ["polymerase chain reaction", "PROBLEM", 66, 91]]], ["Images were from Landsat8.", [["Landsat8", "DNA", 17, 25], ["Images", "TEST", 0, 6], ["Landsat8", "TEST", 17, 25]]], ["Land cover map showed the main classes of land use as a synthesis of various material types, i.e. natural attributes and features on earth used for GlobeLand30 (GLC30) classification from 30 \u00d7 30 m multispectral satellite images.", [["GlobeLand30", "SIMPLE_CHEMICAL", 148, 159], ["GLC30", "PROTEIN", 161, 166], ["Land cover map", "TEST", 0, 14], ["a synthesis of various material types", "PROBLEM", 54, 91], ["multispectral satellite images", "TEST", 198, 228], ["main", "OBSERVATION_MODIFIER", 26, 30], ["various material types", "OBSERVATION_MODIFIER", 69, 91]]], ["Elevation map was obtained from Shuttle Radar Topography Mission (SRTM) of the Consortium for Spatial Information (CGIAR-CSI).", [["Elevation map", "TEST", 0, 13]]], ["Most bats were obtained from markets or directly from hunters and have been hunted in surrounding areas (Lacroix et al., 2017a (Lacroix et al., , 2017b .", [["bats", "ORGANISM", 5, 9]]], ["It was thus important to estimate the area of origin of these hunted bats.", [["origin", "ANATOMY_MODIFIER", 46, 52], ["hunted bats", "OBSERVATION", 62, 73]]], ["A 20-km radius was in agreement with the ecology and potential flying distances of the collected bats (Flemming and Eby, 2003; Kunz and Fenton, 2005; IUCN, 2017) and should then encompass the original environment of the hunted bats.", [["hunted bats", "OBSERVATION", 220, 231]]], ["In this study, this 1256 km 2 (20 km radius) buffer zone was designated as \"Area Of Interest (AOI)\".", [["this study", "TEST", 3, 13]]], ["AOIs are shown in Fig. 2 .", [["Fig", "OBSERVATION_MODIFIER", 18, 21]]], ["Data were extracted using the Patch Analyst extension in Geographical Information Systems (GIS) software ArcMap 10.3.1.", [["the Patch", "TREATMENT", 26, 35], ["software ArcMap", "TEST", 96, 111]]], ["Forest cover was examined more precisely in each AOI: 1) as a simple proportion of forest to each land cover type, 2) using the Shannon diversity index (SDI), 3) using the Fg fragmentation index defined as the ratio of the surface of the forest to the edge length of the forest (Fortin et al., 2005) and 4) using the ED edge density index which is the density of forest borders divided by the forest surface.", [["surface", "ANATOMY", 223, 230], ["surface", "ANATOMY", 400, 407], ["Fg", "GENE_OR_GENE_PRODUCT", 172, 174], ["surface", "CELLULAR_COMPONENT", 400, 407], ["Fg", "PROTEIN", 172, 174], ["the Fg fragmentation index", "TEST", 168, 194], ["the ED edge density index", "TEST", 313, 338], ["edge", "OBSERVATION_MODIFIER", 252, 256], ["edge", "OBSERVATION_MODIFIER", 320, 324], ["density index", "OBSERVATION", 325, 338], ["density", "OBSERVATION_MODIFIER", 352, 359], ["forest borders", "OBSERVATION", 363, 377], ["forest surface", "OBSERVATION", 393, 407]]], ["Administrative data were obtained from the GADM database of Global Administrative Areas (version 2.8, November 2015).", [["Administrative data", "TEST", 0, 19]]], ["Main road networks in Cambodia and Lao PDR were obtained from the Digital Chart of the World (DCW) available on the Diva-gis online resource (www. diva-gis.org) and Google Earth.", [["road networks", "MULTI-TISSUE_STRUCTURE", 5, 18]]], ["The network density in each AOI was assessed by measuring the total road length and the number of intersections.", [["network", "MULTI-TISSUE_STRUCTURE", 4, 11], ["AOI", "CANCER", 28, 31], ["density", "OBSERVATION", 12, 19]]], ["Connectivity index shows the density of roads connections for each AOI as the total length of the main roads (L) and the number of intersections (I).", [["Connectivity index", "TEST", 0, 18], ["density", "OBSERVATION_MODIFIER", 29, 36], ["roads connections", "OBSERVATION", 40, 57], ["total", "OBSERVATION_MODIFIER", 78, 83], ["length", "OBSERVATION_MODIFIER", 84, 90], ["main", "OBSERVATION_MODIFIER", 98, 102]]], ["Connectivity = log (L * l).Statistical analysisA hierarchical analysis, also known as cluster analysis, based on environmental parameters in each AOI was performed in order to describe the different type of habitats using the software R version 3.3.0 (www.r-project.org).", [["Statistical analysisA hierarchical analysis", "TEST", 27, 70], ["cluster analysis", "TEST", 86, 102], ["environmental parameters", "TEST", 113, 137], ["the software R version", "TEST", 222, 244]]], ["The principle of hierarchical analysis is to build a binary tree of data that successively merges similar groups of points.", [["hierarchical analysis", "TEST", 17, 38]]], ["Parameters used for hierarchical analysis were: Land cover [% forest cover, % settlement cover, % grassland, % surface water cover, % cropland cover and % wetland cover]; Mean elevation; and Connectivity.", [["surface", "ANATOMY", 111, 118], ["hierarchical analysis", "TEST", 20, 41], ["Land cover [% forest cover", "TREATMENT", 48, 74], ["% surface water cover", "TREATMENT", 109, 130], ["% cropland cover", "TREATMENT", 132, 148], ["Mean elevation", "PROBLEM", 171, 185]]], ["As a second step, pairs are grouped into larger groups of similarity.", [["larger", "OBSERVATION_MODIFIER", 41, 47]]], ["In this work, Euclidean distances between 8 and 12 were yielded 6 independent clusters and each cluster comprised from 6 to 9 statistically similar AOIs.", [["Euclidean distances", "TEST", 14, 33]]], ["PCA analysis shows statistical, multidimension links between several variables and is used to emphasize variations.", [["PCA analysis", "TEST", 0, 12]]], ["The pattern of similarity of the observed variables is displayed as points on a surface.", [["surface", "ANATOMY", 80, 87], ["surface", "CELLULAR_COMPONENT", 80, 87]]], ["In this case we used PCA to assess the correspondence of spatial environment and anthropogenic factors with respect to (a) astrovirus and coronavirus found on bats, and (b) to spatial environment and anthropogenic factors.", [["astrovirus", "ORGANISM", 123, 133], ["coronavirus", "ORGANISM", 138, 149], ["anthropogenic factors", "PROTEIN", 200, 221], ["coronavirus", "SPECIES", 138, 149], ["PCA", "TREATMENT", 21, 24], ["anthropogenic factors", "PROBLEM", 81, 102], ["a) astrovirus", "PROBLEM", 120, 133], ["coronavirus", "PROBLEM", 138, 149]]], ["As a first step all 11 factors corresponding to A. Afelt et al. Infection, Genetics and Evolution 58 (2018) 181-191 spatial analysis and considered in each AOI were assessed for correlation using a correlation matrix.", [["matrix", "CELLULAR_COMPONENT", 210, 216], ["Infection", "PROBLEM", 64, 73], ["spatial analysis", "TEST", 116, 132], ["a correlation matrix", "TEST", 196, 216]]], ["Out of 11 factors considered, 3 were strongly correlated and dependent, i.e. forest, ED, SDI (r = 0.56-0.76).", [["SDI", "TEST", 89, 92]]], ["Out of these three factors, SDI (Shannon Index) provided a more complete information integrated both forest cover and density.", [["density", "OBSERVATION", 118, 125]]], ["SDI was therefore retained for PCA analysis while forest and ED were excluded from this analysis.", [["PCA analysis", "TEST", 31, 43], ["this analysis", "TEST", 83, 96]]], ["PCA analysis was therefore performed with 9 environment-linked factors: SDI, Fragmentation, Connectivity, Settlements, Cropland, Wetland, Grassland, Water, and Elevation.", [["PCA analysis", "TEST", 0, 12], ["SDI", "PROBLEM", 72, 75], ["Fragmentation", "PROBLEM", 77, 90], ["Fragmentation", "OBSERVATION", 77, 90]]], ["PCA analysis was preceded by data normalization.", [["PCA analysis", "TEST", 0, 12]]], ["Finally, three sets of supplementary variables were investigated, i.e. (i) bats sampled in each AOI, (ii) coronavirus isolated from sampled bats, and (iii) astrovirus isolated from sampled bats.Sampling sitesA total of 1997 bats were sampled, 1128 in Cambodia and 869 in Lao PDR at the interface between humans and bats (Table 1 , Figs.", [["coronavirus", "ORGANISM", 106, 117], ["astrovirus", "ORGANISM", 156, 166], ["bats", "ORGANISM", 224, 228], ["humans", "ORGANISM", 304, 310], ["humans", "SPECIES", 304, 310], ["humans", "SPECIES", 304, 310], ["coronavirus", "PROBLEM", 106, 117], ["astrovirus", "PROBLEM", 156, 166], ["Sampling sitesA", "TEST", 194, 209]]], ["For animals collected in the environment and in guano farms, the exact environmental description of the sampling location was available.", [["guano farms", "MULTI-TISSUE_STRUCTURE", 48, 59]]], ["For samples collected in restaurants and meat shops or directly from hunters, the exact original location of animals remained unknown but they were hunted for market trade near the selling place, i.e., mostly from areas at the border of deep forests, mixed agricultural zones with sparse forests or protected forest areas, close to water surfaces or in limestone karsts areas with mountain forests (Fig. 1)Sampling sitesBat astV 24 59 59 (2) Rhin, Rs \u03b1CoV-4, \u03b2CoV-D2 59 (7) Tph, Hip, Rhin, RsSampling sitesBat astV, cluster7 astV 25 9 9 (0) - A. Afelt et al. Infection, Genetics and Evolution 58 (2018) 181-191 2017b).", [["samples", "ANATOMY", 4, 11], ["meat", "ANATOMY", 41, 45], ["astV 25 9 9", "CHEMICAL", 525, 536], ["meat", "ORGANISM_SUBDIVISION", 41, 45], ["mixed agricultural zones", "PROBLEM", 251, 275], ["sparse forests", "PROBLEM", 281, 295], ["protected forest areas", "PROBLEM", 299, 321], ["Sampling sitesBat astV", "TEST", 406, 428], ["Rhin", "TEST", 442, 446], ["Rs", "TEST", 448, 450], ["CoV", "TEST", 452, 455], ["CoV", "TEST", 460, 463], ["D2", "TEST", 464, 466], ["Tph", "TEST", 474, 477], ["Hip", "TEST", 479, 482], ["Rhin", "TEST", 484, 488], ["RsSampling sites", "TEST", 490, 506], ["Bat astV", "TEST", 506, 514], ["cluster7", "TEST", 516, 524], ["astV", "TEST", 525, 529], ["Infection", "PROBLEM", 559, 568], ["deep forests", "OBSERVATION", 237, 249], ["mixed", "OBSERVATION_MODIFIER", 251, 256], ["agricultural", "OBSERVATION_MODIFIER", 257, 269], ["zones", "OBSERVATION_MODIFIER", 270, 275], ["sparse", "OBSERVATION_MODIFIER", 281, 287], ["forests", "OBSERVATION", 288, 295], ["mountain forests", "OBSERVATION", 381, 397], ["Hip", "ANATOMY", 479, 482]]], ["7 AOI were located between 500 m and 1000 m, mostly in north Cambodia and Lao PDR (mostly rivers valleys) whereas 5 AOI were located above 1000 m in northern Lao PDR.", [["PDR", "DISEASE", 78, 81]]], ["AOI were described by nine statistically independent parameters: i.e. water cover, settlements cover, cropland cover, wetland cover, grassland cover, elevation, forest Shannon index, forest fragmentation index and connectivity index ( Table 2 ).", [["settlements cover", "TREATMENT", 83, 100], ["cropland cover", "TREATMENT", 102, 116], ["wetland cover", "TREATMENT", 118, 131], ["grassland cover", "TREATMENT", 133, 148], ["elevation", "PROBLEM", 150, 159], ["forest Shannon index", "TEST", 161, 181], ["forest fragmentation index", "TEST", 183, 209], ["elevation", "OBSERVATION_MODIFIER", 150, 159], ["forest fragmentation", "OBSERVATION", 183, 203]]], ["Hierarchical analysis based on these 9 parameters resulted into 6 clusters of landscape parametrization (Fig. 3) .", [["Hierarchical analysis", "TEST", 0, 21], ["these 9 parameters", "TEST", 31, 49], ["landscape parametrization", "TREATMENT", 78, 103]]], ["The main parameters for cluster characterization were: grass cover, cropland, Shannon index, fragmentation index and connectivity index.", [["cluster characterization", "TEST", 24, 48], ["Shannon index", "TEST", 78, 91], ["fragmentation index", "TEST", 93, 112], ["connectivity index", "TEST", 117, 135], ["main", "OBSERVATION_MODIFIER", 4, 8], ["fragmentation index", "OBSERVATION", 93, 112], ["connectivity index", "OBSERVATION", 117, 135]]], ["Cluster A included 6 AOIs displaying medium to high elevation, forest percentage of ca.", [["high elevation", "PROBLEM", 47, 61], ["high", "OBSERVATION_MODIFIER", 47, 51], ["elevation", "OBSERVATION", 52, 61], ["ca", "OBSERVATION", 84, 86]]], ["70-80%, low fragmentation, low water and wetland percentage A. Afelt et al. Infection, Genetics and Evolution 58 (2018) 181-191 and high connectivity index (2.5%-2.9%).", [["Infection", "DISEASE", 76, 85], ["low fragmentation", "PROBLEM", 8, 25], ["Infection", "PROBLEM", 76, 85], ["high connectivity index", "TEST", 132, 155], ["low", "OBSERVATION_MODIFIER", 8, 11], ["fragmentation", "OBSERVATION", 12, 25], ["low water", "OBSERVATION_MODIFIER", 27, 36]]], ["Only one AOI (38) was negative for viruses.", [["AOI", "CANCER", 9, 12], ["viruses", "PROBLEM", 35, 42]]], ["AOI 39, 40, 41, 42 and 43 were positive for coronavirus while only two sites (40 and 43) were positive for astrovirus.", [["astrovirus", "DISEASE", 107, 117], ["coronavirus", "ORGANISM", 44, 55], ["astrovirus", "ORGANISM", 107, 117], ["AOI", "TEST", 0, 3], ["coronavirus", "PROBLEM", 44, 55], ["astrovirus", "PROBLEM", 107, 117], ["astrovirus", "OBSERVATION", 107, 117]]], ["Cluster B comprised 9 AOIs (33, 35, 36), including four sites positive for at least one virus.", [["AOIs", "TEST", 22, 26], ["virus", "OBSERVATION", 88, 93]]], ["In these areas, forest cover (80-95%) and Shannon index were higher than for cluster A and the human settlements cover was small or not detected in a 30 \u00d7 30 m resolution, indicating that villages were small and scattered.", [["human", "ORGANISM", 95, 100], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["forest cover", "TEST", 16, 28], ["Shannon index", "TEST", 42, 55], ["the human settlements", "TREATMENT", 91, 112], ["areas", "OBSERVATION_MODIFIER", 9, 14], ["forest", "OBSERVATION_MODIFIER", 16, 22], ["higher", "OBSERVATION_MODIFIER", 61, 67], ["small", "OBSERVATION_MODIFIER", 123, 128], ["small", "OBSERVATION_MODIFIER", 202, 207], ["scattered", "OBSERVATION_MODIFIER", 212, 221]]], ["Both clusters A and B were located in Lao PDR.", [["B", "GENE_OR_GENE_PRODUCT", 20, 21]]], ["Euclidean distance indicated that clusters A and B segregated independently from the other 4 clusters (Fig. 3) .", [["clusters A and B segregated", "PROBLEM", 34, 61]]], ["These remaining clusters were characterized by low cropland cover, low human settlement cover and high Shannon index.", [["human", "ORGANISM", 71, 76], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["low cropland cover", "PROBLEM", 47, 65], ["low human settlement", "PROBLEM", 67, 87], ["high Shannon index", "PROBLEM", 98, 116], ["low cropland", "OBSERVATION", 47, 59], ["low human", "OBSERVATION_MODIFIER", 67, 76], ["settlement", "OBSERVATION_MODIFIER", 77, 87], ["high", "OBSERVATION_MODIFIER", 98, 102], ["Shannon index", "OBSERVATION", 103, 116]]], ["Clusters C, D, E and F corresponded to AOI located in Cambodia.", [["AOI", "DNA", 39, 42], ["Cambodia", "OBSERVATION", 54, 62]]], ["The cluster pairs C & D and E & F were the most similar.", [["E & F", "GENE_OR_GENE_PRODUCT", 28, 33], ["The cluster pairs C & D and E & F", "PROBLEM", 0, 33], ["most similar", "OBSERVATION_MODIFIER", 43, 55]]], ["Cluster C included 6 AOIs with only two (11, 12) where only coronavirus were detected while no astrovirus was present.Sampling sitesThe landscape corresponded to 75 to 92% of forest cover, 1.5 to 2% of grass cover and a similar elevation (300 m above sea level).", [["astrovirus", "DISEASE", 95, 105], ["coronavirus", "ORGANISM", 60, 71], ["astrovirus", "ORGANISM", 95, 105], ["Cluster C included 6 AOIs", "PROBLEM", 0, 25], ["coronavirus", "PROBLEM", 60, 71], ["astrovirus", "PROBLEM", 95, 105], ["Sampling sites", "PROBLEM", 118, 132], ["a similar elevation", "PROBLEM", 218, 237], ["coronavirus", "OBSERVATION", 60, 71], ["astrovirus", "OBSERVATION", 95, 105], ["elevation", "OBSERVATION", 228, 237]]], ["For both AOI 11 and 12, the connectivity index was high whereas the human settlement cover was less than 0.25% indicating that villages were small and scattered.", [["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["both AOI", "TEST", 4, 12], ["the connectivity index", "TEST", 24, 46], ["small", "OBSERVATION_MODIFIER", 141, 146], ["scattered", "OBSERVATION_MODIFIER", 151, 160]]], ["Cluster D comprised 6 AOIs (1-6) displaying cultivated areas with high cropland cover and one of the highest settlement cover (7.2% for AOI 2).", [["Cluster D comprised 6 AOIs", "PROBLEM", 0, 26], ["cultivated areas", "PROBLEM", 44, 60], ["high cropland cover", "TREATMENT", 66, 85], ["high cropland", "OBSERVATION", 66, 79]]], ["Three AOIs (1, 2, 3) were positive for astrovirus, including AOI 1 which displayed a high wetland cover and one of the highest cropland cover.", [["astrovirus", "DISEASE", 39, 49], ["astrovirus", "ORGANISM", 39, 49], ["Three AOIs (1, 2, 3)", "TEST", 0, 20], ["astrovirus", "PROBLEM", 39, 49], ["AOI", "TEST", 61, 64], ["a high wetland cover", "TREATMENT", 83, 103], ["astrovirus", "OBSERVATION", 39, 49], ["high wetland", "OBSERVATION", 85, 97]]], ["Cluster E covered 7 AOIs (22-27) dominated by forest (85-98%) with the lowest connectivity index, one of the lowest forest fragmentation index and limited cultivated and grassland areas.", [["AOIs", "TEST", 20, 24], ["the lowest connectivity index", "TEST", 67, 96], ["the lowest forest fragmentation index", "PROBLEM", 105, 142], ["limited cultivated and grassland areas", "PROBLEM", 147, 185], ["fragmentation index", "OBSERVATION", 123, 142], ["grassland areas", "OBSERVATION", 170, 185]]], ["The Shannon index was also among the lowest.", [["The Shannon index", "TEST", 0, 17], ["Shannon index", "OBSERVATION", 4, 17]]], ["Cluster E represented a wilderness parts of Cambodia.", [["wilderness", "OBSERVATION_MODIFIER", 24, 34]]], ["Cluster E also displayed the highest virus richness, i.e. 4 coronavirus sub-clusters and 5 astrovirus sub-clusters.", [["Cluster E", "GENE_OR_GENE_PRODUCT", 0, 9], ["the highest virus richness", "PROBLEM", 25, 51], ["4 coronavirus sub-clusters", "PROBLEM", 58, 84], ["highest", "OBSERVATION_MODIFIER", 29, 36], ["virus richness", "OBSERVATION", 37, 51]]], ["The last cluster, F, comprised 9 AOIs (13-21) out of which 6 were positive for viruses (13, 14, 15, 17, 19, 21) .", [["viruses", "PROBLEM", 79, 86]]], ["All displayed mostly cultivated land with patches of forest, and the highest connectivity index and wetland cover, corresponding to highly transformed environments.", [["patches of forest", "TREATMENT", 42, 59]]], ["The human settlement cover was rather low (0.1-3.5%) indicating that villages were concentrated in clusters.", [["human", "ORGANISM", 4, 9], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["The human settlement", "TREATMENT", 0, 20], ["settlement", "OBSERVATION_MODIFIER", 10, 20], ["low", "OBSERVATION_MODIFIER", 38, 41]]], ["Cluster F also displayed the highest rate of coronavirus detection (37, including 28 \u03b1CoV_1 in AOI 14) and astrovirus (37 Bat_AstVs, located only in AOIs 13 and 14).", [["Cluster F", "GENE_OR_GENE_PRODUCT", 0, 9], ["coronavirus", "ORGANISM", 45, 56], ["CoV_1", "PROTEIN", 86, 91], ["coronavirus detection", "TEST", 45, 66], ["CoV_1", "TEST", 86, 91], ["AOI", "TEST", 95, 98], ["astrovirus", "PROBLEM", 107, 117], ["Bat_AstVs", "TEST", 122, 131], ["AOIs", "TEST", 149, 153], ["coronavirus", "OBSERVATION", 45, 56]]], ["Another conclusion from this analysis is the higher bat biodiversity observed in Cambodia associated to more anthropized environment than in LAO PDR where dense forest was predominant (Fig. 3) .Landscape typology of virus-positive AOIPCA were performed with the nine selected active independent Astroviruses from the clusters 1, 2, 3, 4, 5, 6, including only bat astVs (Lacroix et al., 2017b) Supplementary variables are shown in italic.Landscape typology of virus-positive AOIA.", [["1, 2, 3, 4, 5, 6", "DNA", 326, 342], ["this analysis", "TEST", 24, 37], ["virus", "PROBLEM", 216, 221], ["positive AOIPCA", "PROBLEM", 222, 237], ["dense", "OBSERVATION_MODIFIER", 155, 160], ["forest", "OBSERVATION", 161, 167], ["virus", "OBSERVATION", 216, 221], ["Astroviruses", "OBSERVATION", 295, 307], ["virus", "OBSERVATION", 459, 464], ["positive AOIA", "OBSERVATION", 465, 478]]], ["Afelt et al. Infection, Genetics and Evolution 58 (2018) A. Afelt et al. Infection, Genetics and Evolution 58 (2018) 181-191 variables (i.e. water cover, settlements cover, cropland cover, wetland cover, grassland cover, elevation, forest Shannon index (SDI), forest fragmentation index and connectivity index) for coronavirus subclusters (Fig. 4a ) and for astrovirus subclusters (Fig. 4b) .Landscape typology of virus-positive AOIOwing to the fact that only 8 AOIs out 43 harbored bats positive for both viruses, the PCA relating to coronaviruses and astroviruses differed slightly.", [["bats", "ORGANISM", 483, 487], ["coronaviruses", "ORGANISM", 535, 548], ["astroviruses", "CANCER", 553, 565], ["Infection", "PROBLEM", 13, 22], ["Infection", "PROBLEM", 73, 82], ["settlements cover", "TREATMENT", 154, 171], ["cropland cover", "TREATMENT", 173, 187], ["wetland cover", "TREATMENT", 189, 202], ["grassland cover", "TREATMENT", 204, 219], ["elevation", "PROBLEM", 221, 230], ["forest Shannon index", "TEST", 232, 252], ["forest fragmentation index", "TEST", 260, 286], ["connectivity index", "TEST", 291, 309], ["coronavirus subclusters", "PROBLEM", 315, 338], ["astrovirus subclusters", "PROBLEM", 358, 380], ["virus", "PROBLEM", 414, 419], ["harbored bats positive", "PROBLEM", 474, 496], ["both viruses", "PROBLEM", 501, 513], ["the PCA", "PROBLEM", 515, 522], ["coronaviruses", "PROBLEM", 535, 548], ["astroviruses", "PROBLEM", 553, 565], ["viruses", "OBSERVATION", 506, 513], ["PCA", "ANATOMY", 519, 522], ["coronaviruses", "OBSERVATION", 535, 548], ["astroviruses", "OBSERVATION", 553, 565]]], ["Although they were established with the same parameters, the positive sites being different, the values associated with these parameters were also slightly different.", [["the positive sites", "PROBLEM", 57, 75], ["these parameters", "TEST", 120, 136], ["slightly", "OBSERVATION_MODIFIER", 147, 155], ["different", "OBSERVATION_MODIFIER", 156, 165]]], ["With respect to the coronavirus-positive bats (Fig. 4a) , the first axis of the PCA (PC1) accounted for 46.1% of the total variability while the second axis (PC2) accounted for 30%, so a total variability of 76.1%.", [["coronavirus", "ORGANISM", 20, 31], ["the coronavirus", "TEST", 16, 31], ["the total variability", "TEST", 113, 134], ["PC2", "TEST", 158, 161], ["a total variability", "TEST", 185, 204], ["coronavirus", "OBSERVATION", 20, 31], ["positive bats", "OBSERVATION", 32, 45], ["PCA", "ANATOMY", 80, 83]]], ["The contributions of the environmental variables to the construction of this axis were the highest for elevation, SDI and grassland which were correlated on the negative side and connectivity, forest fragmentation, cropland cover, water cover, wetland cover and settlement cover which were distributed on the positive side (Fig. 4a) .Landscape typology of virus-positive AOIThe principal dimension of variability of the PCA opposed anthropogenic transformed lands on the positive side to more natural environments (i.e. forest, higher elevation areas and grassland areas, with low fragmentation) on the negative side (Fig. 4a) .", [["elevation, SDI and grassland", "PROBLEM", 103, 131], ["forest fragmentation", "PROBLEM", 193, 213], ["cropland cover", "TREATMENT", 215, 229], ["water cover", "TREATMENT", 231, 242], ["wetland cover", "TREATMENT", 244, 257], ["virus", "PROBLEM", 356, 361], ["higher elevation areas and grassland areas", "PROBLEM", 528, 570], ["low fragmentation", "PROBLEM", 577, 594], ["forest fragmentation", "OBSERVATION", 193, 213], ["virus", "OBSERVATION", 356, 361], ["variability", "OBSERVATION_MODIFIER", 401, 412], ["PCA", "ANATOMY", 420, 423], ["positive side", "OBSERVATION_MODIFIER", 471, 484], ["higher", "OBSERVATION_MODIFIER", 528, 534], ["elevation", "OBSERVATION_MODIFIER", 535, 544], ["areas", "OBSERVATION_MODIFIER", 545, 550], ["grassland", "OBSERVATION_MODIFIER", 555, 564], ["areas", "OBSERVATION_MODIFIER", 565, 570], ["low fragmentation", "OBSERVATION_MODIFIER", 577, 594], ["negative side", "OBSERVATION_MODIFIER", 603, 616]]], ["The second component of the PCA (PC2) accounted for 30% of the total variability.", [["second", "OBSERVATION_MODIFIER", 4, 10], ["component", "OBSERVATION_MODIFIER", 11, 20], ["PCA", "ANATOMY", 28, 31], ["total variability", "OBSERVATION", 63, 80]]], ["Fragmentation index, settlement cover and connectivity index were close to the axis and did not participate to the topology of the PCA.", [["Fragmentation index", "PROBLEM", 0, 19], ["connectivity index", "TEST", 42, 60], ["index", "OBSERVATION_MODIFIER", 14, 19], ["settlement", "OBSERVATION_MODIFIER", 21, 31], ["PCA", "ANATOMY", 131, 134]]], ["Grassland cover, water cover bodies, wetland cover, elevation and cropland cover participated the most to topology on the negative side.", [["Grassland cover", "TREATMENT", 0, 15], ["water cover bodies", "TREATMENT", 17, 35], ["elevation and cropland", "TREATMENT", 52, 74], ["water cover", "OBSERVATION_MODIFIER", 17, 28], ["bodies", "OBSERVATION_MODIFIER", 29, 35], ["wetland", "OBSERVATION_MODIFIER", 37, 44], ["elevation", "OBSERVATION_MODIFIER", 52, 61]]], ["SDI was located on the positive side with a more limited weight (Fig. 4a) .", [["positive side", "OBSERVATION_MODIFIER", 23, 36]]], ["When considering the PCA representing the astrovirus-positive AOIs, contributions were slightly different (Fig. 4b) .", [["astrovirus", "DISEASE", 42, 52], ["astrovirus", "ORGANISM", 42, 52], ["the PCA", "PROBLEM", 17, 24], ["the astrovirus-positive AOIs", "PROBLEM", 38, 66], ["astrovirus", "OBSERVATION", 42, 52], ["slightly", "OBSERVATION_MODIFIER", 87, 95]]], ["The first two axes contributed for a total of 93.09% with axis 1 representing 53.89% of the dispersion and axis 2 representing 39.2%.", [["axis", "TEST", 58, 62], ["axis", "TEST", 107, 111]]], ["The distribution with respect to axis 2 was not affected and remained the same as for coronavirus-positive AOIs.", [["AOIs", "DISEASE", 107, 111], ["coronavirus", "ORGANISM", 86, 97], ["coronavirus", "PROBLEM", 86, 97], ["positive AOIs", "PROBLEM", 98, 111], ["distribution", "OBSERVATION_MODIFIER", 4, 16]]], ["The axis 1 displayed however a slightly different topology (Fig. 4b) .", [["a slightly different topology", "PROBLEM", 29, 58]]], ["SDI moved to the negative side but very close to axis 1 and therefore did not bear any weight in the analysis.", [["the analysis", "TEST", 97, 109]]], ["Settlements cover, connectivity index and fragmentation index moved to the positive side to be moderately distant from the axis and gaining thus in representativeness (Fig. 4b) .Correlation of coronavirus and astrovirus with environmental parametersThe betacoronaviruses \u03b2CoV_D3 and \u03b2CoV_D4 were strongly associated with natural habitats and in particular with grassland and high elevation (Fig. 4a) .", [["astrovirus", "DISEASE", 209, 219], ["coronavirus", "ORGANISM", 193, 204], ["astrovirus", "ORGANISM", 209, 219], ["CoV_D3", "GENE_OR_GENE_PRODUCT", 272, 278], ["\u03b2CoV_D4", "GENE_OR_GENE_PRODUCT", 283, 290], ["betacoronaviruses \u03b2CoV_D3 and \u03b2CoV_D4", "DNA", 253, 290], ["connectivity index", "TEST", 19, 37], ["fragmentation index", "PROBLEM", 42, 61], ["coronavirus", "PROBLEM", 193, 204], ["astrovirus", "PROBLEM", 209, 219], ["environmental parameters", "TEST", 225, 249], ["fragmentation index", "OBSERVATION", 42, 61], ["moderately", "OBSERVATION_MODIFIER", 95, 105], ["distant", "OBSERVATION", 106, 113], ["axis", "ANATOMY", 123, 127], ["coronavirus", "OBSERVATION", 193, 204], ["high elevation", "OBSERVATION", 375, 389]]], ["The betacoronavirus clusters \u03b2CoV_D2 and, to a lower extent, \u03b2CoV_D1 and \u03b2CoV_C, seemed to be more correlated with the forest density gradient. \u03b2CoV-D2 was the most influenced by higher forest density (Fig. 4a) .", [["\u03b2CoV_D2", "GENE_OR_GENE_PRODUCT", 29, 36], ["\u03b2CoV_D1", "GENE_OR_GENE_PRODUCT", 61, 68], ["\u03b2CoV_C", "GENE_OR_GENE_PRODUCT", 73, 79], ["\u03b2CoV-D2", "GENE_OR_GENE_PRODUCT", 144, 151], ["CoV_D2", "PROTEIN", 30, 36], ["\u03b2CoV_D1", "DNA", 61, 68], ["\u03b2CoV_C", "DNA", 73, 79], ["D2", "PROTEIN", 149, 151], ["the forest density gradient", "PROBLEM", 115, 142], ["lower extent", "OBSERVATION_MODIFIER", 47, 59], ["forest density", "OBSERVATION", 119, 133], ["higher", "OBSERVATION_MODIFIER", 179, 185], ["forest density", "OBSERVATION", 186, 200]]], ["The alphacoronavirus \u03b1CoV_1 and \u03b1CoV_2 were strongly associated to anthropogenic environments with wetlands, whereas \u03b1CoV_4 was in contrary slightly more associated with more natural habitats (Fig. 4b) .", [["alphacoronavirus \u03b1CoV_1", "GENE_OR_GENE_PRODUCT", 4, 27], ["\u03b1CoV_2", "GENE_OR_GENE_PRODUCT", 32, 38], ["CoV_4", "GENE_OR_GENE_PRODUCT", 118, 123], ["alphacoronavirus \u03b1CoV_1 and \u03b1CoV_2", "DNA", 4, 38], ["\u03b1CoV_4", "DNA", 117, 123], ["The alphacoronavirus", "TEST", 0, 20], ["\u03b1CoV_2", "PROBLEM", 32, 38]]], ["Astroviruses also displayed a clear differential distribution associated with environmental parameters.", [["Astroviruses", "PROBLEM", 0, 12], ["clear differential", "OBSERVATION_MODIFIER", 30, 48]]], ["The Un-g_AstV cluster was strongly associated to natural environments, in particular grassland and higher elevation, whereas the Mur_AstV cluster was strongly associated to an anthropogenic habitat (Fig. 4b) .", [["Un-g_AstV", "GENE_OR_GENE_PRODUCT", 4, 13], ["Mur_AstV", "GENE_OR_GENE_PRODUCT", 129, 137], ["Un-g_AstV cluster", "DNA", 4, 21], ["Mur_AstV cluster", "DNA", 129, 145], ["The Un-g_AstV cluster", "PROBLEM", 0, 21], ["higher elevation", "PROBLEM", 99, 115], ["the Mur_AstV cluster", "PROBLEM", 125, 145], ["natural environments", "OBSERVATION", 49, 69], ["higher", "OBSERVATION_MODIFIER", 99, 105], ["elevation", "OBSERVATION_MODIFIER", 106, 115]]], ["The Ba-t_AstV cluster was clearly associated to open areas close to water and wetlands (Fig. 4b) .Correspondence between bat genera and environmental dataBat genera displayed a strong correspondence with specific environmental parameters (Fig. 5) .", [["Ba-t_AstV", "GENE_OR_GENE_PRODUCT", 4, 13], ["Ba-t_AstV cluster", "DNA", 4, 21], ["The Ba-t_AstV cluster", "PROBLEM", 0, 21], ["open areas", "PROBLEM", 48, 58], ["open", "OBSERVATION_MODIFIER", 48, 52], ["areas", "OBSERVATION", 53, 58]]], ["The two main axes of the PCA represented a total of 73.9% of inertia, with 54% and 19.9% for axis 1 and axis 2, respectively.", [["inertia", "TEST", 61, 68], ["axis", "TEST", 93, 97], ["axis", "TEST", 104, 108], ["two", "OBSERVATION_MODIFIER", 4, 7], ["main", "OBSERVATION_MODIFIER", 8, 12], ["axes", "OBSERVATION_MODIFIER", 13, 17], ["PCA", "ANATOMY", 25, 28], ["total", "OBSERVATION_MODIFIER", 43, 48]]], ["The genus Myotis was strongly correlated with anthropogenic environments, water areas and wetlands.", [["anthropogenic environments", "TREATMENT", 46, 72], ["genus Myotis", "OBSERVATION", 4, 16]]], ["The distribution of Scotophilus was similarly influenced by forest fragmentation, water areas and anthropogenic environments.", [["Scotophilus", "PROBLEM", 20, 31], ["forest fragmentation", "PROBLEM", 60, 80], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["Scotophilus", "OBSERVATION", 20, 31], ["forest fragmentation", "OBSERVATION", 60, 80], ["anthropogenic environments", "OBSERVATION", 98, 124]]], ["Conversely, the genera Hipposideros, Eonycteris, Ia and Rhinolophus were correlated with more natural habitats comprising dense forests and grassland area at higher elevation.", [["Ia", "GENE_OR_GENE_PRODUCT", 49, 51], ["Rhinolophus", "GENE_OR_GENE_PRODUCT", 56, 67], ["Rhinolophus", "TREATMENT", 56, 67], ["dense forests and grassland area at higher elevation", "PROBLEM", 122, 174], ["dense", "OBSERVATION_MODIFIER", 122, 127], ["forests", "OBSERVATION_MODIFIER", 128, 135], ["grassland", "OBSERVATION_MODIFIER", 140, 149], ["area", "OBSERVATION_MODIFIER", 150, 154], ["higher elevation", "OBSERVATION", 158, 174]]], ["The genus Rousettus was close to the center, indicating the distribution of this genus was not strongly influenced by the parameters.", [["this genus", "PROBLEM", 76, 86], ["genus Rousettus", "OBSERVATION", 4, 19]]], ["Megaderma and Taphozous were strongly opposed to all environmental parameters analyzed indicating that their distribution was influenced by a distinct parameter not considered in this work.DiscussionThis work demonstrates both a clear distribution of bats and batborne viruses depending on environmental factors.", [["Megaderma", "TREATMENT", 0, 9], ["Taphozous", "TREATMENT", 14, 23], ["all environmental parameters", "TEST", 49, 77], ["batborne viruses", "PROBLEM", 260, 276], ["clear", "OBSERVATION", 229, 234]]], ["For example, the Lesser Asian bat (Scotophilus) shows correlation with the anthropogenic, fragmented environments, close to water areas.", [["Asian bat", "SPECIES", 24, 33], ["Lesser", "OBSERVATION_MODIFIER", 17, 23], ["anthropogenic", "OBSERVATION", 75, 88]]], ["The Mouse-eared bat (Myotis) also tends to be collected in anthropogenic areas around lakes or biggest regional river corridors regularly flooded.", [["Mouse-eared bat", "ORGANISM", 4, 19], ["Mouse", "SPECIES", 4, 9], ["Mouse-eared bat", "SPECIES", 4, 19], ["anthropogenic", "OBSERVATION_MODIFIER", 59, 72], ["biggest", "OBSERVATION_MODIFIER", 95, 102], ["river corridors", "OBSERVATION", 112, 127]]], ["These observations are in accordance with their biology and ecology: Myotis and Scotophilus can adapt to many habitats but preferentially settle in anthropogenic habitats, in old buildings or crevasses.", [["Scotophilus", "ORGANISM", 80, 91]]], ["Scotophilus bats are also reared in farms for their guano (Chhay, 2012) .", [["Scotophilus bats", "ORGANISM", 0, 16], ["Scotophilus bats", "SPECIES", 0, 16], ["Scotophilus bats", "PROBLEM", 0, 16]]], ["The presence of Hipposideros, Macroglossus and Rhinolophus, in environments with forest areas mixed with other categories of land cover (mosaic landscape) is also in accordance with their ecology (Bates et al., 2008a; Hutson et al., 2008; Walston et al., 2008) .", [["Hipposideros", "PROBLEM", 16, 28], ["Macroglossus", "PROBLEM", 30, 42], ["Rhinolophus", "PROBLEM", 47, 58], ["forest areas", "PROBLEM", 81, 93], ["Hipposideros", "OBSERVATION", 16, 28], ["Rhinolophus", "OBSERVATION_MODIFIER", 47, 58], ["forest", "OBSERVATION_MODIFIER", 81, 87], ["mosaic landscape", "OBSERVATION", 137, 153]]], ["As a consequence, the two coronavirus sub-clusters \u03b1CoV_1 and \u03b1CoV_2, detected specifically in Scotophilus and Myotis respectively (Lacroix et al., 2017a) displayed the same trend, i.e. a high correlation with anthropogenic environment.", [["\u03b1CoV_1", "GENE_OR_GENE_PRODUCT", 51, 57], ["\u03b1CoV_2", "GENE_OR_GENE_PRODUCT", 62, 68], ["coronavirus sub-clusters \u03b1CoV_1", "DNA", 26, 57], ["\u03b1CoV_2", "DNA", 62, 68], ["CoV_1", "TEST", 52, 57], ["CoV_2", "TEST", 63, 68], ["Myotis", "ANATOMY", 111, 117]]], ["Fruit and forest-dependent bat genera testing positive for viruses (Rousettus, Eonycteris) were correlated with an environment mostly consisting of densely forested areas at a higher elevation.", [["Fruit", "ORGANISM_SUBDIVISION", 0, 5], ["bat", "ORGANISM", 27, 30], ["Fruit", "TEST", 0, 5], ["forest-dependent bat genera testing", "TEST", 10, 45], ["viruses", "PROBLEM", 59, 66], ["densely forested areas", "PROBLEM", 148, 170], ["a higher elevation", "PROBLEM", 174, 192], ["higher elevation", "OBSERVATION", 176, 192]]], ["The betacoronavirus clusters \u03b2CoV_D3 and \u03b2CoV_D4 which were found mostly in bats from the genera Rousettus and Eonycteris also correlated with the same type of environment.", [["\u03b2CoV_D3", "GENE_OR_GENE_PRODUCT", 29, 36], ["\u03b2CoV_D4", "GENE_OR_GENE_PRODUCT", 41, 48], ["Eonycteris", "GENE_OR_GENE_PRODUCT", 111, 121], ["betacoronavirus clusters \u03b2CoV_D3 and \u03b2CoV_D4", "DNA", 4, 48], ["genera Rousettus", "OBSERVATION", 90, 106]]], ["Finding coronavirus sub-clusters specific to a given bat genus in similar environment types indicates that the distribution of viruses is likely to follow the distribution of their hosts.", [["coronavirus", "ORGANISM", 8, 19], ["coronavirus sub-clusters", "PROBLEM", 8, 32], ["viruses", "PROBLEM", 127, 134], ["viruses", "OBSERVATION", 127, 134]]], ["The highest diversity of bats observed in anthropized environments emphasizes furthermore the risk associated with environmental changes.", [["highest", "OBSERVATION_MODIFIER", 4, 11], ["diversity", "OBSERVATION_MODIFIER", 12, 21]]], ["Deforestation and anthropization instead of leading to the elimination of bats generate conversely yield to a higher diversity.", [["Deforestation", "DISEASE", 0, 13], ["Deforestation", "TREATMENT", 0, 13], ["anthropization", "TREATMENT", 18, 32]]], ["This might be explained by the complexity of A. Afelt et al. Infection, Genetics and Evolution 58 (2018) 181-191 the anthropized environments which offer opportunities to different groups of ubiquity bat species whereas natural environments might be more selective and suited for species with more strict ecological requirements.", [["Infection", "PROBLEM", 61, 70], ["ubiquity bat species", "PROBLEM", 191, 211]]], ["This higher biodiversity occurring by definition at the human interface, the risk of virus transmission is therefore increasing as well.DiscussionA particular attention has to be paid to the sub-cluster \u03b1CoV_2 and \u03b2CoV_C.", [["human", "ORGANISM", 56, 61], ["\u03b2CoV_C", "GENE_OR_GENE_PRODUCT", 214, 220], ["sub-cluster \u03b1CoV_2", "DNA", 191, 209], ["\u03b2CoV_C", "DNA", 214, 220], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61], ["virus transmission", "PROBLEM", 85, 103], ["higher", "OBSERVATION_MODIFIER", 5, 11], ["biodiversity", "OBSERVATION", 12, 24], ["virus", "OBSERVATION", 85, 90], ["increasing", "OBSERVATION_MODIFIER", 117, 127]]], ["These sub-clusters are composed by viruses which are highly pathogenic for pigs and humans respectively.", [["pigs", "ORGANISM", 75, 79], ["humans", "ORGANISM", 84, 90], ["pigs", "SPECIES", 75, 79], ["humans", "SPECIES", 84, 90], ["pigs", "SPECIES", 75, 79], ["humans", "SPECIES", 84, 90], ["viruses", "PROBLEM", 35, 42], ["sub", "OBSERVATION_MODIFIER", 6, 9], ["clusters", "OBSERVATION", 10, 18], ["viruses", "OBSERVATION", 35, 42], ["highly", "OBSERVATION_MODIFIER", 53, 59], ["pathogenic", "OBSERVATION", 60, 70]]], ["The sub-cluster \u03b1CoV_2 comprises the coronaviruses responsible for the porcine epidemic diarrhea, which threatens pig farming activities around the world (Song et al., 2015; Lacroix et al., 2017a) . \u03b2CoV_C comprises the zoonotic strain of coronavirus responsible for the Middle East Respiratory Syndrome (MERS) (Omrani et al., 2015) .", [["diarrhea", "DISEASE", 88, 96], ["\u03b2CoV_C", "CHEMICAL", 199, 205], ["coronavirus", "DISEASE", 239, 250], ["Middle East Respiratory Syndrome", "DISEASE", 271, 303], ["MERS", "DISEASE", 305, 309], ["coronaviruses", "ORGANISM", 37, 50], ["porcine", "ORGANISM", 71, 78], ["pig", "ORGANISM", 114, 117], ["\u03b2CoV_C", "GENE_OR_GENE_PRODUCT", 199, 205], ["coronavirus", "ORGANISM", 239, 250], ["sub-cluster \u03b1CoV_2", "DNA", 4, 22], ["\u03b2CoV_C", "PROTEIN", 199, 205], ["porcine", "SPECIES", 71, 78], ["pig", "SPECIES", 114, 117], ["coronavirus", "SPECIES", 239, 250], ["pig", "SPECIES", 114, 117], ["Middle East Respiratory Syndrome (MERS)", "SPECIES", 271, 310], ["the coronaviruses", "PROBLEM", 33, 50], ["the porcine epidemic diarrhea", "PROBLEM", 67, 96], ["CoV_C", "PROBLEM", 200, 205], ["the zoonotic strain", "PROBLEM", 216, 235], ["coronavirus", "PROBLEM", 239, 250], ["the Middle East Respiratory Syndrome", "PROBLEM", 267, 303], ["sub", "OBSERVATION_MODIFIER", 4, 7], ["porcine", "OBSERVATION_MODIFIER", 71, 78], ["epidemic", "OBSERVATION_MODIFIER", 79, 87], ["diarrhea", "OBSERVATION", 88, 96], ["zoonotic strain", "OBSERVATION", 220, 235], ["coronavirus", "OBSERVATION", 239, 250], ["Middle", "ANATOMY_MODIFIER", 271, 277], ["Respiratory Syndrome", "OBSERVATION", 283, 303]]], ["The sub-cluster \u03b1CoV_2 and lineage \u03b2CoV_C are linked to anthropogenic habitats in accordance with the presence of their hosts (Myotis and Pipistrellus, respectively) in the same environment Rosell-Ambal et al., 2008) .", [["\u03b2CoV_C", "GENE_OR_GENE_PRODUCT", 35, 41], ["sub-cluster \u03b1CoV_2", "DNA", 4, 22], ["lineage \u03b2CoV_C", "DNA", 27, 41], ["lineage \u03b2CoV_C", "TREATMENT", 27, 41], ["sub", "OBSERVATION_MODIFIER", 4, 7], ["anthropogenic habitats", "OBSERVATION", 56, 78]]], ["The correspondence with host habitat is even more evident with astroviruses.", [["astroviruses", "PROBLEM", 63, 75], ["host habitat", "OBSERVATION", 24, 36], ["astroviruses", "OBSERVATION", 63, 75]]], ["Ungulate astrovirus found in ungulates and bats are associated with grasslands at higher elevation while murine astroviruses found in rodents and bats are associated with human settlements, indicating that the host bats are present in these same habitats.", [["Ungulate astrovirus", "ORGANISM", 0, 19], ["bats", "ORGANISM", 43, 47], ["murine", "ORGANISM", 105, 111], ["astroviruses", "GENE_OR_GENE_PRODUCT", 112, 124], ["human", "ORGANISM", 171, 176], ["bats", "ORGANISM", 215, 219], ["murine", "SPECIES", 105, 111], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 171, 176], ["Ungulate astrovirus", "PROBLEM", 0, 19], ["grasslands at higher elevation", "PROBLEM", 68, 98], ["murine astroviruses", "PROBLEM", 105, 124], ["astrovirus", "OBSERVATION", 9, 19], ["ungulates", "OBSERVATION_MODIFIER", 29, 38]]], ["Bat astroviruses, found only in bats, are associated with water surface and irrigated cultures.", [["surface", "ANATOMY", 64, 71], ["Bat astroviruses", "ORGANISM", 0, 16], ["Bat astroviruses", "PROBLEM", 0, 16], ["water surface", "TREATMENT", 58, 71], ["irrigated cultures", "TEST", 76, 94], ["astroviruses", "OBSERVATION", 4, 16]]], ["This could be explained by the fact that irrigated cultures provide an important insect biomass and food resources for insectivorous bat populations which are harboring mainly arboviruses (Kunz and Fenton, 2005; Lacroix et al., 2017b) .DiscussionFragmentation of the habitat has been reported as a factor having a major importance in the spatial distribution of species.", [["arboviruses", "DISEASE", 176, 187], ["irrigated cultures", "CELL_LINE", 41, 59], ["irrigated cultures", "TEST", 41, 59], ["insectivorous bat populations", "PROBLEM", 119, 148], ["species", "OBSERVATION", 362, 369]]], ["The distribution pattern of bat population has been found to also impact the viral richness of the host (Henle et al., 2004; Meyer et al., 2008; Gay et al., 2014) .", [["bat", "ORGANISM", 28, 31], ["bat population", "PROBLEM", 28, 42], ["distribution", "OBSERVATION_MODIFIER", 4, 16], ["pattern", "OBSERVATION_MODIFIER", 17, 24], ["bat population", "OBSERVATION", 28, 42], ["viral richness", "OBSERVATION", 77, 91]]], ["The fragmentation of bat populations was linked to a decrease in viral species richness (Gay et al., 2014) .", [["bat", "ORGANISM", 21, 24], ["The fragmentation of bat populations", "PROBLEM", 0, 36], ["a decrease in viral species richness", "PROBLEM", 51, 87], ["fragmentation", "OBSERVATION_MODIFIER", 4, 17], ["bat populations", "OBSERVATION", 21, 36], ["decrease", "OBSERVATION_MODIFIER", 53, 61], ["viral species richness", "OBSERVATION", 65, 87]]], ["However, this work indicates that if fragmentation is an important parameter, it is not sufficient by itself to explain the distribution and must be considered jointly with the Shannon Diversity Index (SDI index) to yield a picture accurate enough.", [["fragmentation", "PROBLEM", 37, 50], ["fragmentation", "OBSERVATION", 37, 50]]], ["In this work, combining these parameters allowed us to clearly associate certain clusters of viruses to given environments and this is to our knowledge, the first time it is achieved in SEA.", [["SEA", "PROTEIN", 186, 189], ["viruses", "OBSERVATION", 93, 100]]], ["This work should thus be accompanied by the modeling of the modification of landscapes (Jung and Threlfall, 2016) over the next decades in order to assess and predict which part of the current biodiversity may increase or be at risk.DiscussionFrom a methodological standpoint, large sampling was not possible because of the status of protected species attached to the reservoir (IUCN, 2017).", [["large sampling", "TEST", 277, 291], ["protected species", "PROBLEM", 334, 351], ["large", "OBSERVATION_MODIFIER", 277, 282], ["reservoir", "ANATOMY_MODIFIER", 368, 377]]], ["On another hand, avoiding the sampling of protected reservoirs for the sake of conservation and thus avoiding early detection and risk assessment is putting human populations at risk and contrary to public health policy (Morse, 2012; Lipkin and Anthony, 2015) .", [["hand", "ANATOMY", 11, 15], ["human", "ORGANISM", 157, 162], ["human", "SPECIES", 157, 162], ["human", "SPECIES", 157, 162], ["the sampling of protected reservoirs", "TREATMENT", 26, 62], ["early detection", "TEST", 110, 125], ["risk assessment", "TEST", 130, 145]]], ["The limited sample size and limited quality of the bat material are a direct consequence of their status of protected species which was respected and enforced.", [["sample", "ANATOMY", 12, 18], ["protected species", "PROBLEM", 108, 125], ["size", "OBSERVATION_MODIFIER", 19, 23]]], ["Indeed, the bat sample collection was opportunistic, and mostly based on animals hunted by local populations (Lacroix et al., 2017a (Lacroix et al., , 2017b .", [["the bat sample collection", "PROBLEM", 8, 33], ["opportunistic", "PROBLEM", 38, 51]]], ["However, if the species level could not be reached with certainty in a significant part of the samples, except for Ia io, Pipistrellus coromandra and Megaerops niphanae, the ecology of the species present in South East Asia was similar within a given genus.", [["Pipistrellus coromandra", "ORGANISM", 122, 145], ["Megaerops niphanae", "ORGANISM", 150, 168], ["Pipistrellus coromandra", "SPECIES", 122, 145], ["Megaerops niphanae", "SPECIES", 150, 168], ["Pipistrellus coromandra", "SPECIES", 122, 145], ["Megaerops niphanae", "SPECIES", 150, 168], ["the species level", "PROBLEM", 12, 29], ["Pipistrellus coromandra", "TREATMENT", 122, 145]]], ["The IUCN red list of threatened species provides the basis for a comparative analysis (IUCN, 2017).", [["threatened species", "PROBLEM", 21, 39], ["a comparative analysis", "TEST", 63, 85]]], ["Scotophilus species found in South East Asia are reported to roost in crevices, cracks in walls, or roof of old buildings as well as leaves and crowns of palms, hollows of trees and among leaves of banana.", [["walls", "ANATOMY", 90, 95], ["leaves", "ANATOMY", 133, 139], ["palms", "ANATOMY", 154, 159], ["leaves", "ANATOMY", 188, 194], ["palms", "ORGANISM_SUBDIVISION", 154, 159], ["banana", "ORGANISM_SUBDIVISION", 198, 204], ["Scotophilus species", "PROBLEM", 0, 19], ["banana", "TREATMENT", 198, 204], ["cracks", "OBSERVATION_MODIFIER", 80, 86], ["walls", "ANATOMY_MODIFIER", 90, 95], ["palms", "ANATOMY", 154, 159]]], ["This is in conformity with the analysis of the distribution of Scotophilus reported in this work as being influenced by forest fragmentation, water areas and anthropogenic environments.", [["Scotophilus", "CHEMICAL", 63, 74], ["the analysis", "TEST", 27, 39], ["Scotophilus", "PROBLEM", 63, 74], ["forest fragmentation", "PROBLEM", 120, 140], ["Scotophilus", "OBSERVATION", 63, 74], ["forest fragmentation", "OBSERVATION", 120, 140], ["anthropogenic environments", "OBSERVATION", 158, 184]]], ["The genus Myotis was found in this work to strongly correlate with anthropogenic environments, water areas and wetlands.", [["genus Myotis", "OBSERVATION", 4, 16]]], ["The ecology of Myotis species in South East Asia is matching this description (IUCN, 2017).", [["Myotis species", "OBSERVATION", 15, 29]]], ["M. annectans was found on a river valley, M. horsfieldii and M. ater are found near to water source and streams in lowland forest as well as disturbed forest and agricultural areas.", [["M. annectans", "ORGANISM", 0, 12], ["M. horsfieldii", "ORGANISM", 42, 56], ["M. ater", "ORGANISM", 61, 68], ["M. annectans", "SPECIES", 0, 12], ["M. horsfieldii", "SPECIES", 42, 56], ["M. ater", "SPECIES", 61, 68], ["M. annectans", "SPECIES", 0, 12], ["M. horsfieldii", "SPECIES", 42, 56], ["M. ater", "SPECIES", 61, 68], ["disturbed forest and agricultural areas", "PROBLEM", 141, 180], ["streams", "OBSERVATION_MODIFIER", 104, 111], ["lowland forest", "OBSERVATION", 115, 129], ["disturbed", "OBSERVATION_MODIFIER", 141, 150], ["forest", "OBSERVATION", 151, 157]]], ["M. rosseti is found in disturbed areas while M. siligorensis has been collected in lowland second growth forests over streams.", [["M. rosseti", "ORGANISM", 0, 10], ["M. siligorensis", "ORGANISM", 45, 60], ["M. rosseti", "SPECIES", 0, 10], ["M. siligorensis", "SPECIES", 45, 60], ["M. rosseti", "SPECIES", 0, 10], ["M. siligorensis", "SPECIES", 45, 60], ["disturbed areas", "PROBLEM", 23, 38], ["rosseti", "OBSERVATION", 3, 10], ["disturbed", "OBSERVATION_MODIFIER", 23, 32]]], ["M. pilosus is a fish-eating bat and therefore strictly dependent on water.", [["M. pilosus", "ORGANISM", 0, 10], ["M. pilosus", "SPECIES", 0, 10], ["M. pilosus", "SPECIES", 0, 10]]], ["We reported in this work that the genera Hipposideros, Eonycteris, Ia and Rhinolophus as correlating with more natural habitats comprising dense forests and grassland area at higher elevation.", [["Rhinolophus", "GENE_OR_GENE_PRODUCT", 74, 85], ["Rhinolophus", "TREATMENT", 74, 85], ["dense forests and grassland area at higher elevation", "PROBLEM", 139, 191], ["dense", "OBSERVATION_MODIFIER", 139, 144], ["forests", "OBSERVATION_MODIFIER", 145, 152], ["grassland", "OBSERVATION_MODIFIER", 157, 166], ["area", "OBSERVATION_MODIFIER", 167, 171], ["higher elevation", "OBSERVATION", 175, 191]]], ["Hipposideros scutinares is known only from caves in limestone areas while H. cineraceus is roosting in hollows of trees in forests in South East Asia.", [["Hipposideros", "CHEMICAL", 0, 12], ["Hipposideros scutinares", "ORGANISM", 0, 23], ["H. cineraceus", "ORGANISM", 74, 87], ["Hipposideros scutinares", "SPECIES", 0, 23], ["H. cineraceus", "SPECIES", 74, 87], ["Hipposideros scutinares", "SPECIES", 0, 23], ["H. cineraceus", "SPECIES", 74, 87], ["Hipposideros scutinares", "PROBLEM", 0, 23]]], ["H. galeritus is found in lowland forests as well as rubber plantations in Southeast Asia (IUCN, 2017) .", [["H. galeritus", "ORGANISM", 0, 12], ["H. galeritus", "SPECIES", 0, 12], ["H. galeritus", "SPECIES", 0, 12], ["H. galeritus", "PROBLEM", 0, 12], ["lowland forests", "OBSERVATION", 25, 40], ["rubber plantations", "OBSERVATION", 52, 70]]], ["H. pomona ecology is not well known but in Southeast Asia it roosts essentially in caves.", [["H. pomona", "ORGANISM", 0, 9], ["H. pomona", "SPECIES", 0, 9], ["H. pomona", "SPECIES", 0, 9]]], ["Similarly not much is known about H. rotalis which is considered to live in dry forests (IUCN, 2017) .", [["H. rotalis", "ORGANISM", 34, 44], ["H. rotalis", "SPECIES", 34, 44], ["H. rotalis", "SPECIES", 34, 44]]], ["Eonycteris spelaea is found in caves in forested areas.", [["Eonycteris spelaea", "ORGANISM", 0, 18], ["Eonycteris spelaea", "SPECIES", 0, 18], ["Eonycteris spelaea", "SPECIES", 0, 18], ["Eonycteris spelaea", "PROBLEM", 0, 18], ["caves", "OBSERVATION", 31, 36], ["forested", "OBSERVATION", 40, 48]]], ["With respect to Rhinolophus, similar features are observed.", [["Rhinolophus", "PROBLEM", 16, 27], ["Rhinolophus", "OBSERVATION", 16, 27]]], ["R. coelophyllus is found in forest, R. lepidus is associated with intact lowland tropical moist forest.", [["R. coelophyllus", "ORGANISM", 0, 15], ["R. lepidus", "ORGANISM", 36, 46], ["R. coelophyllus", "SPECIES", 0, 15], ["R. lepidus", "SPECIES", 36, 46], ["R. coelophyllus", "SPECIES", 0, 15], ["R. lepidus", "SPECIES", 36, 46], ["coelophyllus", "OBSERVATION", 3, 15], ["forest", "OBSERVATION_MODIFIER", 28, 34], ["lepidus", "OBSERVATION", 39, 46], ["intact", "OBSERVATION_MODIFIER", 66, 72], ["lowland", "OBSERVATION_MODIFIER", 73, 80], ["tropical", "OBSERVATION_MODIFIER", 81, 89], ["moist forest", "OBSERVATION", 90, 102]]], ["R. malayanus is found in caves in secondary forest and degraded habitat.", [["R. malayanus", "ORGANISM", 0, 12], ["R. malayanus", "SPECIES", 0, 12], ["R. malayanus", "SPECIES", 0, 12], ["malayanus", "OBSERVATION", 3, 12], ["caves", "OBSERVATION", 25, 30], ["secondary forest", "OBSERVATION", 34, 50], ["habitat", "OBSERVATION_MODIFIER", 64, 71]]], ["R. paradoxolophus was found in dry pine forest, while R. affinis is living in primary and secondary forest (IUCN, 2017) .", [["R. paradoxolophus", "ORGANISM", 0, 17], ["R. affinis", "ORGANISM", 54, 64], ["R. paradoxolophus", "SPECIES", 0, 17], ["R. affinis", "SPECIES", 54, 64], ["R. paradoxolophus", "SPECIES", 0, 17], ["R. affinis", "SPECIES", 54, 64], ["pine forest", "OBSERVATION", 35, 46]]], ["The two Rousettus species described in the IUCN database as present in Lao PDR and Cambodia, Rousettus amplexicaudatus and Rousettus leschenaultia, share the same ecology and roost in caves, old and ruined buildings and disused tunnels in forest, agricultural areas, disturbed habitats and at the forest edge.", [["Rousettus amplexicaudatus", "ORGANISM", 93, 118], ["Rousettus leschenaultia", "ORGANISM", 123, 146], ["Rousettus amplexicaudatus", "SPECIES", 93, 118], ["Rousettus leschenaultia", "SPECIES", 123, 146], ["Rousettus amplexicaudatus", "SPECIES", 93, 118], ["Rousettus leschenaultia", "SPECIES", 123, 146], ["The two Rousettus species", "PROBLEM", 0, 25], ["the IUCN database", "TEST", 39, 56], ["disused tunnels", "TREATMENT", 220, 235], ["forest", "OBSERVATION_MODIFIER", 239, 245], ["disturbed habitats", "OBSERVATION", 267, 285]]], ["Finally, with respect to Taphozous theobaldi and Taphozous melanopogon, they both share the same forest habitat with roosting in caves or abandoned buildings and mines (IUCN, 2017) .", [["Taphozous theobaldi", "ORGANISM", 25, 44], ["Taphozous melanopogon", "ORGANISM", 49, 70], ["Taphozous theobaldi", "SPECIES", 25, 44], ["Taphozous melanopogon", "SPECIES", 49, 70], ["Taphozous theobaldi", "SPECIES", 25, 44], ["Taphozous melanopogon", "SPECIES", 49, 70], ["Taphozous theobaldi", "TREATMENT", 25, 44]]], ["This could have been underestimated or overestimated for some collection sites.", [["some collection sites", "PROBLEM", 57, 78]]], ["This will influence the presence and prevalence of bat-borne viruses which is not only a consequence of environmental change but also of ethology and ecology of bats.", [["bat", "ORGANISM", 51, 54], ["bat-borne viruses", "SPECIES", 51, 68], ["bat-borne viruses", "PROBLEM", 51, 68]]], ["This can thus influence the occurrence of contacts with humans and should be further investigated in order to consider the specificity of each bat genus.", [["humans", "ORGANISM", 56, 62], ["humans", "SPECIES", 56, 62], ["humans", "SPECIES", 56, 62]]], ["However, this problem has been overcome with the definition of AOI considering both economic and ecological aspects.DiscussionAnother key methodological aspect is the resolution and quality of spatial data.", [["AOI", "PROBLEM", 63, 66]]], ["This resolution must be adapted to the observed differing density and a 30 \u00d7 30 m resolution seems to be a good compromise between quality, definition, data access and calculation burden.", [["calculation burden", "TEST", 168, 186], ["density", "OBSERVATION", 58, 65], ["good", "OBSERVATION_MODIFIER", 107, 111], ["compromise", "OBSERVATION", 112, 122]]], ["Therefore, despite this limitation, the statistical approach implemented in this work allowed us to obtain the information needed on association with virus and environment.", [["virus", "TREATMENT", 150, 155]]], ["This can help designing prospective risk scenarios based on the expected evolution of landscape.DiscussionThis brings us to the last aspect which is the possibility to model and develop scenarios of risk management.", [["prospective risk scenarios", "PROBLEM", 24, 50], ["risk management", "TREATMENT", 199, 214]]], ["The prediction of landscape modification, climate change and anthropogenic behaviors (urbanization, roads, development of croplands, animal husbandry, etc.) can be achieved by economic planning and using GIS analysis.", [["landscape modification", "TREATMENT", 18, 40], ["anthropogenic behaviors", "PROBLEM", 61, 84], ["GIS analysis", "TEST", 204, 216], ["landscape modification", "OBSERVATION", 18, 40], ["anthropogenic", "OBSERVATION_MODIFIER", 61, 74]]], ["The association between environmental patterns and viral sub-clusters described in this work will therefore permit to develop a typology of situations at risk depending on (i) the virus involved, (ii) on the evolution of risk of contact, and (iii) the risk of emergence in the different situations which could arise.", [["viral sub-clusters", "PROBLEM", 51, 69]]], ["Preventive and protective actions could therefore be proposed to reduce this risk and hinder the evolution and development of hazardous contexts.", [["Preventive and protective actions", "TREATMENT", 0, 33], ["this risk", "PROBLEM", 72, 81]]], ["This work is a preliminary step and deeper analyses and modeling must be further investigated.", [["deeper analyses", "TEST", 36, 51]]], ["Nevertheless it provides opportunities for developing prospective approaches capable of managing protection of bats and wildlife while protecting human populations from potentially devastating emerging bat-borne viral diseases.DiscussionSupplementary data to this article can be found online at https:// doi.org/10.1016/j.meegid.2017.12.009.", [["viral diseases", "DISEASE", 212, 226], ["human", "ORGANISM", 146, 151], ["human", "SPECIES", 146, 151], ["human", "SPECIES", 146, 151], ["borne viral diseases", "PROBLEM", 206, 226], ["viral diseases", "OBSERVATION", 212, 226]]]], "385825bb42346e5cdd6889b751eb2b162b820c0d": [["SARS-COV-2 virus has impacted health care systems all over the world in an unprecedented manner in recent history.", [["SARS", "DISEASE", 0, 4], ["SARS-COV-2 virus", "ORGANISM", 0, 16], ["SARS-COV-2 virus", "SPECIES", 0, 16], ["SARS", "PROBLEM", 0, 4]]], ["Until August 5 th 2020, over 18,300,000 COVID-19 cases have been confirmed with more than 695,000 associated deaths worldwide, and the daily global numbers are still rising [1] .", [["deaths", "DISEASE", 109, 115], ["the daily global numbers", "TEST", 131, 155]]]], "PMC4894689": [["INTRODUCTIONEbola virus (EBOV) is the causative agent of highly lethal zoonotic infections in humans and nonhuman primates in sub-Saharan Africa (1\u20133).", [["zoonotic infections", "DISEASE", 71, 90], ["INTRODUCTIONEbola virus", "ORGANISM", 0, 23], ["EBOV", "ORGANISM", 25, 29], ["humans", "ORGANISM", 94, 100], ["nonhuman primates", "ORGANISM", 105, 122], ["humans", "SPECIES", 94, 100], ["INTRODUCTIONEbola virus", "SPECIES", 0, 23], ["EBOV", "SPECIES", 25, 29], ["humans", "SPECIES", 94, 100], ["INTRODUCTIONEbola virus (EBOV", "PROBLEM", 0, 29], ["highly lethal zoonotic infections", "PROBLEM", 57, 90], ["highly", "OBSERVATION_MODIFIER", 57, 63], ["lethal", "OBSERVATION_MODIFIER", 64, 70], ["zoonotic", "OBSERVATION_MODIFIER", 71, 79], ["infections", "OBSERVATION", 80, 90], ["sub", "OBSERVATION_MODIFIER", 126, 129]]], ["Despite the emerging roles of EBOV and related members of the family Filoviridae (filoviruses) in human disease, our knowledge of the ecological host range of these agents remains limited.", [["human disease", "DISEASE", 98, 111], ["EBOV", "ORGANISM", 30, 34], ["Filoviridae", "GENE_OR_GENE_PRODUCT", 69, 80], ["filoviruses", "GENE_OR_GENE_PRODUCT", 82, 93], ["human", "ORGANISM", 98, 103], ["human", "SPECIES", 98, 103], ["EBOV", "SPECIES", 30, 34], ["human", "SPECIES", 98, 103], ["EBOV", "TREATMENT", 30, 34], ["the family Filoviridae (filoviruses", "TREATMENT", 58, 93], ["human disease", "PROBLEM", 98, 111], ["these agents", "TREATMENT", 159, 171]]], ["Bats are thought to be important reservoirs for filoviruses; however, conclusive evidence in favor of this hypothesis has been obtained only for Marburg virus (MARV) and Ravn virus (RAVV), which were recently found to circulate in Egyptian rousettes (Rousettus aegyptiacus) (4\u20137).INTRODUCTIONPrevious studies demonstrated that, whereas a broad range of mammalian and avian cell lines are susceptible to EBOV and/or MARV, all tested reptilian and amphibian lines are resistant to infection (8\u201310).", [["cell lines", "ANATOMY", 373, 383], ["lines", "ANATOMY", 456, 461], ["infection", "DISEASE", 479, 488], ["Bats", "CELL", 0, 4], ["Marburg virus", "ORGANISM", 145, 158], ["MARV", "ORGANISM", 160, 164], ["Ravn virus", "ORGANISM", 170, 180], ["RAVV", "ORGANISM", 182, 186], ["Rousettus aegyptiacus", "ORGANISM", 251, 272], ["avian", "ORGANISM", 367, 372], ["cell lines", "CELL", 373, 383], ["EBOV", "ORGANISM", 403, 407], ["MARV", "ORGANISM", 415, 419], ["reptilian", "ORGANISM", 432, 441], ["amphibian lines", "CELL", 446, 461], ["mammalian and avian cell lines", "CELL_LINE", 353, 383], ["Marburg virus", "SPECIES", 145, 158], ["Ravn virus", "SPECIES", 170, 180], ["Rousettus aegyptiacus", "SPECIES", 251, 272], ["Marburg virus", "SPECIES", 145, 158], ["MARV", "SPECIES", 160, 164], ["Ravn virus", "SPECIES", 170, 180], ["RAVV", "SPECIES", 182, 186], ["Egyptian rousettes", "SPECIES", 231, 249], ["Rousettus aegyptiacus", "SPECIES", 251, 272], ["EBOV", "SPECIES", 403, 407], ["MARV", "SPECIES", 415, 419], ["filoviruses", "PROBLEM", 48, 59], ["this hypothesis", "PROBLEM", 102, 117], ["Marburg virus", "PROBLEM", 145, 158], ["Ravn virus", "PROBLEM", 170, 180], ["INTRODUCTIONPrevious studies", "TEST", 280, 308], ["mammalian and avian cell lines", "TREATMENT", 353, 383], ["EBOV", "PROBLEM", 403, 407], ["MARV", "TREATMENT", 415, 419], ["amphibian lines", "TREATMENT", 446, 461], ["infection", "PROBLEM", 479, 488], ["thought to be", "UNCERTAINTY", 9, 22], ["avian cell lines", "OBSERVATION", 367, 383], ["amphibian lines", "OBSERVATION", 446, 461], ["infection", "OBSERVATION", 479, 488]]], ["These findings suggested the existence of one or more unknown determinants of filovirus host range.", [["filovirus", "ORGANISM", 78, 87], ["filovirus host range", "OBSERVATION", 78, 98]]], ["Although the determinants of filovirus infection and disease at the organismal level are likely to be complex, it is well established that interactions between viruses and cell-intrinsic host factors, such as entry receptors, can dictate host range.", [["cell", "ANATOMY", 172, 176], ["filovirus infection", "DISEASE", 29, 48], ["filovirus", "ORGANISM", 29, 38], ["cell", "CELL", 172, 176], ["entry receptors", "PROTEIN", 209, 224], ["filovirus infection", "PROBLEM", 29, 48], ["disease", "PROBLEM", 53, 60], ["filovirus", "OBSERVATION_MODIFIER", 29, 38], ["infection", "OBSERVATION", 39, 48], ["likely to be", "UNCERTAINTY", 89, 101]]], ["For example, ortholog-specific sequence variations in angiotensin-converting enzyme 2 (ACE2) and transferrin receptor (TfR1) influence the host range of viruses for which they serve as receptors (severe acute respiratory syndrome-related coronaviruses [11, 12] and New World mammarenaviruses, canine parvoviruses, and murine mammary tumor virus [13\u201318], respectively).", [["mammary tumor", "ANATOMY", 325, 338], ["angiotensin", "CHEMICAL", 54, 65], ["acute respiratory syndrome-related coronaviruses", "DISEASE", 203, 251], ["canine parvoviruses", "DISEASE", 293, 312], ["mammary tumor", "DISEASE", 325, 338], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 54, 85], ["ACE2", "GENE_OR_GENE_PRODUCT", 87, 91], ["transferrin receptor", "GENE_OR_GENE_PRODUCT", 97, 117], ["TfR1", "GENE_OR_GENE_PRODUCT", 119, 123], ["severe acute respiratory syndrome-related coronaviruses", "ORGANISM", 196, 251], ["canine parvoviruses", "ORGANISM", 293, 312], ["murine mammary tumor virus", "ORGANISM", 318, 344], ["angiotensin-converting enzyme 2", "PROTEIN", 54, 85], ["ACE2", "PROTEIN", 87, 91], ["transferrin receptor", "PROTEIN", 97, 117], ["TfR1", "PROTEIN", 119, 123], ["canine", "SPECIES", 293, 299], ["murine", "SPECIES", 318, 324], ["canine", "SPECIES", 293, 299], ["ortholog", "TEST", 13, 21], ["angiotensin", "TEST", 54, 65], ["converting enzyme", "TEST", 66, 83], ["ACE2", "TEST", 87, 91], ["transferrin receptor (TfR1)", "TREATMENT", 97, 124], ["viruses", "PROBLEM", 153, 160], ["severe acute respiratory syndrome", "PROBLEM", 196, 229], ["coronaviruses", "PROBLEM", 238, 251], ["canine parvoviruses", "PROBLEM", 293, 312], ["murine mammary tumor virus", "PROBLEM", 318, 344], ["viruses", "OBSERVATION", 153, 160], ["severe", "OBSERVATION_MODIFIER", 196, 202], ["acute", "OBSERVATION_MODIFIER", 203, 208], ["respiratory syndrome", "OBSERVATION", 209, 229], ["canine parvoviruses", "OBSERVATION", 293, 312], ["mammary", "ANATOMY", 325, 332], ["tumor", "OBSERVATION", 333, 338]]], ["Jae and coworkers demonstrated that chicken cells are resistant to infection by an Old World arenavirus, Lassa virus, because of a single amino acid difference in the chicken ortholog of its intracellular receptor, LAMP1 (19).INTRODUCTIONWe and others recently demonstrated that Niemann-Pick C1 (NPC1), a large endo/lysosomal membrane protein involved in cellular cholesterol trafficking, is an essential intracellular receptor for filovirus entry and infection (20\u201323).", [["cells", "ANATOMY", 44, 49], ["intracellular", "ANATOMY", 191, 204], ["lysosomal membrane", "ANATOMY", 316, 334], ["cellular", "ANATOMY", 355, 363], ["intracellular", "ANATOMY", 405, 418], ["infection", "DISEASE", 67, 76], ["Lassa virus", "DISEASE", 105, 116], ["amino acid", "CHEMICAL", 138, 148], ["cholesterol", "CHEMICAL", 364, 375], ["infection", "DISEASE", 452, 461], ["amino acid", "CHEMICAL", 138, 148], ["cholesterol", "CHEMICAL", 364, 375], ["chicken", "ORGANISM", 36, 43], ["cells", "CELL", 44, 49], ["Old World arenavirus", "ORGANISM", 83, 103], ["Lassa virus", "ORGANISM", 105, 116], ["amino acid", "AMINO_ACID", 138, 148], ["chicken", "ORGANISM", 167, 174], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 191, 204], ["LAMP1", "GENE_OR_GENE_PRODUCT", 215, 220], ["Niemann-Pick C1", "GENE_OR_GENE_PRODUCT", 279, 294], ["NPC1", "GENE_OR_GENE_PRODUCT", 296, 300], ["lysosomal membrane", "CELLULAR_COMPONENT", 316, 334], ["cellular", "CELL", 355, 363], ["cholesterol", "SIMPLE_CHEMICAL", 364, 375], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 405, 418], ["chicken cells", "CELL_TYPE", 36, 49], ["chicken ortholog", "PROTEIN", 167, 183], ["intracellular receptor", "PROTEIN", 191, 213], ["LAMP1 (19)", "PROTEIN", 215, 225], ["Niemann-Pick C1", "PROTEIN", 279, 294], ["NPC1", "PROTEIN", 296, 300], ["endo/lysosomal membrane protein", "PROTEIN", 311, 342], ["chicken", "SPECIES", 36, 43], ["Lassa virus", "SPECIES", 105, 116], ["chicken", "SPECIES", 167, 174], ["chicken", "SPECIES", 36, 43], ["Old World arenavirus", "SPECIES", 83, 103], ["Lassa virus", "SPECIES", 105, 116], ["chicken", "SPECIES", 167, 174], ["chicken cells", "PROBLEM", 36, 49], ["infection", "PROBLEM", 67, 76], ["an Old World arenavirus", "PROBLEM", 80, 103], ["Lassa virus", "PROBLEM", 105, 116], ["a single amino acid difference", "PROBLEM", 129, 159], ["Niemann", "TEST", 279, 286], ["a large endo/lysosomal membrane protein", "TREATMENT", 303, 342], ["cellular cholesterol trafficking", "TREATMENT", 355, 387], ["filovirus entry", "PROBLEM", 432, 447], ["infection", "PROBLEM", 452, 461], ["large", "OBSERVATION_MODIFIER", 305, 310], ["endo", "OBSERVATION", 311, 315], ["lysosomal membrane protein", "OBSERVATION", 316, 342], ["cellular cholesterol trafficking", "OBSERVATION", 355, 387], ["infection", "OBSERVATION", 452, 461]]], ["We also found that NPC1 could influence the cellular host range of filoviruses\u2014human NPC1 conferred susceptibility to filovirus entry and infection when expressed in the nonpermissive reptilian cell line VH-2, derived from a Russell\u2019s viper (Daboia russellii) (22).", [["cellular", "ANATOMY", 44, 52], ["cell line VH-2", "ANATOMY", 194, 208], ["infection", "DISEASE", 138, 147], ["NPC1", "GENE_OR_GENE_PRODUCT", 19, 23], ["cellular", "CELL", 44, 52], ["filoviruses", "GENE_OR_GENE_PRODUCT", 67, 78], ["NPC1", "GENE_OR_GENE_PRODUCT", 85, 89], ["filovirus", "ORGANISM", 118, 127], ["cell line VH-2", "CELL", 194, 208], ["Russell\u2019s viper", "ORGANISM", 225, 240], ["Daboia russellii", "ORGANISM", 242, 258], ["NPC1", "PROTEIN", 19, 23], ["filoviruses", "PROTEIN", 67, 78], ["NPC1", "DNA", 85, 89], ["nonpermissive reptilian cell line VH-2", "CELL_LINE", 170, 208], ["Daboia russellii", "SPECIES", 242, 258], ["Russell\u2019s viper", "SPECIES", 225, 240], ["Daboia russellii", "SPECIES", 242, 258], ["NPC1", "PROBLEM", 19, 23], ["filoviruses\u2014human NPC1", "TREATMENT", 67, 89], ["filovirus entry", "PROBLEM", 118, 133], ["infection", "PROBLEM", 138, 147], ["NPC1", "OBSERVATION", 19, 23], ["cellular host range", "OBSERVATION", 44, 63], ["reptilian cell line", "OBSERVATION", 184, 203]]], ["In that study, however, we did not establish the molecular basis of the NPC1-dependent block to viral entry in VH-2 cells.INTRODUCTIONRecently, we found that a single amino acid residue (position 502) in the second luminal domain of NPC1, domain C, is under positive selection in bats and controls the susceptibility of bat cells to EBOV infection in a host species-dependent manner (24, 25).", [["VH-2 cells", "ANATOMY", 111, 121], ["cells", "ANATOMY", 324, 329], ["amino acid", "CHEMICAL", 167, 177], ["luminal", "CHEMICAL", 215, 222], ["EBOV infection", "DISEASE", 333, 347], ["amino acid", "CHEMICAL", 167, 177], ["NPC1", "GENE_OR_GENE_PRODUCT", 72, 76], ["VH-2 cells", "CELL", 111, 121], ["amino acid", "AMINO_ACID", 167, 177], ["NPC1", "GENE_OR_GENE_PRODUCT", 233, 237], ["domain C", "GENE_OR_GENE_PRODUCT", 239, 247], ["bat cells", "CELL", 320, 329], ["EBOV", "ORGANISM", 333, 337], ["NPC1", "PROTEIN", 72, 76], ["VH-2 cells", "CELL_LINE", 111, 121], ["luminal domain", "PROTEIN", 215, 229], ["NPC1", "PROTEIN", 233, 237], ["domain C", "PROTEIN", 239, 247], ["bat cells", "CELL_TYPE", 320, 329], ["EBOV", "SPECIES", 333, 337], ["that study", "TEST", 3, 13], ["the NPC1", "PROBLEM", 68, 76], ["dependent block", "PROBLEM", 77, 92], ["a single amino acid residue", "PROBLEM", 158, 185], ["domain C", "PROBLEM", 239, 247], ["the susceptibility of bat cells", "PROBLEM", 298, 329], ["EBOV infection", "PROBLEM", 333, 347], ["NPC1", "OBSERVATION", 233, 237], ["positive selection", "OBSERVATION", 258, 276], ["bat cells", "OBSERVATION", 320, 329], ["EBOV", "OBSERVATION_MODIFIER", 333, 337], ["infection", "OBSERVATION", 338, 347], ["host species", "OBSERVATION_MODIFIER", 353, 365], ["dependent", "OBSERVATION_MODIFIER", 366, 375]]], ["Here, we demonstrate that an adjacent residue, 503, highly conserved in domain C of NPC1, influences EBOV host range in reptilian cells by controlling its activity as a filovirus receptor.", [["cells", "ANATOMY", 130, 135], ["NPC1", "GENE_OR_GENE_PRODUCT", 84, 88], ["EBOV", "ORGANISM", 101, 105], ["reptilian cells", "CELL", 120, 135], ["domain C", "PROTEIN", 72, 80], ["NPC1", "PROTEIN", 84, 88], ["reptilian cells", "CELL_TYPE", 120, 135], ["filovirus receptor", "PROTEIN", 169, 187], ["an adjacent residue", "PROBLEM", 26, 45], ["NPC1", "PROBLEM", 84, 88], ["reptilian cells", "TREATMENT", 120, 135], ["a filovirus receptor", "TREATMENT", 167, 187], ["reptilian cells", "OBSERVATION", 120, 135]]], ["The recently solved structure of the EBOV entry glycoprotein (GP1,2; hereafter referred to as GP) bound to domain C shows that these two residues are in a loop that dips into the exposed receptor-binding site (26).", [["EBOV", "ORGANISM", 37, 41], ["EBOV entry glycoprotein", "PROTEIN", 37, 60], ["GP1,2", "PROTEIN", 62, 67], ["GP", "PROTEIN", 94, 96], ["domain C", "PROTEIN", 107, 115], ["exposed receptor-binding site", "PROTEIN", 179, 208], ["these two residues", "PROBLEM", 127, 145]]], ["Therefore, our findings identify a hot spot in NPC1 at the EBOV GP-binding interface that influences virus-receptor recognition and host cell susceptibility, suggesting evolutionary scenarios in which antagonism with filoviruses could sculpt host NPC1 genes selectively, without compromising their ancient, and essential, function in cellular cholesterol homeostasis.The second luminal domain of the Russell\u2019s viper NPC1 ortholog binds poorly to the Ebola virus glycoprotein. ::: RESULTSWe postulated that EBOV fails to enter and infect Russell\u2019s viper VH-2 cells because the EBOV entry glycoprotein, GP, cannot recognize the viper ortholog of the filovirus intracellular receptor, Niemann-Pick C1 (Daboia russellii NPC1 [DrNPC1]).", [["cell", "ANATOMY", 137, 141], ["cellular", "ANATOMY", 334, 342], ["\u2019s viper VH-2 cells", "ANATOMY", 544, 563], ["intracellular", "ANATOMY", 658, 671], ["cholesterol", "CHEMICAL", 343, 354], ["luminal", "CHEMICAL", 378, 385], ["cholesterol", "CHEMICAL", 343, 354], ["NPC1", "GENE_OR_GENE_PRODUCT", 47, 51], ["EBOV", "ORGANISM", 59, 63], ["host cell", "CELL", 132, 141], ["filoviruses", "GENE_OR_GENE_PRODUCT", 217, 228], ["NPC1", "GENE_OR_GENE_PRODUCT", 247, 251], ["cellular", "CELL", 334, 342], ["cholesterol", "SIMPLE_CHEMICAL", 343, 354], ["NPC1", "GENE_OR_GENE_PRODUCT", 416, 420], ["Ebola virus", "ORGANISM", 450, 461], ["EBOV", "ORGANISM", 506, 510], ["VH-2 cells", "CELL", 553, 563], ["EBOV", "ORGANISM", 576, 580], ["GP", "GENE_OR_GENE_PRODUCT", 601, 603], ["viper", "GENE_OR_GENE_PRODUCT", 626, 631], ["filovirus", "ORGANISM", 648, 657], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 658, 671], ["Niemann-Pick C1", "GENE_OR_GENE_PRODUCT", 682, 697], ["Daboia russellii NPC1", "GENE_OR_GENE_PRODUCT", 699, 720], ["DrNPC1", "GENE_OR_GENE_PRODUCT", 722, 728], ["NPC1", "PROTEIN", 47, 51], ["EBOV GP", "PROTEIN", 59, 66], ["NPC1 genes", "DNA", 247, 257], ["Russell\u2019s viper NPC1 ortholog", "PROTEIN", 400, 429], ["Ebola virus glycoprotein", "PROTEIN", 450, 474], ["Russell\u2019s viper VH-2 cells", "CELL_LINE", 537, 563], ["EBOV entry glycoprotein", "PROTEIN", 576, 599], ["GP", "PROTEIN", 601, 603], ["viper ortholog", "PROTEIN", 626, 640], ["filovirus intracellular receptor", "PROTEIN", 648, 680], ["Niemann-Pick C1", "PROTEIN", 682, 697], ["NPC1", "PROTEIN", 716, 720], ["DrNPC1", "PROTEIN", 722, 728], ["Ebola virus", "SPECIES", 450, 461], ["Daboia russellii", "SPECIES", 699, 715], ["Russell\u2019s viper", "SPECIES", 400, 415], ["Ebola virus", "SPECIES", 450, 461], ["EBOV", "SPECIES", 506, 510], ["Russell\u2019s viper", "SPECIES", 537, 552], ["EBOV", "SPECIES", 576, 580], ["Daboia russellii", "SPECIES", 699, 715], ["a hot spot in NPC1", "PROBLEM", 33, 51], ["influences virus", "PROBLEM", 90, 106], ["host cell susceptibility", "PROBLEM", 132, 156], ["evolutionary scenarios", "PROBLEM", 169, 191], ["filoviruses", "PROBLEM", 217, 228], ["EBOV", "PROBLEM", 506, 510], ["Niemann", "TEST", 682, 689], ["host cell susceptibility", "OBSERVATION", 132, 156], ["suggesting", "UNCERTAINTY", 158, 168], ["evolutionary scenarios", "OBSERVATION", 169, 191], ["cellular cholesterol homeostasis", "OBSERVATION", 334, 366], ["luminal", "ANATOMY_MODIFIER", 378, 385]]], ["We previously showed that the second luminal domain (C) of human NPC1 (Homo sapiens NPC1 [HsNPC1]) directly contacts a cleaved form of EBOV GP (GPCL) and that GPCL-HsNPC1 domain C binding is essential for filovirus entry (22, 23).", [["luminal", "CHEMICAL", 37, 44], ["human", "ORGANISM", 59, 64], ["NPC1", "GENE_OR_GENE_PRODUCT", 65, 69], ["Homo sapiens NPC1", "GENE_OR_GENE_PRODUCT", 71, 88], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 90, 96], ["EBOV GP", "GENE_OR_GENE_PRODUCT", 135, 142], ["GPCL", "GENE_OR_GENE_PRODUCT", 144, 148], ["GPCL-HsNPC1 domain C", "GENE_OR_GENE_PRODUCT", 159, 179], ["luminal domain", "PROTEIN", 37, 51], ["human NPC1", "PROTEIN", 59, 69], ["Homo sapiens NPC1", "PROTEIN", 71, 88], ["HsNPC1", "PROTEIN", 90, 96], ["EBOV GP", "PROTEIN", 135, 142], ["GPCL", "PROTEIN", 144, 148], ["GPCL", "PROTEIN", 159, 163], ["HsNPC1 domain C", "PROTEIN", 164, 179], ["human", "SPECIES", 59, 64], ["Homo sapiens", "SPECIES", 71, 83], ["human", "SPECIES", 59, 64], ["Homo sapiens", "SPECIES", 71, 83], ["the second luminal domain (C) of human NPC1 (Homo sapiens NPC1 [HsNPC1]", "TREATMENT", 26, 97], ["GPCL", "TEST", 159, 163], ["HsNPC1 domain C binding", "PROBLEM", 164, 187]]], ["Accordingly, we investigated the capacity of DrNPC1 domain C to bind to GPCL and support EBOV entry and infection.The second luminal domain of the Russell\u2019s viper NPC1 ortholog binds poorly to the Ebola virus glycoprotein. ::: RESULTSWe first used reverse transcription-PCR (RT-PCR) to isolate and sequence DrNPC1 domain C. Alignment of domain C amino acid sequences from HsNPC1 and DrNPC1 revealed a substantial degree of conservation (80% amino acid identity), with identical arrangements of cysteine residues and similar predicted secondary structures, suggesting a similar overall fold for the two proteins (Fig. 1).The second luminal domain of the Russell\u2019s viper NPC1 ortholog binds poorly to the Ebola virus glycoprotein. ::: RESULTSTo facilitate in vitro GPCL-NPC1-binding studies, we engineered a soluble form of DrNPC1 domain C, as previously described for HsNPC1 (22).", [["infection", "DISEASE", 104, 113], ["luminal", "CHEMICAL", 125, 132], ["amino acid", "CHEMICAL", 346, 356], ["amino acid", "CHEMICAL", 441, 451], ["luminal", "CHEMICAL", 631, 638], ["amino acid", "CHEMICAL", 346, 356], ["amino acid", "CHEMICAL", 441, 451], ["cysteine", "CHEMICAL", 494, 502], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 45, 60], ["GPCL", "GENE_OR_GENE_PRODUCT", 72, 76], ["EBOV", "ORGANISM", 89, 93], ["NPC1", "GENE_OR_GENE_PRODUCT", 163, 167], ["Ebola virus", "ORGANISM", 197, 208], ["amino acid", "AMINO_ACID", 346, 356], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 372, 378], ["amino acid", "AMINO_ACID", 441, 451], ["cysteine", "AMINO_ACID", 494, 502], ["NPC1", "GENE_OR_GENE_PRODUCT", 669, 673], ["Ebola virus", "ORGANISM", 703, 714], ["GPCL", "GENE_OR_GENE_PRODUCT", 763, 767], ["NPC1", "GENE_OR_GENE_PRODUCT", 768, 772], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 822, 837], ["DrNPC1 domain C", "PROTEIN", 45, 60], ["GPCL", "PROTEIN", 72, 76], ["Russell\u2019s viper NPC1 ortholog", "PROTEIN", 147, 176], ["Ebola virus glycoprotein", "PROTEIN", 197, 221], ["domain C amino acid sequences", "PROTEIN", 337, 366], ["HsNPC1", "PROTEIN", 372, 378], ["DrNPC1", "PROTEIN", 383, 389], ["Russell\u2019s viper NPC1 ortholog", "PROTEIN", 653, 682], ["Ebola virus glycoprotein", "PROTEIN", 703, 727], ["GPCL", "PROTEIN", 763, 767], ["NPC1", "PROTEIN", 768, 772], ["DrNPC1 domain C", "PROTEIN", 822, 837], ["HsNPC1", "PROTEIN", 867, 873], ["Ebola virus", "SPECIES", 197, 208], ["Ebola virus", "SPECIES", 703, 714], ["EBOV", "SPECIES", 89, 93], ["Russell\u2019s viper", "SPECIES", 147, 162], ["Ebola virus", "SPECIES", 197, 208], ["Russell\u2019s viper", "SPECIES", 653, 668], ["Ebola virus", "SPECIES", 703, 714], ["DrNPC1 domain C", "TREATMENT", 45, 60], ["GPCL", "TREATMENT", 72, 76], ["infection", "PROBLEM", 104, 113], ["reverse transcription", "TREATMENT", 248, 269], ["PCR", "TEST", 270, 273], ["RT-PCR", "TEST", 275, 281], ["sequence DrNPC1 domain C. Alignment of domain C amino acid sequences", "TEST", 298, 366], ["HsNPC1", "TEST", 372, 378], ["DrNPC1", "TEST", 383, 389], ["amino acid identity", "TEST", 441, 460], ["cysteine residues", "PROBLEM", 494, 511], ["binding studies", "TEST", 773, 788], ["DrNPC1 domain C", "TREATMENT", 822, 837], ["HsNPC1", "TEST", 867, 873], ["EBOV", "OBSERVATION", 89, 93], ["infection", "OBSERVATION", 104, 113], ["luminal", "ANATOMY_MODIFIER", 125, 132], ["substantial", "OBSERVATION_MODIFIER", 401, 412], ["degree", "OBSERVATION_MODIFIER", 413, 419], ["cysteine residues", "OBSERVATION", 494, 511], ["luminal", "ANATOMY_MODIFIER", 631, 638]]], ["Transfection of HEK 293T cells with this construct afforded the secretion of an extensively N-glycosylated form of DrNPC1 domain C (Fig. 2A).", [["HEK 293T cells", "ANATOMY", 16, 30], ["N", "CHEMICAL", 92, 93], ["HEK 293T cells", "CELL", 16, 30], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 115, 130], ["Fig. 2A", "GENE_OR_GENE_PRODUCT", 132, 139], ["HEK 293T cells", "CELL_LINE", 16, 30], ["N-glycosylated form", "PROTEIN", 92, 111], ["DrNPC1 domain C", "PROTEIN", 115, 130], ["Fig. 2A", "PROTEIN", 132, 139], ["this construct", "PROBLEM", 36, 50], ["DrNPC1 domain C", "TREATMENT", 115, 130]]], ["As shown previously, purified HsNPC1 domain C could bind to recombinant vesicular stomatitis virus Indiana particles bearing cleaved EBOV GP (rVSV-GPCL), as measured by enzyme-linked immunosorbent assay (ELISA) (22); in contrast, DrNPC1 domain C exhibited no binding by ELISA, even at the highest concentration tested (Fig. 2B).", [["HsNPC1 domain C", "GENE_OR_GENE_PRODUCT", 30, 45], ["recombinant", "ORGANISM", 60, 71], ["vesicular stomatitis virus", "ORGANISM", 72, 98], ["Indiana", "ORGANISM", 99, 106], ["EBOV", "ORGANISM", 133, 137], ["GP", "ORGANISM", 138, 140], ["rVSV-GPCL", "GENE_OR_GENE_PRODUCT", 142, 151], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 230, 245], ["HsNPC1 domain C", "PROTEIN", 30, 45], ["EBOV GP", "PROTEIN", 133, 140], ["rVSV", "PROTEIN", 142, 146], ["GPCL", "PROTEIN", 147, 151], ["DrNPC1 domain C", "PROTEIN", 230, 245], ["stomatitis virus", "SPECIES", 82, 98], ["stomatitis virus", "SPECIES", 82, 98], ["purified HsNPC1 domain C", "PROBLEM", 21, 45], ["recombinant vesicular stomatitis", "PROBLEM", 60, 92], ["rVSV", "TEST", 142, 146], ["enzyme", "TEST", 169, 175], ["immunosorbent assay", "TEST", 183, 202], ["ELISA", "TEST", 204, 209], ["DrNPC1 domain C", "PROBLEM", 230, 245], ["ELISA", "TEST", 270, 275], ["vesicular stomatitis", "ANATOMY", 72, 92]]], ["Therefore, DrNPC1 domain C, in contrast to its human counterpart, recognizes the EBOV glycoprotein poorly or not at all.DrNPC1 domain C can substitute for HsNPC1 domain C in mediating endo/lysosomal cholesterol clearance but not EBOV entry and infection. ::: RESULTSWhile the efficient secretion of the soluble, glycosylated DrNPC1 domain C construct suggested that it was not misfolded, it was nevertheless conceivable that subtle structural aberrations rendered this protein biologically inactive.", [["lysosomal", "ANATOMY", 189, 198], ["cholesterol", "CHEMICAL", 199, 210], ["infection", "DISEASE", 244, 253], ["cholesterol", "CHEMICAL", 199, 210], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 11, 26], ["human", "ORGANISM", 47, 52], ["EBOV", "ORGANISM", 81, 85], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 120, 135], ["HsNPC1 domain C", "GENE_OR_GENE_PRODUCT", 155, 170], ["lysosomal cholesterol", "SIMPLE_CHEMICAL", 189, 210], ["EBOV", "ORGANISM", 229, 233], ["DrNPC1", "GENE_OR_GENE_PRODUCT", 325, 331], ["DrNPC1 domain C", "PROTEIN", 11, 26], ["EBOV glycoprotein", "PROTEIN", 81, 98], ["DrNPC1 domain C", "PROTEIN", 120, 135], ["HsNPC1 domain C", "PROTEIN", 155, 170], ["DrNPC1 domain C", "PROTEIN", 325, 340], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["EBOV", "SPECIES", 81, 85], ["EBOV", "SPECIES", 229, 233], ["DrNPC1 domain C", "TREATMENT", 11, 26], ["HsNPC1 domain C", "TREATMENT", 155, 170], ["endo/lysosomal cholesterol clearance", "TREATMENT", 184, 220], ["infection", "PROBLEM", 244, 253], ["the soluble", "TREATMENT", 299, 310], ["glycosylated DrNPC1 domain C construct", "TEST", 312, 350], ["subtle structural aberrations", "PROBLEM", 425, 454], ["lysosomal cholesterol", "OBSERVATION", 189, 210], ["infection", "OBSERVATION", 244, 253], ["subtle", "OBSERVATION_MODIFIER", 425, 431], ["structural aberrations", "OBSERVATION", 432, 454]]], ["Accordingly, we assessed the capacity of DrNPC1 domain C to support NPC1\u2019s best-established cellular function\u2014clearance of unesterified cholesterol from endo/lysosomal compartments (Fig. 3A and B).", [["cellular", "ANATOMY", 92, 100], ["lysosomal compartments", "ANATOMY", 158, 180], ["cholesterol", "CHEMICAL", 136, 147], ["cholesterol", "CHEMICAL", 136, 147], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 41, 56], ["NPC1", "GENE_OR_GENE_PRODUCT", 68, 72], ["cellular", "CELL", 92, 100], ["cholesterol", "SIMPLE_CHEMICAL", 136, 147], ["lysosomal compartments", "CELLULAR_COMPONENT", 158, 180], ["B", "GENE_OR_GENE_PRODUCT", 194, 195], ["DrNPC1 domain C", "PROTEIN", 41, 56], ["NPC1", "PROTEIN", 68, 72], ["DrNPC1 domain C", "TREATMENT", 41, 56], ["NPC1", "TREATMENT", 68, 72], ["unesterified cholesterol", "TEST", 123, 147], ["endo/lysosomal compartments", "TEST", 153, 180]]], ["This activity requires the full-length NPC1 protein, including all three major luminal domains, A, C, and I. We therefore generated and tested an HsNPC1 chimera in which domain C (residues 373 to 620) was seamlessly replaced with its viper counterpart (HsNPC1-DrC)\u2014we previously found that replacing domain C in NPC1 using restriction site cloning, which introduced two additional amino acid residues at each junction, resulted in proteins that were defective in localization and cholesterol clearance.", [["luminal", "ANATOMY", 79, 86], ["amino acid", "CHEMICAL", 381, 391], ["cholesterol", "CHEMICAL", 480, 491], ["amino acid", "CHEMICAL", 381, 391], ["cholesterol", "CHEMICAL", 480, 491], ["NPC1", "GENE_OR_GENE_PRODUCT", 39, 43], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 146, 152], ["HsNPC1-DrC", "GENE_OR_GENE_PRODUCT", 253, 263], ["NPC1", "GENE_OR_GENE_PRODUCT", 312, 316], ["amino acid", "AMINO_ACID", 381, 391], ["cholesterol", "SIMPLE_CHEMICAL", 480, 491], ["NPC1 protein", "PROTEIN", 39, 51], ["major luminal domains", "PROTEIN", 73, 94], ["C", "PROTEIN", 99, 100], ["HsNPC1 chimera", "PROTEIN", 146, 160], ["domain C", "PROTEIN", 170, 178], ["residues 373 to 620", "PROTEIN", 180, 199], ["viper counterpart", "PROTEIN", 234, 251], ["HsNPC1", "PROTEIN", 253, 259], ["DrC", "PROTEIN", 260, 263], ["domain C", "PROTEIN", 300, 308], ["NPC1", "PROTEIN", 312, 316], ["the full-length NPC1 protein", "TREATMENT", 23, 51], ["an HsNPC1 chimera", "TREATMENT", 143, 160], ["domain C in NPC1", "TREATMENT", 300, 316], ["restriction site cloning", "TREATMENT", 323, 347], ["two additional amino acid residues at each junction", "TREATMENT", 366, 417], ["proteins", "PROBLEM", 431, 439], ["cholesterol clearance", "TEST", 480, 501], ["acid residues", "OBSERVATION", 387, 400]]], ["The wild-type (WT) HsNPC1 and HsNPC1-DrC chimera constructs were then stably expressed in the NPC1-null Chinese hamster ovary (CHO) M12 cell line (24).", [["hamster ovary (CHO) M12 cell line", "ANATOMY", 112, 145], ["wild-type (WT)", "ORGANISM", 4, 18], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 19, 25], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 30, 36], ["DrC", "GENE_OR_GENE_PRODUCT", 37, 40], ["NPC1", "GENE_OR_GENE_PRODUCT", 94, 98], ["CHO) M12 cell line", "CELL", 127, 145], ["wild-type (WT) HsNPC1 and HsNPC1-DrC chimera constructs", "DNA", 4, 59], ["NPC1-null Chinese hamster ovary (CHO) M12 cell line", "CELL_LINE", 94, 145], ["Chinese hamster", "SPECIES", 104, 119], ["HsNPC1", "TEST", 19, 25], ["HsNPC1", "TEST", 30, 36], ["DrC chimera constructs", "TREATMENT", 37, 59], ["null Chinese hamster ovary (CHO) M12 cell line", "TREATMENT", 99, 145], ["NPC1", "ANATOMY", 94, 98], ["ovary", "ANATOMY", 120, 125]]], ["As expected, immunostaining of WT HsNPC1 transiently expressed in a U2OS NPC1\u2212/\u2212 cell line (27) showed colocalization with the endo/lysosomal marker LAMP1 (Fig. 3A) The behavior of HsNPC1-DrC resembled that of WT HsNPC1, indicating that it too localizes to endo/lysosomal compartments (Fig. 3A).", [["U2OS NPC1\u2212/\u2212 cell line", "ANATOMY", 68, 90], ["lysosomal", "ANATOMY", 132, 141], ["lysosomal compartments", "ANATOMY", 262, 284], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 34, 40], ["U2OS", "CELL", 68, 72], ["NPC1", "GENE_OR_GENE_PRODUCT", 73, 77], ["lysosomal", "CELLULAR_COMPONENT", 132, 141], ["LAMP1", "GENE_OR_GENE_PRODUCT", 149, 154], ["HsNPC1-DrC", "GENE_OR_GENE_PRODUCT", 181, 191], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 213, 219], ["WT HsNPC1", "PROTEIN", 31, 40], ["U2OS NPC1\u2212/\u2212 cell line", "CELL_LINE", 68, 90], ["endo/lysosomal marker LAMP1 (Fig. 3A)", "PROTEIN", 127, 164], ["HsNPC1", "PROTEIN", 181, 187], ["DrC", "PROTEIN", 188, 191], ["WT HsNPC1", "PROTEIN", 210, 219], ["WT HsNPC1", "TEST", 31, 40], ["a U2OS NPC1", "TEST", 66, 77], ["cell line", "TEST", 81, 90], ["the endo/lysosomal marker LAMP1", "TREATMENT", 123, 154], ["HsNPC1", "TEST", 181, 187], ["WT HsNPC1", "TREATMENT", 210, 219], ["endo/lysosomal compartments", "TEST", 257, 284], ["cell line", "OBSERVATION", 81, 90]]], ["These results suggest that DrNPC1 domain C is correctly folded and does not interfere with the correct folding and trafficking of full-length HsNPC1.DrNPC1 domain C can substitute for HsNPC1 domain C in mediating endo/lysosomal cholesterol clearance but not EBOV entry and infection. ::: RESULTSWe next monitored the cholesterol clearance activity of each protein upon stable expression in NPC1-null M12 cells (Fig. 3B).", [["lysosomal", "ANATOMY", 218, 227], ["NPC1-null M12 cells", "ANATOMY", 390, 409], ["cholesterol", "CHEMICAL", 228, 239], ["infection", "DISEASE", 273, 282], ["cholesterol", "CHEMICAL", 317, 328], ["cholesterol", "CHEMICAL", 228, 239], ["cholesterol", "CHEMICAL", 317, 328], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 27, 42], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 142, 148], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 149, 164], ["HsNPC1 domain C", "GENE_OR_GENE_PRODUCT", 184, 199], ["lysosomal cholesterol", "SIMPLE_CHEMICAL", 218, 239], ["EBOV", "ORGANISM", 258, 262], ["cholesterol", "SIMPLE_CHEMICAL", 317, 328], ["NPC1", "GENE_OR_GENE_PRODUCT", 390, 394], ["Fig. 3B", "CELL", 411, 418], ["DrNPC1 domain C", "PROTEIN", 27, 42], ["HsNPC1", "PROTEIN", 142, 148], ["DrNPC1 domain C", "PROTEIN", 149, 164], ["HsNPC1 domain C", "PROTEIN", 184, 199], ["NPC1-null M12 cells", "CELL_LINE", 390, 409], ["EBOV", "SPECIES", 258, 262], ["DrNPC1 domain C", "PROBLEM", 27, 42], ["full-length HsNPC1", "TREATMENT", 130, 148], ["HsNPC1 domain C", "TREATMENT", 184, 199], ["endo/lysosomal cholesterol clearance", "TREATMENT", 213, 249], ["infection", "PROBLEM", 273, 282], ["the cholesterol clearance", "TEST", 313, 338], ["NPC1", "TEST", 390, 394], ["lysosomal cholesterol", "OBSERVATION", 218, 239], ["infection", "OBSERVATION", 273, 282], ["stable", "OBSERVATION_MODIFIER", 369, 375], ["M12 cells", "OBSERVATION", 400, 409]]], ["Filipin, a fluorescent probe for free cholesterol, extensively stained the cholesterol-laden endo/lysosomal compartments of the parental M12 cells, as shown previously (24).", [["lysosomal compartments", "ANATOMY", 98, 120], ["M12 cells", "ANATOMY", 137, 146], ["Filipin", "CHEMICAL", 0, 7], ["cholesterol", "CHEMICAL", 38, 49], ["cholesterol", "CHEMICAL", 75, 86], ["Filipin", "CHEMICAL", 0, 7], ["cholesterol", "CHEMICAL", 38, 49], ["cholesterol", "CHEMICAL", 75, 86], ["Filipin", "SIMPLE_CHEMICAL", 0, 7], ["cholesterol", "SIMPLE_CHEMICAL", 38, 49], ["cholesterol", "SIMPLE_CHEMICAL", 75, 86], ["M12 cells", "CELL", 137, 146], ["parental M12 cells", "CELL_LINE", 128, 146], ["Filipin", "TREATMENT", 0, 7], ["a fluorescent probe", "TREATMENT", 9, 28], ["free cholesterol", "TEST", 33, 49], ["the cholesterol", "TEST", 71, 86], ["M12 cells", "ANATOMY", 137, 146]]], ["Ectopic HsNPC1 expression could clear this accumulated cholesterol, as previously described (20), substantially reducing filipin staining.", [["cholesterol", "CHEMICAL", 55, 66], ["filipin", "CHEMICAL", 121, 128], ["cholesterol", "CHEMICAL", 55, 66], ["filipin", "CHEMICAL", 121, 128], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 8, 14], ["cholesterol", "SIMPLE_CHEMICAL", 55, 66], ["filipin", "SIMPLE_CHEMICAL", 121, 128], ["HsNPC1", "PROTEIN", 8, 14], ["Ectopic HsNPC1 expression", "PROBLEM", 0, 25], ["this accumulated cholesterol", "PROBLEM", 38, 66], ["substantially reducing filipin staining", "PROBLEM", 98, 137], ["accumulated", "OBSERVATION_MODIFIER", 43, 54], ["cholesterol", "OBSERVATION_MODIFIER", 55, 66], ["reducing", "OBSERVATION_MODIFIER", 112, 120], ["filipin staining", "OBSERVATION", 121, 137]]], ["Remarkably, HsNPC1-DrC could rescue cholesterol clearance as efficiently as WT HsNPC1 (Fig. 3B).", [["HsNPC1-DrC", "CHEMICAL", 12, 22], ["cholesterol", "CHEMICAL", 36, 47], ["cholesterol", "CHEMICAL", 36, 47], ["HsNPC1-DrC", "GENE_OR_GENE_PRODUCT", 12, 22], ["cholesterol", "SIMPLE_CHEMICAL", 36, 47], ["HsNPC1", "PROTEIN", 12, 18], ["DrC", "PROTEIN", 19, 22], ["WT HsNPC1", "PROTEIN", 76, 85], ["HsNPC1", "TEST", 12, 18], ["rescue cholesterol clearance", "TREATMENT", 29, 57], ["WT HsNPC1", "TEST", 76, 85]]], ["These findings affirm that DrNPC1 domain C is biologically active and competent to perform a major housekeeping function of its human counterpart, despite its divergence from the latter at 48 out of 248 amino acid positions (Fig. 1).DrNPC1 domain C can substitute for HsNPC1 domain C in mediating endo/lysosomal cholesterol clearance but not EBOV entry and infection. ::: RESULTSFinally, we challenged M12 cell lines expressing WT HsNPC1 or HsNPC1-DrC with authentic EBOV (Fig. 3C).", [["lysosomal", "ANATOMY", 302, 311], ["M12 cell lines", "ANATOMY", 402, 416], ["amino acid", "CHEMICAL", 203, 213], ["cholesterol", "CHEMICAL", 312, 323], ["infection", "DISEASE", 357, 366], ["amino acid", "CHEMICAL", 203, 213], ["cholesterol", "CHEMICAL", 312, 323], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 27, 42], ["human", "ORGANISM", 128, 133], ["amino acid", "AMINO_ACID", 203, 213], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 233, 248], ["HsNPC1 domain C", "GENE_OR_GENE_PRODUCT", 268, 283], ["lysosomal cholesterol", "SIMPLE_CHEMICAL", 302, 323], ["EBOV", "ORGANISM", 342, 346], ["M12 cell lines", "CELL", 402, 416], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 431, 437], ["HsNPC1-DrC", "GENE_OR_GENE_PRODUCT", 441, 451], ["EBOV", "ORGANISM", 467, 471], ["DrNPC1 domain C", "PROTEIN", 27, 42], ["DrNPC1 domain C", "PROTEIN", 233, 248], ["HsNPC1 domain C", "PROTEIN", 268, 283], ["M12 cell lines", "CELL_LINE", 402, 416], ["WT HsNPC1", "PROTEIN", 428, 437], ["HsNPC1", "PROTEIN", 441, 447], ["DrC", "PROTEIN", 448, 451], ["human", "SPECIES", 128, 133], ["human", "SPECIES", 128, 133], ["EBOV", "SPECIES", 342, 346], ["DrNPC1 domain C", "PROBLEM", 27, 42], ["DrNPC1 domain C", "TREATMENT", 233, 248], ["HsNPC1 domain C", "TREATMENT", 268, 283], ["endo/lysosomal cholesterol clearance", "TREATMENT", 297, 333], ["EBOV entry", "PROBLEM", 342, 352], ["infection", "PROBLEM", 357, 366], ["M12 cell lines", "TREATMENT", 402, 416], ["HsNPC1", "TEST", 431, 437], ["HsNPC1", "TEST", 441, 447], ["authentic EBOV", "TREATMENT", 457, 471], ["active", "OBSERVATION_MODIFIER", 59, 65], ["lysosomal cholesterol", "OBSERVATION", 302, 323], ["not", "UNCERTAINTY", 338, 341], ["EBOV", "OBSERVATION", 342, 346], ["infection", "OBSERVATION", 357, 366], ["M12 cell lines", "OBSERVATION", 402, 416]]], ["Replacement of human domain C with its Russell\u2019s viper ortholog reduced EBOV infection by almost 3 orders of magnitude.", [["EBOV infection", "DISEASE", 72, 86], ["human", "ORGANISM", 15, 20], ["domain C", "GENE_OR_GENE_PRODUCT", 21, 29], ["Russell\u2019s viper", "ORGANISM", 39, 54], ["EBOV", "ORGANISM", 72, 76], ["human domain C", "PROTEIN", 15, 29], ["Russell\u2019s viper ortholog", "PROTEIN", 39, 63], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 15, 20], ["EBOV", "SPECIES", 72, 76], ["Replacement of human domain C", "TREATMENT", 0, 29], ["EBOV infection", "PROBLEM", 72, 86], ["reduced", "OBSERVATION_MODIFIER", 64, 71], ["EBOV", "OBSERVATION_MODIFIER", 72, 76], ["infection", "OBSERVATION", 77, 86]]], ["Similar results were obtained in infections with rVSV-EBOV GP (Fig. 3D), confirming that the DrNPC1 domain C-imposed infection block occurs at the viral entry step.", [["infections", "DISEASE", 33, 43], ["infection", "DISEASE", 117, 126], ["rVSV-EBOV GP", "ORGANISM", 49, 61], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 93, 108], ["DrNPC1 domain C", "PROTEIN", 93, 108], ["rVSV-EBOV", "SPECIES", 49, 58], ["infections", "PROBLEM", 33, 43], ["rVSV", "TEST", 49, 53], ["the DrNPC1 domain C", "PROBLEM", 89, 108], ["imposed infection block", "PROBLEM", 109, 132], ["infection", "OBSERVATION", 117, 126]]], ["First, the failure of DrNPC1 to support EBOV entry and infection arises at least in part because its domain C cannot bind to EBOV GPCL.", [["infection", "DISEASE", 55, 64], ["DrNPC1", "GENE_OR_GENE_PRODUCT", 22, 28], ["EBOV", "ORGANISM", 40, 44], ["EBOV", "ORGANISM", 125, 129], ["GPCL", "GENE_OR_GENE_PRODUCT", 130, 134], ["DrNPC1", "PROTEIN", 22, 28], ["domain C", "PROTEIN", 101, 109], ["EBOV GPCL", "PROTEIN", 125, 134], ["EBOV", "SPECIES", 40, 44], ["DrNPC1", "TREATMENT", 22, 28], ["EBOV entry", "PROBLEM", 40, 50], ["infection", "PROBLEM", 55, 64], ["EBOV GPCL", "TEST", 125, 134], ["failure", "OBSERVATION", 11, 18], ["infection", "OBSERVATION", 55, 64]]], ["Second, one or more differences between the domain C sequences of HsNPC1 and DrNPC1 render DrNPC1 bereft of viral receptor activity without perturbing its normal function in cellular cholesterol homeostasis.Differences in N-glycosylation do not explain the defect in EBOV GPCL-DrNPC1 domain C binding. ::: RESULTSTo uncover the molecular basis of DrNPC1\u2019s defective viral receptor function, we engineered and tested a panel of mutant, soluble NPC1 domain C constructs in both HsNPC1 and DrNPC1 backgrounds.", [["cellular", "ANATOMY", 174, 182], ["cholesterol", "CHEMICAL", 183, 194], ["cholesterol", "CHEMICAL", 183, 194], ["N", "CHEMICAL", 222, 223], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 66, 72], ["DrNPC1", "GENE_OR_GENE_PRODUCT", 77, 83], ["DrNPC1", "GENE_OR_GENE_PRODUCT", 91, 97], ["cellular", "CELL", 174, 182], ["cholesterol", "SIMPLE_CHEMICAL", 183, 194], ["EBOV", "ORGANISM", 267, 271], ["GPCL", "GENE_OR_GENE_PRODUCT", 272, 276], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 277, 292], ["DrNPC1", "GENE_OR_GENE_PRODUCT", 347, 353], ["NPC1 domain C", "GENE_OR_GENE_PRODUCT", 443, 456], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 476, 482], ["domain C sequences", "DNA", 44, 62], ["HsNPC1", "PROTEIN", 66, 72], ["DrNPC1", "PROTEIN", 77, 83], ["DrNPC1", "PROTEIN", 91, 97], ["viral receptor", "PROTEIN", 108, 122], ["GPCL", "PROTEIN", 272, 276], ["DrNPC1 domain C", "PROTEIN", 277, 292], ["DrNPC1", "PROTEIN", 347, 353], ["viral receptor", "PROTEIN", 366, 380], ["NPC1 domain C constructs", "DNA", 443, 467], ["HsNPC1", "PROTEIN", 476, 482], ["EBOV", "SPECIES", 267, 271], ["the domain C sequences", "TEST", 40, 62], ["HsNPC1", "TEST", 66, 72], ["DrNPC1", "TREATMENT", 77, 83], ["viral receptor activity", "PROBLEM", 108, 131], ["N-glycosylation", "TREATMENT", 222, 237], ["the defect", "PROBLEM", 253, 263], ["defective viral receptor function", "PROBLEM", 356, 389], ["a panel", "TEST", 416, 423], ["soluble NPC1 domain C constructs", "TREATMENT", 435, 467], ["viral receptor activity", "OBSERVATION", 108, 131], ["normal function", "OBSERVATION", 155, 170], ["cellular cholesterol homeostasis", "OBSERVATION", 174, 206], ["defect", "OBSERVATION", 257, 263], ["viral receptor function", "OBSERVATION", 366, 389]]], ["We first considered the possibility that one or more differences in N-linked glycosylation sites determine the HsNPC1-DrNPC1 difference, because it is either required for GPCL-HsNPC1 binding or deleterious for GPCL-DrNPC1 binding (Fig. 4).", [["N", "CHEMICAL", 68, 69], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 111, 117], ["DrNPC1", "GENE_OR_GENE_PRODUCT", 118, 124], ["GPCL-HsNPC1", "GENE_OR_GENE_PRODUCT", 171, 182], ["GPCL-DrNPC1", "GENE_OR_GENE_PRODUCT", 210, 221], ["N-linked glycosylation sites", "PROTEIN", 68, 96], ["HsNPC1", "PROTEIN", 111, 117], ["DrNPC1", "PROTEIN", 118, 124], ["GPCL", "PROTEIN", 171, 175], ["HsNPC1", "PROTEIN", 176, 182], ["GPCL", "PROTEIN", 210, 214], ["DrNPC1", "PROTEIN", 215, 221], ["N-linked glycosylation sites", "TREATMENT", 68, 96], ["the HsNPC1", "TEST", 107, 117], ["GPCL", "TEST", 171, 175], ["HsNPC1 binding", "PROBLEM", 176, 190], ["deleterious", "PROBLEM", 194, 205], ["GPCL", "PROBLEM", 210, 214], ["DrNPC1 binding", "PROBLEM", 215, 229]]], ["Six sequons are conserved between the two proteins, but DrNPC1 and HsNPC1 domains C contain two and one unique sequons, respectively.", [["DrNPC1", "GENE_OR_GENE_PRODUCT", 56, 62], ["HsNPC1 domains C", "GENE_OR_GENE_PRODUCT", 67, 83], ["DrNPC1", "PROTEIN", 56, 62], ["HsNPC1 domains C", "PROTEIN", 67, 83], ["the two proteins", "TEST", 34, 50], ["DrNPC1", "TEST", 56, 62], ["two", "OBSERVATION_MODIFIER", 92, 95]]], ["Accordingly, we generated soluble domain C proteins containing or lacking each unique sequon and tested these putative gain-of-function and loss-of-function mutants for binding to EBOV GPCL.", [["EBOV", "ORGANISM", 180, 184], ["GPCL", "GENE_OR_GENE_PRODUCT", 185, 189], ["soluble domain C proteins", "PROTEIN", 26, 51], ["loss-of-function mutants", "PROTEIN", 140, 164], ["EBOV GPCL", "PROTEIN", 180, 189], ["soluble domain C proteins", "TREATMENT", 26, 51], ["loss", "PROBLEM", 140, 144], ["EBOV GPCL", "TEST", 180, 189]]], ["\u201cHumanized\u201d DrNPC1 domain C proteins engineered to lack their unique sequons at position 414 or 498 (HsNPC1 numbering) or to gain the sequon at position 598 remained defective at EBOV GPCL binding in the ELISA.", [["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 12, 27], ["EBOV", "ORGANISM", 179, 183], ["GPCL", "GENE_OR_GENE_PRODUCT", 184, 188], ["\u201cHumanized\u201d DrNPC1 domain C proteins", "PROTEIN", 0, 36], ["position 598", "PROTEIN", 144, 156], ["GPCL", "PROTEIN", 184, 188], ["EBOV", "SPECIES", 179, 183], ["Humanized\u201d DrNPC1 domain C proteins", "TREATMENT", 1, 36], ["defective at EBOV GPCL binding", "PROBLEM", 166, 196], ["defective", "OBSERVATION", 166, 175]]], ["Conversely, HsNPC1 domain C proteins engineered to resemble DrNPC1 at each of these three positions remained fully competent to bind to EBOV GPCL.", [["HsNPC1 domain C", "GENE_OR_GENE_PRODUCT", 12, 27], ["DrNPC1", "GENE_OR_GENE_PRODUCT", 60, 66], ["EBOV", "ORGANISM", 136, 140], ["GPCL", "GENE_OR_GENE_PRODUCT", 141, 145], ["HsNPC1 domain C proteins", "PROTEIN", 12, 36], ["DrNPC1", "PROTEIN", 60, 66], ["EBOV GPCL", "PROTEIN", 136, 145], ["HsNPC1 domain C proteins", "PROBLEM", 12, 36], ["DrNPC1", "TREATMENT", 60, 66], ["EBOV GPCL", "TEST", 136, 145]]], ["Therefore, differences in N-linked glycosylation between the domains C of HsNPC1 and DrNPC1 do not account for the defective EBOV receptor activity of DrNPC1.A single point mutation renders DrNPC1 domain C competent to bind to EBOV GPCL. ::: RESULTSHaving ruled out a role for variations in N-glycosylation, we next adopted a systematic approach to identify determinative sequences in NPC1 domain C. We expressed a series of soluble HsNPC1-DrNPC1 domain C chimeras and measured their activity in the GPCL-binding ELISA (Fig. 5).", [["N", "CHEMICAL", 26, 27], ["N", "CHEMICAL", 291, 292], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 74, 80], ["DrNPC1", "GENE_OR_GENE_PRODUCT", 85, 91], ["EBOV receptor", "GENE_OR_GENE_PRODUCT", 125, 138], ["DrNPC1", "GENE_OR_GENE_PRODUCT", 151, 157], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 190, 205], ["EBOV", "ORGANISM", 227, 231], ["NPC1", "GENE_OR_GENE_PRODUCT", 385, 389], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 433, 439], ["GPCL", "SIMPLE_CHEMICAL", 500, 504], ["domains C", "PROTEIN", 61, 70], ["HsNPC1", "PROTEIN", 74, 80], ["DrNPC1", "PROTEIN", 85, 91], ["EBOV receptor", "PROTEIN", 125, 138], ["DrNPC1", "PROTEIN", 151, 157], ["DrNPC1 domain C", "PROTEIN", 190, 205], ["EBOV GPCL", "PROTEIN", 227, 236], ["determinative sequences", "DNA", 358, 381], ["NPC1 domain C.", "PROTEIN", 385, 399], ["HsNPC1", "PROTEIN", 433, 439], ["DrNPC1 domain C chimeras", "PROTEIN", 440, 464], ["GPCL", "PROTEIN", 500, 504], ["N-linked glycosylation", "TREATMENT", 26, 48], ["HsNPC1", "TREATMENT", 74, 80], ["DrNPC1", "TREATMENT", 85, 91], ["DrNPC1", "TREATMENT", 151, 157], ["A single point mutation", "TREATMENT", 158, 181], ["N-glycosylation", "TREATMENT", 291, 306], ["a systematic approach", "TREATMENT", 324, 345], ["soluble HsNPC1", "TREATMENT", 425, 439], ["DrNPC1 domain C chimeras", "TREATMENT", 440, 464], ["do not account for", "UNCERTAINTY", 92, 110], ["EBOV", "OBSERVATION", 125, 129]]], ["However, only chimera 2, DrNPC1 domain C containing HsNPC1 residues 476 to 536, afforded GPCL-NPC1 binding (Fig. 5A).A single point mutation renders DrNPC1 domain C competent to bind to EBOV GPCL. ::: RESULTSChimera 2 introduced 14 Russell\u2019s viper\u2192human amino acid changes into DrNPC1.", [["amino acid", "CHEMICAL", 254, 264], ["amino acid", "CHEMICAL", 254, 264], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 25, 40], ["GPCL-NPC1", "GENE_OR_GENE_PRODUCT", 89, 98], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 149, 164], ["EBOV", "ORGANISM", 186, 190], ["GPCL", "GENE_OR_GENE_PRODUCT", 191, 195], ["viper\u2192human", "SIMPLE_CHEMICAL", 242, 253], ["amino acid", "AMINO_ACID", 254, 264], ["chimera 2", "PROTEIN", 14, 23], ["DrNPC1 domain C", "PROTEIN", 25, 40], ["HsNPC1 residues 476 to 536", "PROTEIN", 52, 78], ["GPCL", "PROTEIN", 89, 93], ["NPC1", "PROTEIN", 94, 98], ["DrNPC1 domain C", "PROTEIN", 149, 164], ["EBOV GPCL", "PROTEIN", 186, 195], ["DrNPC1", "PROTEIN", 278, 284], ["HsNPC1 residues", "TEST", 52, 67], ["A single point mutation", "TREATMENT", 117, 140], ["EBOV GPCL", "TEST", 186, 195], ["viper\u2192human amino acid changes", "TREATMENT", 242, 272]]], ["To further dissect their roles, we generated and tested three additional chimeras containing subsets of these amino acid changes (chimeras 4 to 6, Fig. 5B) in the GPCL-binding ELISA.", [["amino acid", "CHEMICAL", 110, 120], ["amino acid", "CHEMICAL", 110, 120], ["amino acid", "AMINO_ACID", 110, 120], ["GPCL", "GENE_OR_GENE_PRODUCT", 163, 167], ["chimeras 4 to 6", "PROTEIN", 130, 145], ["Fig. 5B", "PROTEIN", 147, 154], ["GPCL", "PROTEIN", 163, 167], ["these amino acid changes", "TREATMENT", 104, 128], ["chimeras", "TEST", 130, 138], ["amino acid", "OBSERVATION", 110, 120], ["binding ELISA", "OBSERVATION", 168, 181]]], ["The subregion chimera 5 fully reconstituted GPCL-DrNPC1 domain C binding, providing evidence that one or more of the 6 HsNPC1 residues in this construct confer gain of function on DrNPC1.A single point mutation renders DrNPC1 domain C competent to bind to EBOV GPCL. ::: RESULTSTo assess the individual contributions of the six Russell\u2019s viper\u2192human amino acid changes in chimera 5, we separately introduced these changes into soluble DrNPC1 domain C and tested the capacity of each point mutant to bind to EBOV GPCL (Fig. 6).", [["amino acid", "CHEMICAL", 350, 360], ["amino acid", "CHEMICAL", 350, 360], ["GPCL", "GENE_OR_GENE_PRODUCT", 44, 48], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 49, 64], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 119, 125], ["DrNPC1", "GENE_OR_GENE_PRODUCT", 180, 186], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 219, 234], ["EBOV", "ORGANISM", 256, 260], ["amino acid", "AMINO_ACID", 350, 360], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 435, 450], ["EBOV", "ORGANISM", 507, 511], ["subregion chimera 5", "PROTEIN", 4, 23], ["GPCL", "PROTEIN", 44, 48], ["DrNPC1 domain C", "PROTEIN", 49, 64], ["HsNPC1 residues", "PROTEIN", 119, 134], ["DrNPC1", "PROTEIN", 180, 186], ["DrNPC1 domain C", "PROTEIN", 219, 234], ["EBOV GPCL", "PROTEIN", 256, 265], ["chimera 5", "PROTEIN", 372, 381], ["DrNPC1 domain C", "PROTEIN", 435, 450], ["EBOV GPCL", "PROTEIN", 507, 516], ["DrNPC1 domain C binding", "PROBLEM", 49, 72], ["the 6 HsNPC1 residues", "TREATMENT", 113, 134], ["DrNPC1", "TREATMENT", 180, 186], ["A single point mutation", "TREATMENT", 187, 210], ["amino acid changes", "PROBLEM", 350, 368], ["soluble DrNPC1 domain C", "TREATMENT", 427, 450]]], ["A single conservative mutation, Y503\u2192F, fully restored GPCL-DrNPC1 domain C binding, whereas the other 5 mutations had no discernible effect.", [["GPCL-DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 55, 75], ["GPCL", "PROTEIN", 55, 59], ["DrNPC1 domain C", "PROTEIN", 60, 75], ["A single conservative mutation", "TEST", 0, 30], ["DrNPC1 domain C binding", "PROBLEM", 60, 83], ["discernible effect", "PROBLEM", 122, 140]]], ["Thus, the presence of Y instead of F at position 503 appears to completely explain the failure of DrNPC1 to bind to EBOV GPCL.F\u2194Y sequence change at residue 503 controls NPC1\u2019s function as an EBOV entry receptor without affecting its housekeeping function. ::: RESULTSWe postulated that the F\u2194Y sequence change at residue 503 might influence EBOV GPCL-NPC1 binding in a bidirectional manner.", [["DrNPC1", "GENE_OR_GENE_PRODUCT", 98, 104], ["EBOV", "ORGANISM", 116, 120], ["GPCL", "GENE_OR_GENE_PRODUCT", 121, 125], ["F\u2194Y", "GENE_OR_GENE_PRODUCT", 126, 129], ["residue 503", "AMINO_ACID", 149, 160], ["NPC1", "GENE_OR_GENE_PRODUCT", 170, 174], ["F\u2194Y", "GENE_OR_GENE_PRODUCT", 291, 294], ["residue 503", "AMINO_ACID", 314, 325], ["EBOV", "ORGANISM", 342, 346], ["GPCL", "GENE_OR_GENE_PRODUCT", 347, 351], ["NPC1", "GENE_OR_GENE_PRODUCT", 352, 356], ["DrNPC1", "PROTEIN", 98, 104], ["EBOV GPCL", "PROTEIN", 116, 125], ["NPC1", "PROTEIN", 170, 174], ["EBOV entry receptor", "PROTEIN", 192, 211], ["F\u2194Y sequence", "DNA", 291, 303], ["GPCL", "PROTEIN", 347, 351], ["NPC1", "PROTEIN", 352, 356], ["EBOV", "SPECIES", 342, 346], ["the failure of DrNPC1", "PROBLEM", 83, 104], ["EBOV GPCL", "TEST", 116, 125], ["the F\u2194Y sequence change at residue", "TREATMENT", 287, 321], ["failure", "OBSERVATION", 87, 94]]], ["Accordingly, we expressed and purified the reciprocal DrNPC1(Y503F) and HsNPC1(F503Y) domain C mutants and tested them in the GPCL-binding ELISA (Fig. 7).", [["DrNPC1", "GENE_OR_GENE_PRODUCT", 54, 60], ["HsNPC1(F503Y) domain C", "GENE_OR_GENE_PRODUCT", 72, 94], ["GPCL", "SIMPLE_CHEMICAL", 126, 130], ["DrNPC1", "PROTEIN", 54, 60], ["Y503F", "PROTEIN", 61, 66], ["HsNPC1(F503Y) domain C mutants", "PROTEIN", 72, 102], ["GPCL", "PROTEIN", 126, 130], ["HsNPC1", "TREATMENT", 72, 78], ["domain C mutants", "PROBLEM", 86, 102]]], ["Purified DrNPC1(Y503F) domain C bound almost as well as its human counterpart to EBOV GPCL (50% effective concentration [EC50] for binding, \u22483 nM [Russell\u2019s viper] versus 0.5 nM [human]).", [["DrNPC1", "GENE_OR_GENE_PRODUCT", 9, 15], ["Y503F) domain C", "GENE_OR_GENE_PRODUCT", 16, 31], ["human", "ORGANISM", 60, 65], ["EBOV", "ORGANISM", 81, 85], ["human", "ORGANISM", 179, 184], ["DrNPC1(Y503F) domain C", "PROTEIN", 9, 31], ["EBOV GPCL", "PROTEIN", 81, 90], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 179, 184], ["human", "SPECIES", 60, 65], ["EBOV", "SPECIES", 81, 85], ["human", "SPECIES", 179, 184], ["domain C bound", "PROBLEM", 23, 37], ["EBOV GPCL", "TEST", 81, 90], ["EC50", "TEST", 121, 125], ["binding", "PROBLEM", 131, 138]]], ["Conversely, no detectable GPCL binding was obtained with the HsNPC1(F503Y) domain C protein (EC50, >1 \u00b5M).F\u2194Y sequence change at residue 503 controls NPC1\u2019s function as an EBOV entry receptor without affecting its housekeeping function. ::: RESULTSTo examine the consequences of the 503(F\u2194Y) sequence change for the cellular and viral receptor functions of NPC1, we introduced the F503Y and Y503F mutations into full-length WT HsNPC1 and the HsNPC1-DrC chimera, respectively, and expressed them transiently in U2OS NPC1\u2212/\u2212 cell lines.", [["cellular", "ANATOMY", 316, 324], ["U2OS NPC1\u2212/\u2212 cell lines", "ANATOMY", 510, 533], ["GPCL", "GENE_OR_GENE_PRODUCT", 26, 30], ["F\u2194Y", "GENE_OR_GENE_PRODUCT", 106, 109], ["residue 503", "AMINO_ACID", 129, 140], ["NPC1", "GENE_OR_GENE_PRODUCT", 150, 154], ["cellular", "CELL", 316, 324], ["NPC1", "GENE_OR_GENE_PRODUCT", 357, 361], ["F503Y", "GENE_OR_GENE_PRODUCT", 381, 386], ["Y503F", "GENE_OR_GENE_PRODUCT", 391, 396], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 427, 433], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 442, 448], ["DrC", "GENE_OR_GENE_PRODUCT", 449, 452], ["U2OS NPC1\u2212/\u2212 cell lines", "CELL", 510, 533], ["GPCL", "PROTEIN", 26, 30], ["HsNPC1(F503Y) domain C protein", "PROTEIN", 61, 91], ["NPC1", "PROTEIN", 150, 154], ["EBOV entry receptor", "PROTEIN", 172, 191], ["NPC1", "PROTEIN", 357, 361], ["F503Y and Y503F mutations", "DNA", 381, 406], ["HsNPC1", "PROTEIN", 427, 433], ["HsNPC1", "PROTEIN", 442, 448], ["DrC chimera", "PROTEIN", 449, 460], ["U2OS NPC1\u2212/\u2212 cell lines", "CELL_LINE", 510, 533], ["detectable GPCL binding", "PROBLEM", 15, 38], ["the HsNPC1", "TEST", 57, 67], ["domain C protein", "TEST", 75, 91], ["EC50", "TEST", 93, 97], ["HsNPC1", "TEST", 427, 433], ["the HsNPC1-DrC chimera", "TREATMENT", 438, 460], ["U2OS NPC1\u2212/\u2212 cell lines", "TREATMENT", 510, 533], ["\u2212 cell lines", "OBSERVATION", 521, 533]]], ["Immunostaining of NPC1 in these cell lines revealed colocalization with LAMP1 for both WT HsNPC1 and HsNPC1-DrC (Fig. 8A and 3A).", [["cell lines", "ANATOMY", 32, 42], ["NPC1", "GENE_OR_GENE_PRODUCT", 18, 22], ["cell lines", "CELL", 32, 42], ["LAMP1", "GENE_OR_GENE_PRODUCT", 72, 77], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 90, 96], ["HsNPC1-DrC", "GENE_OR_GENE_PRODUCT", 101, 111], ["Fig. 8A", "GENE_OR_GENE_PRODUCT", 113, 120], ["NPC1", "PROTEIN", 18, 22], ["LAMP1", "PROTEIN", 72, 77], ["HsNPC1", "PROTEIN", 90, 96], ["HsNPC1", "PROTEIN", 101, 107], ["DrC", "PROTEIN", 108, 111], ["Fig. 8A and 3A", "PROTEIN", 113, 127], ["Immunostaining of NPC1", "PROBLEM", 0, 22], ["LAMP1", "TEST", 72, 77], ["HsNPC1", "TEST", 90, 96], ["HsNPC1", "TEST", 101, 107], ["NPC1", "OBSERVATION", 18, 22], ["cell lines", "OBSERVATION", 32, 42]]], ["Furthermore, filipin staining showed little or no cholesterol accumulation in CHO-M12 cells stably expressing HsNPC1(F503Y) or HsNPC1-DrC(Y503F) (Fig. 8B).", [["CHO-M12 cells", "ANATOMY", 78, 91], ["filipin", "CHEMICAL", 13, 20], ["cholesterol", "CHEMICAL", 50, 61], ["filipin", "CHEMICAL", 13, 20], ["cholesterol", "CHEMICAL", 50, 61], ["filipin", "SIMPLE_CHEMICAL", 13, 20], ["cholesterol", "SIMPLE_CHEMICAL", 50, 61], ["CHO-M12 cells", "CELL", 78, 91], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 110, 116], ["HsNPC1-DrC", "GENE_OR_GENE_PRODUCT", 127, 137], ["CHO-M12 cells", "CELL_LINE", 78, 91], ["HsNPC1", "PROTEIN", 110, 116], ["F503Y", "PROTEIN", 117, 122], ["HsNPC1", "PROTEIN", 127, 133], ["DrC", "PROTEIN", 134, 137], ["Y503F", "PROTEIN", 138, 143], ["Fig. 8B", "PROTEIN", 146, 153], ["CHO-M12", "SPECIES", 78, 85], ["filipin staining", "TEST", 13, 29], ["cholesterol accumulation", "PROBLEM", 50, 74], ["HsNPC1", "TEST", 110, 116], ["HsNPC1", "TEST", 127, 133], ["no", "UNCERTAINTY", 47, 49], ["cholesterol accumulation", "OBSERVATION", 50, 74]]], ["Therefore, the F503Y and Y503F mutations do not substantially affect the folding, endosomal delivery, and cholesterol clearance function of NPC1.F\u2194Y sequence change at residue 503 controls NPC1\u2019s function as an EBOV entry receptor without affecting its housekeeping function. ::: RESULTSFinally, we challenged cell lines expressing the 503(F\u2194Y) NPC1 mutants with authentic EBOV and rVSV-EBOV GP (Fig. 8C).", [["endosomal", "ANATOMY", 82, 91], ["cell lines", "ANATOMY", 310, 320], ["cholesterol", "CHEMICAL", 106, 117], ["cholesterol", "CHEMICAL", 106, 117], ["F503Y", "GENE_OR_GENE_PRODUCT", 15, 20], ["Y503F", "GENE_OR_GENE_PRODUCT", 25, 30], ["endosomal", "CELLULAR_COMPONENT", 82, 91], ["cholesterol", "SIMPLE_CHEMICAL", 106, 117], ["NPC1", "GENE_OR_GENE_PRODUCT", 140, 144], ["F\u2194Y", "GENE_OR_GENE_PRODUCT", 145, 148], ["residue 503", "AMINO_ACID", 168, 179], ["NPC1", "GENE_OR_GENE_PRODUCT", 189, 193], ["cell lines", "CELL", 310, 320], ["F\u2194Y)", "GENE_OR_GENE_PRODUCT", 340, 344], ["NPC1", "GENE_OR_GENE_PRODUCT", 345, 349], ["EBOV", "ORGANISM", 373, 377], ["rVSV-EBOV GP", "ORGANISM", 382, 394], ["NPC1", "PROTEIN", 140, 144], ["NPC1", "PROTEIN", 189, 193], ["EBOV entry receptor", "PROTEIN", 211, 230], ["challenged cell lines", "CELL_LINE", 299, 320], ["503(F\u2194Y) NPC1 mutants", "PROTEIN", 336, 357], ["rVSV", "PROTEIN", 382, 386], ["EBOV GP", "PROTEIN", 387, 394], ["EBOV", "SPECIES", 373, 377], ["the F503Y and Y503F mutations", "TREATMENT", 11, 40], ["endosomal delivery", "TREATMENT", 82, 100], ["cholesterol clearance function of NPC1", "PROBLEM", 106, 144], ["authentic EBOV", "TREATMENT", 363, 377], ["rVSV", "TEST", 382, 386], ["cell lines", "OBSERVATION", 310, 320]]], ["The capacities of both authentic and surrogate viruses to enter and infect these cells were fully congruent with the results of the GP-binding experiments.", [["cells", "ANATOMY", 81, 86], ["cells", "CELL", 81, 86], ["surrogate viruses", "PROBLEM", 37, 54]]], ["The viper\u2192human Y503F mutation afforded the complete restoration of viral infection in cells expressing the HsNPC1-DrC chimera (\u22483 log10 unit increase).", [["cells", "ANATOMY", 87, 92], ["viral infection", "DISEASE", 68, 83], ["Y503F", "GENE_OR_GENE_PRODUCT", 16, 21], ["cells", "CELL", 87, 92], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 108, 114], ["DrC", "GENE_OR_GENE_PRODUCT", 115, 118], ["viper\u2192human Y503F mutation", "DNA", 4, 30], ["HsNPC1", "PROTEIN", 108, 114], ["DrC chimera", "PROTEIN", 115, 126], ["The viper\u2192human Y503F mutation", "TREATMENT", 0, 30], ["viral infection in cells", "PROBLEM", 68, 92], ["DrC chimera", "TREATMENT", 115, 126], ["viral infection", "OBSERVATION", 68, 83]]], ["Reciprocally, the human\u2192viper F503Y mutation reduced viral infection in cells expressing HsNPC1 by \u22482 log10 units.", [["cells", "ANATOMY", 72, 77], ["viral infection", "DISEASE", 53, 68], ["F503Y", "GENE_OR_GENE_PRODUCT", 30, 35], ["cells", "CELL", 72, 77], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 89, 95], ["HsNPC1", "PROTEIN", 89, 95], ["the human\u2192viper F503Y mutation", "TREATMENT", 14, 44], ["viral infection in cells", "PROBLEM", 53, 77], ["viral infection", "OBSERVATION", 53, 68]]], ["Thus, the infection data correlate with the GPCL-domain C-binding data, demonstrating that switching the residue at position 503 changes the ability of human and Russell\u2019s viper NPC1 domain C to bind EBOV GPCL, thereby determining the ability of these NPC1 proteins to be used as EBOV receptors.A bulky, hydrophobic amino acid residue at position 503 favors EBOV GPCL-NPC1 domain C binding. ::: RESULTSTo determine the mechanism by which the change in NPC1 residue 503 controls binding of HsNPC1 to EBOV GPCL, we engineered a series of NPC1 domain C proteins bearing amino acid residues with divergent physicochemical properties at position 503.", [["infection", "DISEASE", 10, 19], ["amino acid", "CHEMICAL", 316, 326], ["amino acid", "CHEMICAL", 567, 577], ["amino acid", "CHEMICAL", 316, 326], ["amino acid", "CHEMICAL", 567, 577], ["human", "ORGANISM", 152, 157], ["NPC1 domain C", "GENE_OR_GENE_PRODUCT", 178, 191], ["EBOV", "ORGANISM", 200, 204], ["GPCL", "GENE_OR_GENE_PRODUCT", 205, 209], ["NPC1", "GENE_OR_GENE_PRODUCT", 252, 256], ["EBOV", "ORGANISM", 280, 284], ["amino acid", "AMINO_ACID", 316, 326], ["position 503", "AMINO_ACID", 338, 350], ["EBOV", "ORGANISM", 358, 362], ["NPC1 domain C", "GENE_OR_GENE_PRODUCT", 368, 381], ["NPC1", "GENE_OR_GENE_PRODUCT", 452, 456], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 489, 495], ["EBOV", "ORGANISM", 499, 503], ["GPCL", "GENE_OR_GENE_PRODUCT", 504, 508], ["NPC1 domain C", "GENE_OR_GENE_PRODUCT", 536, 549], ["amino acid", "AMINO_ACID", 567, 577], ["GPCL", "PROTEIN", 44, 48], ["domain C", "PROTEIN", 49, 57], ["position 503", "PROTEIN", 116, 128], ["human and Russell\u2019s viper NPC1 domain C", "PROTEIN", 152, 191], ["EBOV GPCL", "PROTEIN", 200, 209], ["NPC1 proteins", "PROTEIN", 252, 265], ["EBOV receptors", "PROTEIN", 280, 294], ["GPCL", "PROTEIN", 363, 367], ["NPC1 domain C", "PROTEIN", 368, 381], ["NPC1 residue 503", "PROTEIN", 452, 468], ["HsNPC1", "PROTEIN", 489, 495], ["EBOV GPCL", "PROTEIN", 499, 508], ["NPC1 domain C proteins", "PROTEIN", 536, 558], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 152, 157], ["EBOV", "SPECIES", 280, 284], ["EBOV", "SPECIES", 499, 503], ["the infection data", "PROBLEM", 6, 24], ["the GPCL", "TEST", 40, 48], ["the residue", "PROBLEM", 101, 112], ["Russell\u2019s viper NPC1 domain C", "TREATMENT", 162, 191], ["these NPC1 proteins", "TREATMENT", 246, 265], ["EBOV receptors", "TREATMENT", 280, 294], ["A bulky, hydrophobic amino acid residue", "PROBLEM", 295, 334], ["NPC1 domain C binding", "PROBLEM", 368, 389], ["the change in NPC1 residue", "PROBLEM", 438, 464], ["HsNPC1", "TREATMENT", 489, 495], ["NPC1 domain C proteins bearing amino acid residues", "TREATMENT", 536, 586], ["infection", "OBSERVATION", 10, 19], ["bulky", "OBSERVATION_MODIFIER", 297, 302], ["hydrophobic amino", "OBSERVATION", 304, 321], ["acid residue", "OBSERVATION", 322, 334]]], ["Examination of these mutants by GPCL-binding ELISA revealed that binding avidity was generally correlated with amino acid size and polarity (Fig. 9A).", [["amino acid", "CHEMICAL", 111, 121], ["amino acid", "CHEMICAL", 111, 121], ["GPCL", "GENE_OR_GENE_PRODUCT", 32, 36], ["amino acid", "AMINO_ACID", 111, 121], ["GPCL", "PROTEIN", 32, 36], ["Examination", "TEST", 0, 11], ["these mutants", "TEST", 15, 28], ["GPCL-binding ELISA", "TEST", 32, 50], ["binding avidity", "PROBLEM", 65, 80], ["amino acid size", "TEST", 111, 126]]], ["Specifically, residues with bulky, hydrophobic side chains (L and W) afforded GPCL-NPC1 binding at WT levels, whereas residues with polar side chains (D, H, and S) abrogated binding.", [["H", "CHEMICAL", 154, 155], ["GPCL-NPC1", "GENE_OR_GENE_PRODUCT", 78, 87], ["D", "SIMPLE_CHEMICAL", 151, 152], ["GPCL", "PROTEIN", 78, 82], ["NPC1", "PROTEIN", 83, 87], ["bulky, hydrophobic side chains", "PROBLEM", 28, 58], ["GPCL", "PROBLEM", 78, 82], ["NPC1 binding", "PROBLEM", 83, 95], ["WT levels", "TEST", 99, 108], ["polar side chains", "TREATMENT", 132, 149], ["bulky", "OBSERVATION_MODIFIER", 28, 33], ["hydrophobic", "OBSERVATION_MODIFIER", 35, 46], ["NPC1", "OBSERVATION", 83, 87], ["polar", "ANATOMY_MODIFIER", 132, 137]]], ["Binding was greatly reduced, but detectable, with A and T at residue 503.", [["greatly", "OBSERVATION_MODIFIER", 12, 19], ["reduced", "OBSERVATION_MODIFIER", 20, 27]]], ["The recently solved structure of EBOV GPCL bound to NPC1 domain C shows that residue 503 inserts into the hydrophobic trough of EBOV GPCL (28, 29), similarly to residue F225 of the EBOV glycan cap (Fig. 9B and C) (26).The tyrosine residue at position 503 controls EBOV GPCL-binding function in reptile NPC1 domain C orthologs. ::: RESULTSFinally, we asked if our findings had implications for host cell range in other vertebrates, especially reptiles, which appear to be refractory to infection by EBOV (8, 30).", [["cell", "ANATOMY", 398, 402], ["tyrosine", "CHEMICAL", 222, 230], ["infection", "DISEASE", 485, 494], ["tyrosine", "CHEMICAL", 222, 230], ["EBOV", "ORGANISM", 33, 37], ["GPCL", "GENE_OR_GENE_PRODUCT", 38, 42], ["NPC1 domain C", "GENE_OR_GENE_PRODUCT", 52, 65], ["residue 503", "AMINO_ACID", 77, 88], ["EBOV", "ORGANISM", 128, 132], ["tyrosine", "AMINO_ACID", 222, 230], ["position 503", "AMINO_ACID", 242, 254], ["EBOV", "ORGANISM", 264, 268], ["GPCL", "GENE_OR_GENE_PRODUCT", 269, 273], ["NPC1 domain C", "GENE_OR_GENE_PRODUCT", 302, 315], ["host cell", "CELL", 393, 402], ["EBOV", "ORGANISM", 498, 502], ["EBOV GPCL", "PROTEIN", 33, 42], ["NPC1 domain C", "PROTEIN", 52, 65], ["EBOV GPCL", "PROTEIN", 128, 137], ["EBOV glycan cap", "PROTEIN", 181, 196], ["GPCL", "PROTEIN", 269, 273], ["reptile NPC1 domain C orthologs", "DNA", 294, 325], ["EBOV", "SPECIES", 33, 37], ["EBOV", "SPECIES", 498, 502], ["EBOV GPCL bound", "PROBLEM", 33, 48], ["NPC1 domain C", "TEST", 52, 65], ["the hydrophobic trough", "TEST", 102, 124], ["EBOV GPCL", "TEST", 128, 137], ["the EBOV glycan cap", "TEST", 177, 196], ["The tyrosine residue", "TREATMENT", 218, 238], ["EBOV GPCL", "TEST", 264, 273], ["host cell range", "TEST", 393, 408], ["infection", "PROBLEM", 485, 494], ["EBOV GPCL", "OBSERVATION", 33, 42], ["tyrosine residue", "OBSERVATION", 222, 238], ["appear to be", "UNCERTAINTY", 458, 470], ["refractory", "OBSERVATION_MODIFIER", 471, 481], ["infection", "OBSERVATION", 485, 494]]], ["An alignment of available NPC1 domain C sequences from a panel of vertebrate species revealed that, although there exist a number of differences in amino acid sequence around residue 503, the F at this position is itself very well conserved among vertebrates, with only two NPC1 orthologs\u2014those of the Russell\u2019s viper and king cobra (Ophiophagus hannah)\u2014encoding a Y at this position (Fig. 10A).", [["amino acid", "CHEMICAL", 148, 158], ["amino acid", "CHEMICAL", 148, 158], ["NPC1 domain C", "GENE_OR_GENE_PRODUCT", 26, 39], ["amino acid", "AMINO_ACID", 148, 158], ["residue 503", "AMINO_ACID", 175, 186], ["NPC1", "GENE_OR_GENE_PRODUCT", 274, 278], ["Russell\u2019s viper", "ORGANISM", 302, 317], ["king cobra", "ORGANISM", 322, 332], ["Ophiophagus hannah", "ORGANISM", 334, 352], ["NPC1 domain C sequences", "DNA", 26, 49], ["amino acid sequence", "PROTEIN", 148, 167], ["NPC1 orthologs", "PROTEIN", 274, 288], ["Russell\u2019s viper", "PROTEIN", 302, 317], ["king cobra", "PROTEIN", 322, 332], ["Ophiophagus hannah", "PROTEIN", 334, 352], ["Ophiophagus hannah", "SPECIES", 334, 352], ["Russell\u2019s viper", "SPECIES", 302, 317], ["Ophiophagus hannah", "SPECIES", 334, 352], ["An alignment of available NPC1 domain C sequences", "TEST", 0, 49], ["a panel of vertebrate species", "TEST", 55, 84], ["amino acid sequence", "TEST", 148, 167]]], ["Interestingly, the predicted NPC1 polypeptide sequences of two additional snakes, the Burmese python (Python bivittatus) and the common garter snake (Thamnophis sirtalis), show an F at position 503 (Fig. 10A).", [["NPC1", "GENE_OR_GENE_PRODUCT", 29, 33], ["Burmese python", "ORGANISM", 86, 100], ["Python bivittatus", "ORGANISM", 102, 119], ["garter snake", "ORGANISM", 136, 148], ["Thamnophis sirtalis", "ORGANISM", 150, 169], ["NPC1 polypeptide sequences", "DNA", 29, 55], ["Python bivittatus", "SPECIES", 102, 119], ["garter snake", "SPECIES", 136, 148], ["Thamnophis sirtalis", "SPECIES", 150, 169], ["Burmese python", "SPECIES", 86, 100], ["Python bivittatus", "SPECIES", 102, 119], ["garter snake", "SPECIES", 136, 148], ["Thamnophis sirtalis", "SPECIES", 150, 169], ["the predicted NPC1 polypeptide sequences", "TREATMENT", 15, 55], ["common garter", "ANATOMY", 129, 142]]], ["To investigate the GPCL-binding capacities of the snake NPC1 orthologs, we expressed and purified soluble NPC1 domain C proteins for the king cobra and Burmese python and tested them for binding to EBOV GPCL.", [["GPCL", "GENE_OR_GENE_PRODUCT", 19, 23], ["NPC1", "GENE_OR_GENE_PRODUCT", 56, 60], ["NPC1 domain C proteins", "GENE_OR_GENE_PRODUCT", 106, 128], ["king cobra", "ORGANISM", 137, 147], ["EBOV", "ORGANISM", 198, 202], ["GPCL", "GENE_OR_GENE_PRODUCT", 203, 207], ["GPCL", "PROTEIN", 19, 23], ["snake NPC1 orthologs", "PROTEIN", 50, 70], ["NPC1 domain C proteins", "PROTEIN", 106, 128], ["king cobra", "PROTEIN", 137, 147], ["EBOV GPCL", "PROTEIN", 198, 207], ["Burmese python", "SPECIES", 152, 166], ["EBOV", "SPECIES", 198, 202], ["purified soluble NPC1 domain C proteins", "TREATMENT", 89, 128], ["the king cobra", "TREATMENT", 133, 147], ["Burmese python", "PROBLEM", 152, 166], ["EBOV GPCL", "TEST", 198, 207], ["binding capacities", "OBSERVATION", 24, 42]]], ["The capacity of these proteins to bind to EBOV GPCL was concordant with the identity of the residue at NPC1 codon 503.", [["EBOV", "ORGANISM", 42, 46], ["GPCL", "GENE_OR_GENE_PRODUCT", 47, 51], ["NPC1", "GENE_OR_GENE_PRODUCT", 103, 107], ["EBOV GPCL", "PROTEIN", 42, 51], ["NPC1 codon 503", "DNA", 103, 117], ["these proteins", "PROBLEM", 16, 30], ["EBOV GPCL", "TEST", 42, 51], ["the residue at NPC1 codon", "PROBLEM", 88, 113]]], ["Thus, king cobra NPC1 domain C(Y503) resembled viper NPC1 domain C in its inability to bind to EBOV GPCL, whereas Burmese python NPC1 domain C(F503) readily bound to EBOV GPCL (Fig. 10B).", [["king cobra", "ORGANISM", 6, 16], ["NPC1 domain C", "GENE_OR_GENE_PRODUCT", 17, 30], ["Y503", "AMINO_ACID", 31, 35], ["viper NPC1 domain C", "GENE_OR_GENE_PRODUCT", 47, 66], ["EBOV", "ORGANISM", 95, 99], ["GPCL", "GENE_OR_GENE_PRODUCT", 100, 104], ["NPC1 domain C(F503)", "GENE_OR_GENE_PRODUCT", 129, 148], ["EBOV", "ORGANISM", 166, 170], ["king cobra NPC1 domain C", "PROTEIN", 6, 30], ["Y503", "PROTEIN", 31, 35], ["viper NPC1 domain C", "PROTEIN", 47, 66], ["EBOV GPCL", "PROTEIN", 95, 104], ["Burmese python NPC1 domain C", "PROTEIN", 114, 142], ["F503", "PROTEIN", 143, 147], ["EBOV GPCL", "PROTEIN", 166, 175], ["Fig. 10B", "PROTEIN", 177, 185], ["king cobra NPC1 domain C(Y503)", "TREATMENT", 6, 36], ["viper NPC1 domain C", "PROBLEM", 47, 66], ["EBOV GPCL", "TEST", 95, 104], ["EBOV GPCL", "TEST", 166, 175]]], ["We tested two more reptilian NPC1 orthologs\u2014from Chinese softshell turtle and Carolina anole (both carrying F503)\u2014and found that they could all bind to EBOV GPCL (Fig. 10C).", [["NPC1", "GENE_OR_GENE_PRODUCT", 29, 33], ["softshell turtle", "ORGANISM", 57, 73], ["Carolina anole", "ORGANISM", 78, 92], ["EBOV", "ORGANISM", 152, 156], ["reptilian NPC1 orthologs", "DNA", 19, 43], ["EBOV GPCL", "PROTEIN", 152, 161], ["Chinese softshell turtle", "SPECIES", 49, 73], ["Carolina anole", "SPECIES", 78, 92]]], ["These findings provide additional evidence that NPC1-encoded residue 503 influences the cellular host range of EBOV at the level of virus-receptor recognition and raise the possibility that sequence differences at this position influence the susceptibility of reptiles to filovirus infection in nature.DISCUSSIONThe essential entry receptor NPC1 is the first known molecular determinant of the cellular host range of EBOV and other filoviruses (25, 26).", [["cellular", "ANATOMY", 88, 96], ["cellular", "ANATOMY", 394, 402], ["filovirus infection", "DISEASE", 272, 291], ["NPC1", "GENE_OR_GENE_PRODUCT", 48, 52], ["residue 503", "AMINO_ACID", 61, 72], ["cellular", "CELL", 88, 96], ["EBOV", "ORGANISM", 111, 115], ["filovirus", "ORGANISM", 272, 281], ["NPC1", "GENE_OR_GENE_PRODUCT", 341, 345], ["cellular", "CELL", 394, 402], ["EBOV", "ORGANISM", 417, 421], ["NPC1", "PROTEIN", 48, 52], ["NPC1", "PROTEIN", 341, 345], ["EBOV", "SPECIES", 111, 115], ["EBOV", "SPECIES", 417, 421], ["NPC1", "TEST", 48, 52], ["EBOV", "PROBLEM", 111, 115], ["filovirus infection", "PROBLEM", 272, 291], ["EBOV", "PROBLEM", 417, 421], ["host range", "OBSERVATION_MODIFIER", 97, 107], ["essential", "OBSERVATION_MODIFIER", 316, 325], ["entry", "OBSERVATION_MODIFIER", 326, 331], ["receptor NPC1", "OBSERVATION", 332, 345], ["cellular host range", "OBSERVATION", 394, 413], ["EBOV", "OBSERVATION", 417, 421], ["filoviruses", "OBSERVATION_MODIFIER", 432, 443]]], ["In this study, we uncover one mechanism by which NPC1 imposes a species-specific barrier to EBOV infection.", [["EBOV infection", "DISEASE", 92, 106], ["NPC1", "GENE_OR_GENE_PRODUCT", 49, 53], ["EBOV", "ORGANISM", 92, 96], ["NPC1", "PROTEIN", 49, 53], ["EBOV", "SPECIES", 92, 96], ["this study", "TEST", 3, 13], ["a species", "PROBLEM", 62, 71], ["EBOV infection", "PROBLEM", 92, 106], ["EBOV", "OBSERVATION_MODIFIER", 92, 96], ["infection", "OBSERVATION", 97, 106]]], ["We show that reptilian cells derived from the Russell\u2019s viper, Daboia russellii, are largely resistant to EBOV entry and infection because of the presence of a Y residue at position 503 in NPC1, whereas the NPC1 orthologs of most other types of animals, include humans, carry a highly conserved F residue.", [["cells", "ANATOMY", 23, 28], ["infection", "DISEASE", 121, 130], ["reptilian cells", "CELL", 13, 28], ["Russell\u2019s viper", "ORGANISM", 46, 61], ["Daboia russellii", "ORGANISM", 63, 79], ["EBOV", "ORGANISM", 106, 110], ["NPC1", "GENE_OR_GENE_PRODUCT", 189, 193], ["NPC1", "GENE_OR_GENE_PRODUCT", 207, 211], ["humans", "ORGANISM", 262, 268], ["reptilian cells", "CELL_TYPE", 13, 28], ["position 503", "PROTEIN", 173, 185], ["NPC1", "PROTEIN", 189, 193], ["NPC1 orthologs", "PROTEIN", 207, 221], ["Daboia russellii", "SPECIES", 63, 79], ["humans", "SPECIES", 262, 268], ["Russell\u2019s viper", "SPECIES", 46, 61], ["Daboia russellii", "SPECIES", 63, 79], ["EBOV", "SPECIES", 106, 110], ["humans", "SPECIES", 262, 268], ["reptilian cells", "PROBLEM", 13, 28], ["Daboia russellii", "PROBLEM", 63, 79], ["EBOV entry", "PROBLEM", 106, 116], ["infection", "PROBLEM", 121, 130], ["a Y residue at position", "PROBLEM", 158, 181], ["reptilian cells", "OBSERVATION", 13, 28], ["resistant", "OBSERVATION_MODIFIER", 93, 102], ["infection", "OBSERVATION", 121, 130]]], ["Unexpectedly, toggling this residue between F and Y in either human or Russell's viper NPC1 backgrounds switched each protein\u2019s ability to act as an EBOV receptor.", [["human", "ORGANISM", 62, 67], ["Russell's viper", "ORGANISM", 71, 86], ["NPC1", "GENE_OR_GENE_PRODUCT", 87, 91], ["EBOV", "ORGANISM", 149, 153], ["EBOV receptor", "PROTEIN", 149, 162], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67], ["an EBOV receptor", "TREATMENT", 146, 162]]], ["NPC1\u2019s crucial housekeeping function\u2014distribution of cholesterol from the endo/lysosomal compartment to other cellular membranes\u2014remained unaffected by these changes.", [["lysosomal compartment", "ANATOMY", 79, 100], ["cellular", "ANATOMY", 110, 118], ["cholesterol", "CHEMICAL", 53, 64], ["cholesterol", "CHEMICAL", 53, 64], ["NPC1", "GENE_OR_GENE_PRODUCT", 0, 4], ["cholesterol", "SIMPLE_CHEMICAL", 53, 64], ["lysosomal compartment", "CELLULAR_COMPONENT", 79, 100], ["cellular", "CELL", 110, 118], ["NPC1", "PROTEIN", 0, 4], ["NPC1", "TREATMENT", 0, 4], ["housekeeping function\u2014distribution", "OBSERVATION", 15, 49], ["lysosomal compartment", "OBSERVATION", 79, 100], ["cellular membranes\u2014remained", "OBSERVATION", 110, 137]]], ["Thus, our work identifies a genetic determinant in NPC1 that controls its viral receptor function, and consequently host susceptibility to EBOV infection, in a manner that is selective and yet transferable between highly divergent NPC1 orthologs.DISCUSSIONThe determinative F503\u2192Y change is located in NPC1\u2019s second luminal domain (C), which directly binds to a cleaved form of the EBOV entry glycoprotein (GPCL) during viral entry (22, 23, 26).", [["EBOV infection", "DISEASE", 139, 153], ["luminal", "CHEMICAL", 316, 323], ["NPC1", "GENE_OR_GENE_PRODUCT", 51, 55], ["EBOV", "ORGANISM", 139, 143], ["NPC1", "GENE_OR_GENE_PRODUCT", 231, 235], ["NPC1", "GENE_OR_GENE_PRODUCT", 302, 306], ["EBOV entry glycoprotein", "GENE_OR_GENE_PRODUCT", 382, 405], ["GPCL", "GENE_OR_GENE_PRODUCT", 407, 411], ["NPC1", "PROTEIN", 51, 55], ["NPC1 orthologs", "DNA", 231, 245], ["F503", "DNA", 274, 278], ["NPC1", "PROTEIN", 302, 306], ["luminal domain", "PROTEIN", 316, 330], ["EBOV entry glycoprotein", "PROTEIN", 382, 405], ["GPCL", "PROTEIN", 407, 411], ["EBOV", "SPECIES", 139, 143], ["a genetic determinant in NPC1", "PROBLEM", 26, 55], ["EBOV infection", "PROBLEM", 139, 153], ["viral entry", "TEST", 420, 431], ["EBOV", "OBSERVATION_MODIFIER", 139, 143], ["infection", "OBSERVATION", 144, 153]]], ["Here, we found that F503\u2192Y renders cells nonpermissive to EBOV infection because it reduces the apparent binding affinity of GPCL for NPC1 domain C by more than 1,000-fold.", [["cells", "ANATOMY", 35, 40], ["EBOV infection", "DISEASE", 58, 72], ["F503", "CHEMICAL", 20, 24], ["cells", "CELL", 35, 40], ["EBOV", "ORGANISM", 58, 62], ["GPCL", "GENE_OR_GENE_PRODUCT", 125, 129], ["NPC1 domain C", "GENE_OR_GENE_PRODUCT", 134, 147], ["F503", "PROTEIN", 20, 24], ["GPCL", "PROTEIN", 125, 129], ["NPC1 domain C", "PROTEIN", 134, 147], ["EBOV", "SPECIES", 58, 62], ["Y renders cells", "PROBLEM", 25, 40], ["EBOV infection", "PROBLEM", 58, 72], ["NPC1 domain C", "PROBLEM", 134, 147], ["EBOV", "OBSERVATION_MODIFIER", 58, 62], ["infection", "OBSERVATION", 63, 72]]], ["What mechanism might account for this extraordinary effect of a single hydroxyl group on virus-receptor interaction?DISCUSSIONThe recently solved structure of the EBOV GPCL bound to NPC1 domain C reveals that F503 in human NPC1 domain C inserts deeply into the hydrophobic GPCL trough during GP-NPC1 interaction, in a manner that resembles the interaction of F225 in the GP glycan cap with the GPCL trough in uncleaved GP (Fig. 9B and C) (26).", [["hydroxyl", "CHEMICAL", 71, 79], ["hydroxyl", "CHEMICAL", 71, 79], ["hydroxyl", "SIMPLE_CHEMICAL", 71, 79], ["EBOV", "ORGANISM", 163, 167], ["GPCL", "GENE_OR_GENE_PRODUCT", 168, 172], ["NPC1 domain C", "GENE_OR_GENE_PRODUCT", 182, 195], ["F503", "GENE_OR_GENE_PRODUCT", 209, 213], ["human", "ORGANISM", 217, 222], ["NPC1 domain C", "GENE_OR_GENE_PRODUCT", 223, 236], ["GPCL", "GENE_OR_GENE_PRODUCT", 273, 277], ["NPC1", "GENE_OR_GENE_PRODUCT", 295, 299], ["F225", "GENE_OR_GENE_PRODUCT", 359, 363], ["EBOV GPCL", "PROTEIN", 163, 172], ["NPC1 domain C", "PROTEIN", 182, 195], ["F503", "PROTEIN", 209, 213], ["human NPC1 domain C", "PROTEIN", 217, 236], ["hydrophobic GPCL trough", "PROTEIN", 261, 284], ["GP", "PROTEIN", 292, 294], ["NPC1", "PROTEIN", 295, 299], ["F225", "PROTEIN", 359, 363], ["GP glycan cap", "PROTEIN", 371, 384], ["GPCL trough", "PROTEIN", 394, 405], ["uncleaved GP", "PROTEIN", 409, 421], ["human", "SPECIES", 217, 222], ["human", "SPECIES", 217, 222], ["a single hydroxyl group on virus", "TREATMENT", 62, 94], ["the EBOV GPCL bound", "PROBLEM", 159, 178], ["NPC1 domain C", "TEST", 182, 195], ["F503 in human NPC1 domain C inserts", "TREATMENT", 209, 244], ["the hydrophobic GPCL trough", "TEST", 257, 284], ["the GPCL trough", "TEST", 390, 405], ["might account for", "UNCERTAINTY", 15, 32]]], ["The introduction, at position 503, of a polar hydroxyl group (Y) or other polar side chains (D, H, S, and G) is likely to be energetically unfavorable, thereby reducing the affinity of GPCL-NPC1 binding.DISCUSSIONWe recently demonstrated that residue 502 in NPC1 was under positive selection in bats and was responsible for the reduced susceptibility of African straw-colored fruit bat cells to EBOV infection (25, 31).", [["fruit bat cells", "ANATOMY", 376, 391], ["hydroxyl", "CHEMICAL", 46, 54], ["EBOV infection", "DISEASE", 395, 409], ["hydroxyl", "CHEMICAL", 46, 54], ["H", "CHEMICAL", 96, 97], ["polar side chains", "SIMPLE_CHEMICAL", 74, 91], ["D", "SIMPLE_CHEMICAL", 93, 94], ["GPCL", "GENE_OR_GENE_PRODUCT", 185, 189], ["NPC1", "GENE_OR_GENE_PRODUCT", 190, 194], ["NPC1", "GENE_OR_GENE_PRODUCT", 258, 262], ["bats", "ORGANISM", 295, 299], ["fruit bat cells", "CELL", 376, 391], ["EBOV", "ORGANISM", 395, 399], ["GPCL", "PROTEIN", 185, 189], ["NPC1", "PROTEIN", 190, 194], ["NPC1", "PROTEIN", 258, 262], ["African straw-colored fruit bat cells", "CELL_TYPE", 354, 391], ["fruit bat", "SPECIES", 376, 385], ["African straw-colored fruit bat", "SPECIES", 354, 385], ["EBOV", "SPECIES", 395, 399], ["a polar hydroxyl group (Y", "TREATMENT", 38, 63], ["other polar side chains", "TEST", 68, 91], ["D, H, S, and G)", "TEST", 93, 108], ["GPCL", "PROBLEM", 185, 189], ["NPC1 binding", "PROBLEM", 190, 202], ["residue 502 in NPC1", "PROBLEM", 243, 262], ["the reduced susceptibility of African straw", "PROBLEM", 324, 367], ["colored fruit bat cells", "PROBLEM", 368, 391], ["EBOV infection", "PROBLEM", 395, 409], ["polar", "ANATOMY_MODIFIER", 74, 79], ["likely to be", "UNCERTAINTY", 112, 124], ["NPC1 binding", "OBSERVATION", 190, 202], ["fruit bat cells", "OBSERVATION", 376, 391], ["EBOV infection", "OBSERVATION", 395, 409]]], ["Since none of the bat species genes encodes a Y at position 503 in NPC1, there was no observed signature of positive selection at this residue.", [["NPC1", "GENE_OR_GENE_PRODUCT", 67, 71], ["bat species genes", "DNA", 18, 35], ["NPC1", "DNA", 67, 71], ["positive selection", "PROBLEM", 108, 126], ["no observed", "UNCERTAINTY", 83, 94], ["positive selection", "OBSERVATION", 108, 126]]], ["The structure rationalizes the effect of these residues on GP-NPC1 binding, as both are located in the \u03b14-\u03b15 loop of NPC1 domain C that directly interacts with EBOV GPCL (\u201cloop 2\u201d [26]) (Fig. 9C).DISCUSSIONIt is unclear what relationships, if any, exist (or have existed) in nature between filoviruses and snakes or other reptiles.", [["NPC1", "GENE_OR_GENE_PRODUCT", 62, 66], ["NPC1 domain C", "GENE_OR_GENE_PRODUCT", 117, 130], ["EBOV", "ORGANISM", 160, 164], ["GP", "PROTEIN", 59, 61], ["NPC1", "PROTEIN", 62, 66], ["\u03b14", "PROTEIN", 103, 105], ["\u03b15 loop", "PROTEIN", 106, 113], ["NPC1 domain C", "PROTEIN", 117, 130], ["EBOV GPCL", "PROTEIN", 160, 169], ["these residues", "PROBLEM", 41, 55], ["EBOV GPCL", "TEST", 160, 169], ["loop", "TEST", 172, 176], ["residues", "OBSERVATION_MODIFIER", 47, 55], ["NPC1 binding", "OBSERVATION", 62, 74]]], ["Experimental infections of wild-caught reptiles and amphibians by Swanepoel and colleagues (30) showed a general refractoriness to EBOV infection or replication, but minimal titers were recovered on a few occasions from the brown house snake (Lamprophis fuliginosus).", [["infections", "DISEASE", 13, 23], ["EBOV infection", "DISEASE", 131, 145], ["EBOV", "ORGANISM", 131, 135], ["snake", "ORGANISM_SUBDIVISION", 236, 241], ["Lamprophis fuliginosus", "ORGANISM", 243, 265], ["Lamprophis fuliginosus", "SPECIES", 243, 265], ["EBOV", "SPECIES", 131, 135], ["brown house snake", "SPECIES", 224, 241], ["Lamprophis fuliginosus", "SPECIES", 243, 265], ["Experimental infections", "PROBLEM", 0, 23], ["a general refractoriness to EBOV infection", "PROBLEM", 103, 145], ["minimal titers", "PROBLEM", 166, 180], ["infections", "OBSERVATION", 13, 23], ["EBOV", "OBSERVATION_MODIFIER", 131, 135], ["infection", "OBSERVATION", 136, 145], ["minimal", "OBSERVATION_MODIFIER", 166, 173], ["titers", "OBSERVATION_MODIFIER", 174, 180]]], ["Following outbreaks of the Ebola virus relative Marburg virus (MARV) at the mine in Kitaka Cave, the nearby \u201cPython Cave\u201d in Queen Elizabeth National Park in Uganda (32, 33), and the Goroumbwa Mine in the Democratic Republic of the Congo (31), a number of Egyptian fruit bats were found to be infected with MARV (5, 6, 24, 34).", [["Ebola virus relative Marburg virus", "DISEASE", 27, 61], ["MARV", "DISEASE", 307, 311], ["Ebola virus", "ORGANISM", 27, 38], ["Marburg virus", "ORGANISM", 48, 61], ["MARV", "ORGANISM", 63, 67], ["bats", "ORGANISM", 271, 275], ["MARV", "ORGANISM", 307, 311], ["Ebola virus", "SPECIES", 27, 38], ["Marburg virus", "SPECIES", 48, 61], ["Ebola virus", "SPECIES", 27, 38], ["Marburg virus", "SPECIES", 48, 61], ["MARV", "SPECIES", 63, 67], ["MARV", "SPECIES", 307, 311], ["the Ebola virus", "PROBLEM", 23, 38], ["Egyptian fruit bats", "PROBLEM", 256, 275], ["fruit bats", "OBSERVATION", 265, 275], ["infected", "OBSERVATION", 293, 301]]], ["Unfortunately, though the African rock python (Python sebae) and forest cobra (Naja Melanoleuca) are part of the fauna in these locations, there were no reports on investigations of snakes from these caves for filovirus infection (6, 22, 31).", [["filovirus infection", "DISEASE", 210, 229], ["rock python", "ORGANISM", 34, 45], ["Python sebae", "ORGANISM", 47, 59], ["forest cobra", "ORGANISM", 65, 77], ["Naja Melanoleuca", "ORGANISM", 79, 95], ["snakes", "ORGANISM_SUBDIVISION", 182, 188], ["Python sebae", "SPECIES", 47, 59], ["forest cobra", "SPECIES", 65, 77], ["Naja Melanoleuca", "SPECIES", 79, 95], ["African rock python", "SPECIES", 26, 45], ["Python sebae", "SPECIES", 47, 59], ["the African rock python", "PROBLEM", 22, 45], ["Python sebae)", "TREATMENT", 47, 60], ["forest cobra (Naja Melanoleuca)", "TREATMENT", 65, 96], ["snakes", "PROBLEM", 182, 188], ["filovirus infection", "PROBLEM", 210, 229]]], ["Nevertheless, our finding that two snake NPC1 orthologs are nonpermissive to filovirus entry and infection due to a single amino acid change leads us to speculate that this change was an adaptation to reduce infection by a filovirus, thereby increasing host survivability.", [["infection", "DISEASE", 97, 106], ["amino acid", "CHEMICAL", 123, 133], ["infection", "DISEASE", 208, 217], ["filovirus", "DISEASE", 223, 232], ["amino acid", "CHEMICAL", 123, 133], ["NPC1", "GENE_OR_GENE_PRODUCT", 41, 45], ["amino acid", "AMINO_ACID", 123, 133], ["snake NPC1 orthologs", "DNA", 35, 55], ["two snake NPC1 orthologs", "PROBLEM", 31, 55], ["filovirus entry", "PROBLEM", 77, 92], ["infection", "PROBLEM", 97, 106], ["a single amino acid change", "PROBLEM", 114, 140], ["infection", "PROBLEM", 208, 217], ["a filovirus", "PROBLEM", 221, 232], ["infection", "OBSERVATION", 208, 217]]], ["More-extensive wildlife sampling coupled with genetic and functional analysis of host-virus interactions associated with filovirus infection may uncover additional evidence for evolutionary arms races between filoviruses and multiple types of animals (bats, reptiles, and rodents).Cells. ::: MATERIALS AND METHODSVero grivet HEK 293T and U2OS cells were maintained in high-glucose Dulbecco\u2019s modified Eagle\u2019s medium (DMEM; Thermo Fisher Scientific, Waltham MA) supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals, Flowery Branch, GA) and 1% penicillin-streptomycin (Thermo Fisher Scientific) at 37\u00b0C and 5% CO2.", [["Cells", "ANATOMY", 281, 286], ["HEK 293T", "ANATOMY", 325, 333], ["U2OS cells", "ANATOMY", 338, 348], ["fetal bovine serum", "ANATOMY", 483, 501], ["FBS", "ANATOMY", 503, 506], ["filovirus infection", "DISEASE", 121, 140], ["glucose", "CHEMICAL", 373, 380], ["penicillin", "CHEMICAL", 556, 566], ["streptomycin", "CHEMICAL", 567, 579], ["CO2", "CHEMICAL", 622, 625], ["glucose", "CHEMICAL", 373, 380], ["penicillin", "CHEMICAL", 556, 566], ["streptomycin", "CHEMICAL", 567, 579], ["CO2", "CHEMICAL", 622, 625], ["host-virus", "ORGANISM", 81, 91], ["Cells", "CELL", 281, 286], ["METHODSVero grivet HEK 293T", "CELL", 306, 333], ["U2OS cells", "CELL", 338, 348], ["bovine", "ORGANISM", 489, 495], ["serum", "ORGANISM_SUBSTANCE", 496, 501], ["FBS", "ORGANISM_SUBSTANCE", 503, 506], ["penicillin-streptomycin", "SIMPLE_CHEMICAL", 556, 579], ["CO2", "SIMPLE_CHEMICAL", 622, 625], ["METHODSVero grivet HEK 293T", "CELL_LINE", 306, 333], ["U2OS cells", "CELL_LINE", 338, 348], ["bovine", "SPECIES", 489, 495], ["bovine", "SPECIES", 489, 495], ["host-virus interactions", "PROBLEM", 81, 104], ["filovirus infection", "PROBLEM", 121, 140], ["evolutionary arms races", "PROBLEM", 177, 200], ["filoviruses", "PROBLEM", 209, 220], ["METHODSVero grivet HEK", "TEST", 306, 328], ["U2OS cells", "TEST", 338, 348], ["Thermo Fisher Scientific, Waltham MA)", "TREATMENT", 423, 460], ["10% fetal bovine serum (FBS", "TREATMENT", 479, 506], ["Atlanta Biologicals, Flowery Branch, GA", "TREATMENT", 508, 547], ["penicillin", "TREATMENT", 556, 566], ["streptomycin", "TREATMENT", 567, 579], ["multiple", "OBSERVATION_MODIFIER", 225, 233]]], ["U2OS NPC1\u2212/\u2212 cell lines were generated by CRISPR/Cas9 genome editing as previously described (27) and transiently transfected with NPC1 constructs for colocalization experiments.", [["U2OS NPC1\u2212/\u2212 cell lines", "ANATOMY", 0, 23], ["U2OS", "CELL", 0, 4], ["NPC1", "GENE_OR_GENE_PRODUCT", 5, 9], ["NPC1", "GENE_OR_GENE_PRODUCT", 131, 135], ["U2OS NPC1\u2212/\u2212 cell lines", "CELL_LINE", 0, 23], ["CRISPR", "DNA", 42, 48], ["NPC1 constructs", "DNA", 131, 146], ["U2OS NPC1\u2212/\u2212 cell lines", "TREATMENT", 0, 23], ["CRISPR/Cas9 genome editing", "TREATMENT", 42, 68], ["NPC1 constructs", "TREATMENT", 131, 146], ["colocalization experiments", "TEST", 151, 177], ["cell lines", "OBSERVATION", 13, 23]]], ["Chinese hamster ovary (CHO) cells were maintained in DMEM\u2013Ham\u2019s F-12 medium (50/50 mix) (Thermo Fisher Scientific) supplemented with 10% FBS at 37\u00b0C and 5% CO2.", [["hamster ovary (CHO) cells", "ANATOMY", 8, 33], ["FBS", "ANATOMY", 137, 140], ["CO2", "CHEMICAL", 156, 159], ["CO2", "CHEMICAL", 156, 159], ["hamster ovary (CHO) cells", "CELL", 8, 33], ["DMEM\u2013Ham", "CELL", 53, 61], ["FBS", "ORGANISM_SUBSTANCE", 137, 140], ["CO2", "SIMPLE_CHEMICAL", 156, 159], ["Chinese hamster ovary (CHO) cells", "CELL_LINE", 0, 33], ["Chinese hamster", "SPECIES", 0, 15], ["Chinese hamster ovary (CHO) cells", "TREATMENT", 0, 33], ["10% FBS", "TREATMENT", 133, 140], ["ovary", "ANATOMY", 16, 21]]], ["Cell lines were generated by a retroviral transduction system, as previously described (22), to stably overexpress the NPC1 constructs in CHO-M12 cells, which contain a deletion in the NPC1 locus (24).", [["Cell lines", "ANATOMY", 0, 10], ["CHO-M12 cells", "ANATOMY", 138, 151], ["Cell lines", "CELL", 0, 10], ["NPC1", "GENE_OR_GENE_PRODUCT", 119, 123], ["CHO-M12 cells", "CELL", 138, 151], ["NPC1", "GENE_OR_GENE_PRODUCT", 185, 189], ["NPC1 constructs", "DNA", 119, 134], ["CHO-M12 cells", "CELL_LINE", 138, 151], ["NPC1 locus", "DNA", 185, 195], ["CHO-M12", "SPECIES", 138, 145], ["Cell lines", "TREATMENT", 0, 10], ["a retroviral transduction system", "TREATMENT", 29, 61], ["a deletion in the NPC1 locus", "PROBLEM", 167, 195], ["retroviral transduction system", "OBSERVATION", 31, 61], ["NPC1 constructs", "OBSERVATION", 119, 134], ["M12 cells", "ANATOMY", 142, 151], ["deletion", "OBSERVATION", 169, 177]]], ["FreeStyle 293-F cells were maintained in Gibco FreeStyle 293 expression medium (Thermo Fisher Scientific) at 37\u00b0C and 8% CO2.NPC1 constructs. ::: MATERIALS AND METHODSNPC1 domain C sequences (residues 373 to 620) flanked by sequences that form antiparallel coiled coils as previously described (35) were cloned into the pcDNA3.1(+) vector.", [["FreeStyle 293-F cells", "ANATOMY", 0, 21], ["CO2", "CHEMICAL", 121, 124], ["CO2", "CHEMICAL", 121, 124], ["FreeStyle 293-F cells", "CELL", 0, 21], ["Gibco FreeStyle 293", "CELL", 41, 60], ["CO2", "SIMPLE_CHEMICAL", 121, 124], ["NPC1", "GENE_OR_GENE_PRODUCT", 125, 129], ["pcDNA3", "GENE_OR_GENE_PRODUCT", 320, 326], ["FreeStyle 293-F cells", "CELL_LINE", 0, 21], ["NPC1 constructs", "DNA", 125, 140], ["METHODSNPC1 domain C sequences", "DNA", 160, 190], ["antiparallel coiled coils", "PROTEIN", 244, 269], ["pcDNA3", "DNA", 320, 326], ["1(+) vector", "DNA", 327, 338], ["FreeStyle", "TREATMENT", 0, 9], ["NPC1 constructs", "TREATMENT", 125, 140], ["METHODSNPC1 domain C sequences", "TEST", 160, 190], ["antiparallel coiled coils", "TREATMENT", 244, 269], ["pcDNA3", "ANATOMY", 320, 326]]], ["Constructs made included glycosylation mutants in HsNPC1 domain C (L414N+D416T, K498N+G500S, and N598A), while those in DrNPC1 domain C were N414A, N498A, and R600T.", [["HsNPC1 domain C", "GENE_OR_GENE_PRODUCT", 50, 65], ["DrNPC1 domain C", "GENE_OR_GENE_PRODUCT", 120, 135], ["glycosylation mutants", "PROTEIN", 25, 46], ["HsNPC1 domain C", "PROTEIN", 50, 65], ["L414N", "PROTEIN", 67, 72], ["D416T", "PROTEIN", 73, 78], ["K498N", "PROTEIN", 80, 85], ["N598A", "PROTEIN", 97, 102], ["DrNPC1 domain C", "PROTEIN", 120, 135], ["N414A", "PROTEIN", 141, 146], ["N498A", "PROTEIN", 148, 153], ["R600T", "PROTEIN", 159, 164], ["glycosylation mutants", "TREATMENT", 25, 46], ["HsNPC1 domain C", "TEST", 50, 65], ["L414N", "TEST", 67, 72], ["D416T", "TEST", 73, 78], ["K498N", "TEST", 80, 85], ["G500S", "TEST", 86, 91], ["DrNPC1 domain C", "TEST", 120, 135]]], ["DrNPC1 domain C chimeras were made by substituting these residues for human residues 373 to 475 (chimera 1), 476 to 536 (chimera 2), 537 to 620 (chimera 3), 493 to 502 (chimera 4), 502 to 512 (chimera 5), and 513 to 522 (chimera 6), and the point mutations made were E502D, Y503F, I505V, H506Y, F509Y, and S511T.", [["DrNPC1", "GENE_OR_GENE_PRODUCT", 0, 6], ["human", "ORGANISM", 70, 75], ["DrNPC1 domain C chimeras", "PROTEIN", 0, 24], ["chimera 1", "PROTEIN", 97, 106], ["chimera 2", "PROTEIN", 121, 130], ["chimera 3", "PROTEIN", 145, 154], ["chimera 4", "PROTEIN", 169, 178], ["chimera 5", "PROTEIN", 193, 202], ["513 to 522", "DNA", 209, 219], ["chimera 6", "PROTEIN", 221, 230], ["human", "SPECIES", 70, 75], ["human", "SPECIES", 70, 75], ["DrNPC1 domain C chimeras", "TREATMENT", 0, 24], ["human residues", "TEST", 70, 84], ["chimera", "TEST", 121, 128], ["chimera", "TEST", 145, 152], ["chimera", "TEST", 169, 176], ["chimera", "TEST", 193, 200], ["chimera", "TEST", 221, 228]]], ["The constructs were then transiently transfected into HEK 293T cells, and the supernatant with secreted protein was harvested after 72 h and used in ELISAs.", [["HEK 293T cells", "ANATOMY", 54, 68], ["supernatant", "ANATOMY", 78, 89], ["HEK 293T cells", "CELL", 54, 68], ["HEK 293T cells", "CELL_LINE", 54, 68], ["secreted protein", "PROTEIN", 95, 111], ["secreted protein", "TREATMENT", 95, 111], ["293T cells", "OBSERVATION", 58, 68]]], ["Purified proteins were made by transfecting FreeStyle 293-F cells in suspension, harvesting cells 72 h posttransfection, and purifying them by incubation with His-60 nickel resin.", [["FreeStyle 293-F cells", "ANATOMY", 44, 65], ["cells", "ANATOMY", 92, 97], ["His-60 nickel", "CHEMICAL", 159, 172], ["His", "CHEMICAL", 159, 162], ["nickel", "CHEMICAL", 166, 172], ["FreeStyle 293-F cells", "CELL", 44, 65], ["cells", "CELL", 92, 97], ["His-60 nickel resin", "SIMPLE_CHEMICAL", 159, 178], ["FreeStyle 293", "CELL_LINE", 44, 57], ["F cells", "CELL_LINE", 58, 65], ["cells in suspension", "TREATMENT", 60, 79], ["harvesting cells", "TEST", 81, 97], ["His-60 nickel resin", "TREATMENT", 159, 178]]], ["The proteins were eluted at 500 mM imidazole and pH 7.6 and dialyzed into 50 mM 2-(N-morpholino)ethanesulfonic acid (MES), 150 mM NaCl, pH 5.5.", [["imidazole", "CHEMICAL", 35, 44], ["2-(N-morpholino)ethanesulfonic acid", "CHEMICAL", 80, 115], ["MES", "CHEMICAL", 117, 120], ["NaCl", "CHEMICAL", 130, 134], ["imidazole", "CHEMICAL", 35, 44], ["2-(N-morpholino)ethanesulfonic acid", "CHEMICAL", 80, 115], ["MES", "CHEMICAL", 117, 120], ["NaCl", "CHEMICAL", 130, 134], ["imidazole", "SIMPLE_CHEMICAL", 35, 44], ["2-(N-morpholino)ethanesulfonic acid", "SIMPLE_CHEMICAL", 80, 115], ["MES", "SIMPLE_CHEMICAL", 117, 120], ["The proteins", "TEST", 0, 12], ["pH", "TEST", 49, 51], ["NaCl", "TEST", 130, 134], ["pH", "TEST", 136, 138]]], ["Domain C chimeras in the full-length NPC1 were generated by seamlessly replacing the domain C sequences in HsNPC1.", [["NPC1", "GENE_OR_GENE_PRODUCT", 37, 41], ["HsNPC1", "GENE_OR_GENE_PRODUCT", 107, 113], ["Domain C chimeras", "PROTEIN", 0, 17], ["NPC1", "DNA", 37, 41], ["domain C sequences", "DNA", 85, 103], ["HsNPC1", "PROTEIN", 107, 113], ["Domain C chimeras in the full-length NPC1", "TREATMENT", 0, 41], ["the domain C sequences in HsNPC1", "TREATMENT", 81, 113]]], ["The constructs were subcloned into the pBABE-puro retroviral vector and stably transfected into CHO-M12 cells by retroviral transduction, as previously described (22).", [["CHO-M12 cells", "ANATOMY", 96, 109], ["pBABE", "GENE_OR_GENE_PRODUCT", 39, 44], ["retroviral", "ORGANISM", 50, 60], ["CHO-M12 cells", "CELL", 96, 109], ["retroviral", "ORGANISM", 113, 123], ["pBABE-puro retroviral vector", "DNA", 39, 67], ["CHO-M12 cells", "CELL_LINE", 96, 109], ["puro retroviral vector", "TREATMENT", 45, 67], ["retroviral transduction", "TREATMENT", 113, 136], ["retroviral vector", "OBSERVATION", 50, 67], ["M12 cells", "OBSERVATION", 100, 109], ["retroviral transduction", "OBSERVATION", 113, 136]]], ["All constructs possessed N-terminal Flag tags.VSV pseudotype infections. ::: MATERIALS AND METHODSReplication-incompetent vesicular stomatitis virus Indiana (VSV) pseudotypes encoding enhanced green fluorescent protein (eGFP) in the first position and EBOV GP in place of VSV G were made as previously described (9, 36).", [["pseudotype infections", "DISEASE", 50, 71], ["VSV pseudotype", "ORGANISM", 46, 60], ["vesicular stomatitis virus Indiana", "ORGANISM", 122, 156], ["VSV", "ORGANISM", 158, 161], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 193, 218], ["eGFP", "GENE_OR_GENE_PRODUCT", 220, 224], ["EBOV", "ORGANISM", 252, 256], ["VSV", "ORGANISM", 272, 275], ["N-terminal Flag tags", "PROTEIN", 25, 45], ["enhanced green fluorescent protein", "PROTEIN", 184, 218], ["eGFP", "PROTEIN", 220, 224], ["EBOV GP", "PROTEIN", 252, 259], ["VSV", "SPECIES", 46, 49], ["stomatitis virus Indiana", "SPECIES", 132, 156], ["VSV", "SPECIES", 46, 49], ["VSV", "SPECIES", 158, 161], ["VSV", "SPECIES", 272, 275], ["VSV pseudotype infections", "PROBLEM", 46, 71], ["METHODSReplication", "TEST", 91, 109], ["incompetent vesicular stomatitis virus Indiana (VSV) pseudotypes encoding enhanced green fluorescent protein", "PROBLEM", 110, 218], ["EBOV GP", "TEST", 252, 259], ["VSV G", "TREATMENT", 272, 277], ["N-terminal Flag tags", "OBSERVATION", 25, 45], ["pseudotype infections", "OBSERVATION", 50, 71], ["vesicular stomatitis", "OBSERVATION", 122, 142], ["EBOV GP", "OBSERVATION", 252, 259]]], ["EBOV GP\u0394Muc matches the EBOV/H.sapiens-tc/COD/1976/Yambuku-Mayinga isolate amino acid sequence (GenBank accession number AF086833) but lacks the mucin-like domain (\u0394309\u2013489; \u0394Muc) (37).", [["amino acid", "CHEMICAL", 75, 85], ["amino acid", "CHEMICAL", 75, 85], ["EBOV", "ORGANISM", 0, 4], ["EBOV", "ORGANISM", 24, 28], ["H.sapiens", "GENE_OR_GENE_PRODUCT", 29, 38], ["amino acid", "AMINO_ACID", 75, 85], ["mucin", "GENE_OR_GENE_PRODUCT", 145, 150], ["EBOV GP\u0394Muc", "PROTEIN", 0, 11], ["Yambuku", "PROTEIN", 51, 58], ["Mayinga isolate amino acid sequence", "PROTEIN", 59, 94], ["mucin-like domain", "PROTEIN", 145, 162], ["\u0394309\u2013489", "PROTEIN", 164, 172], ["\u0394Muc", "PROTEIN", 174, 178], ["EBOV", "SPECIES", 0, 4], ["EBOV/H.sapiens-tc/COD/1976/Yambuku-Mayinga", "SPECIES", 24, 66], ["H.sapiens", "TEST", 29, 38], ["Yambuku", "TEST", 51, 58], ["amino acid sequence", "TEST", 75, 94]]], ["Unless otherwise indicated, virus titers were determined on Vero grivet monkey cells by manual counting of eGFP-positive cells.", [["cells", "ANATOMY", 79, 84], ["cells", "ANATOMY", 121, 126], ["Vero grivet monkey cells", "CELL", 60, 84], ["eGFP", "GENE_OR_GENE_PRODUCT", 107, 111], ["cells", "CELL", 121, 126], ["Vero grivet monkey cells", "CELL_LINE", 60, 84], ["eGFP-positive cells", "CELL_LINE", 107, 126], ["Vero grivet monkey", "SPECIES", 60, 78], ["virus titers", "TEST", 28, 40], ["eGFP", "TEST", 107, 111], ["positive cells", "PROBLEM", 112, 126], ["positive cells", "OBSERVATION", 112, 126]]], ["Cleaved EBOV GP (GPCL) was generated in vitro using the bacterial protease thermolysin (250 \u00b5g/ml) (Sigma-Aldrich, St. Louis, MO) for 1 h at 37\u00b0C as described previously (38, 39), and the reaction was stopped by adding the metalloprotease inhibitor phosphoramidon (1 mM) (Sigma-Aldrich).Authentic Ebola virus infections. ::: MATERIALS AND METHODSCHO cells, seeded in black Cellcoat 96-well plates (Greiner Bio-One, North America, Monroe, NC) were incubated with Ebola virus/H.sapiens-tc/COD/1995/Kikwit-9510621 at the indicated multiplicity of infection in a biosafety level 4 (BSL-4) laboratory located at USAMRIID.", [["METHODSCHO cells", "ANATOMY", 339, 355], ["phosphoramidon", "CHEMICAL", 249, 263], ["Ebola virus infections", "DISEASE", 297, 319], ["Kikwit-9510621", "CHEMICAL", 496, 510], ["infection", "DISEASE", 544, 553], ["phosphoramidon", "CHEMICAL", 249, 263], ["Kikwit-9510621", "CHEMICAL", 496, 510], ["EBOV", "ORGANISM", 8, 12], ["GPCL", "GENE_OR_GENE_PRODUCT", 17, 21], ["St. Louis", "ORGANISM", 115, 124], ["C", "GENE_OR_GENE_PRODUCT", 144, 145], ["phosphoramidon", "SIMPLE_CHEMICAL", 249, 263], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 272, 285], ["Ebola virus", "ORGANISM", 297, 308], ["METHODSCHO cells", "CELL", 339, 355], ["Ebola virus", "ORGANISM", 462, 473], ["H.sapiens", "ORGANISM", 474, 483], ["Kikwit-9510621", "CELL", 496, 510], ["EBOV GP", "PROTEIN", 8, 15], ["GPCL", "PROTEIN", 17, 21], ["METHODSCHO cells", "CELL_LINE", 339, 355], ["Ebola virus", "SPECIES", 297, 308], ["Ebola virus", "SPECIES", 462, 473], ["Ebola virus", "SPECIES", 297, 308], ["Ebola virus/H.sapiens-tc/COD/1995/Kikwit-9510621", "SPECIES", 462, 510], ["the bacterial protease thermolysin", "TREATMENT", 52, 86], ["the reaction", "PROBLEM", 184, 196], ["the metalloprotease inhibitor phosphoramidon", "TREATMENT", 219, 263], ["Authentic Ebola virus infections", "PROBLEM", 287, 319], ["black Cellcoat", "TEST", 367, 381], ["Ebola virus", "TEST", 462, 473], ["H.sapiens", "TEST", 474, 483], ["Kikwit", "TEST", 496, 502], ["infection", "PROBLEM", 544, 553], ["BSL", "TEST", 578, 581], ["Ebola virus infections", "OBSERVATION", 297, 319], ["METHODSCHO cells", "OBSERVATION", 339, 355], ["infection", "OBSERVATION", 544, 553]]], ["Following a 1-h absorption, virus inoculum was removed and cells were washed once with phosphate-buffered saline (PBS).", [["cells", "ANATOMY", 59, 64], ["phosphate", "CHEMICAL", 87, 96], ["phosphate", "CHEMICAL", 87, 96], ["cells", "CELL", 59, 64], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 87, 112], ["a 1-h absorption, virus inoculum", "TREATMENT", 10, 42], ["cells", "TREATMENT", 59, 64], ["phosphate-buffered saline (PBS", "TREATMENT", 87, 117]]], ["Cells were then incubated at 37\u00b0C, 5% CO2, and 80% humidity for 72 h, at which time the cells were washed once with PBS and submerged in 10% formalin prior to removal from the BSL-4 laboratory.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 88, 93], ["CO2", "CHEMICAL", 38, 41], ["formalin", "CHEMICAL", 141, 149], ["CO2", "CHEMICAL", 38, 41], ["formalin", "CHEMICAL", 141, 149], ["Cells", "CELL", 0, 5], ["CO2", "SIMPLE_CHEMICAL", 38, 41], ["cells", "CELL", 88, 93], ["formalin", "SIMPLE_CHEMICAL", 141, 149], ["PBS", "TREATMENT", 116, 119], ["removal", "TREATMENT", 159, 166]]], ["Formalin was removed, and cells were washed 3 times with PBS.", [["cells", "ANATOMY", 26, 31], ["Formalin", "CHEMICAL", 0, 8], ["Formalin", "CHEMICAL", 0, 8], ["Formalin", "SIMPLE_CHEMICAL", 0, 8], ["cells", "CELL", 26, 31], ["Formalin", "TREATMENT", 0, 8], ["PBS", "TREATMENT", 57, 60]]], ["Cells were blocked by adding 3% bovine serum albumin (BSA)-PBS to each well and incubating the cells at 37\u00b0C for 2 h.", [["Cells", "ANATOMY", 0, 5], ["serum", "ANATOMY", 39, 44], ["cells", "ANATOMY", 95, 100], ["Cells", "CELL", 0, 5], ["bovine", "ORGANISM", 32, 38], ["serum", "ORGANISM_SUBSTANCE", 39, 44], ["albumin", "SIMPLE_CHEMICAL", 45, 52], ["BSA", "SIMPLE_CHEMICAL", 54, 57], ["cells", "CELL", 95, 100], ["bovine", "SPECIES", 32, 38], ["3% bovine serum albumin (BSA", "TREATMENT", 29, 57]]], ["Cells were incubated with EBOV GP-specific monoclonal antibody (MAb) KZ52, diluted to 1 \u00b5g/ml in 3% BSA-PBS, at room temperature for 2 h.", [["Cells", "ANATOMY", 0, 5], ["BSA", "CHEMICAL", 100, 103], ["Cells", "CELL", 0, 5], ["EBOV", "ORGANISM", 26, 30], ["KZ52", "SIMPLE_CHEMICAL", 69, 73], ["BSA-PBS", "SIMPLE_CHEMICAL", 100, 107], ["EBOV GP-specific monoclonal antibody", "PROTEIN", 26, 62], ["MAb", "PROTEIN", 64, 67], ["EBOV", "SPECIES", 26, 30], ["Cells", "TEST", 0, 5], ["EBOV GP", "TEST", 26, 33], ["specific monoclonal antibody", "TEST", 34, 62], ["KZ52", "TEST", 69, 73]]], ["Cells were washed 3 times with PBS prior to addition of goat anti-human IgG-Alexa Fluor 488 (Thermo Fisher Scientific) secondary antibody.", [["Cells", "ANATOMY", 0, 5], ["Alexa Fluor 488", "CHEMICAL", 76, 91], ["Cells", "CELL", 0, 5], ["goat", "ORGANISM", 56, 60], ["Alexa Fluor 488", "SIMPLE_CHEMICAL", 76, 91], ["goat anti-human IgG", "PROTEIN", 56, 75], ["Alexa Fluor 488 (Thermo Fisher Scientific) secondary antibody", "PROTEIN", 76, 137], ["goat", "SPECIES", 56, 60], ["goat", "SPECIES", 56, 60], ["Cells", "TEST", 0, 5], ["PBS", "TREATMENT", 31, 34], ["goat anti-human IgG", "TREATMENT", 56, 75], ["Alexa Fluor", "TREATMENT", 76, 87]]], ["Following a 1-h incubation with secondary antibody, cells were washed 3 times prior to addition of Hoechst 33342 (Thermo Fisher Scientific) diluted in PBS.", [["cells", "ANATOMY", 52, 57], ["Hoechst 33342", "CHEMICAL", 99, 112], ["Hoechst 33342", "CHEMICAL", 99, 112], ["cells", "CELL", 52, 57], ["Hoechst 33342", "SIMPLE_CHEMICAL", 99, 112], ["a 1-h incubation", "TREATMENT", 10, 26], ["secondary antibody, cells", "PROBLEM", 32, 57], ["Hoechst", "TREATMENT", 99, 106]]], ["Cells were imaged and percentages of virus-infected cells were calculated using the Operetta high-content imaging system (PerkinElmer, Waltham, MA) and Harmony high-content imaging and analysis software (PerkinElmer).GPCL-NPC1 domain C capture ELISA. ::: MATERIALS AND METHODSNormalization of NPC1 domain C supernatants and proteins was carried out as previously described (25): resolution on SDS-PAGE gels followed by immunoblotting with anti-Flag primary antibody (Sigma-Aldrich) and anti-mouse Alexa-680 secondary antibody (Thermo Fisher Scientific) and quantification on the Li-Cor Odyssey imager (Li-Cor Biosciences, Lincoln, NE).", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 52, 57], ["Cells", "CELL", 0, 5], ["cells", "CELL", 52, 57], ["GPCL-NPC1", "GENE_OR_GENE_PRODUCT", 217, 226], ["NPC1 domain C", "GENE_OR_GENE_PRODUCT", 293, 306], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 467, 480], ["Alexa-680", "SIMPLE_CHEMICAL", 497, 506], ["virus-infected cells", "CELL_TYPE", 37, 57], ["GPCL", "PROTEIN", 217, 221], ["NPC1 domain C", "PROTEIN", 222, 235], ["NPC1 domain C", "PROTEIN", 293, 306], ["anti-Flag primary antibody", "PROTEIN", 439, 465], ["Sigma-Aldrich) and anti-mouse Alexa-680 secondary antibody", "PROTEIN", 467, 525], ["anti-mouse", "SPECIES", 486, 496], ["Cells", "TEST", 0, 5], ["virus", "PROBLEM", 37, 42], ["infected cells", "PROBLEM", 43, 57], ["the Operetta", "TEST", 80, 92], ["Harmony high-content imaging", "TEST", 152, 180], ["analysis software", "TEST", 185, 202], ["GPCL", "TEST", 217, 221], ["NPC1 domain C supernatants and proteins", "TEST", 293, 332], ["SDS", "TEST", 393, 396], ["anti-mouse Alexa", "TEST", 486, 502], ["infected cells", "OBSERVATION", 43, 57]]], ["Capture ELISAs were also performed as previously described (22, 25).", [["Capture ELISAs", "TEST", 0, 14]]], ["Briefly, high-binding 96-well ELISA plates (Corning, Corning, NY) were coated with KZ52 (40) (2 \u00b5g/ml in PBS) and then blocked using PBS containing 3% bovine serum albumin (PBSA).", [["serum", "ANATOMY", 158, 163], ["KZ52", "CHEMICAL", 83, 87], ["KZ52 (40)", "CHEMICAL", 83, 92], ["bovine", "ORGANISM", 151, 157], ["serum", "ORGANISM_SUBSTANCE", 158, 163], ["albumin", "SIMPLE_CHEMICAL", 164, 171], ["PBSA", "SIMPLE_CHEMICAL", 173, 177], ["bovine", "SPECIES", 151, 157], ["KZ52", "TREATMENT", 83, 87], ["PBS", "TREATMENT", 133, 136], ["3% bovine serum albumin", "TREATMENT", 148, 171]]], ["Pseudotyped EBOV was cleaved with thermolysin (250 \u00b5g/ml) at 37\u00b0C for 1 h and captured on the plate.", [["EBOV", "ORGANISM", 12, 16], ["thermolysin", "GENE_OR_GENE_PRODUCT", 34, 45], ["thermolysin", "PROTEIN", 34, 45], ["EBOV", "SPECIES", 12, 16], ["Pseudotyped EBOV", "PROBLEM", 0, 16], ["thermolysin", "TREATMENT", 34, 45], ["plate", "ANATOMY", 94, 99]]], ["Unbound virus was washed off, and serial dilutions of either Flag-tagged purified soluble NPC1 domain C (domain C; 0 to 40 \u00b5g/ml) or supernatants from transient transfections of the NPC1 constructs on HEK 293T cells were added.", [["supernatants", "ANATOMY", 133, 145], ["HEK 293T cells", "ANATOMY", 201, 215], ["Flag", "GENE_OR_GENE_PRODUCT", 61, 65], ["NPC1 domain C (domain C", "GENE_OR_GENE_PRODUCT", 90, 113], ["NPC1", "GENE_OR_GENE_PRODUCT", 182, 186], ["HEK 293T cells", "CELL", 201, 215], ["Flag", "PROTEIN", 61, 65], ["tagged purified soluble NPC1 domain C", "PROTEIN", 66, 103], ["domain C", "PROTEIN", 105, 113], ["NPC1 constructs", "DNA", 182, 197], ["HEK 293T cells", "CELL_LINE", 201, 215], ["Unbound virus", "PROBLEM", 0, 13], ["serial dilutions", "TREATMENT", 34, 50], ["Flag-tagged purified soluble NPC1 domain C (domain C", "TREATMENT", 61, 113], ["supernatants", "PROBLEM", 133, 145], ["HEK 293T cells", "TREATMENT", 201, 215], ["virus", "OBSERVATION", 8, 13]]], ["Bound domain C was detected by a horseradish peroxidase-conjugated anti-Flag antibody and Ultra-TMB substrate (Thermo Fisher).", [["Bound domain C", "GENE_OR_GENE_PRODUCT", 0, 14], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 33, 55], ["Bound domain C", "PROTEIN", 0, 14], ["horseradish peroxidase", "PROTEIN", 33, 55], ["anti-Flag antibody", "PROTEIN", 67, 85], ["Ultra-TMB substrate", "PROTEIN", 90, 109], ["horseradish", "SPECIES", 33, 44], ["Bound domain C", "PROBLEM", 0, 14], ["a horseradish peroxidase", "TEST", 31, 55], ["conjugated anti-Flag antibody", "TEST", 56, 85], ["Ultra", "TEST", 90, 95]]], ["EC50 values were calculated from binding curves generated by nonlinear regression analysis using Prism (GraphPad Software, La Jolla, CA).", [["EC50 values", "TEST", 0, 11], ["binding curves", "TEST", 33, 47], ["nonlinear regression analysis", "TEST", 61, 90], ["Prism (GraphPad Software", "TEST", 97, 121]]], ["Binding ELISAs were done in duplicate and in at least two independent experiments.", [["Binding ELISAs", "TEST", 0, 14]]], ["All incubation steps were done at 37\u00b0C for 1 h or at 4\u00b0C overnight.Immunofluorescence. ::: MATERIALS AND METHODSImaging was performed in U2OS or CHO cells grown on 12-mm coverslips and fixed with 4% paraformaldehyde.", [["U2OS", "ANATOMY", 137, 141], ["CHO cells", "ANATOMY", 145, 154], ["paraformaldehyde", "CHEMICAL", 199, 215], ["U2OS", "CELL", 137, 141], ["CHO cells", "CELL", 145, 154], ["paraformaldehyde", "SIMPLE_CHEMICAL", 199, 215], ["U2OS", "CELL_LINE", 137, 141], ["CHO cells", "CELL_LINE", 145, 154], ["All incubation steps", "TREATMENT", 0, 20], ["Immunofluorescence", "TEST", 67, 85], ["METHODSImaging", "TEST", 105, 119], ["CHO cells", "TEST", 145, 154], ["4% paraformaldehyde", "TREATMENT", 196, 215]]], ["For antibody staining, the coverslips were incubated with an anti-Flag antibody (Sigma-Aldrich) in PBS containing 0.1% Triton X-100 and 1% BSA.", [["coverslips", "ANATOMY", 27, 37], ["Triton X-100", "CHEMICAL", 119, 131], ["BSA", "CHEMICAL", 139, 142], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 81, 94], ["PBS", "SIMPLE_CHEMICAL", 99, 102], ["Triton X-100", "SIMPLE_CHEMICAL", 119, 131], ["BSA", "SIMPLE_CHEMICAL", 139, 142], ["anti-Flag antibody", "PROTEIN", 61, 79], ["antibody staining", "PROBLEM", 4, 21], ["the coverslips", "TEST", 23, 37], ["an anti-Flag antibody", "TEST", 58, 79]]], ["Detection was by incubation with Alexa 488-conjugated secondary antibodies (Thermo Fisher Scientific).", [["Alexa 488", "CHEMICAL", 33, 42], ["Alexa 488", "CHEMICAL", 33, 42], ["Alexa 488", "SIMPLE_CHEMICAL", 33, 42], ["Alexa 488", "PROTEIN", 33, 42], ["secondary antibodies", "PROTEIN", 54, 74], ["Alexa", "TEST", 33, 38]]], ["For filipin staining, the coverslips were stained with 50 \u03bcg/ml of Streptomyces filipinensis filipin III complex (Sigma-Aldrich) in PBS for 1 h.", [["coverslips", "ANATOMY", 26, 36], ["filipin", "CHEMICAL", 4, 11], ["filipin", "CHEMICAL", 93, 100], ["Sigma-Aldrich", "CHEMICAL", 114, 127], ["filipin", "CHEMICAL", 4, 11], ["filipin", "SIMPLE_CHEMICAL", 4, 11], ["Streptomyces filipinensis", "ORGANISM", 67, 92], ["filipin III", "SIMPLE_CHEMICAL", 93, 104], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 114, 127], ["Streptomyces filipinensis", "SPECIES", 67, 92], ["Streptomyces filipinensis", "SPECIES", 67, 92], ["filipin staining", "PROBLEM", 4, 20], ["the coverslips", "TREATMENT", 22, 36], ["Streptomyces filipinensis filipin III complex (Sigma-Aldrich) in PBS", "TREATMENT", 67, 135]]], ["Coverslips were mounted on glass slides using ProLong antifade reagent (Thermo Fisher Scientific), and images were acquired with an inverted fluorescence microscope equipped with a 63\u00d7 high-numerical-aperture oil objective.", [["ProLong antifade reagent", "TREATMENT", 46, 70], ["an inverted fluorescence microscope", "TEST", 129, 164]]]], "8c87e20c74fc7ec96982f29b282f0ac16e3d12bc": [["INTRODUCTIONThe atypical pneumonia\u2212Corona Virus Disease 2019 (COVID-19) is rapidly spreading throughout the world.", [["pneumonia", "DISEASE", 25, 34], ["Corona Virus Disease", "DISEASE", 35, 55], ["COVID-19", "CHEMICAL", 62, 70], ["Corona Virus", "ORGANISM", 35, 47], ["Corona Virus Disease 2019 (COVID-19", "SPECIES", 35, 70], ["atypical pneumonia", "PROBLEM", 16, 34], ["Corona Virus Disease", "PROBLEM", 35, 55], ["COVID", "TEST", 62, 67], ["atypical", "OBSERVATION_MODIFIER", 16, 24], ["pneumonia", "OBSERVATION", 25, 34], ["Virus Disease", "OBSERVATION", 42, 55], ["rapidly", "OBSERVATION_MODIFIER", 75, 82], ["spreading", "OBSERVATION_MODIFIER", 83, 92]]], ["The World Health Organization (WHO) has declared the outbreak of COVID-19 as pandemic.", [["COVID", "TEST", 65, 70], ["pandemic", "PROBLEM", 77, 85]]], ["The causal pathogen, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a newly isolated coronavirus, which first massively spread in the South China Seafood Market in Wuhan.", [["acute respiratory syndrome coronavirus", "DISEASE", 28, 66], ["coronavirus", "DISEASE", 103, 114], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 21, 68], ["SARS-CoV-2", "ORGANISM", 70, 80], ["coronavirus", "ORGANISM", 103, 114], ["severe acute respiratory syndrome coronavirus", "SPECIES", 21, 66], ["SARS-CoV-2", "SPECIES", 70, 80], ["The causal pathogen", "PROBLEM", 0, 19], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 21, 66], ["SARS-CoV", "TEST", 70, 78], ["a newly isolated coronavirus", "PROBLEM", 86, 114], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["acute", "OBSERVATION_MODIFIER", 28, 33], ["respiratory syndrome coronavirus", "OBSERVATION", 34, 66], ["coronavirus", "OBSERVATION", 103, 114], ["spread", "OBSERVATION_MODIFIER", 138, 144]]], ["This is the third large-scale epidemic caused by coronaviruses in the last two decades after There is still uncertainty about the transmission route of the SARS-CoV-2.", [["SARS", "DISEASE", 156, 160], ["coronaviruses", "ORGANISM", 49, 62], ["SARS-CoV-2", "ORGANISM", 156, 166], ["SARS-CoV", "SPECIES", 156, 164], ["coronaviruses", "PROBLEM", 49, 62], ["the SARS", "TEST", 152, 160], ["coronaviruses", "OBSERVATION", 49, 62]]], ["According to the New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 7) published by Chinese National Health Commission on March 3, 2020, 1 the main human-to-human transmission routes are close contacts (direct/indirect) and large respiratory droplets by coughs or sneezes or droplets of saliva, but the aerosol and fecal-oral transmission could not be excluded and need further investigation.", [["respiratory droplets", "ANATOMY", 249, 269], ["oral", "ANATOMY", 340, 344], ["Pneumonia", "DISEASE", 33, 42], ["human", "ORGANISM", 167, 172], ["human", "ORGANISM", 176, 181], ["saliva", "ORGANISM_SUBSTANCE", 306, 312], ["fecal", "ORGANISM_SUBDIVISION", 334, 339], ["oral", "ORGANISM_SUBDIVISION", 340, 344], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 176, 181], ["New Coronavirus Pneumonia", "PROBLEM", 17, 42], ["large respiratory droplets", "TREATMENT", 243, 269], ["saliva", "TREATMENT", 306, 312], ["the aerosol", "TREATMENT", 318, 329], ["fecal-oral transmission", "TREATMENT", 334, 357], ["further investigation", "TEST", 389, 410], ["New", "OBSERVATION_MODIFIER", 17, 20], ["Coronavirus", "OBSERVATION_MODIFIER", 21, 32], ["Pneumonia", "OBSERVATION", 33, 42], ["large", "OBSERVATION_MODIFIER", 243, 248], ["respiratory droplets", "OBSERVATION", 249, 269]]], ["Different from large droplets, the aerosols are particles small enough to suspend in the air for prolonged time, normally with an aerodynamic diameter less than 10 \u03bcm, and often referred to as \"droplet nuclei.\" 2 It was shown that 87% of the exhaled particles were below 1 \u03bcm.", [["nuclei", "ANATOMY", 202, 208], ["nuclei", "CELLULAR_COMPONENT", 202, 208], ["large droplets", "PROBLEM", 15, 29], ["the exhaled particles", "TEST", 238, 259], ["large", "OBSERVATION_MODIFIER", 15, 20], ["droplets", "OBSERVATION", 21, 29], ["aerosols", "OBSERVATION_MODIFIER", 35, 43], ["air", "ANATOMY", 89, 92], ["aerodynamic diameter", "OBSERVATION_MODIFIER", 130, 150]]], ["3 There was potential evidence for the aerosol transmission route of SARS.", [["SARS", "DISEASE", 69, 73], ["the aerosol transmission route", "TREATMENT", 35, 65], ["SARS", "PROBLEM", 69, 73], ["potential evidence for", "UNCERTAINTY", 12, 34]]], ["4 Studies have suggested that aerosols could be an important mode of transmission for influenza over both short and longer distances.", [["influenza", "DISEASE", 86, 95], ["4 Studies", "TEST", 0, 9], ["aerosols", "TREATMENT", 30, 38], ["influenza", "PROBLEM", 86, 95]]], ["5\u22127 However, the issue of long-range infection is still contentious, since the risk of long-range transmission by aerosols is dependent on the amount of the virus-containing particles, biologic decay, and infectious dose.", [["infection", "DISEASE", 37, 46], ["long-range infection", "PROBLEM", 26, 46], ["long-range transmission", "TREATMENT", 87, 110], ["the virus", "PROBLEM", 153, 162], ["infection", "OBSERVATION", 37, 46]]], ["A recent study has detected SARS-CoV-2 in aerosols.", [["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 28, 38], ["A recent study", "TEST", 0, 14], ["SARS", "TEST", 28, 32], ["CoV", "TEST", 33, 36]]], ["9 However, the role of the aerosol transmission is still uncertain.", [["the aerosol transmission", "TEST", 23, 47]]], ["A thorough assessment of aerosol transmission risk is required to better understand and control its influences.", [["A thorough assessment", "TEST", 0, 21], ["aerosol transmission risk", "TREATMENT", 25, 50]]], ["Quantitative Microbial Risk Assessment (QMRA) is an effective methodology to estimate the risk of infectious diseases.", [["infectious diseases", "DISEASE", 98, 117], ["infectious diseases", "PROBLEM", 98, 117], ["infectious", "OBSERVATION", 98, 108]]], ["QMRA has been utilized to investigate the inhalation health risk of pathogens generated Special Issue: Environmental Transmission and Control of COVID-19 from reused water 10, 11 and waste management facilities for livestock farms.", [["QMRA", "CHEMICAL", 0, 4], ["COVID-19", "CHEMICAL", 145, 153], ["COVID-19", "CHEMICAL", 145, 153], ["pathogens", "PROBLEM", 68, 77], ["COVID", "TEST", 145, 150]]], ["12, 13 Recently, the QMRA method has been adopted to investigate the airborne infection risk of MERS-CoV in a hospital, which indicated that the daily mean risk of infection for the nurses and healthcare workers was relatively high (>10 \u22124 ).", [["infection", "DISEASE", 78, 87], ["infection", "DISEASE", 164, 173], ["MERS-CoV", "ORGANISM", 96, 104], ["MERS-CoV", "SPECIES", 96, 104], ["the QMRA method", "TREATMENT", 17, 32], ["the airborne infection", "PROBLEM", 65, 87], ["infection", "PROBLEM", 164, 173], ["infection", "OBSERVATION", 78, 87], ["infection", "OBSERVATION", 164, 173]]], ["14 Atmospheric dispersion models were utilized in the QMRA studies 15 for foot-and-mouth-disease virus, 16\u221221 avian influenza virus, 22, 23 Legionella, 24 the spore-forming bacterium B.anthracis, 25\u221227 and the C. burnetii bacterium for Q fever.", [["influenza virus", "DISEASE", 116, 131], ["Q fever", "DISEASE", 236, 243], ["foot-and-mouth-disease virus", "ORGANISM", 74, 102], ["16\u221221", "ORGANISM", 104, 109], ["avian influenza virus", "ORGANISM", 110, 131], ["B.anthracis", "ORGANISM", 183, 194], ["C. burnetii", "ORGANISM", 210, 221], ["foot-and-mouth-disease virus", "SPECIES", 74, 102], ["avian influenza virus", "SPECIES", 110, 131], ["C. burnetii", "SPECIES", 210, 221], ["foot-and-mouth-disease virus", "SPECIES", 74, 102], ["16\u221221 avian influenza virus", "SPECIES", 104, 131], ["C. burnetii", "SPECIES", 210, 221], ["Atmospheric dispersion models", "TEST", 3, 32], ["the QMRA studies", "TEST", 50, 66], ["foot", "TEST", 74, 78], ["mouth-disease virus", "PROBLEM", 83, 102], ["avian influenza virus", "PROBLEM", 110, 131], ["Legionella", "TEST", 140, 150], ["the spore", "TEST", 155, 164], ["the C. burnetii bacterium", "TEST", 206, 231], ["fever", "PROBLEM", 238, 243], ["foot", "ANATOMY", 74, 78], ["mouth", "ANATOMY", 83, 88]]], ["28, 29 The atmospheric dispersion models 30\u221232 estimate the temporal and spatial distribution of hazardous pollutants for a large scale and long period, which is difficult to achieve by field sampling and measurements.", [["The atmospheric dispersion models", "TEST", 7, 40], ["field sampling", "TEST", 186, 200], ["atmospheric", "OBSERVATION_MODIFIER", 11, 22], ["dispersion", "OBSERVATION_MODIFIER", 23, 33], ["temporal", "OBSERVATION_MODIFIER", 60, 68], ["spatial", "OBSERVATION_MODIFIER", 73, 80], ["distribution", "OBSERVATION_MODIFIER", 81, 93], ["hazardous pollutants", "OBSERVATION", 97, 117], ["large", "OBSERVATION_MODIFIER", 124, 129], ["long period", "OBSERVATION_MODIFIER", 140, 151]]], ["15 In this study, we evaluated the infection risk of SARS-CoV-2 induced by aerosol transmission during the initial phase of the spread in the South China Seafood Market in December 2019 based on the QMRA method, by assuming one infected shopkeeper working inside Street No. 7 and by integrating the best available information about the virus as well as their uncertainties.", [["infection", "DISEASE", 35, 44], ["SARS", "DISEASE", 53, 57], ["SARS-CoV-2", "ORGANISM", 53, 63], ["SARS-CoV", "SPECIES", 53, 61], ["this study", "TEST", 6, 16], ["the infection risk", "PROBLEM", 31, 49], ["SARS", "PROBLEM", 53, 57], ["aerosol transmission", "TREATMENT", 75, 95], ["the virus", "PROBLEM", 332, 341], ["infection", "OBSERVATION", 35, 44]]], ["A zone model 37 and a three-dimensional Lagrangian dispersion model 38 were utilized to estimate the airborne virus concentration and exposure in the market and outdoor environments.", [["A zone model", "TEST", 0, 12], ["the airborne virus concentration", "TREATMENT", 97, 129], ["airborne virus", "OBSERVATION", 101, 115]]], ["The key processes were integrated into the assessment, including viral shedding, dispersion in air, deposition, biologic decay, and lung deposition.", [["lung", "ANATOMY", 132, 136], ["lung", "ORGAN", 132, 136], ["the assessment", "TEST", 39, 53], ["viral shedding", "PROBLEM", 65, 79], ["air", "ANATOMY", 95, 98], ["lung", "ANATOMY", 132, 136], ["deposition", "OBSERVATION", 137, 147]]], ["The infection risk was assessed using the dose\u2212response model developed for SARS-CoV.", [["infection", "DISEASE", 4, 13], ["SARS-CoV", "DISEASE", 76, 84], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 76, 84], ["SARS-CoV", "SPECIES", 76, 84], ["The infection risk", "PROBLEM", 0, 18], ["the dose\u2212response model", "TEST", 38, 61], ["SARS", "PROBLEM", 76, 80], ["CoV", "PROBLEM", 81, 84], ["infection", "OBSERVATION", 4, 13]]], ["39 Monte Carlo simulations are conducted to take into account the uncertainties in viral shedding, biologic decay, and the dose\u2212response parameters.", [["viral shedding", "PROBLEM", 83, 97], ["the dose\u2212response parameters", "TEST", 119, 147]]], ["The infection risk by aerosol transmission was quantified for people in various scenarios, e.g., costumers and shopkeepers inside the market and pedestrians near the market and at the neighboring area hundreds of meters away from the market.", [["infection", "DISEASE", 4, 13], ["people", "ORGANISM", 62, 68], ["people", "SPECIES", 62, 68], ["The infection risk", "PROBLEM", 0, 18], ["infection", "OBSERVATION", 4, 13]]], ["The infection risks due to close contact (direct/indirect) and large respiratory droplets by coughs or sneezes or droplets of saliva were not included in this study.MATERIALS AND METHODS2.1.", [["respiratory droplets", "ANATOMY", 69, 89], ["infection", "DISEASE", 4, 13], ["saliva", "ORGANISM_SUBSTANCE", 126, 132], ["The infection risks", "PROBLEM", 0, 19], ["large respiratory droplets", "PROBLEM", 63, 89], ["coughs", "PROBLEM", 93, 99], ["sneezes", "PROBLEM", 103, 110], ["droplets of saliva", "PROBLEM", 114, 132], ["this study", "TEST", 154, 164], ["METHODS2", "TEST", 179, 187], ["infection", "OBSERVATION", 4, 13], ["large", "OBSERVATION_MODIFIER", 63, 68], ["respiratory droplets", "OBSERVATION", 69, 89]]], ["The assessment focused on the Wuhan South China Seafood Market (Figure 1 ), where the virus massively spread during the initial phase.", [["The assessment", "TEST", 0, 14], ["the virus", "PROBLEM", 82, 91]]], ["The ventilation system inside the market had not been used for years, 40 so it was assumed that the air exchange inside the market was only dependent on natural ventilation.MATERIALS AND METHODSThe market-related infected cases contributed about 55% (26/47) to the total reported number before January 1, 2020, when the market was closed.", [["The ventilation system", "TREATMENT", 0, 22], ["the air exchange", "PROBLEM", 96, 112], ["natural ventilation", "TREATMENT", 153, 172], ["infected cases", "PROBLEM", 213, 227], ["air exchange", "OBSERVATION", 100, 112], ["dependent", "OBSERVATION_MODIFIER", 140, 149], ["natural ventilation", "OBSERVATION", 153, 172], ["infected", "OBSERVATION_MODIFIER", 213, 221]]], ["41 The onset of illness of the first market related case was on December 13, 2019.", [["illness", "DISEASE", 16, 23], ["illness", "PROBLEM", 16, 23], ["illness", "OBSERVATION", 16, 23]]], ["41 The virus might have already spread inside the market at the beginning of December considering the normal incubation period of about 2 weeks.", [["The virus", "PROBLEM", 3, 12], ["virus", "OBSERVATION", 7, 12], ["normal", "OBSERVATION", 102, 108]]], ["As a result, the assessment covered the whole December of 2019.MATERIALS AND METHODSAccording to Chinese Center for Disease Control and Prevention (China CDC), about 42.4% of the positive environmental samples for SARS-CoV-2 were from Street No. 7 and No. 8, 42 which are shown in Figure 1c .", [["SARS", "DISEASE", 214, 218], ["SARS-CoV", "SPECIES", 214, 222], ["the assessment", "TEST", 13, 27], ["Disease Control", "TREATMENT", 116, 131], ["SARS", "PROBLEM", 214, 218], ["CoV", "TEST", 219, 222]]], ["The spatial distribution of the infected cases is still uncertain.", [["the infected cases", "PROBLEM", 28, 46], ["spatial", "OBSERVATION_MODIFIER", 4, 11], ["distribution", "OBSERVATION_MODIFIER", 12, 24], ["infected cases", "OBSERVATION", 32, 46]]], ["In this study, it was assumed that there was one infected person inside Street No. 7 working from 6:00 to 18:00 every day, and the air flow was dominantly along the street due to the symmetrical structure of the market.", [["person", "SPECIES", 58, 64], ["this study", "TEST", 3, 13], ["the air flow", "TEST", 127, 139], ["infected", "OBSERVATION", 49, 57], ["air flow", "OBSERVATION", 131, 139], ["symmetrical structure", "OBSERVATION", 183, 204]]], ["After the simplification, the virus concentration was only calculated in the area defined by the red dashed line in Figure 1c .", [["red dashed line", "CELL_LINE", 97, 112], ["the virus concentration", "TREATMENT", 26, 49], ["the red dashed line", "TREATMENT", 93, 112], ["red", "OBSERVATION_MODIFIER", 97, 100], ["dashed line", "OBSERVATION", 101, 112]]], ["The geometrical dimension of the market was estimated from the satellite images and the street photos.", [["geometrical", "OBSERVATION_MODIFIER", 4, 15], ["dimension", "OBSERVATION_MODIFIER", 16, 25], ["market", "OBSERVATION_MODIFIER", 33, 39]]], ["The length and width of each street were respectively about 70 and 9 m, with a height of 5 m.", [["length", "OBSERVATION_MODIFIER", 4, 10], ["width", "OBSERVATION_MODIFIER", 15, 20]]], ["The sizes of the entrances for the street were about 3 m in width and 2.5 m in height.MATERIALS AND METHODS2.2.", [["sizes", "OBSERVATION_MODIFIER", 4, 9], ["entrances", "OBSERVATION_MODIFIER", 17, 26], ["street", "OBSERVATION", 35, 41], ["3 m", "OBSERVATION_MODIFIER", 53, 56], ["width", "OBSERVATION_MODIFIER", 60, 65], ["2.5 m", "OBSERVATION_MODIFIER", 70, 75]]], ["Viral Shedding from Infected Person.", [["Viral", "ORGANISM", 0, 5], ["Infected", "OBSERVATION", 20, 28]]], ["The virus concentration of SARS-CoV during the growth of post infection was about 10 5 to 10 7 plaque-forming units per mL (PFU mL \u22121 ) 43 in the respiratory fluid from the apical surface of the human airway epithelial cell culture system (HAE), which is an in vitro model of the human airway epithelium.", [["respiratory fluid", "ANATOMY", 146, 163], ["apical surface", "ANATOMY", 173, 187], ["airway epithelial cell culture system", "ANATOMY", 201, 238], ["airway epithelium", "ANATOMY", 286, 303], ["SARS", "DISEASE", 27, 31], ["infection", "DISEASE", 62, 71], ["HAE", "DISEASE", 240, 243], ["SARS-CoV", "ORGANISM", 27, 35], ["apical surface", "CELLULAR_COMPONENT", 173, 187], ["human", "ORGANISM", 195, 200], ["airway epithelial cell culture system", "CELL", 201, 238], ["human", "ORGANISM", 280, 285], ["airway epithelium", "TISSUE", 286, 303], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 280, 285], ["SARS-CoV", "SPECIES", 27, 35], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 280, 285], ["The virus concentration of SARS", "PROBLEM", 0, 31], ["post infection", "PROBLEM", 57, 71], ["the respiratory fluid", "TEST", 142, 163], ["virus", "OBSERVATION", 4, 9], ["CoV", "OBSERVATION_MODIFIER", 32, 35], ["growth", "OBSERVATION_MODIFIER", 47, 53], ["infection", "OBSERVATION", 62, 71], ["respiratory fluid", "OBSERVATION", 146, 163], ["apical", "ANATOMY_MODIFIER", 173, 179], ["surface", "ANATOMY_MODIFIER", 180, 187], ["human airway", "ANATOMY", 195, 207], ["epithelial cell", "OBSERVATION", 208, 223], ["human airway epithelium", "OBSERVATION", 280, 303]]], ["A similar level of MERS-CoV concentration was also found in the HAE system.", [["HAE", "DISEASE", 64, 67], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 19, 27], ["MERS", "PROTEIN", 19, 23], ["CoV concentration", "PROBLEM", 24, 41], ["MERS", "OBSERVATION", 19, 23]]], ["44 It is reasonable to assume SARS-CoV-2 has The GRAL calculation domain for the wind field and atmospheric dispersion in the area populated by buildings.", [["SARS", "DISEASE", 30, 34], ["GRAL calculation domain", "PROTEIN", 49, 72], ["SARS", "PROBLEM", 30, 34], ["The GRAL calculation domain", "TREATMENT", 45, 72], ["atmospheric dispersion", "TREATMENT", 96, 118], ["atmospheric dispersion", "OBSERVATION", 96, 118], ["area", "OBSERVATION_MODIFIER", 126, 130]]], ["The shielding effects of the surrounding buildings have been considered. (c) The calculation domain for the zone model, which was developed and utilized to calculate the aerosol transport and deposition inside the market. a similar concentration.", [["The shielding effects", "TREATMENT", 0, 21], ["The calculation domain", "TEST", 77, 99], ["the zone model", "TEST", 104, 118], ["the aerosol transport", "TREATMENT", 166, 187], ["shielding effects", "OBSERVATION", 4, 21], ["concentration", "OBSERVATION_MODIFIER", 232, 245]]], ["If the virus concentration is homogeneous in the respiratory fluid, the total viral shedding E virus can be estimated asMATERIALS AND METHODSwhere C virus is the viral concentration in the respiratory fluid, N i is particle number in size bin i, and d 0,i is the diameter of the expelled fresh droplets before evaporation.", [["respiratory fluid", "ANATOMY", 49, 66], ["respiratory fluid", "ANATOMY", 189, 206], ["E virus", "ORGANISM", 93, 100], ["METHODSwhere C virus", "ORGANISM", 134, 154], ["E virus", "SPECIES", 93, 100], ["C virus", "SPECIES", 147, 154], ["the virus concentration", "PROBLEM", 3, 26], ["the respiratory fluid", "PROBLEM", 45, 66], ["the total viral shedding E virus", "PROBLEM", 68, 100], ["C virus", "PROBLEM", 147, 154], ["the viral concentration", "PROBLEM", 158, 181], ["virus", "OBSERVATION", 7, 12], ["homogeneous", "OBSERVATION_MODIFIER", 30, 41], ["respiratory fluid", "OBSERVATION", 49, 66], ["viral concentration", "OBSERVATION", 162, 181], ["respiratory fluid", "OBSERVATION", 189, 206], ["size", "OBSERVATION_MODIFIER", 234, 238], ["fresh droplets", "OBSERVATION", 288, 302]]], ["The aerodynamic diameters of the particles generated by breathing were mainly below 5 \u03bcm, and they had already achieved an equilibrium state after evaporation, 45 with a diameter of d eq .", [["aerodynamic", "OBSERVATION_MODIFIER", 4, 15], ["diameters", "OBSERVATION_MODIFIER", 16, 25], ["particles", "OBSERVATION_MODIFIER", 33, 42]]], ["The number concentrations of the expelled droplet nuclei were about 0.098 particles cm \u22123 for mouth breathing, 45 including four size bins (d eq ): 0 to 0.8 \u03bcm (0.084 cm \u22123 ), 0.8 to 1.8 \u03bcm (0.009 cm \u22123 ), 1.8 to 3.5 \u03bcm (0.003 cm \u22123 ), and 3.5 to 5.5 \u03bcm (0.002 cm \u22123 ).", [["droplet nuclei", "ANATOMY", 42, 56], ["mouth", "ANATOMY", 94, 99], ["the expelled droplet nuclei", "TREATMENT", 29, 56], ["mouth breathing", "TEST", 94, 109], ["number", "OBSERVATION_MODIFIER", 4, 10], ["concentrations", "OBSERVATION_MODIFIER", 11, 25], ["droplet nuclei", "OBSERVATION", 42, 56]]], ["The tidal volume was set as 500 mL per inspiration, and 20 inspirations per minute for an adult.", [["The tidal volume", "TEST", 0, 16], ["tidal volume", "OBSERVATION", 4, 16]]], ["46 The relation between the initial droplet diameter d 0 and the diameter of the equilibrium droplet nuclei d eq was estimated following the method proposed by Nicas et al., 47 assuming that the solute in the respiratory fluid was dominated by ions:MATERIALS AND METHODSThe virus concentration in respiratory fluid C virus was treated as a stochastic variable in this study.", [["respiratory fluid", "ANATOMY", 209, 226], ["respiratory fluid", "ANATOMY", 297, 314], ["respiratory fluid C virus", "ORGANISM", 297, 322], ["C virus", "SPECIES", 315, 322], ["METHODSThe virus concentration", "TREATMENT", 263, 293], ["respiratory fluid C virus", "PROBLEM", 297, 322], ["this study", "TEST", 363, 373], ["droplet diameter", "OBSERVATION", 36, 52], ["diameter", "OBSERVATION_MODIFIER", 65, 73], ["equilibrium", "OBSERVATION_MODIFIER", 81, 92], ["droplet nuclei", "OBSERVATION", 93, 107], ["respiratory fluid", "OBSERVATION", 209, 226], ["respiratory fluid", "OBSERVATION", 297, 314]]], ["Based on the experimental data, 43, 44 C virus was assumed to follow a log-normal distribution log 10 (C virus ) \u223c N(6, 0.3).", [["the experimental data", "TEST", 9, 30], ["44 C virus", "PROBLEM", 36, 46], ["C virus", "TEST", 103, 110]]], ["The estimated concentration by the log-normal distribution was mainly between 10 5 and 10 7 PFU mL \u22121 .", [["The estimated concentration", "TEST", 0, 27], ["concentration", "OBSERVATION_MODIFIER", 14, 27], ["normal", "OBSERVATION", 39, 45]]], ["Monte Carlo simulations were conducted to incorporate the influences of the uncertain concentrations into the uncertainties of the final infection risk assessment.", [["infection", "DISEASE", 137, 146], ["Monte Carlo simulations", "TREATMENT", 0, 23], ["the final infection risk assessment", "TEST", 127, 162], ["infection", "OBSERVATION", 137, 146]]], ["The estimated viral shedding was mostly between 1 and 10 3 PFU per hour, comparable to the shedding of infectious influenza virus with a geometric mean of 37 fluorescent focus units (FFU), a similar unit to PFU, per 30 min sample of fine aerosol with aerodynamic diameter below 5 \u03bcm, measured during natural breathing and prompted speed.", [["influenza", "DISEASE", 114, 123], ["infectious influenza virus", "ORGANISM", 103, 129], ["infectious influenza virus", "SPECIES", 103, 129], ["infectious influenza virus", "SPECIES", 103, 129], ["The estimated viral shedding", "PROBLEM", 0, 28], ["infectious influenza virus", "PROBLEM", 103, 129], ["viral shedding", "OBSERVATION", 14, 28], ["infectious", "OBSERVATION", 103, 113], ["aerodynamic diameter", "OBSERVATION", 251, 271]]], ["48 A recent study 49 investigated the respiratory shedding of coronavirus (NL63, OC43, HKU1, and 229E) in exhaled breath, and the results indicated that there were 10 2 to 10 5 virus copies in the aerosol particles below 5 \u03bcm collected for 30 min without wearing masks.", [["respiratory", "ANATOMY", 38, 49], ["coronavirus", "ORGANISM", 62, 73], ["OC43", "CELL", 81, 85], ["HKU1", "GENE_OR_GENE_PRODUCT", 87, 91], ["A recent study", "TEST", 3, 17], ["the respiratory shedding of coronavirus", "PROBLEM", 34, 73], ["OC43", "TEST", 81, 85], ["HKU1", "TEST", 87, 91], ["exhaled breath", "TEST", 106, 120], ["the aerosol particles", "TREATMENT", 193, 214]]], ["A previous study on SARS-CoV 50 showed that about 300 viral genome copies were present per PFU.", [["SARS", "DISEASE", 20, 24], ["SARS-CoV 50", "ORGANISM", 20, 31], ["viral genome copies", "DNA", 54, 73], ["SARS-CoV", "SPECIES", 20, 28], ["A previous study", "TEST", 0, 16], ["SARS-CoV", "TEST", 20, 28], ["viral genome copies", "PROBLEM", 54, 73]]], ["As a result, our estimations are about 3 \u00d7 10 2 to 3 \u00d7 10 5 copies per hour, which agrees well with a recent study.", [["a recent study", "TEST", 100, 114]]], ["49 It should be noted that about 30% to 56% of the total collected samples were positive in the aforementioned virus shedding studies.", [["samples", "ANATOMY", 67, 74], ["samples", "CANCER", 67, 74], ["the total collected samples", "TEST", 47, 74], ["the aforementioned virus shedding studies", "TEST", 92, 133]]], ["48, 49 We assumed all the infected persons would shed virus, which may lead to overestimation of the risk, but it is reasonable to keep some safety margins.MATERIALS AND METHODS2.3.", [["persons", "ORGANISM", 35, 42], ["persons", "SPECIES", 35, 42], ["infected", "OBSERVATION", 26, 34]]], ["Biologic Decay of Coronavirus in Ambient Environments.", [["Coronavirus", "PROBLEM", 18, 29], ["Coronavirus", "OBSERVATION", 18, 29]]], ["Only one study is available for the biologic decay of SARS-CoV-2, 51 which indicated that the half-lives of SARS-CoV-2 and SARS-CoV were similar in aerosols, about 1.1 to 1.2 h at 21\u221223\u00b0C and 65% relative humidity.", [["SARS", "DISEASE", 54, 58], ["SARS", "DISEASE", 108, 112], ["SARS-CoV-2", "ORGANISM", 108, 118], ["SARS-CoV", "ORGANISM", 123, 131], ["SARS-CoV", "SPECIES", 54, 62], ["SARS-CoV", "SPECIES", 108, 116], ["SARS-CoV", "SPECIES", 123, 131], ["one study", "TEST", 5, 14], ["SARS", "TEST", 54, 58], ["CoV", "TEST", 59, 62], ["SARS", "TEST", 108, 112], ["CoV", "TEST", 113, 116], ["SARS", "PROBLEM", 123, 127]]], ["The decay information reported in the literature for other coronaviruses, including common human coronavirus (HCoV), MERS-CoV, SARS-CoV, transmissible gastroenteritis virus (TGEV), and mouse hepatitis virus (MHV) were collected as shown in Table 1 , to evaluate the uncertainties of this parameter.MATERIALS AND METHODSThe half-life periods were from 0.5 h to 10 2 h as shown in Table 1 .", [["SARS-CoV", "DISEASE", 127, 135], ["transmissible gastroenteritis virus", "DISEASE", 137, 172], ["mouse hepatitis virus", "DISEASE", 185, 206], ["coronaviruses", "ORGANISM", 59, 72], ["human coronavirus", "ORGANISM", 91, 108], ["HCoV", "ORGANISM", 110, 114], ["MERS-CoV", "ORGANISM", 117, 125], ["SARS-CoV", "ORGANISM", 127, 135], ["transmissible gastroenteritis virus", "ORGANISM", 137, 172], ["TGEV", "ORGANISM", 174, 178], ["mouse hepatitis virus", "ORGANISM", 185, 206], ["MHV", "ORGANISM", 208, 211], ["human", "SPECIES", 91, 96], ["coronavirus", "SPECIES", 97, 108], ["SARS-CoV", "SPECIES", 127, 135], ["transmissible gastroenteritis virus", "SPECIES", 137, 172], ["TGEV", "SPECIES", 174, 178], ["mouse", "SPECIES", 185, 190], ["hepatitis virus", "SPECIES", 191, 206], ["human coronavirus", "SPECIES", 91, 108], ["HCoV", "SPECIES", 110, 114], ["MERS-CoV", "SPECIES", 117, 125], ["SARS-CoV", "SPECIES", 127, 135], ["transmissible gastroenteritis virus", "SPECIES", 137, 172], ["TGEV", "SPECIES", 174, 178], ["mouse hepatitis virus", "SPECIES", 185, 206], ["MHV", "SPECIES", 208, 211], ["other coronaviruses", "PROBLEM", 53, 72], ["common human coronavirus", "PROBLEM", 84, 108], ["MERS", "PROBLEM", 117, 121], ["CoV", "PROBLEM", 122, 125], ["SARS", "PROBLEM", 127, 131], ["CoV", "PROBLEM", 132, 135], ["transmissible gastroenteritis virus", "PROBLEM", 137, 172], ["mouse hepatitis virus", "PROBLEM", 185, 206], ["METHODSThe half-life periods", "TREATMENT", 312, 340]]], ["The data indicated that a low temperature was normally favorable for viruses to survive in the air, but the role of relative humidity (RH) was more complicated.", [["The data", "TEST", 0, 8], ["a low temperature", "PROBLEM", 24, 41], ["viruses", "PROBLEM", 69, 76]]], ["It seemed that there was an optimal RH for the virus to survive, which was about 50% implied for the HCoV.", [["HCoV", "SPECIES", 101, 105], ["the virus", "PROBLEM", 43, 52]]], ["52 Higher or lower RHs might enhance the inactivation of the viruses.", [["Higher or lower RHs", "PROBLEM", 3, 22], ["viruses", "OBSERVATION", 61, 68]]], ["However, more data are still needed to confirm the RH effects.", [["the RH effects", "PROBLEM", 47, 61]]], ["Considering the relatively wide range, the half-life periods were treated as a stochastic variable following the triangular distribution in this study.", [["the half-life periods", "TREATMENT", 39, 60], ["this study", "TEST", 140, 150], ["relatively", "OBSERVATION_MODIFIER", 16, 26], ["wide", "OBSERVATION_MODIFIER", 27, 31], ["triangular", "OBSERVATION_MODIFIER", 113, 123], ["distribution", "OBSERVATION_MODIFIER", 124, 136]]], ["On the basis of the available data in Table 1 , the lower limit, upper limit, and mode of the distribution were respectively set as log 10 (0.5), log 10 (100), and log 10 (10).", [["lower limit", "OBSERVATION_MODIFIER", 52, 63], ["upper limit", "OBSERVATION_MODIFIER", 65, 76]]], ["Halflife periods were sampled following a triangular distribution and utilized by the Monte Carlo simulations.MATERIALS AND METHODS2.4.", [["Halflife periods", "TREATMENT", 0, 16]]], ["A zone model was developed to estimate the virus concentration and deposition inside Street No. 7 of the market using the above viral shedding and biologic decay data.", [["A zone model", "TEST", 0, 12], ["the virus concentration", "PROBLEM", 39, 62], ["the above viral shedding", "TREATMENT", 118, 142], ["virus", "OBSERVATION", 43, 48]]], ["The zone model assumed that the virus concentration was homogeneous due to the mixing by human movements.", [["human", "ORGANISM", 89, 94], ["human", "SPECIES", 89, 94], ["human", "SPECIES", 89, 94], ["the virus concentration", "PROBLEM", 28, 51], ["virus", "OBSERVATION", 32, 37]]], ["The variation of the airborne concentration of active viruses inside the market was controlled by the following relation:MATERIALS AND METHODSis the viral concentration, Q is the ventilation rate (m 3 s \u22121 ); S v , S u , and S d are the areas (m 2 ) of vertical, upward-facing, and downward-facing surfaces of Street No. 7, respectively; v dv , v du , and v dd are deposition velocities (m s \u22121 ) for the corresponding surface; \u03bb is the biologic decay rate of the virus (s \u22121 ); and \u03c3 is the viral shedding rate (PFU s \u22121 ).", [["surface", "ANATOMY", 419, 426], ["surface", "CELLULAR_COMPONENT", 419, 426], ["\u03c3", "GENE_OR_GENE_PRODUCT", 483, 484], ["\u03bb", "PROTEIN", 428, 429], ["active viruses", "PROBLEM", 47, 61], ["the viral concentration", "TREATMENT", 145, 168], ["the ventilation rate", "TEST", 175, 195], ["deposition velocities", "TEST", 365, 386], ["the virus", "PROBLEM", 460, 469], ["the viral shedding rate", "TEST", 488, 511], ["PFU s", "TEST", 513, 518], ["variation", "OBSERVATION_MODIFIER", 4, 13], ["airborne concentration", "OBSERVATION", 21, 43], ["active", "OBSERVATION_MODIFIER", 47, 53], ["viruses", "OBSERVATION", 54, 61], ["market", "OBSERVATION_MODIFIER", 73, 79], ["viral concentration", "OBSERVATION", 149, 168], ["vertical", "OBSERVATION_MODIFIER", 253, 261], ["upward", "OBSERVATION_MODIFIER", 263, 269], ["downward", "OBSERVATION_MODIFIER", 282, 290], ["v du", "OBSERVATION", 345, 349], ["deposition", "OBSERVATION", 365, 375], ["surface", "OBSERVATION_MODIFIER", 419, 426]]], ["The airflow was hourly updated.", [["airflow", "OBSERVATION", 4, 11]]], ["The concentration inside Street No. 7 at hour t was calculated asMATERIALS AND METHODSThe ventilation rate Q was estimated using the airflow network (AFN) analysis, following the method proposed by Karava et al. 54 The deposition velocities were estimated following the method proposed by Lai et al. 37 The detailed methods are introduced in the Supporting Information.MATERIALS AND METHODS2.5.", [["METHODSThe ventilation rate", "TREATMENT", 79, 106], ["the airflow network", "TEST", 129, 148], ["the method", "TREATMENT", 175, 185], ["The deposition velocities", "TEST", 215, 240], ["the method", "TREATMENT", 266, 276], ["deposition", "OBSERVATION_MODIFIER", 219, 229], ["velocities", "OBSERVATION_MODIFIER", 230, 240]]], ["Atmospheric Dispersion Model.", [["Dispersion Model", "OBSERVATION", 12, 28]]], ["The atmospheric dispersion in the ambient environment was calculated using the coupled model system of GRAMM/GRAL 38 (version 19.03), where GRAMM (Graz Mesoscale Model wind fields) is an Eulerian mesoscale numerical weather prediction model and GRAL (microphysics Graz Lagrangian Model) is a Lagrangian dispersion model.", [["a Lagrangian dispersion model", "TREATMENT", 290, 319], ["atmospheric", "OBSERVATION_MODIFIER", 4, 15], ["dispersion", "OBSERVATION_MODIFIER", 16, 26], ["Lagrangian dispersion", "OBSERVATION", 292, 313]]], ["The model system was designed to reproduce the atmospheric transport of pollutants in complex terrain, e.g., the inner-Alpine basins.", [["the inner-Alpine basins", "TREATMENT", 109, 132], ["pollutants", "OBSERVATION", 72, 82], ["complex", "OBSERVATION_MODIFIER", 86, 93], ["terrain", "OBSERVATION_MODIFIER", 94, 101], ["Alpine basins", "OBSERVATION", 119, 132]]], ["It has already been utilized to simulate NOx and particulate matter concentrations with high resolution in Zurich.", [["NOx", "CHEMICAL", 41, 44], ["NOx", "CHEMICAL", 41, 44], ["NOx", "SIMPLE_CHEMICAL", 41, 44]]], ["The size of the domain was about 20 km (west\u2212 east) \u00d7 12 km (south\u2212north), with a horizontal resolution of 300 m.", [["size", "OBSERVATION_MODIFIER", 4, 8], ["300 m.", "OBSERVATION_MODIFIER", 107, 113]]], ["There were 15 layers in the vertical direction.", [["15 layers", "OBSERVATION_MODIFIER", 11, 20], ["vertical", "OBSERVATION_MODIFIER", 28, 36]]], ["The thickness of the first layer was 10 m, and the vertical stretching factor was 1.4.", [["vertical stretching factor", "PROTEIN", 51, 77], ["the vertical stretching factor", "TEST", 47, 77], ["thickness", "OBSERVATION_MODIFIER", 4, 13], ["first", "OBSERVATION_MODIFIER", 21, 26], ["layer", "OBSERVATION_MODIFIER", 27, 32], ["10 m", "OBSERVATION_MODIFIER", 37, 41]]], ["The height of the domain was 3874 m.", [["The height of the domain", "TEST", 0, 24]]], ["56 The topography data were from the Shuttle Radar Topography Mission (SRTM) digital elevation data with 1 arc-second resolution.", [["The topography data", "TEST", 3, 22], ["digital elevation data", "TEST", 77, 99]]], ["57 The land cover data were from the Finer Resolution Observation and Monitoring of Global Land Cover (FROM-GLC) 2017v1 with 30 m resolution.", [["Global Land Cover", "TREATMENT", 84, 101]]], ["58 The building data were acquired from Baidu Map.MATERIALS AND METHODSThe GRAL model utilized the GRAMM data to further calculate the wind flow and aerosol dispersion inside the area populated by buildings.", [["the GRAMM data", "TEST", 95, 109], ["the wind flow", "TREATMENT", 131, 144], ["aerosol dispersion", "TREATMENT", 149, 167], ["aerosol dispersion", "OBSERVATION", 149, 167], ["area", "OBSERVATION_MODIFIER", 179, 183]]], ["The computational domain of GRAL is shown in Figure 1a .", [["GRAL", "PROTEIN", 28, 32]]], ["The domain was about 1.86 km (west\u2212 east) \u00d7 1.43 km (south\u2212north), with a horizontal resolution of 2 m and 163 vertical layers.", [["horizontal", "OBSERVATION_MODIFIER", 74, 84], ["resolution", "OBSERVATION_MODIFIER", 85, 95], ["vertical layers", "OBSERVATION_MODIFIER", 111, 126]]], ["The thickness of the first layer was 2 m, and the stretching factor was 1.01.", [["the stretching factor", "TEST", 46, 67], ["thickness", "OBSERVATION_MODIFIER", 4, 13], ["first", "OBSERVATION_MODIFIER", 21, 26], ["layer", "OBSERVATION_MODIFIER", 27, 32]]], ["The dose\u2212response relation is normally utilized to assess the infection risk as a function of the exposure dose.", [["infection", "DISEASE", 62, 71], ["the infection risk", "PROBLEM", 58, 76], ["the exposure dose", "TREATMENT", 94, 111], ["infection", "OBSERVATION", 62, 71]]], ["However, there is no available information about the dose\u2212response relation for SARS-CoV-2.", [["SARS", "DISEASE", 80, 84], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 80, 90], ["SARS-CoV", "SPECIES", 80, 88], ["SARS", "TEST", 80, 84], ["CoV", "TEST", 85, 88], ["no", "UNCERTAINTY", 18, 20]]], ["SARS-CoV-2 and SARS-CoV share the same host cell receptor angiotensin-converting enzyme 2 (ACE2), and they also share similar profiles of cellular tropism, 59 indicating commonalities between the infectivity of these two viruses.", [["cell", "ANATOMY", 44, 48], ["cellular", "ANATOMY", 138, 146], ["angiotensin", "CHEMICAL", 58, 69], ["SARS-CoV-2", "ORGANISM", 0, 10], ["SARS-CoV", "ORGANISM", 15, 23], ["host cell receptor", "GENE_OR_GENE_PRODUCT", 39, 57], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 58, 89], ["ACE2", "GENE_OR_GENE_PRODUCT", 91, 95], ["cellular", "CELL", 138, 146], ["host cell receptor angiotensin-converting enzyme 2", "PROTEIN", 39, 89], ["ACE2", "PROTEIN", 91, 95], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "TEST", 0, 4], ["CoV", "TEST", 5, 8], ["SARS", "PROBLEM", 15, 19], ["angiotensin", "TEST", 58, 69], ["converting enzyme", "TEST", 70, 87], ["cellular tropism", "TEST", 138, 154], ["cellular tropism", "OBSERVATION", 138, 154], ["two viruses", "OBSERVATION", 217, 228]]], ["60 As a result, the exponential model developed by Watanabe et al. 39 for SARS-CoV could be a reasonable surrogate for the infection risk assessment in this study.", [["infection", "DISEASE", 123, 132], ["SARS-CoV", "ORGANISM", 74, 82], ["SARS-CoV", "SPECIES", 74, 82], ["SARS-CoV", "PROBLEM", 74, 82], ["the infection risk assessment", "TEST", 119, 148], ["this study", "TEST", 152, 162], ["infection", "OBSERVATION", 123, 132]]], ["The exponential model is expressed asMATERIALS AND METHODSwhere p(d) is the infection risk at a dose of d in units of plaque-forming units (PFU) and k is a pathogen dependent parameter, which was optimally estimated as 4.1 \u00d7 10 2 PFU for SARS-CoV based on the data for the infection of transgenic mice susceptible to SARS-CoV.", [["plaque", "ANATOMY", 118, 124], ["infection", "DISEASE", 76, 85], ["SARS", "DISEASE", 238, 242], ["infection", "DISEASE", 273, 282], ["SARS", "DISEASE", 317, 321], ["SARS-CoV", "ORGANISM", 238, 246], ["mice", "ORGANISM", 297, 301], ["SARS-CoV", "ORGANISM", 317, 325], ["mice", "SPECIES", 297, 301], ["SARS-CoV", "SPECIES", 238, 246], ["mice", "SPECIES", 297, 301], ["SARS-CoV", "SPECIES", 317, 325], ["the infection risk", "PROBLEM", 72, 90], ["plaque", "TREATMENT", 118, 124], ["a pathogen dependent parameter", "PROBLEM", 154, 184], ["SARS", "PROBLEM", 238, 242], ["CoV", "PROBLEM", 243, 246], ["the data", "TEST", 256, 264], ["the infection", "PROBLEM", 269, 282], ["CoV", "PROBLEM", 322, 325], ["infection", "OBSERVATION", 76, 85], ["infection", "OBSERVATION", 273, 282]]], ["39 The study 39 also estimated that k ranged between 10 and 10 4 PFU based on the experiments challenging humans or mice with different coronaviruses, including HCoV-229E, 61 MHV-S, 62 MHV-2, 63 and HEV-67N.", [["humans", "ORGANISM", 106, 112], ["mice", "ORGANISM", 116, 120], ["coronaviruses", "ORGANISM", 136, 149], ["HCoV-229E", "ORGANISM", 161, 170], ["MHV-S", "ORGANISM", 175, 180], ["MHV-2", "ORGANISM", 185, 190], ["HEV-67N", "ORGANISM", 199, 206], ["humans", "SPECIES", 106, 112], ["mice", "SPECIES", 116, 120], ["humans", "SPECIES", 106, 112], ["mice", "SPECIES", 116, 120], ["HCoV-229E", "SPECIES", 161, 170], ["MHV-S", "SPECIES", 175, 180], ["MHV-2", "SPECIES", 185, 190], ["HEV-67N", "SPECIES", 199, 206], ["The study", "TEST", 3, 12], ["k", "TEST", 36, 37], ["different coronaviruses", "PROBLEM", 126, 149], ["HCoV", "TEST", 161, 165], ["MHV", "TEST", 175, 178], ["MHV", "TEST", 185, 188], ["HEV", "TEST", 199, 202]]], ["The lower end the distribution was about 20 PFU, with infectivity 20 times higher than the optimal value.", [["infectivity", "TEST", 54, 65], ["lower", "ANATOMY_MODIFIER", 4, 9], ["distribution", "OBSERVATION_MODIFIER", 18, 30], ["20 PFU", "OBSERVATION_MODIFIER", 41, 47]]], ["The dose d was estimated by 8) where N resp is the total number of respirations (20 times per minute), V tidal is the tidal volume (500 mL per inspiration), c air,i (t) is the airborne virus concentration carried by the particles in size bin i, and f dep is the deposition fraction of the particles in size bin i in the human respiratory tract, including anterior nasal, naso-oropharynx/larynx, bronchi, bronchioles, and alveolar interstitial.", [["respiratory tract", "ANATOMY", 326, 343], ["anterior nasal", "ANATOMY", 355, 369], ["naso-oropharynx", "ANATOMY", 371, 386], ["larynx", "ANATOMY", 387, 393], ["bronchi", "ANATOMY", 395, 402], ["bronchioles", "ANATOMY", 404, 415], ["alveolar interstitial", "ANATOMY", 421, 442], ["human", "ORGANISM", 320, 325], ["respiratory tract", "ORGANISM_SUBDIVISION", 326, 343], ["anterior nasal", "MULTI-TISSUE_STRUCTURE", 355, 369], ["oropharynx", "ORGAN", 376, 386], ["larynx", "ORGAN", 387, 393], ["bronchi", "MULTI-TISSUE_STRUCTURE", 395, 402], ["bronchioles", "MULTI-TISSUE_STRUCTURE", 404, 415], ["alveolar interstitial", "MULTI-TISSUE_STRUCTURE", 421, 442], ["human", "SPECIES", 320, 325], ["human", "SPECIES", 320, 325], ["respirations", "TEST", 67, 79], ["the tidal volume", "TEST", 114, 130], ["the airborne virus concentration", "PROBLEM", 172, 204], ["the deposition fraction", "PROBLEM", 258, 281], ["anterior nasal, naso-oropharynx/larynx, bronchi, bronchioles, and alveolar interstitial", "PROBLEM", 355, 442], ["deposition", "OBSERVATION_MODIFIER", 262, 272], ["fraction", "OBSERVATION_MODIFIER", 273, 281], ["particles", "OBSERVATION_MODIFIER", 289, 298], ["size", "OBSERVATION_MODIFIER", 302, 306], ["human", "ANATOMY_MODIFIER", 320, 325], ["respiratory tract", "ANATOMY", 326, 343], ["anterior", "ANATOMY_MODIFIER", 355, 363], ["nasal", "ANATOMY", 364, 369], ["naso", "ANATOMY_MODIFIER", 371, 375], ["oropharynx", "ANATOMY", 376, 386], ["larynx", "ANATOMY", 387, 393], ["bronchi", "ANATOMY", 395, 402], ["bronchioles", "ANATOMY", 404, 415], ["alveolar", "ANATOMY_MODIFIER", 421, 429], ["interstitial", "ANATOMY_MODIFIER", 430, 442]]], ["The deposition fraction f dep was calculated using the deposition model for pathogenic bioaerosols, 66 as shown in Figure S2 .MATERIALS AND METHODS3.", [["The deposition fraction f dep", "PROBLEM", 0, 29], ["the deposition model", "TREATMENT", 51, 71], ["deposition", "OBSERVATION_MODIFIER", 4, 14], ["fraction", "OBSERVATION_MODIFIER", 15, 23]]], ["The average temperature in Wuhan was about 6 to 10\u00b0C in December, and the relative humidity was about 75%.", [["The average temperature", "TEST", 0, 23], ["the relative humidity", "TEST", 70, 91], ["average", "OBSERVATION_MODIFIER", 4, 11], ["temperature", "OBSERVATION_MODIFIER", 12, 23]]], ["Figure 2a shows the distribution of wind speed and direction at 10 m above the ground.", [["distribution", "OBSERVATION_MODIFIER", 20, 32]]], ["Figure 2b shows the GRAMM results for the most dominant wind scenario with a speed of about 5 m s \u22121 , a direction of 8\u00b0, and neutral atmospheric stability, accounting for about 3.62% of all meteorological conditions.", [["atmospheric stability", "OBSERVATION", 134, 155]]], ["The wind direction was nearly the same in the whole area due to the relatively flat terrain, but the wind speed was much higher above water surfaces, e.g., the Yangtze River and lakes, due to the low surface roughness.MATERIALS AND METHODSThe GRAL model was applied for detailed wind and dispersion calculations considering the effects of buildings with a resolution of 2 m.", [["surface", "ANATOMY", 200, 207], ["the low surface roughness", "PROBLEM", 192, 217], ["METHODSThe GRAL model", "TREATMENT", 232, 253], ["dispersion calculations", "TREATMENT", 288, 311], ["relatively", "OBSERVATION_MODIFIER", 68, 78], ["flat", "OBSERVATION_MODIFIER", 79, 83]]], ["The black box in Figure 2b indicates the computational domain of the GRAL calculation.", [["GRAL", "PROTEIN", 69, 73], ["The black box", "TREATMENT", 0, 13], ["the GRAL calculation", "TEST", 65, 85], ["black box", "OBSERVATION", 4, 13]]], ["The wind was nearly homogeneous except for the area near walls due to friction.", [["friction", "PROBLEM", 70, 78], ["nearly", "OBSERVATION_MODIFIER", 13, 19], ["homogeneous", "OBSERVATION", 20, 31], ["friction", "OBSERVATION", 70, 78]]], ["The reference wind speed and direction for the windward and leeward facades in the airflow analysis to estimate the natural ventilation were calculated as averages within the black-dashed boxes in Figure 2c .MATERIALS AND METHODS3.2.", [["the windward and leeward facades", "TREATMENT", 43, 75], ["the airflow analysis", "TEST", 79, 99], ["natural ventilation", "OBSERVATION", 116, 135]]], ["Four different cases were calculated to investigate the influences of particle size on the virus concentrations inside the market.", [["particle size", "PROBLEM", 70, 83], ["the virus concentrations", "TREATMENT", 87, 111], ["particle", "OBSERVATION_MODIFIER", 70, 78], ["size", "OBSERVATION_MODIFIER", 79, 83], ["virus", "OBSERVATION", 91, 96]]], ["The virus containing particles were assumed to be monodisperse in the four cases, with a diameter of 0.8, 1.8, 3.5, and 5.5 \u03bcm, which could be suspended in the air for a relatively long time.", [["The virus containing particles", "PROBLEM", 0, 30], ["virus", "OBSERVATION", 4, 9], ["particles", "OBSERVATION_MODIFIER", 21, 30], ["assumed to be", "UNCERTAINTY", 36, 49], ["monodisperse", "OBSERVATION_MODIFIER", 50, 62], ["four", "OBSERVATION_MODIFIER", 70, 74], ["diameter", "OBSERVATION_MODIFIER", 89, 97], ["5.5 \u03bcm", "OBSERVATION_MODIFIER", 120, 126], ["air", "OBSERVATION", 160, 163]]], ["Most of the particles generated by normal breathing were within this range.", [["normal breathing", "OBSERVATION", 35, 51]]], ["45 In all cases, one infected patient was assumed to be inside the market from 6:00 to 18:00 each day, with viral shedding rates of 50 PFU per hour, and the half-life periods were set as 12 h.", [["patient", "ORGANISM", 30, 37], ["patient", "SPECIES", 30, 37], ["viral shedding rates", "TREATMENT", 108, 128], ["infected", "OBSERVATION", 21, 29]]], ["The air flow speeds inside Street No. 7 were about 0.5 cm s \u22121 and 0.2 cm s \u22121 on these 2 days.", [["The air flow speeds", "TEST", 0, 19], ["air flow", "OBSERVATION", 4, 12], ["0.2 cm", "OBSERVATION_MODIFIER", 67, 73]]], ["The results indicated that the concentration started to increase from 6:00 in the morning after the arrival of the infected person and decreased in the evening after 18:00 due to the lack of viral shedding, the deposition, the biologic degradation, and the ventilation.", [["person", "SPECIES", 124, 130], ["the concentration", "PROBLEM", 27, 44], ["viral shedding", "PROBLEM", 191, 205], ["the biologic degradation", "PROBLEM", 223, 247], ["the ventilation", "TREATMENT", 253, 268], ["infected", "OBSERVATION", 115, 123], ["viral", "OBSERVATION", 191, 196]]], ["Large particles (e.g., 5.5 \u03bcm) had a lower concentration and rapidly reached equilibrium due to the higher deposition rate.", [["Large particles", "PROBLEM", 0, 15], ["a lower concentration", "PROBLEM", 35, 56], ["the higher deposition rate", "PROBLEM", 96, 122], ["particles", "OBSERVATION", 6, 15], ["lower concentration", "OBSERVATION_MODIFIER", 37, 56], ["higher deposition", "OBSERVATION", 100, 117]]], ["Small particles were more difficult to remove from the air, so the concentration was higher and it constantly increased during the day with insufficient ventilation on December 13.", [["Small particles", "PROBLEM", 0, 15], ["insufficient ventilation", "TREATMENT", 140, 164], ["particles", "OBSERVATION", 6, 15], ["air", "OBSERVATION", 55, 58], ["higher", "OBSERVATION_MODIFIER", 85, 91], ["increased", "OBSERVATION_MODIFIER", 110, 119]]], ["The large particles (3.5 and 5.5 \u03bcm) were commonly completely removed from the air during the nights, but some of the small particles (0.8 and 1.8 \u03bcm) were able to remain suspended in the air.MATERIALS AND METHODSThe other four similar cases were also calculated to investigate the influences of the viral biologic decay on the concentration.", [["the small particles", "PROBLEM", 114, 133], ["large", "OBSERVATION_MODIFIER", 4, 9], ["particles", "OBSERVATION_MODIFIER", 10, 19], ["removed", "OBSERVATION", 62, 69], ["air", "OBSERVATION", 79, 82], ["small", "OBSERVATION_MODIFIER", 118, 123], ["particles", "OBSERVATION_MODIFIER", 124, 133], ["air", "OBSERVATION", 188, 191]]], ["The particles were monodisperse with a diameter of 3.5 \u03bcm in these cases with half-life periods of 1, 12, 24, and 70 h, covering the range of reported values for coronaviruses.", [["coronaviruses", "ORGANISM", 162, 175], ["coronaviruses", "PROBLEM", 162, 175], ["particles", "OBSERVATION_MODIFIER", 4, 13], ["monodisperse", "OBSERVATION_MODIFIER", 19, 31], ["diameter", "OBSERVATION_MODIFIER", 39, 47], ["3.5 \u03bcm", "OBSERVATION_MODIFIER", 51, 57]]], ["The viral shedding was the same with the previous cases.", [["The viral shedding", "PROBLEM", 0, 18], ["viral shedding", "OBSERVATION", 4, 18]]], ["Faster degradation, e.g., a 1 h half-life period, led to much lower concentration.", [["Faster degradation", "PROBLEM", 0, 18]]], ["The biologic decay only had marginal influences on airborne virus concentrations when the half-life period was longer than 12 h.MATERIALS AND METHODS3.3.", [["airborne virus concentrations", "TREATMENT", 51, 80], ["marginal", "OBSERVATION_MODIFIER", 28, 36], ["airborne virus", "OBSERVATION", 51, 65]]], ["Monte Carlo (MC) simulations were conducted to investigate the airborne virus concentration inside Street No. 7 and the release into the outdoor environment using polydisperse particles, considering the uncertainties in the viral shedding and the biologic decay.", [["Monte Carlo", "CHEMICAL", 0, 11], ["Monte Carlo (MC) simulations", "TREATMENT", 0, 28], ["polydisperse particles", "TREATMENT", 163, 185], ["the viral shedding", "PROBLEM", 220, 238]]], ["Figure 4a shows the MC results of the airborne virus concentrations inside the market.", [["the airborne virus concentrations", "PROBLEM", 34, 67], ["airborne virus", "OBSERVATION", 38, 52]]], ["The data for the whole month are shown in Figure S3 in the SI.", [["Figure S3", "OBSERVATION", 42, 51], ["SI", "ANATOMY", 59, 61]]], ["The median Environmental Science & Technology pubs.acs.org/est Article concentrations were close to those of large particles (3.5 and 5.5 \u03bcm) as shown in Figure 3 .", [["est Article concentrations", "TREATMENT", 59, 85]]], ["It was suggested that breath aerosols were generated by fluid film ruptures in lungs during inhalation due to the expansion of the bronchiole, 67 so the viral shedding was proportional to the particle volume as shown in eq 1.", [["lungs", "ANATOMY", 79, 84], ["bronchiole", "ANATOMY", 131, 141], ["fluid film", "MULTI-TISSUE_STRUCTURE", 56, 66], ["lungs", "ORGAN", 79, 84], ["breath aerosols", "TREATMENT", 22, 37], ["fluid film ruptures", "TREATMENT", 56, 75], ["the expansion of the bronchiole", "PROBLEM", 110, 141], ["the viral shedding", "PROBLEM", 149, 167], ["the particle volume", "TREATMENT", 188, 207], ["ruptures", "OBSERVATION", 67, 75], ["lungs", "ANATOMY", 79, 84], ["expansion", "OBSERVATION", 114, 123], ["bronchiole", "ANATOMY", 131, 141]]], ["The viral shedding within the investigated range (<5.5 \u03bcm) was dominated by the large particles due to the high volume, in spite of their low number concentrations, based on the assumption of homogeneous viral concentration in respiratory fluid.", [["respiratory fluid", "ANATOMY", 227, 244], ["The viral shedding", "PROBLEM", 0, 18], ["the high volume", "PROBLEM", 103, 118], ["homogeneous viral concentration in respiratory fluid", "PROBLEM", 192, 244], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["large", "OBSERVATION_MODIFIER", 80, 85], ["particles", "OBSERVATION", 86, 95], ["high volume", "OBSERVATION", 107, 118], ["homogeneous", "OBSERVATION_MODIFIER", 192, 203], ["viral concentration", "OBSERVATION", 204, 223], ["respiratory fluid", "OBSERVATION", 227, 244]]], ["It should be noted that the assumption maybe was not valid for large droplets (>5.5 \u03bcm), which could have different generation mechanisms.", [["large droplets", "PROBLEM", 63, 77]]], ["Some studies have shown that the viral shedding in droplets was comparable with that in aerosols.", [["Some studies", "TEST", 0, 12], ["the viral shedding in droplets", "PROBLEM", 29, 59], ["viral", "OBSERVATION_MODIFIER", 33, 38]]], ["48, 49 In the MC simulations, most of the halflife periods were several hours, following the available biologic decay data of coronavirus.", [["coronavirus", "DISEASE", 126, 137], ["coronavirus", "ORGANISM", 126, 137], ["coronavirus", "PROBLEM", 126, 137]]], ["51\u221253 The 95% confidence intervals of the MC simulations were shown as the shaded areas, which indicated the influences of the uncertain viral shedding and biologic decay.", [["the MC simulations", "TEST", 38, 56], ["the uncertain viral shedding", "PROBLEM", 123, 151]]], ["The virus inside the market was transported into the outdoor environment by natural ventilation.", [["natural ventilation", "TREATMENT", 76, 95], ["virus", "OBSERVATION", 4, 9], ["natural ventilation", "OBSERVATION", 76, 95]]], ["As shown in Figure 4 , the virus release is generally anticorrelated with the airborne concentration in Street No. 7 of the market.", [["the virus release", "PROBLEM", 23, 40]]], ["Outdoor Concentration Due to Atmospheric Dispersion.", [["Atmospheric Dispersion", "OBSERVATION", 29, 51]]], ["The estimated release of virus into the ambient environment was utilized as the source term for the atmospheric dispersion calculations in the GRAL model.", [["The estimated release of virus", "TREATMENT", 0, 30], ["the atmospheric dispersion calculations in the GRAL model", "TREATMENT", 96, 153], ["virus", "OBSERVATION", 25, 30], ["atmospheric dispersion", "OBSERVATION", 100, 122]]], ["The source was at the outlet of the indoor flow, either the western or the eastern exit of the market street, which was dependent on the ambient wind direction.", [["outlet", "OBSERVATION_MODIFIER", 22, 28], ["indoor flow", "OBSERVATION", 36, 47]]], ["The area was dominated by north and northeast wind as shown in Figure 2a , so the virus was primarily released from the western exit.", [["the virus", "PROBLEM", 78, 87], ["virus", "OBSERVATION", 82, 87]]], ["Figure 5a displays the three-dimensional isosurface of 10 \u22126 PFU m \u22123 , to show the interaction between the plume and the surrounding buildings, in the most dominant wind scenario shown in Figure 2 .", [["interaction", "OBSERVATION", 84, 95], ["plume", "OBSERVATION_MODIFIER", 108, 113], ["dominant", "OBSERVATION_MODIFIER", 157, 165], ["wind scenario", "OBSERVATION", 166, 179]]], ["The plume was initially horizontally transported above the parking lot by the wind among the buildings.", [["plume", "OBSERVATION_MODIFIER", 4, 9]]], ["The expanding width of the plume indicated rapid dilution.", [["rapid dilution", "PROBLEM", 43, 57], ["expanding", "OBSERVATION_MODIFIER", 4, 13], ["width", "OBSERVATION_MODIFIER", 14, 19], ["plume", "OBSERVATION_MODIFIER", 27, 32], ["rapid", "OBSERVATION_MODIFIER", 43, 48], ["dilution", "OBSERVATION", 49, 57]]], ["The virus was confined Environmental Science & Technology pubs.acs.org/est Article near the ground level during the early phase due to the absence of vertical air flow.", [["The virus", "PROBLEM", 0, 9], ["vertical air flow", "PROBLEM", 150, 167], ["virus", "OBSERVATION", 4, 9], ["vertical", "OBSERVATION_MODIFIER", 150, 158], ["air flow", "OBSERVATION", 159, 167]]], ["The plume was then elevated by the building and vertically transported to high altitudes, which decreased the ground level concentration.", [["plume", "OBSERVATION_MODIFIER", 4, 9], ["elevated", "OBSERVATION_MODIFIER", 19, 27], ["high altitudes", "OBSERVATION", 74, 88], ["ground level", "OBSERVATION_MODIFIER", 110, 122]]], ["Figure 5b shows the plume emitted from the eastern exit with 2.5 m s \u22121 southwest wind (210\u00b0).", [["Figure 5b", "TEST", 0, 9], ["plume", "OBSERVATION_MODIFIER", 20, 25], ["emitted", "OBSERVATION_MODIFIER", 26, 33]]], ["The results also indicated that the virus containing plume was near the ground level close to the market.", [["the virus containing plume", "PROBLEM", 32, 58], ["virus", "OBSERVATION", 36, 41], ["plume", "OBSERVATION_MODIFIER", 53, 58]]], ["Figure 6a shows the time averaged (between 6:00 to 18:00 in December 2019) spatial distribution of the virus concentration at 1.5 m above ground and the ground deposition.", [["Figure 6a", "TEST", 0, 9], ["the virus concentration", "PROBLEM", 99, 122], ["ground deposition", "OBSERVATION", 153, 170]]], ["The outdoor concentration was orders of magnitude lower than that inside the market due to the strong dilution by the ambient air.", [["ambient air", "OBSERVATION", 118, 129]]], ["The southwestern region had relatively high concentration due to the dominant north and northeast wind.", [["high concentration", "OBSERVATION", 39, 57], ["dominant", "OBSERVATION_MODIFIER", 69, 77], ["north", "OBSERVATION_MODIFIER", 78, 83], ["northeast wind", "OBSERVATION", 88, 102]]], ["The results also indicated that the outdoor air .", [["outdoor air", "OBSERVATION", 36, 47]]], ["Infection risk through aerosol transmission: (a) infection risk for 1 h exposure, the band inside the box was the median, the lower and upper boundaries of the box were respectively the first (25th percentile) and third quartiles (75th percentile), and the ends of the whiskers here represented the 2.5th and 97.5th percentiles.", [["infection", "DISEASE", 49, 58], ["a) infection risk", "PROBLEM", 46, 63], ["lower", "ANATOMY_MODIFIER", 126, 131], ["upper", "ANATOMY_MODIFIER", 136, 141]]], ["The outdoor risk was estimated by the assumption of standing in the downwind direction, namely, the maximum risk at a certain distance. (b) Risk for prolonged exposure inside the market, e.g., for shopkeepers working inside the market day after day. (c) Contributions of the uncertain parameters to the final uncertainty of the assessment. concentration significantly decreased with the increasing distance from the exits.", [["the assessment", "TEST", 324, 338], ["significantly", "OBSERVATION_MODIFIER", 354, 367], ["decreased", "OBSERVATION_MODIFIER", 368, 377], ["increasing", "OBSERVATION_MODIFIER", 387, 397], ["distance", "OBSERVATION_MODIFIER", 398, 406]]], ["The concentration was about 10 \u22124 PFU m \u22123 near the market exits, but it decreased to about 10 \u22129 PFU m \u22123 in the square in front of the train station, which was about 500 m to the west of the market.", [["concentration", "OBSERVATION_MODIFIER", 4, 17], ["decreased", "OBSERVATION_MODIFIER", 73, 82]]], ["There were intensive concentration gradients near the market exits as shown in Figure 6b .", [["intensive concentration gradients", "PROBLEM", 11, 44], ["intensive", "OBSERVATION_MODIFIER", 11, 20], ["concentration", "OBSERVATION_MODIFIER", 21, 34], ["gradients", "OBSERVATION_MODIFIER", 35, 44]]], ["The concentration decreased by 3 orders of magnitude from 10 \u22124 PFU m \u22123 to 10 \u22127 PFU m \u22123 within about 50 m near the western exit.MATERIALS AND METHODSThe time averaged ground deposition of the virus containing particles is shown in Figure 6c and d.", [["the virus containing particles", "PROBLEM", 191, 221], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["decreased", "OBSERVATION_MODIFIER", 18, 27], ["virus", "OBSERVATION", 195, 200]]], ["The most contaminated outdoor area was the parking lot close to the western exit, with deposition rates between 10 \u22127 and 10 \u22125 PFU m \u22122 h \u22121 .", [["deposition rates", "TEST", 87, 103], ["most", "OBSERVATION_MODIFIER", 4, 8], ["contaminated", "OBSERVATION_MODIFIER", 9, 21]]], ["The deposition rate was below 10 \u22127 PFU m \u22122 h \u22121 in other areas.", [["The deposition rate", "TEST", 0, 19], ["deposition", "OBSERVATION_MODIFIER", 4, 14], ["rate", "OBSERVATION_MODIFIER", 15, 19]]], ["The virus could be accumulated if they were able to survive on the surfaces.", [["The virus", "PROBLEM", 0, 9], ["virus", "OBSERVATION", 4, 9]]], ["As a result, the accumulated active virus deposition near the exit could be up to 10 \u22123 PFU m \u22122 .MATERIALS AND METHODS3.5.", [["the accumulated active virus deposition", "PROBLEM", 13, 52], ["active", "OBSERVATION_MODIFIER", 29, 35], ["virus deposition", "OBSERVATION", 36, 52]]], ["Infection Risk through Aerosol Transmission.", [["Infection", "PROBLEM", 0, 9]]], ["The infection risk was assessed based on the exposure dose d and the exponential dose\u2212response model by Monte Carlo simulations.", [["infection", "DISEASE", 4, 13], ["The infection risk", "PROBLEM", 0, 18], ["the exponential dose\u2212response model", "TREATMENT", 65, 100], ["infection", "OBSERVATION", 4, 13]]], ["The uncertainties in three key factors were considered: biologic decay, viral shedding, and dose\u2212response parameter.", [["biologic decay", "PROBLEM", 56, 70], ["viral shedding", "PROBLEM", 72, 86]]], ["There were 100 values for each parameter, so 1 million runs were conducted.", [["1 million runs", "TREATMENT", 45, 59]]], ["Figure 7a shows the infection risk through aerosol transmission for 1 h of exposure.", [["infection", "DISEASE", 20, 29], ["the infection risk", "PROBLEM", 16, 34], ["aerosol transmission", "TREATMENT", 43, 63], ["infection", "OBSERVATION", 20, 29]]], ["It should be noted that the following results were all based on the assumption of one infected person in the market.", [["person", "SPECIES", 95, 101], ["infected", "OBSERVATION", 86, 94]]], ["The risk would be increased if multiple infected persons were simultaneously inside the market.", [["persons", "ORGANISM", 49, 56], ["persons", "SPECIES", 49, 56], ["multiple infected persons", "PROBLEM", 31, 56], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["multiple", "OBSERVATION_MODIFIER", 31, 39], ["infected", "OBSERVATION", 40, 48]]], ["Conversely, the risk would be decreased with less exposure duration.", [["decreased", "OBSERVATION_MODIFIER", 30, 39]]], ["The highest risk was observed inside the market because of the high virus concentration.", [["the high virus concentration", "PROBLEM", 59, 87], ["high virus", "OBSERVATION", 63, 73]]], ["The median infection risk of SARS-CoV-2 induced by aerosol transmission was 2.23 \u00d7 10 \u22125 , and the 95% confidence interval (CI) was from 1.90 \u00d7 10 \u22126 (2.5% percentile) to 2.34 \u00d7 10 \u22124 (97.5% percentile) for 1 h of exposure in Street No. 7 of the market, approximate to the risk of consumers in the market.MATERIALS AND METHODSThe infection risk by aerosol transmission for the pedestrians outside the market rapidly decreased due to dilution by ambient air.", [["infection", "DISEASE", 11, 20], ["SARS", "DISEASE", 29, 33], ["infection", "DISEASE", 330, 339], ["SARS-CoV-2", "ORGANISM", 29, 39], ["SARS-CoV", "SPECIES", 29, 37], ["The median infection risk of SARS", "PROBLEM", 0, 33], ["CoV", "TEST", 34, 37], ["aerosol transmission", "TEST", 51, 71], ["CI", "TEST", 124, 126], ["METHODSThe infection risk", "PROBLEM", 319, 344], ["aerosol transmission", "TREATMENT", 348, 368], ["median", "OBSERVATION_MODIFIER", 4, 10], ["infection", "OBSERVATION", 11, 20], ["infection", "OBSERVATION", 330, 339]]], ["Figure 7a shows the infection risk at 2 to 600 m away from the market exit if one stands in the downwind direction, namely, the maximum risk at a certain distance.", [["infection", "DISEASE", 20, 29], ["the infection risk", "PROBLEM", 16, 34], ["infection", "OBSERVATION", 20, 29]]], ["The median risk at 5 m outside the market was 7.49 \u00d7 10 \u22128 (95% CI: 4.12 \u00d7 10 \u22129 to 1.13 \u00d7 10 \u22126 ) for 1 h of exposure, which was about 2 orders of magnitude lower than the risk inside the market.", [["CI", "TEST", 64, 66], ["median", "OBSERVATION_MODIFIER", 4, 10]]], ["The Hankou Train Station was about 600 m away from the market, with a median infection risk of 1.44 \u00d7 10 \u221211 (95% CI: 9.28 \u00d7 10 \u221213 to 1.92 \u00d7 10 \u221210 ).", [["infection", "DISEASE", 77, 86], ["a median infection risk", "PROBLEM", 68, 91], ["CI", "TEST", 114, 116]]], ["The infection risk due to accumulated exposure in December was also estimated for the shopkeepers in Street No. 7 as shown in Figure 7b .", [["infection", "DISEASE", 4, 13], ["The infection risk", "PROBLEM", 0, 18], ["infection", "OBSERVATION", 4, 13]]], ["The final median infection risk through aerosol transmission was 9.76 \u00d7 10 \u22123 (95% CI: 9.10 \u00d7 10 \u22124 to 9.69 \u00d7 10 \u22122 ).", [["infection", "DISEASE", 17, 26], ["aerosol transmission", "TEST", 40, 60], ["CI", "TEST", 83, 85], ["median", "OBSERVATION_MODIFIER", 10, 16], ["infection", "OBSERVATION", 17, 26]]], ["The infection risk through aerosol transmission was considerable for a person with prolonged exposure in the place without sufficient ventilation.MATERIALS AND METHODSThe 95% confidence interval of the estimated risk normally covered about 2 orders of magnitude, indicating significant uncertainties in the assessment caused by the current limited and uncertain information about SARS-CoV-2.", [["infection", "DISEASE", 4, 13], ["person", "SPECIES", 71, 77], ["SARS-CoV", "SPECIES", 380, 388], ["The infection risk", "PROBLEM", 0, 18], ["aerosol transmission", "TREATMENT", 27, 47], ["sufficient ventilation", "TREATMENT", 123, 145], ["METHODSThe", "TEST", 160, 170], ["the estimated risk", "PROBLEM", 198, 216], ["the assessment", "TEST", 303, 317], ["infection", "OBSERVATION", 4, 13], ["significant", "OBSERVATION_MODIFIER", 274, 285], ["uncertainties", "OBSERVATION", 286, 299]]], ["Figure 7c shows that the dose\u2212response model, viral shedding, and biological decay respectively contributed about 56.8%, 34.5%, and 8.7% to the final uncertainty.", [["Figure 7c", "TEST", 0, 9], ["the dose\u2212response model", "TEST", 21, 44], ["viral shedding", "PROBLEM", 46, 60]]], ["The shares of contributions nearly remained the same at different locations, except that the contribution of biological decay slightly increased from 8.66% in the market to 8.81% at 600 m away from the market because decay became more significant with longer transport time.", [["biological decay", "PROBLEM", 109, 125], ["decay", "OBSERVATION_MODIFIER", 120, 125], ["slightly", "OBSERVATION_MODIFIER", 126, 134], ["increased", "OBSERVATION_MODIFIER", 135, 144]]], ["The results suggested that the dose\u2212response relation and viral shedding were the dominant factors for the uncertainties, thus more efforts should be taken to further investigate these factors.MATERIALS AND METHODSWe investigated the reduction of risk by enhancing the air changes per hour (ACH) as shown in Figure 8 .", [["viral shedding", "PROBLEM", 58, 72], ["METHODSWe", "TREATMENT", 207, 216], ["air", "OBSERVATION", 269, 272]]], ["The insufficient ventilation about 0.1 ACH was one important reason for the relatively high risk in the market.", [["The insufficient ventilation", "TREATMENT", 0, 28], ["insufficient", "OBSERVATION_MODIFIER", 4, 16], ["ventilation", "OBSERVATION", 17, 28]]], ["Increasing the ventilation to about 9 ACHs, as in healthcare facilities, made the risk about 10 times lower than the situation with natural ventilation.", [["Increasing the ventilation", "TREATMENT", 0, 26], ["natural ventilation", "TREATMENT", 132, 151], ["ventilation", "OBSERVATION", 15, 26], ["natural ventilation", "OBSERVATION", 132, 151]]], ["The typical air change rates shown in Figure 8 were the total rates, which included mechanical and natural ventilation rates.", [["The typical air change rates", "PROBLEM", 0, 28], ["mechanical and natural ventilation rates", "TREATMENT", 84, 124], ["typical", "OBSERVATION_MODIFIER", 4, 11], ["air change", "OBSERVATION", 12, 22], ["natural ventilation", "OBSERVATION", 99, 118]]], ["68 It was reported 69 that mechanical systems accounted for about 70% of the total air exchange in retail stores, so mechanical ventilation is an important factor for enhancing the ventilation rates.IMPLICATIONSIn this study, the aerosol transmission risk of SARS-CoV-2 was quantitatively assessed based on the current available information about SARS-CoV-2, SARS-CoV, and other coronaviruses.", [["SARS", "DISEASE", 259, 263], ["SARS-CoV-2", "ORGANISM", 259, 269], ["SARS-CoV-2", "ORGANISM", 347, 357], ["SARS-CoV", "ORGANISM", 359, 367], ["coronaviruses", "ORGANISM", 379, 392], ["SARS-CoV", "SPECIES", 259, 267], ["SARS-CoV", "SPECIES", 347, 355], ["SARS-CoV", "SPECIES", 359, 367], ["mechanical ventilation", "TREATMENT", 117, 139], ["enhancing the ventilation rates", "TREATMENT", 167, 198], ["this study", "TEST", 214, 224], ["SARS", "PROBLEM", 259, 263], ["SARS", "TEST", 347, 351], ["CoV", "TEST", 352, 355], ["SARS", "PROBLEM", 359, 363], ["other coronaviruses", "PROBLEM", 373, 392], ["air exchange", "OBSERVATION", 83, 95], ["mechanical ventilation", "OBSERVATION", 117, 139], ["ventilation rates", "OBSERVATION", 181, 198]]], ["The most probable range (95% confidence interval) of risk was estimated.", [["most probable", "UNCERTAINTY", 4, 17]]], ["The results suggested that the dose\u2212response relation was the dominant factor for the uncertainties, followed by viral shedding.", [["viral shedding", "PROBLEM", 113, 127]]], ["SARS-CoV-2 seems to have stronger transmissibility, and a recent study indicated that SARS-CoV-2 has a higher binding affinity with the host cell receptor (ACE2) than SARS-CoV.", [["cell", "ANATOMY", 141, 145], ["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 86, 90], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS-CoV-2", "ORGANISM", 86, 96], ["host cell receptor", "GENE_OR_GENE_PRODUCT", 136, 154], ["ACE2", "GENE_OR_GENE_PRODUCT", 156, 160], ["SARS-CoV", "ORGANISM", 167, 175], ["host cell receptor", "PROTEIN", 136, 154], ["ACE2", "PROTEIN", 156, 160], ["SARS-CoV", "SPECIES", 86, 94], ["SARS-CoV", "SPECIES", 167, 175], ["a recent study", "TEST", 56, 70], ["SARS", "TEST", 86, 90], ["CoV", "TEST", 91, 94], ["a higher binding affinity", "PROBLEM", 101, 126]]], ["The uncertainties will remain, until enough information, e.g., the dose\u2212response relation and viral shedding of SARS-CoV-2, are obtained, which could take a long time.IMPLICATIONSConsidering the current uncertainties, the infection risk from aerosol transmission could not be ruled out for the consumers in the poorly ventilated markets.", [["SARS", "DISEASE", 112, 116], ["infection", "DISEASE", 222, 231], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 112, 122], ["SARS-CoV", "SPECIES", 112, 120], ["SARS", "PROBLEM", 112, 116], ["CoV", "TEST", 117, 120], ["the infection risk", "PROBLEM", 218, 236], ["aerosol transmission", "TREATMENT", 242, 262], ["infection", "OBSERVATION", 222, 231]]], ["According to the Wuhan Municipal Health Commission, there were 12 822 available hospital beds for COVID-19 treatment (Feb. 11, 2020) , about 1.17 \u00d7 10 \u22123 per capita, 71 shown as the blue dashed line in Figure 7a .", [["COVID-19", "CHEMICAL", 98, 106], ["COVID-19", "CHEMICAL", 98, 106], ["COVID-19 treatment", "TREATMENT", 98, 116]]], ["We consider the risk to be manageable if all the expected infected people in Wuhan can be handled by the available medical resources, in other words, if the infection probability is lower than the number of local hospital beds for COVID-19 treatment per capita.", [["infection", "DISEASE", 157, 166], ["COVID-19", "CHEMICAL", 231, 239], ["people", "ORGANISM", 67, 73], ["people", "SPECIES", 67, 73], ["the infection probability", "PROBLEM", 153, 178], ["COVID", "TREATMENT", 231, 236], ["infection", "OBSERVATION", 157, 166]]], ["The manageable risk could be higher if home quarantine is allowed for patients with mild symptoms.", [["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["home quarantine", "TREATMENT", 39, 54], ["mild symptoms", "PROBLEM", 84, 97]]], ["With the assumption of one infected shopkeeper in the market, the 97.5th percentile infection risk by aerosol transmission was about 2.34 \u00d7 10 \u22124 and could be reduced to about 10 \u22124 with the typical ventilation rate (1 ACH) as shown in Figure 8 , for customers with 1 h of exposure in poorly ventilated markets similar to the seafood market.", [["infection", "DISEASE", 84, 93], ["aerosol transmission", "TEST", 102, 122], ["one", "OBSERVATION_MODIFIER", 23, 26], ["infected", "OBSERVATION_MODIFIER", 27, 35], ["shopkeeper", "OBSERVATION", 36, 46]]], ["The risk was about 5 to 10 times lower than the manageable risk (1.17 \u00d7 10 \u22123 ), but it could be increased by several times if multiple infected shopkeepers were simultaneously in the market, becoming close to the manageable risk.", [["multiple infected shopkeepers", "PROBLEM", 127, 156], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["multiple", "OBSERVATION_MODIFIER", 127, 135], ["infected", "OBSERVATION", 136, 144]]], ["We would recommend that people working in poorly ventilated markets wear masks to reduce potential viral shedding, and the consumers could also shorten the time in the markets to keep the risk by aerosol transmission well below the limit of the local medical resources.IMPLICATIONSAbout the results presented in this study, it should be noted that only one infected person was assumed to be inside the market, but there might be simultaneously multiple infected people, which could increase the risk.", [["people", "ORGANISM", 24, 30], ["person", "ORGANISM", 366, 372], ["people", "ORGANISM", 462, 468], ["people", "SPECIES", 24, 30], ["person", "SPECIES", 366, 372], ["people", "SPECIES", 462, 468], ["poorly ventilated markets wear masks", "TREATMENT", 42, 78], ["potential viral shedding", "PROBLEM", 89, 113], ["aerosol transmission", "TREATMENT", 196, 216], ["this study", "TEST", 312, 322], ["simultaneously multiple infected people", "PROBLEM", 429, 468], ["infected", "OBSERVATION", 357, 365], ["might be", "UNCERTAINTY", 420, 428], ["simultaneously", "OBSERVATION_MODIFIER", 429, 443], ["multiple", "OBSERVATION_MODIFIER", 444, 452], ["infected", "OBSERVATION", 453, 461]]], ["More detailed risk assessment should be further conducted for the aerosol transmission in poorly ventilated markets with multiple infected shopkeepers.", [["detailed risk assessment", "TEST", 5, 29], ["the aerosol transmission", "TREATMENT", 62, 86], ["multiple infected shopkeepers", "PROBLEM", 121, 150], ["multiple", "OBSERVATION_MODIFIER", 121, 129], ["infected", "OBSERVATION", 130, 138]]], ["The infection risk due to close contact (direct/indirect) and large respiratory droplets by coughs or sneezes or droplets of saliva was not included in this study.* s\u0131 Supporting InformationThe Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.est.0c02895.* s\u0131 Supporting InformationWind driven cross ventilation, estimation of the friction velocity inside the market, deposition inside the market, lung deposition, viral concentration in the market in December 2019, Figures S1\u2212S3, and eqs S1\u2212S21 (PDF)", [["respiratory droplets", "ANATOMY", 68, 88], ["lung", "ANATOMY", 440, 444], ["infection", "DISEASE", 4, 13], ["coughs", "DISEASE", 92, 98], ["saliva", "ORGANISM_SUBSTANCE", 125, 131], ["lung", "ORGAN", 440, 444], ["The infection risk", "PROBLEM", 0, 18], ["large respiratory droplets", "PROBLEM", 62, 88], ["coughs", "PROBLEM", 92, 98], ["sneezes", "PROBLEM", 102, 109], ["droplets of saliva", "PROBLEM", 113, 131], ["this study", "TEST", 152, 162], ["cross ventilation", "TREATMENT", 336, 353], ["the friction velocity", "TEST", 369, 390], ["lung deposition", "PROBLEM", 440, 455], ["viral concentration", "PROBLEM", 457, 476], ["Figures", "TEST", 509, 516], ["infection", "OBSERVATION", 4, 13], ["large", "OBSERVATION_MODIFIER", 62, 67], ["respiratory droplets", "OBSERVATION", 68, 88], ["friction velocity", "OBSERVATION", 373, 390], ["lung", "ANATOMY", 440, 444], ["deposition", "OBSERVATION", 445, 455], ["viral concentration", "OBSERVATION", 457, 476], ["S3", "ANATOMY", 520, 522]]]]}